0000310158-20-000030.txt : 20201105 0000310158-20-000030.hdr.sgml : 20201105 20201105165558 ACCESSION NUMBER: 0000310158-20-000030 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 92 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201105 DATE AS OF CHANGE: 20201105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Merck & Co., Inc. CENTRAL INDEX KEY: 0000310158 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 221918501 STATE OF INCORPORATION: NJ FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06571 FILM NUMBER: 201291337 BUSINESS ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 BUSINESS PHONE: 908-740-4000 MAIL ADDRESS: STREET 1: 2000 GALLOPING HILL ROAD CITY: KENILWORTH STATE: NJ ZIP: 07033 FORMER COMPANY: FORMER CONFORMED NAME: Merck & Co. Inc. DATE OF NAME CHANGE: 20091103 FORMER COMPANY: FORMER CONFORMED NAME: SCHERING PLOUGH CORP DATE OF NAME CHANGE: 19920703 10-Q 1 mrk-20200930.htm 10-Q mrk-20200930
FALSE2020Q3000031015812/3100003101582020-01-012020-09-300000310158us-gaap:CommonStockMember2020-01-012020-09-300000310158mrk:A1.125Notesdue2021Member2020-01-012020-09-300000310158mrk:A0.500Notesdue2024Member2020-01-012020-09-300000310158mrk:A1.875Notesdue2026Member2020-01-012020-09-300000310158mrk:A2.500Notesdue2034Member2020-01-012020-09-300000310158mrk:A1.375Notesdue2036Member2020-01-012020-09-30xbrli:shares00003101582020-10-31iso4217:USD00003101582020-07-012020-09-3000003101582019-07-012019-09-3000003101582019-01-012019-09-30iso4217:USDxbrli:shares00003101582020-09-3000003101582019-12-3100003101582018-12-3100003101582019-09-300000310158srt:ScenarioForecastMembermrk:VelosBioMember2020-11-012020-11-300000310158mrk:SeagenMember2020-09-012020-09-300000310158mrk:SeagenMember2020-09-300000310158us-gaap:ForwardContractsMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300000310158us-gaap:ForwardContractsMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:SubsequentEventMember2020-10-012020-10-310000310158mrk:RegulatoryMilestonesMembermrk:SeagenMember2020-09-012020-09-300000310158mrk:SalesBasedMilestonesMembermrk:SeagenMember2020-09-012020-09-300000310158mrk:TukysaMembermrk:SeagenMember2020-09-012020-09-300000310158mrk:TukysaMembermrk:RegulatoryMilestonesMembermrk:SeagenMember2020-09-012020-09-30xbrli:pure0000310158srt:MinimumMembermrk:TukysaMembermrk:SeagenMember2020-09-012020-09-300000310158mrk:TukysaMembersrt:MaximumMembermrk:SeagenMember2020-09-012020-09-30iso4217:EUR0000310158mrk:DunboyneMember2020-09-012020-09-300000310158mrk:DunboyneMember2020-09-300000310158mrk:SentinelMember2020-07-012020-07-310000310158mrk:SentinelMemberus-gaap:DevelopedTechnologyRightsMember2020-07-012020-07-310000310158mrk:SentinelMemberus-gaap:DevelopedTechnologyRightsMember2020-07-310000310158us-gaap:DevelopedTechnologyRightsMembermrk:SentinelMember2020-07-012020-07-310000310158mrk:ThemisMember2020-06-012020-06-300000310158mrk:ThemisMember2020-06-300000310158mrk:DevelopmentMilestonesMembermrk:ThemisMember2020-06-300000310158mrk:ThemisMembermrk:RegulatoryMilestonesMember2020-06-300000310158mrk:ThemisMembermrk:SalesBasedMilestonesMember2020-06-300000310158mrk:IAVIMember2020-05-012020-05-310000310158mrk:ArQuleMember2020-01-162020-01-160000310158mrk:ArQuleMember2020-01-160000310158us-gaap:MeasurementInputDiscountRateMembermrk:ArQuleMember2020-01-160000310158mrk:PelotonMember2019-07-012019-07-310000310158mrk:PelotonMembermrk:RegulatoryMilestonesMember2019-07-310000310158mrk:PelotonMembermrk:CommercialMilestoneMember2019-07-310000310158mrk:PelotonMembermrk:SalesBasedMilestonesMember2019-07-310000310158mrk:PelotonMember2019-07-310000310158mrk:AntelliqMember2019-04-012019-04-010000310158mrk:AntelliqMember2019-04-010000310158srt:MinimumMembermrk:AntelliqMemberus-gaap:DevelopedTechnologyRightsMember2019-04-012019-04-010000310158mrk:AntelliqMembersrt:MaximumMemberus-gaap:DevelopedTechnologyRightsMember2019-04-012019-04-010000310158us-gaap:MeasurementInputDiscountRateMembermrk:AntelliqMember2019-04-010000310158mrk:ImmuneDesignMember2019-04-012019-04-300000310158mrk:ImmuneDesignMember2019-04-300000310158mrk:AstraZenecaMember2017-07-012017-07-310000310158mrk:LynparzaMembermrk:AstraZenecaMembermrk:SalesBasedMilestonesMember2020-04-012020-06-300000310158mrk:LynparzaMembermrk:AstraZenecaMembermrk:SalesBasedMilestonesMember2020-06-300000310158mrk:LynparzaMembermrk:AstraZenecaMembermrk:SalesBasedMilestonesMember2017-08-012019-12-310000310158mrk:LynparzaMembermrk:AstraZenecaMembermrk:SalesBasedMilestonesMember2019-01-012019-12-310000310158mrk:LynparzaMembermrk:AstraZenecaMembermrk:SalesBasedMilestonesMember2018-01-012018-12-310000310158mrk:LynparzaMembermrk:AstraZenecaMembermrk:SalesBasedMilestonesMember2020-01-012020-09-300000310158mrk:AstraZenecaMembermrk:SalesBasedMilestonesMember2020-01-012020-09-300000310158mrk:LynparzaMembermrk:AstraZenecaMembermrk:RegulatoryMilestonesMember2020-04-012020-06-300000310158mrk:LynparzaMembermrk:AstraZenecaMembermrk:RegulatoryMilestonesMember2019-01-012019-12-310000310158mrk:LynparzaMembermrk:AstraZenecaMembermrk:RegulatoryMilestonesMember2018-01-012018-12-310000310158mrk:LynparzaMembermrk:AstraZenecaMembermrk:RegulatoryMilestonesMember2020-01-012020-09-300000310158mrk:LynparzaMemberus-gaap:OtherNoncurrentAssetsMember2020-09-300000310158mrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-07-012020-09-300000310158mrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2019-07-012019-09-300000310158mrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-01-012020-09-300000310158mrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2019-01-012019-09-300000310158mrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-07-012020-09-300000310158mrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2019-07-012019-09-300000310158mrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-01-012020-09-300000310158mrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2019-01-012019-09-300000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-07-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2019-07-012019-09-300000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-01-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2019-01-012019-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2019-07-012019-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2019-01-012019-09-300000310158mrk:AstraZenecaMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2019-07-012019-09-300000310158mrk:AstraZenecaMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2019-01-012019-09-300000310158mrk:AstraZenecaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2019-07-012019-09-300000310158mrk:AstraZenecaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158mrk:AstraZenecaMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2019-01-012019-09-300000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:OtherCurrentAssetsMember2020-09-300000310158mrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMemberus-gaap:OtherCurrentAssetsMember2019-12-310000310158mrk:AstraZenecaMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2020-09-300000310158mrk:AstraZenecaMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2019-12-310000310158mrk:EisaiMember2018-03-012018-03-310000310158mrk:EisaiMembersrt:ScenarioForecastMember2018-03-012021-03-310000310158mrk:EisaiMember2019-03-012019-03-310000310158mrk:EisaiMember2020-03-012020-03-310000310158mrk:EisaiMembersrt:ScenarioForecastMember2021-03-012021-03-310000310158mrk:EisaiMembermrk:LenvimaMembermrk:SalesBasedMilestonesMember2020-04-012020-06-300000310158mrk:EisaiMembermrk:LenvimaMembermrk:SalesBasedMilestonesMember2020-06-300000310158mrk:EisaiMembermrk:LenvimaMembermrk:SalesBasedMilestonesMember2018-04-012019-12-310000310158mrk:EisaiMembermrk:LenvimaMembermrk:SalesBasedMilestonesMember2019-01-012019-12-310000310158mrk:EisaiMembermrk:LenvimaMembermrk:SalesBasedMilestonesMember2020-01-012020-09-300000310158mrk:EisaiMembermrk:SalesBasedMilestonesMember2020-01-012020-09-300000310158mrk:EisaiMembermrk:LenvimaMembermrk:RegulatoryMilestonesMember2018-01-012018-12-310000310158mrk:EisaiMembermrk:RegulatoryMilestonesMember2020-01-012020-09-300000310158us-gaap:OtherNoncurrentAssetsMembermrk:LenvimaMember2020-09-300000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-07-012020-09-300000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2019-07-012019-09-300000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2020-01-012020-09-300000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementMemberus-gaap:SalesMember2019-01-012019-09-300000310158mrk:EisaiMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158mrk:EisaiMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2019-07-012019-09-300000310158mrk:EisaiMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158mrk:EisaiMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2019-01-012019-09-300000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2019-07-012019-09-300000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2019-01-012019-09-300000310158mrk:EisaiMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2020-07-012020-09-300000310158mrk:EisaiMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2019-07-012019-09-300000310158mrk:EisaiMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2020-01-012020-09-300000310158mrk:EisaiMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2019-01-012019-09-300000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementMemberus-gaap:OtherCurrentAssetsMember2020-09-300000310158mrk:EisaiMemberus-gaap:CollaborativeArrangementMemberus-gaap:OtherCurrentAssetsMember2019-12-310000310158mrk:EisaiMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2020-09-300000310158mrk:EisaiMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2019-12-310000310158mrk:EisaiMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:CollaborativeArrangementMember2020-09-300000310158mrk:EisaiMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:CollaborativeArrangementMember2019-12-310000310158mrk:SalesBasedMilestonesMembermrk:BayerAGMember2019-01-012019-12-310000310158mrk:SalesBasedMilestonesMembermrk:BayerAGMember2018-01-012018-12-310000310158mrk:SalesBasedMilestonesMembermrk:BayerAGMember2020-01-012020-09-300000310158us-gaap:OtherIntangibleAssetsMembermrk:AdempasMember2020-09-300000310158us-gaap:CollaborativeArrangementMemberus-gaap:SalesMembermrk:BayerAGMember2020-07-012020-09-300000310158us-gaap:CollaborativeArrangementMemberus-gaap:SalesMembermrk:BayerAGMember2019-07-012019-09-300000310158us-gaap:CollaborativeArrangementMemberus-gaap:SalesMembermrk:BayerAGMember2020-01-012020-09-300000310158us-gaap:CollaborativeArrangementMemberus-gaap:SalesMembermrk:BayerAGMember2019-01-012019-09-300000310158us-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-07-012020-09-300000310158us-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2019-07-012019-09-300000310158us-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-01-012020-09-300000310158us-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2019-01-012019-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-07-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2019-07-012019-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-01-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2019-01-012019-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-07-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2019-07-012019-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-01-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2019-01-012019-09-300000310158us-gaap:CollaborativeArrangementMemberus-gaap:OtherCurrentAssetsMembermrk:BayerAGMember2020-09-300000310158us-gaap:CollaborativeArrangementMemberus-gaap:OtherCurrentAssetsMembermrk:BayerAGMember2019-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2020-09-300000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:CollaborativeArrangementMembermrk:BayerAGMember2019-12-310000310158srt:ScenarioForecastMember2020-12-310000310158us-gaap:CostOfSalesMemberus-gaap:OneTimeTerminationBenefitsMember2020-07-012020-09-300000310158us-gaap:CostOfSalesMembermrk:AcceleratedDepreciationMember2020-07-012020-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2020-07-012020-09-300000310158us-gaap:CostOfSalesMember2020-07-012020-09-300000310158us-gaap:CostOfSalesMemberus-gaap:OneTimeTerminationBenefitsMember2020-01-012020-09-300000310158us-gaap:CostOfSalesMembermrk:AcceleratedDepreciationMember2020-01-012020-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2020-01-012020-09-300000310158us-gaap:CostOfSalesMember2020-01-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OneTimeTerminationBenefitsMember2020-07-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AcceleratedDepreciationMember2020-07-012020-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-07-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-07-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OneTimeTerminationBenefitsMember2020-01-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AcceleratedDepreciationMember2020-01-012020-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2020-01-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OneTimeTerminationBenefitsMember2020-07-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AcceleratedDepreciationMember2020-07-012020-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2020-07-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OneTimeTerminationBenefitsMember2020-01-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AcceleratedDepreciationMember2020-01-012020-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2020-07-012020-09-300000310158us-gaap:RestructuringChargesMembermrk:AcceleratedDepreciationMember2020-07-012020-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2020-07-012020-09-300000310158us-gaap:RestructuringChargesMember2020-07-012020-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2020-01-012020-09-300000310158us-gaap:RestructuringChargesMembermrk:AcceleratedDepreciationMember2020-01-012020-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2020-01-012020-09-300000310158us-gaap:RestructuringChargesMember2020-01-012020-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2020-07-012020-09-300000310158mrk:AcceleratedDepreciationMember2020-07-012020-09-300000310158us-gaap:OtherRestructuringMember2020-07-012020-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2020-01-012020-09-300000310158mrk:AcceleratedDepreciationMember2020-01-012020-09-300000310158us-gaap:OtherRestructuringMember2020-01-012020-09-300000310158us-gaap:CostOfSalesMemberus-gaap:OneTimeTerminationBenefitsMember2019-07-012019-09-300000310158us-gaap:CostOfSalesMembermrk:AcceleratedDepreciationMember2019-07-012019-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2019-07-012019-09-300000310158us-gaap:CostOfSalesMember2019-07-012019-09-300000310158us-gaap:CostOfSalesMemberus-gaap:OneTimeTerminationBenefitsMember2019-01-012019-09-300000310158us-gaap:CostOfSalesMembermrk:AcceleratedDepreciationMember2019-01-012019-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2019-01-012019-09-300000310158us-gaap:CostOfSalesMember2019-01-012019-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OneTimeTerminationBenefitsMember2019-07-012019-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AcceleratedDepreciationMember2019-07-012019-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-07-012019-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-07-012019-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:OneTimeTerminationBenefitsMember2019-01-012019-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AcceleratedDepreciationMember2019-01-012019-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2019-01-012019-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OneTimeTerminationBenefitsMember2019-07-012019-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AcceleratedDepreciationMember2019-07-012019-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2019-07-012019-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2019-07-012019-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:OneTimeTerminationBenefitsMember2019-01-012019-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AcceleratedDepreciationMember2019-01-012019-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2019-07-012019-09-300000310158us-gaap:RestructuringChargesMembermrk:AcceleratedDepreciationMember2019-07-012019-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2019-07-012019-09-300000310158us-gaap:RestructuringChargesMember2019-07-012019-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2019-01-012019-09-300000310158us-gaap:RestructuringChargesMembermrk:AcceleratedDepreciationMember2019-01-012019-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2019-01-012019-09-300000310158us-gaap:RestructuringChargesMember2019-01-012019-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2019-07-012019-09-300000310158mrk:AcceleratedDepreciationMember2019-07-012019-09-300000310158us-gaap:OtherRestructuringMember2019-07-012019-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2019-01-012019-09-300000310158mrk:AcceleratedDepreciationMember2019-01-012019-09-300000310158us-gaap:OtherRestructuringMember2019-01-012019-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2019-12-310000310158mrk:AcceleratedDepreciationMember2019-12-310000310158us-gaap:OtherRestructuringMember2019-12-310000310158us-gaap:OneTimeTerminationBenefitsMember2020-09-300000310158mrk:AcceleratedDepreciationMember2020-09-300000310158us-gaap:OtherRestructuringMember2020-09-300000310158srt:MaximumMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-01-012020-09-300000310158us-gaap:NondesignatedMembersrt:MaximumMember2020-01-012020-09-300000310158us-gaap:ForeignExchangeContractMember2020-07-012020-09-300000310158us-gaap:ForeignExchangeContractMember2019-07-012019-09-300000310158us-gaap:ForeignExchangeContractMember2020-01-012020-09-300000310158us-gaap:ForeignExchangeContractMember2019-01-012019-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2020-07-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2019-07-012019-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2020-01-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:ForeignExchangeContractMember2019-01-012019-09-300000310158mrk:EurodominatedNotesMember2020-07-012020-09-300000310158mrk:EurodominatedNotesMember2019-07-012019-09-300000310158mrk:EurodominatedNotesMember2020-01-012020-09-300000310158mrk:EurodominatedNotesMember2019-01-012019-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-07-012020-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2019-07-012019-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2020-01-012020-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2019-01-012019-09-30mrk:interest_rate_swap0000310158us-gaap:InterestRateSwapMember2020-02-290000310158mrk:A1.85NotesDue2020Member2020-02-290000310158us-gaap:InterestRateSwapMember2020-09-300000310158mrk:A3.875NotesDue2021Memberus-gaap:InterestRateSwapMember2020-09-300000310158us-gaap:InterestRateSwapMembermrk:A2.40NotesDue2022Member2020-09-300000310158us-gaap:InterestRateSwapMembermrk:A2.35NotesDue2022Member2020-09-300000310158mrk:LongTermDebtCurrentMaturitiesMember2020-09-300000310158mrk:LongTermDebtCurrentMaturitiesMember2019-12-310000310158mrk:LongTermDebtExcludingCurrentMaturitiesMember2020-09-300000310158mrk:LongTermDebtExcludingCurrentMaturitiesMember2019-12-310000310158us-gaap:InterestRateContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000310158us-gaap:InterestRateContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000310158us-gaap:OtherAssetsMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000310158us-gaap:OtherAssetsMemberus-gaap:InterestRateContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000310158us-gaap:InterestRateContractMemberus-gaap:AccruedLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000310158us-gaap:InterestRateContractMemberus-gaap:AccruedLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000310158us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000310158us-gaap:OtherAssetsMemberus-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:AccruedLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:AccruedLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMember2020-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMember2019-12-310000310158us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMember2020-09-300000310158us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentAssetsMember2019-12-310000310158us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccruedLiabilitiesMember2020-09-300000310158us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMemberus-gaap:AccruedLiabilitiesMember2019-12-310000310158us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberus-gaap:AccruedLiabilitiesMember2020-09-300000310158us-gaap:ForwardContractsMemberus-gaap:NondesignatedMemberus-gaap:AccruedLiabilitiesMember2019-12-310000310158us-gaap:NondesignatedMember2020-09-300000310158us-gaap:NondesignatedMember2019-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2020-07-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2019-07-012019-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2020-01-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2019-01-012019-09-300000310158us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeContractMember2020-07-012020-09-300000310158us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeContractMember2019-07-012019-09-300000310158us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeContractMember2020-01-012020-09-300000310158us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMemberus-gaap:ForeignExchangeContractMember2019-01-012019-09-300000310158us-gaap:InterestRateSwapMember2020-07-012020-09-300000310158us-gaap:InterestRateSwapMember2019-07-012019-09-300000310158us-gaap:InterestRateSwapMember2020-01-012020-09-300000310158us-gaap:InterestRateSwapMember2019-01-012019-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2020-07-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2019-07-012019-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2020-01-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2019-01-012019-09-300000310158us-gaap:ForeignExchangeFutureMemberus-gaap:SalesMember2020-07-012020-09-300000310158us-gaap:ForeignExchangeFutureMemberus-gaap:SalesMember2019-07-012019-09-300000310158us-gaap:ForeignExchangeFutureMemberus-gaap:SalesMember2020-01-012020-09-300000310158us-gaap:ForeignExchangeFutureMemberus-gaap:SalesMember2019-01-012019-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:TreasuryLockMember2020-07-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:TreasuryLockMember2019-07-012019-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:TreasuryLockMember2020-01-012020-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:TreasuryLockMember2019-01-012019-09-300000310158us-gaap:ForwardContractsMemberus-gaap:ResearchAndDevelopmentExpenseMember2019-07-012019-09-300000310158us-gaap:ForwardContractsMemberus-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-09-300000310158us-gaap:ForwardContractsMemberus-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2020-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2019-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMember2020-09-300000310158us-gaap:ForeignGovernmentDebtSecuritiesMember2019-12-310000310158us-gaap:CommercialPaperMember2020-09-300000310158us-gaap:CommercialPaperMember2019-12-310000310158us-gaap:CorporateDebtSecuritiesMember2020-09-300000310158us-gaap:CorporateDebtSecuritiesMember2019-12-310000310158us-gaap:AssetBackedSecuritiesMember2020-09-300000310158us-gaap:AssetBackedSecuritiesMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignGovernmentDebtSecuritiesMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:ForeignGovernmentDebtSecuritiesMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Memberus-gaap:ForeignGovernmentDebtSecuritiesMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel2Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:CommercialPaperMember2019-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-300000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-09-300000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-09-300000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-300000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:AssetBackedSecuritiesMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:AssetBackedSecuritiesMember2019-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateSwapMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Memberus-gaap:InterestRateSwapMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMemberus-gaap:FairValueInputsLevel3Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2019-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2020-09-300000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2020-09-300000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2020-09-300000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2020-09-300000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2019-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2019-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2019-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForwardContractsMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel2Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForwardContractsMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel2Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMemberus-gaap:FairValueInputsLevel3Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForwardContractsMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel2Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel3Member2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2020-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMember2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel2Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMemberus-gaap:FairValueInputsLevel3Member2019-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2019-12-310000310158us-gaap:AssetBackedSecuritiesMember2020-01-012020-09-300000310158us-gaap:FairValueInputsLevel2Member2020-09-300000310158us-gaap:FairValueInputsLevel2Member2019-12-310000310158mrk:SanofiPasteurMember2020-09-300000310158mrk:SanofiPasteurMember2019-12-310000310158mrk:SanofiPasteurMemberus-gaap:MeasurementInputDiscountRateMember2020-09-3000003101582019-10-012019-12-310000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2020-09-300000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2019-12-310000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2020-09-300000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2019-12-310000310158mrk:SivextroMember2019-07-012019-09-3000003101582020-06-300000310158mrk:A0.75notesdue2026Member2020-06-300000310158mrk:A1.45notesdue2030Member2020-06-300000310158mrk:A2.35notesdue2040Member2020-06-300000310158mrk:A2.45notesdue2050Member2020-06-30mrk:Case0000310158mrk:FosamaxMember2020-09-300000310158mrk:FosamaxMembermrk:FederalMembermrk:FemurFractureLitigationMember2014-03-012014-03-310000310158mrk:FosamaxMembermrk:FederalMembermrk:FemurFractureLitigationMember2020-09-300000310158mrk:FosamaxMembermrk:FemurFractureLitigationMembermrk:NewJerseyStateCourtMember2020-09-300000310158mrk:FosamaxMembermrk:CaliforniaStateCourtMembermrk:FemurFractureLitigationMember2020-09-300000310158mrk:FosamaxMembermrk:OtherStateCourtMembermrk:FemurFractureLitigationMember2020-09-30mrk:Claim0000310158mrk:JanuviaMember2020-09-300000310158mrk:JanuviaMembermrk:OtherStateCourtMember2020-09-300000310158mrk:JanuviaMembermrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember2020-09-300000310158mrk:ZetiaantitrustlitigationMember2020-09-300000310158us-gaap:PatentsMember2020-01-012020-09-300000310158us-gaap:PatentsMember2020-09-300000310158mrk:LegalDefenseCostsMember2020-09-300000310158mrk:LegalDefenseCostsMember2019-12-310000310158us-gaap:CommonStockMember2019-06-300000310158us-gaap:AdditionalPaidInCapitalMember2019-06-300000310158us-gaap:RetainedEarningsMember2019-06-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-06-300000310158us-gaap:TreasuryStockMember2019-06-300000310158us-gaap:NoncontrollingInterestMember2019-06-3000003101582019-06-300000310158us-gaap:RetainedEarningsMember2019-07-012019-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-07-012019-09-300000310158us-gaap:TreasuryStockMember2019-07-012019-09-300000310158us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300000310158us-gaap:NoncontrollingInterestMember2019-07-012019-09-300000310158us-gaap:CommonStockMember2019-09-300000310158us-gaap:AdditionalPaidInCapitalMember2019-09-300000310158us-gaap:RetainedEarningsMember2019-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-09-300000310158us-gaap:TreasuryStockMember2019-09-300000310158us-gaap:NoncontrollingInterestMember2019-09-300000310158us-gaap:CommonStockMember2020-06-300000310158us-gaap:AdditionalPaidInCapitalMember2020-06-300000310158us-gaap:RetainedEarningsMember2020-06-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-06-300000310158us-gaap:TreasuryStockMember2020-06-300000310158us-gaap:NoncontrollingInterestMember2020-06-300000310158us-gaap:RetainedEarningsMember2020-07-012020-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-07-012020-09-300000310158us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300000310158us-gaap:TreasuryStockMember2020-07-012020-09-300000310158us-gaap:NoncontrollingInterestMember2020-07-012020-09-300000310158us-gaap:CommonStockMember2020-09-300000310158us-gaap:AdditionalPaidInCapitalMember2020-09-300000310158us-gaap:RetainedEarningsMember2020-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-09-300000310158us-gaap:TreasuryStockMember2020-09-300000310158us-gaap:NoncontrollingInterestMember2020-09-300000310158us-gaap:CommonStockMember2018-12-310000310158us-gaap:AdditionalPaidInCapitalMember2018-12-310000310158us-gaap:RetainedEarningsMember2018-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2018-12-310000310158us-gaap:TreasuryStockMember2018-12-310000310158us-gaap:NoncontrollingInterestMember2018-12-310000310158us-gaap:RetainedEarningsMember2019-01-012019-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-01-012019-09-300000310158us-gaap:AdditionalPaidInCapitalMember2019-01-012019-09-300000310158us-gaap:TreasuryStockMember2019-01-012019-09-300000310158us-gaap:NoncontrollingInterestMember2019-01-012019-09-300000310158us-gaap:CommonStockMember2019-12-310000310158us-gaap:AdditionalPaidInCapitalMember2019-12-310000310158us-gaap:RetainedEarningsMember2019-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2019-12-310000310158us-gaap:TreasuryStockMember2019-12-310000310158us-gaap:NoncontrollingInterestMember2019-12-310000310158us-gaap:RetainedEarningsMember2020-01-012020-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-01-012020-09-300000310158us-gaap:TreasuryStockMember2020-01-012020-09-300000310158us-gaap:AdditionalPaidInCapitalMember2020-01-012020-09-300000310158us-gaap:NoncontrollingInterestMember2020-01-012020-09-300000310158us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300000310158us-gaap:RestrictedStockUnitsRSUMember2019-01-012019-09-300000310158us-gaap:PerformanceSharesMember2020-01-012020-09-300000310158us-gaap:PerformanceSharesMember2019-01-012019-09-300000310158us-gaap:PensionPlansDefinedBenefitMember2020-01-012020-09-300000310158country:USus-gaap:PensionPlansDefinedBenefitMember2020-07-012020-09-300000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-07-012020-09-300000310158country:USus-gaap:PensionPlansDefinedBenefitMember2019-07-012019-09-300000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-07-012019-09-300000310158country:USus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-09-300000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2020-01-012020-09-300000310158country:USus-gaap:PensionPlansDefinedBenefitMember2019-01-012019-09-300000310158us-gaap:ForeignPlanMemberus-gaap:PensionPlansDefinedBenefitMember2019-01-012019-09-300000310158country:US2020-09-300000310158us-gaap:ForeignPlanMember2020-09-300000310158country:US2020-01-012020-09-300000310158us-gaap:ForeignPlanMember2020-01-012020-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-01-012020-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-07-012020-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-07-012019-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2019-01-012019-09-300000310158mrk:HealthcareServicesSegmentMember2019-01-012019-09-300000310158us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2019-01-012019-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-06-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-06-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-06-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2019-06-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-07-012019-09-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-07-012019-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-07-012019-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2019-07-012019-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-09-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2019-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-06-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-06-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-06-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-06-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-07-012020-09-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-07-012020-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-07-012020-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-07-012020-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-09-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2018-12-310000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2018-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2018-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2018-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-01-012019-09-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-01-012019-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-01-012019-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2019-01-012019-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2019-12-310000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2019-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2019-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2019-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-01-012020-09-300000310158us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-01-012020-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-01-012020-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-01-012020-09-30mrk:segment0000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:KeytrudaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:KeytrudaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:KeytrudaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:KeytrudaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:KeytrudaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:LenvimaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LenvimaMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LenvimaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:LenvimaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LenvimaMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LenvimaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:LenvimaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LenvimaMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LenvimaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:LenvimaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LenvimaMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:LenvimaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:EmendMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:EmendMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:EmendMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:EmendMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:EmendMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:EmendMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:EmendMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:EmendMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:EmendMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:EmendMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:EmendMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:EmendMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:GardasilGardasil9Membermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:Pneumovax23Member2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:Pneumovax23Membermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:Pneumovax23Member2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:Pneumovax23Member2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:Pneumovax23Membermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:Pneumovax23Member2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:Pneumovax23Member2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:Pneumovax23Membermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:Pneumovax23Member2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:Pneumovax23Member2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:Pneumovax23Membermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:Pneumovax23Member2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:RotateqMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:RotateqMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:RotateqMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:RotateqMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:RotateqMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:RotateqMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:RotateqMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:RotateqMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:RotateqMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:RotateqMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:RotateqMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:RotateqMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:VaqtaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaqtaMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaqtaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:VaqtaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaqtaMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaqtaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:VaqtaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaqtaMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaqtaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:VaqtaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaqtaMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:VaqtaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:BridionMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:BridionMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:BridionMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:BridionMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:BridionMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:NoxafilMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:PrevymisMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrevymisMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrevymisMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:PrevymisMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrevymisMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrevymisMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:PrevymisMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrevymisMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrevymisMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:PrevymisMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrevymisMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:PrevymisMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PrimaxinMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:InvanzMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InvanzMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InvanzMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:InvanzMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InvanzMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InvanzMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:InvanzMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InvanzMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InvanzMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:InvanzMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InvanzMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InvanzMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:CancidasMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CancidasMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CancidasMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:CancidasMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CancidasMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CancidasMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:CancidasMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CancidasMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CancidasMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:CancidasMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CancidasMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CancidasMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:CubicinMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:CubicinMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CubicinMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:CubicinMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:CubicinMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CubicinMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:CubicinMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:CubicinMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CubicinMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:CubicinMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:CubicinMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:CubicinMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZerbaxaMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:SimponiMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:SimponiMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:SimponiMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:SimponiMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:SimponiMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:SimponiMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:SimponiMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:SimponiMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:SimponiMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:RemicadeMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:BelsomraMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:BelsomraMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:BelsomraMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:BelsomraMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:BelsomraMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:IsentressIsentressHDMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZepatierMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZepatierMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZepatierMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZepatierMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZepatierMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZepatierMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZepatierMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZepatierMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZepatierMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZepatierMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZepatierMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ZepatierMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ZetiaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZetiaMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZetiaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ZetiaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZetiaMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZetiaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ZetiaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZetiaMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZetiaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ZetiaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZetiaMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ZetiaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:VytorinMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:VytorinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:VytorinMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:VytorinMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:VytorinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:VytorinMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:VytorinMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:VytorinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:VytorinMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:VytorinMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:VytorinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:VytorinMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AtozetMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AtozetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AtozetMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AtozetMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AtozetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AtozetMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AtozetMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AtozetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AtozetMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AtozetMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AtozetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AtozetMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AllianceRevenueAdempasMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AllianceRevenueAdempasMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AllianceRevenueAdempasMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AllianceRevenueAdempasMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AllianceRevenueAdempasMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AllianceRevenueAdempasMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AllianceRevenueAdempasMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AllianceRevenueAdempasMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AllianceRevenueAdempasMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AllianceRevenueAdempasMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AllianceRevenueAdempasMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AllianceRevenueAdempasMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AdempasMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AdempasMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AdempasMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AdempasMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AdempasMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AdempasMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AdempasMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AdempasMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AdempasMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:AdempasMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AdempasMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:AdempasMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanuviaMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:JanumetMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ImplanonNexplanonMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ImplanonNexplanonMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ImplanonNexplanonMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ImplanonNexplanonMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ImplanonNexplanonMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ImplanonNexplanonMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ImplanonNexplanonMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ImplanonNexplanonMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ImplanonNexplanonMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:ImplanonNexplanonMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ImplanonNexplanonMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:ImplanonNexplanonMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:NuvaringMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:NuvaringMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:NuvaringMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:NuvaringMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:NuvaringMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:NuvaringMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:NuvaringMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:NuvaringMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:NuvaringMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:NuvaringMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:NuvaringMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:NuvaringMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:SingulairMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:SingulairMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:SingulairMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:SingulairMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:SingulairMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:SingulairMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:SingulairMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:SingulairMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:SingulairMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:SingulairMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:SingulairMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:SingulairMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:NasonexMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:NasonexMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:NasonexMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:NasonexMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:NasonexMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:NasonexMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:NasonexMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:NasonexMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:NasonexMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:NasonexMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:NasonexMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:NasonexMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ArcoxiaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ArcoxiaMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ArcoxiaMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ArcoxiaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ArcoxiaMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ArcoxiaMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ArcoxiaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ArcoxiaMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ArcoxiaMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:ArcoxiaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ArcoxiaMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:ArcoxiaMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:CozaarHyzaarMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:CozaarHyzaarMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:CozaarHyzaarMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:CozaarHyzaarMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:CozaarHyzaarMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:CozaarHyzaarMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:CozaarHyzaarMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:CozaarHyzaarMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:CozaarHyzaarMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:CozaarHyzaarMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:CozaarHyzaarMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:CozaarHyzaarMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:FollistimAqMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:FollistimAqMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:FollistimAqMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:FollistimAqMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:FollistimAqMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:FollistimAqMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:FollistimAqMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:FollistimAqMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:FollistimAqMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:FollistimAqMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:FollistimAqMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:FollistimAqMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:OtherPharmaceuticalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:PharmaceuticalsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:LivestockMembermrk:AnimalHealthsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:LivestockMembermrk:AnimalHealthsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:LivestockMembermrk:AnimalHealthsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:LivestockMembermrk:AnimalHealthsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:LivestockMembermrk:AnimalHealthsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMembermrk:CompanionAnimalsMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMembermrk:CompanionAnimalsMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMembermrk:CompanionAnimalsMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMembermrk:CompanionAnimalsMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:USmrk:AnimalHealthsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:AnimalHealthsegmentMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembercountry:US2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembercountry:US2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembercountry:US2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembercountry:US2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMemberus-gaap:AllOtherSegmentsMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:US2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMember2020-07-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:US2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMember2019-07-012019-09-300000310158us-gaap:OperatingSegmentsMembercountry:US2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMember2020-01-012020-09-300000310158us-gaap:OperatingSegmentsMembercountry:US2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:OperatingSegmentsMember2019-01-012019-09-300000310158country:USus-gaap:CorporateNonSegmentMember2020-07-012020-09-300000310158us-gaap:CorporateNonSegmentMembermrk:InternationalMember2020-07-012020-09-300000310158us-gaap:CorporateNonSegmentMember2020-07-012020-09-300000310158country:USus-gaap:CorporateNonSegmentMember2019-07-012019-09-300000310158us-gaap:CorporateNonSegmentMembermrk:InternationalMember2019-07-012019-09-300000310158us-gaap:CorporateNonSegmentMember2019-07-012019-09-300000310158country:USus-gaap:CorporateNonSegmentMember2020-01-012020-09-300000310158us-gaap:CorporateNonSegmentMembermrk:InternationalMember2020-01-012020-09-300000310158us-gaap:CorporateNonSegmentMember2020-01-012020-09-300000310158country:USus-gaap:CorporateNonSegmentMember2019-01-012019-09-300000310158us-gaap:CorporateNonSegmentMembermrk:InternationalMember2019-01-012019-09-300000310158us-gaap:CorporateNonSegmentMember2019-01-012019-09-300000310158country:US2020-07-012020-09-300000310158mrk:InternationalMember2020-07-012020-09-300000310158country:US2019-07-012019-09-300000310158mrk:InternationalMember2019-07-012019-09-300000310158country:US2020-01-012020-09-300000310158mrk:InternationalMember2020-01-012020-09-300000310158country:US2019-01-012019-09-300000310158mrk:InternationalMember2019-01-012019-09-300000310158us-gaap:EMEAMember2020-07-012020-09-300000310158us-gaap:EMEAMember2019-07-012019-09-300000310158us-gaap:EMEAMember2020-01-012020-09-300000310158us-gaap:EMEAMember2019-01-012019-09-300000310158country:CN2020-07-012020-09-300000310158country:CN2019-07-012019-09-300000310158country:CN2020-01-012020-09-300000310158country:CN2019-01-012019-09-300000310158country:JP2020-07-012020-09-300000310158country:JP2019-07-012019-09-300000310158country:JP2020-01-012020-09-300000310158country:JP2019-01-012019-09-300000310158srt:AsiaPacificMember2020-07-012020-09-300000310158srt:AsiaPacificMember2019-07-012019-09-300000310158srt:AsiaPacificMember2020-01-012020-09-300000310158srt:AsiaPacificMember2019-01-012019-09-300000310158srt:LatinAmericaMember2020-07-012020-09-300000310158srt:LatinAmericaMember2019-07-012019-09-300000310158srt:LatinAmericaMember2020-01-012020-09-300000310158srt:LatinAmericaMember2019-01-012019-09-300000310158mrk:OtherCountriesMember2020-07-012020-09-300000310158mrk:OtherCountriesMember2019-07-012019-09-300000310158mrk:OtherCountriesMember2020-01-012020-09-300000310158mrk:OtherCountriesMember2019-01-012019-09-300000310158us-gaap:MaterialReconcilingItemsMember2020-07-012020-09-300000310158us-gaap:MaterialReconcilingItemsMember2019-07-012019-09-300000310158us-gaap:MaterialReconcilingItemsMember2020-01-012020-09-300000310158us-gaap:MaterialReconcilingItemsMember2019-01-012019-09-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
 
(Mark One)
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2020
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File No. 1-6571
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey22-1918501
(State or other jurisdiction of incorporation)
(I.R.S Employer Identification No.)
2000 Galloping Hill Road
KenilworthNew Jersey07033
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  ☒   No  ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  ☒   No  ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐ Smaller reporting company☐
Emerging growth company☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No ☒
Securities Registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock ($0.50 par value)MRKNew York Stock Exchange
1.125% Notes due 2021MRK/21New York Stock Exchange
0.500% Notes due 2024MRK 24New York Stock Exchange
1.875% Notes due 2026MRK/26New York Stock Exchange
2.500% Notes due 2034MRK/34New York Stock Exchange
1.375% Notes due 2036MRK 36ANew York Stock Exchange
The number of shares of common stock outstanding as of the close of business on October 31, 2020: 2,530,034,437




Table of Contents




Part I - Financial Information
Item 1. Financial Statements
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(Unaudited, $ in millions except per share amounts)
 
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2020201920202019
Sales$12,551 $12,397 $35,479 $34,972 
Costs, Expenses and Other
Cost of sales3,481 3,990 9,952 10,443 
Selling, general and administrative2,450 2,589 7,383 7,726 
Research and development3,390 3,204 7,721 7,324 
Restructuring costs114 232 269 444 
Other (income) expense, net(312)35 (630)362 
 9,123 10,050 24,695 26,299 
Income Before Taxes3,428 2,347 10,784 8,673 
Taxes on Income483 440 1,611 1,259 
Net Income2,945 1,907 9,173 7,414 
Less: Net Income (Loss) Attributable to Noncontrolling Interests4 6 12 (73)
Net Income Attributable to Merck & Co., Inc.$2,941 $1,901 $9,161 $7,487 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders
$1.16 $0.74 $3.62 $2.91 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders
$1.16 $0.74 $3.61 $2.89 
 
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited, $ in millions)
 
 Three Months Ended
September 30,		Nine Months Ended
September 30,
 2020201920202019
Net Income Attributable to Merck & Co., Inc.$2,941 $1,901 $9,161 $7,487 
Other Comprehensive Income (Loss) Net of Taxes:
Net unrealized (loss) gain on derivatives, net of reclassifications(137)91 (153)(9)
Net unrealized (loss) gain on investments, net of reclassifications— (17)(18)109 
Benefit plan net gain and prior service credit, net of amortization
62 15 161 41 
Cumulative translation adjustment
85 (117)(180)14 
 10 (28)(190)155 
Comprehensive Income Attributable to Merck & Co., Inc.$2,951 $1,873 $8,971 $7,642 
 The accompanying notes are an integral part of these condensed consolidated financial statements.
- 3 -


MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited, $ in millions except per share amounts)
 
September 30, 2020December 31, 2019
Assets
Current Assets
Cash and cash equivalents
$7,356 $9,676 
Short-term investments
— 774 
Accounts receivable (net of allowance for doubtful accounts of $89 in 2020
 and $86 in 2019)
8,422 6,778 
Inventories (excludes inventories of $2,081 in 2020 and $1,480 in 2019
classified in Other assets - see Note 6)
6,128 5,978 
Other current assets
4,671 4,277 
Total current assets26,577 27,483 
Investments1,372 1,469 
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,572
in 2020 and $17,686 in 2019
16,919 15,053 
Goodwill20,248 19,425 
Other Intangibles, Net16,677 14,196 
Other Assets8,007 6,771 
 $89,800 $84,397 
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt
$2,420 $3,610 
Trade accounts payable
3,744 3,738 
Accrued and other current liabilities
11,690 12,549 
Income taxes payable
984 736 
Dividends payable
1,567 1,587 
Total current liabilities20,405 22,220 
Long-Term Debt26,321 22,736 
Deferred Income Taxes1,777 1,470 
Other Noncurrent Liabilities12,027 11,970 
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2020 and 2019
1,788 1,788 
Other paid-in capital
39,489 39,660 
Retained earnings
51,107 46,602 
Accumulated other comprehensive loss
(6,383)(6,193)
86,001 81,857 
Less treasury stock, at cost:
1,047,343,390 shares in 2020 and 1,038,087,496 shares in 2019
56,815 55,950 
Total Merck & Co., Inc. stockholders’ equity29,186 25,907 
Noncontrolling Interests84 94 
Total equity29,270 26,001 
 $89,800 $84,397 
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 4 -


MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited, $ in millions)
 
 Nine Months Ended
September 30,
 20202019
Cash Flows from Operating Activities
Net income$9,173 $7,414 
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
2,721 2,716 
Intangible asset impairment charges
35 864 
Charge for acquisition of Peloton Therapeutics, Inc.— 982 
Deferred income taxes
47 (386)
Share-based compensation
354 306 
Other
(445)219 
Net changes in assets and liabilities
(5,638)(3,469)
Net Cash Provided by Operating Activities6,247 8,646 
Cash Flows from Investing Activities
Capital expenditures(3,170)(2,336)
Purchases of securities and other investments(78)(2,380)
Proceeds from sales of securities and other investments1,894 7,459 
Acquisition of ArQule, Inc., net of cash acquired(2,545)— 
Acquisition of Antelliq Corporation, net of cash acquired— (3,620)
Acquisition of Peloton Therapeutics, Inc., net of cash acquired— (1,040)
Other acquisitions, net of cash acquired(907)(269)
Other141 320 
Net Cash Used in Investing Activities(4,665)(1,866)
Cash Flows from Financing Activities
Net change in short-term borrowings(311)(3,892)
Payments on debt(1,954)— 
Proceeds from issuance of debt4,419 4,958 
Purchases of treasury stock(1,281)(3,730)
Dividends paid to stockholders(4,673)(4,290)
Proceeds from exercise of stock options68 344 
Other(472)(240)
Net Cash Used in Financing Activities(4,204)(6,850)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash89 (26)
Net Decrease in Cash, Cash Equivalents and Restricted Cash(2,533)(96)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted
cash of $258 at January 1, 2020 included in Other Assets)
9,934 7,967 
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash
of $45 at September 30, 2020 included in Other Assets)
$7,401 $7,871 
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 5 -
Notes to Condensed Consolidated Financial Statements (unaudited)

1.Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2020.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Planned Spin-Off of Women’s Health, Biosimilars and Established Brands into New Company
In February 2020, Merck announced its intention to spin-off products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including Zetia (ezetimibe) and Vytorin (ezetimibe and simvastatin), as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the second quarter of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women’s health, biosimilars and established brands businesses will be reflected as discontinued operations in the Company’s consolidated financial statements.
Recently Adopted Accounting Standards
In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company’s collaborative arrangements.
Recently Issued Accounting Standards Not Yet Adopted
In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by: removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
- 6 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
2.    Acquisitions, Research Collaborations and License Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
In November 2020, Merck and VelosBio, Inc. (VelosBio) announced that the companies had entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion, subject to certain customary adjustments. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate targeting ROR1 that is currently being evaluated in a Phase 1 and a Phase 2 clinical trial for the treatment of patients with hematologic malignancies and solid tumors, respectively. The closing of the transaction, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected by the end of 2020.
In September 2020, Merck and Seagen Inc. (Seagen, formerly known as Seattle Genetics, Inc.) announced an oncology collaboration to globally develop and commercialize Seagen’s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Keytruda (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600 million and a $1.0 billion equity investment in 5 million shares of Seagen common stock at a price of $200 per share. Merck recorded $622 million in Research and development expenses in the third quarter and first nine months of 2020 related to this transaction reflecting the upfront payment as well as a $22 million mark-to-market loss on the purchase commitment (forward contract) relating to the equity shares (calculated based on the closing price of Seagen common stock on September 30, 2020). The closing of the equity investment occurred in October 2020 and resulted in the recognition of a $6 million reduction to Research and development expenses based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6 billion, including $850 million in development milestones and $1.75 billion in sales milestones.
Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210 million, which were recorded as Research and development expenses in the third quarter and first nine months of 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65 million and will receive tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck’s territories.
Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for €256 million ($302 million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289 million and other net assets of $13 million. There are no future contingent payments associated with the acquisition.
In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410 million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401 million related to currently marketed products and inventory of $9 million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.
Also, in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482, formerly known as EIDD-2801), an orally
- 7 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
available antiviral candidate currently in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones, as well as a share of the net profits of molnupiravir and related molecules, if approved. Merck and Ridgeback are committed to ensure that any medicines developed for SARS-CoV-2 (the causative agent of COVID-19) will be accessible and affordable globally.
In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer for $366 million. Merck may make additional contingent payments of up to $740 million, including up to $80 million for development milestones, up to $260 million for regulatory approval milestones, and up to $400 million for commercial milestones. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur and licensed exclusively to Themis for select viral indications. The acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform and is expected to accelerate the development of the COVID-19 vaccine candidate (V591), which is currently in Phase 1 clinical development. The transaction was accounted for as an acquisition of a business. The Company determined the fair value of the contingent consideration was $97 million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payment. Merck recognized intangible assets for in-process research and development (IPR&D) of $136 million, cash of $59 million, deferred tax assets of $71 million and other net liabilities of $32 million. The excess of the consideration transferred over the fair value of net assets acquired of $229 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&D were determined using an income approach. Actual cash flows are likely to be different than those assumed. In connection with the transaction, Merck has entered into a memorandum of understanding that reflects the parties’ commitments to address the COVID-19 pandemic by developing, manufacturing and distributing the vaccine on a global basis and with pricing that makes the vaccine both available around the world and accessible to those who need it.
In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a new collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis for Merck’s approved Ebola Zaire virus vaccine, Ervebo (Ebola Zaire Vaccine, Live), which was the first rVSV vaccine approved for use in humans. Under the terms of the agreement, Merck made an upfront payment of $6.5 million and may make additional contingent payments of up to $100 million for sales-based milestones, as well as royalty payments. Merck has also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the United States Department of Health and Human Services, to provide initial funding support for this effort. Under the agreement, IAVI and Merck will work together to advance the development and global clinical evaluation of a SARS-CoV-2 vaccine candidate designed and engineered by IAVI scientists. The vaccine candidate is currently in Phase 1 clinical development. Merck will lead regulatory filings globally. Both organizations will work together to develop the vaccine and make it accessible and affordable globally, if approved.
In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138 million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95 million of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in Selling, general and administrative expenses in the first nine months of 2020. ArQule’s lead investigational candidate, MK-1026 (formerly known as ARQ 531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.

- 8 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:
($ in millions)January 16, 2020
Cash and cash equivalents$145 
IPR&D MK-1026 (formerly ARQ 531) (1)
2,280 
Licensing arrangement for ARQ 08780 
Deferred income tax liabilities(389)
Other assets and liabilities, net34 
Total identifiable net assets
2,150 
Goodwill (2)
540 
Consideration transferred$2,690 
(1)    The estimated fair value of the identifiable intangible asset related to IPR&D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.
In July 2019, Merck acquired Peloton Therapeutics, Inc. (Peloton), a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. Peloton’s lead candidate, MK-6482 (formerly known as PT2977), is a novel investigational oral HIF-2α inhibitor in late-stage development for renal cell carcinoma. Merck made an upfront payment of $1.2 billion; additionally, former Peloton shareholders will be eligible to receive $50 million upon U.S. regulatory approval, $50 million upon first commercial sale in the United States, and up to $1.05 billion of sales-based milestones. The transaction was accounted for as an acquisition of an asset. Merck recorded cash of $157 million, deferred tax liabilities of $64 million, and other net liabilities of $6 million at the acquisition date and Research and development expenses of $982 million in the third quarter and first nine months of 2019 related to the transaction.
On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $2.3 billion to acquire all outstanding shares of Antelliq and spent $1.3 billion to repay Antelliq’s debt. The transaction was accounted for as an acquisition of a business.
The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:
($ in millions)April 1, 2019
Cash and cash equivalents$31 
Accounts receivable73 
Inventories93 
Property, plant and equipment60 
Identifiable intangible assets (useful lives ranging from 18-24 years) (1)
2,689 
Deferred income tax liabilities(589)
Other assets and liabilities, net(82)
Total identifiable net assets
2,275 
Goodwill (2)
1,376 
Consideration transferred$3,651 
(1)    The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.

The Company’s results for the first nine months of 2019 include five months of activity for Antelliq. The Company incurred $47 million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in Selling, general and administrative expenses in the first nine months of 2019.
Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease, for $301 million in cash. The transaction was accounted for as an acquisition of a business. Merck recognized intangible assets of $156 million, cash of $83 million and other net assets of $42 million. The excess of the consideration transferred over the fair value of net assets acquired of $20
- 9 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&D were determined using an income approach. Actual cash flows are likely to be different than those assumed.
3.    Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca
In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda and Imfinzi. The companies will also jointly develop and commercialize AstraZeneca’s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple indications. In April 2020, Koselugo was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of Keytruda in combination with Lynparza or Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca of $1.6 billion in 2017 and made payments of $750 million over a multi-year period for certain license options. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
In the second quarter of 2020, Merck determined it was probable that sales of Lynparza in the future would trigger $400 million of sales-based milestone payments from Merck to AstraZeneca. Accordingly, Merck recorded a $400 million liability and a corresponding increase to the intangible asset related to Lynparza. Prior to 2020, Merck accrued sales-based milestone payments aggregating $1.0 billion related to Lynparza, of which $200 million and $250 million was paid to AstraZeneca in 2019 and 2018, respectively, and $250 million was paid in the first nine months of 2020. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
In the second quarter of 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of $135 million from Merck to AstraZeneca. In 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of $60 million and $140 million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.4 billion remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.3 billion at September 30, 2020 and is included in Other Intangibles, Net on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.

- 10 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Alliance revenue - Lynparza$196 $123 $519 $313 
Alliance revenue - Koselugo3 — 3 — 
Total alliance revenue$199 $123 $522 $313 
Cost of sales (1)
41 28 205 120 
Selling, general and administrative40 36 112 96 
Research and development20 44 93 122 
($ in millions)September 30, 2020December 31, 2019
Receivables from AstraZeneca included in Other current assets
$197 $128 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
309 577 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
400 — 
(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone payments.
Eisai
In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with Keytruda for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development, including for studies evaluating Lenvima as monotherapy, are shared equally by the two companies and reflected in Research and development expenses.
Under the agreement, Merck made an upfront payment to Eisai of $750 million and agreed to make payments of up to $650 million for certain option rights through 2021 (of which $325 million was paid in March 2019, $200 million was paid in March 2020 and $125 million is expected to be paid in March 2021). In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
In the second quarter of 2020, Merck determined it was probable that sales of Lenvima in the future would trigger sales-based milestone payments aggregating $370 million from Merck to Eisai. Accordingly, Merck recorded a $370 million liability and a corresponding increase to the intangible asset related to Lenvima. Prior to 2020, Merck accrued sales-based milestone payments aggregating $950 million. Of these amounts, $50 million was paid to Eisai in 2019 and an additional $500 million was paid in the first nine months of 2020. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
In 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of $250 million in the aggregate from Merck to Eisai. Potential future regulatory milestone payments of $135 million remain under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $1.1 billion at September 30, 2020 and is included in Other Intangibles, Net on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.

- 11 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Alliance revenue - Lenvima$142 $109 $421 $280 
Cost of sales (1)
46 23 215 97 
Selling, general and administrative18 21 48 59 
Research and development48 37 168 146 
($ in millions)September 30, 2020December 31, 2019
Receivables from Eisai included in Other current assets
$170 $150 
Payables to Eisai included in Accrued and other current liabilities (2)
325 700 
Payables to Eisai included in Other Noncurrent Liabilities (3)
570 525 
(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone and future option payments.
(3) Includes accrued milestone payments.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer’s vericiguat, which is in development for the potential treatment of worsening heart failure. Vericiguat is currently under review by regulatory authorities in the United States, the EU and Japan. Under the agreement, Bayer leads commercialization of Adempas in the Americas, while Merck leads commercialization in the rest of the world. For vericiguat, if approved, Bayer will lead commercialization in the rest of world and Merck will lead in the Americas. Both companies share in development costs and profits on sales and have the right to co-promote in territories where they are not the lead. Merck records sales of Adempas in its marketing territories, as well as alliance revenue, which is Merck’s share of profits from the sale of Adempas in Bayer’s marketing territories. In addition, the agreement provides for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.
Prior to 2020, Merck accrued $725 million of sales-based milestone payments for this collaboration, of which $350 million was paid to Bayer in 2018. There is an additional $400 million potential future sales-based milestone payment that has not yet been accrued as it is not deemed by the Company to be probable at this time.
The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was $838 million at September 30, 2020 and is included in Other Intangibles, Net on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Alliance revenue - Adempas$83 $50 $216 $144 
Net sales of Adempas recorded by Merck55 57 167 158 
Total sales$138 $107 $383 $302 
Cost of sales (1)
29 28 85 86 
Selling, general and administrative19 12 42 31 
Research and development12 31 53 94 
($ in millions)September 30, 2020December 31, 2019
Receivables from Bayer included in Other current assets
$70 $49 
Payables to Bayer included in Other Noncurrent Liabilities (2)
375 375 
(1) Includes amortization of intangible assets.
(2) Represents accrued milestone payment.
- 12 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
4.    Restructuring
In early 2019, Merck approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $2.5 billion. The Company estimates that approximately 60% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 40% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately $800 million in 2020 related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.
The Company recorded total pretax costs of $186 million and $296 million in the third quarter of 2020 and 2019, respectively, and $504 million and $642 million for the first nine months of 2020 and 2019, respectively, related to restructuring program activities. Since inception of the Restructuring Program through September 30, 2020, Merck has recorded total pretax accumulated costs of approximately $1.4 billion. For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to restructuring program activities by type of cost:
 Three Months Ended September 30, 2020Nine Months Ended September 30, 2020
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotalSeparation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $33 $5 $38 $— $89 $42 $131 
Selling, general and administrative— 15 — 15 — 37 — 37 
Research and development— 18 1 19 — 66 1 67 
Restructuring costs61 — 53 114 143 — 126 269 
$61 $66 $59 $186 $143 $192 $169 $504 
 Three Months Ended September 30, 2019Nine Months Ended September 30, 2019
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotalSeparation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $41 $21 $62 $— $139 $22 $161 
Selling, general and administrative— 1 — 1 — 33 — 33 
Research and development— (1)2 1 — 1 3 4 
Restructuring costs205 — 27 232 358 — 86 444 
$205 $41 $50 $296 $358 $173 $111 $642 
Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 2020 and 2019 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 12) and share-based compensation.

- 13 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September 30, 2020:
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Restructuring reserves January 1, 2020$690 $— $69 $759 
Expense143 192 169 504 
(Payments) receipts, net(395)— (237)(632)
Non-cash activity— (192)39 (153)
Restructuring reserves September 30, 2020 (1)
$438 $— $40 $478 
(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.
5.    Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other comprehensive income (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated other comprehensive income (AOCI) and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured
- 14 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI and remain in AOCI until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended September 30,Nine Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)20202019202020192020201920202019
Net Investment Hedging Relationships
Foreign exchange contracts
$10 $1 $15 $8 $(4)$(8)$(15)$(23)
Euro-denominated notes162 (150)182 (152)— — — — 
(1) No amounts were reclassified from AOCI into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk.
In February 2020, five interest rate swaps with notional amounts of $250 million each matured. These swaps effectively converted the Company’s $1.25 billion, 1.85% fixed-rate notes due 2020 to variable rate debt. At September 30, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.
September 30, 2020
($ in millions)Par Value of DebtNumber of Interest Rate Swaps HeldTotal Swap Notional Amount
3.875% notes due 2021
$1,150 5 $1,150 
2.40% notes due 2022
1,000 4 1,000 
2.35% notes due 2022
1,250 5 1,250 
The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.

- 15 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
Carrying Amount of Hedged LiabilitiesCumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount
($ in millions)September 30, 2020December 31, 2019September 30, 2020December 31, 2019
Balance Sheet Line Item in which Hedged Item is Included
Loans payable and current portion of long-term debt$1,155 $1,249 $5 $(1)
Long-Term Debt2,309 3,409 62 14 
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  September 30, 2020December 31, 2019
  Fair Value of DerivativeU.S. Dollar
Notional		Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)Balance Sheet CaptionAssetLiabilityAssetLiability
Derivatives Designated as Hedging Instruments
Interest rate swap contractsOther current assets$6 $— $1,150 $— $— $— 
Interest rate swap contractsOther Assets63 — 2,250 15 — 3,400 
Interest rate swap contractsAccrued and other current liabilities— — — — 1 1,250 
Foreign exchange contractsOther current assets30 — 4,120 152 — 6,117 
Foreign exchange contractsOther Assets59 — 1,881 55 — 2,160 
Foreign exchange contractsAccrued and other current liabilities— 104 3,096 — 22 1,748 
Foreign exchange contractsOther Noncurrent Liabilities— 1 157 — 1 53 
  $158 $105 $12,654 $222 $24 $14,728 
Derivatives Not Designated as Hedging Instruments
       
Foreign exchange contractsOther current assets$81 $— $5,455 $66 $— $7,245 
Foreign exchange contractsAccrued and other current liabilities— 171 8,042 — 73 8,693 
Forward contract related to Seagen common stockAccrued and other current liabilities— 22 1,000 — — — 
  $81 $193 $14,497 $66 $73 $15,938 
  $239 $298 $27,151 $288 $97 $30,666 
As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 September 30, 2020December 31, 2019
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$239 $298 $288 $97 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet
(140)(140)(84)(84)
Cash collateral received— — (34)— 
Net amounts$99 $158 $170 $13 
- 16 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:
Sales
Other (income) expense, net (1)
Other comprehensive income (loss)Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
Three Months Ended September 30,Three Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,
($ in millions)202020192020201920202019202020192020201920202019
Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded$12,551 $12,397 $(312)$35 $10 $(28)$35,479 $34,972 $(630)$362 $(190)$155 
(Gain) loss on fair value hedging relationships
Interest rate swap contracts
Hedged items
— — (14)13 — — — — 54 101 — — 
Derivatives designated as hedging instruments
— — — (6)— — — — (76)(74)— — 
Impact of cash flow hedging relationships
Foreign exchange contracts
Amount of (loss) gain recognized in OCI on derivatives
— — — — (195)186 — — — — (126)183 
Increase (decrease) in Sales as a result of AOCI reclassifications
(23)70 — — 23 (70)65 189 — — (65)(189)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — (1)(1)— — — — (3)(3)— — 
Amount of loss recognized in OCI on derivatives
— — — — (1)(1)— — — — (3)(6)
(1) Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended
September 30,		Nine Months Ended September 30,
($ in millions)Income Statement Caption2020201920202019
Derivatives Not Designated as Hedging Instruments
Foreign exchange contracts (1)
Other (income) expense, net$(7)$(8)$(138)$112 
Foreign exchange contracts (2)
Sales7 (11)4 (7)
Interest rate contracts (3)
Other (income) expense, net— — 9 — 
Forward contract related to Seagen common stockResearch and development expenses22 — 22 — 
(1) These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2) These derivative contracts serve as economic hedges of forecasted transactions.
(3) These derivatives serve as economic hedges against rising treasury rates.
At September 30, 2020, the Company estimates $155 million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCI to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.

- 17 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 September 30, 2020December 31, 2019
 Amortized
Cost		Gross UnrealizedFair
Value		Amortized
Cost		Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
U.S. government and agency securities$74 $— $— $74 $266 $3 $— $269 
Foreign government bonds2 — — 2 — — — — 
Commercial paper— — — — 668 — — 668 
Corporate notes and bonds— — — — 608 13 — 621 
Asset-backed securities— — — — 226 1 — 227 
Total debt securities$76 $— $— $76 $1,768 $17 $— $1,785 
Publicly traded equity securities (1)
1,477 838 
Total debt and publicly traded equity securities
$1,553 $2,623 
(1) Unrealized net (gains) losses recognized in Other (income) expense, net on equity securities still held at September 30, 2020 were $(43) million and $(512) million in the third quarter and first nine months of 2020, respectively. Unrealized net losses (gains) recognized in Other (income) expense, net on equity securities still held at September 30, 2019 were $25 million and $(41) million in the third quarter and first nine months of 2019, respectively.
At September 30, 2020 and September 30, 2019, the Company also had $508 million and $393 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company recognizes unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and recognizes unrealized losses based on unfavorable observable price changes. During the first nine months of 2020, the Company recognized unrealized gains of $21 million and unrealized losses of $3 million in Other (income) expense, net related to these equity investments held at September 30, 2020. During the first nine months of 2019, the Company recognized unrealized gains of $4 million and unrealized losses of $12 million in Other (income) expense, net related to these investments held at September 30, 2019. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values still held at September 30, 2020 were $128 million and $24 million, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
- 18 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)September 30, 2020December 31, 2019
Assets
Investments
Foreign government bonds$— $2 $— $2 $— $— $— $— 
Commercial paper— — — — — 668 — 668 
Corporate notes and bonds— — — — — 621 — 621 
Asset-backed securities (1)
— — — — — 227 — 227 
U.S. government and agency securities
— — — — — 209 — 209 
Publicly traded equity securities
1,370 — — 1,370 518 — — 518 
 1,370 2 — 1,372 518 1,725 — 2,243 
Other assets (2)
U.S. government and agency securities
74 — — 74 60 — — 60 
Publicly traded equity securities107 — — 107 320 — — 320 
181 — — 181 380 — — 380 
Derivative assets (3)
Forward exchange contracts— 116 — 116 — 169 — 169 
Interest rate swaps— 69 — 69 — 15 — 15 
Purchased currency options— 54 — 54 — 104 — 104 
 — 239 — 239 — 288 — 288 
Total assets$1,551 $241 $— $1,792 $898 $2,013 $— $2,911 
Liabilities
Other liabilities
Contingent consideration$— $— $829 $829 $— $— $767 $767 
Derivative liabilities (3)
Forward exchange contracts— 275 — 275 — 95 — 95 
Forward contract related to Seagen common stock— 22 — 22 — — — — 
Written currency options— 1 — 1 — 1 — 1 
Interest rate swaps— — — — — 1 — 1 
— 298 — 298 — 97 — 97 
Total liabilities$— $298 $829 $1,127 $— $97 $767 $864 
(1)Primarily all of the asset-backed securities were highly rated (Standard & Poor’s rating of AAA and Moody’s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily 5 years or less.
(2)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(3)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of September 30, 2020 and December 31, 2019, Cash and cash equivalents included $6.6 billion and $8.9 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
- 19 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Contingent Consideration
Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:
Nine Months Ended September 30,
($ in millions)20202019
Fair value January 1$767 $788 
Additions97 — 
Changes in estimated fair value (1)
71 52 
Payments(106)(85)
Fair value September 30 (2)(3)
$829 $755 
(1) Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2) Balance at September 30, 2020 includes $140 million recorded as a current liability for amounts expected to be paid within the next 12 months.
(3) At September 30, 2020 and December 31, 2019, $637 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.
The additions to contingent consideration in 2020 relate to the acquisition of Themis (see Note 2). The payments of contingent consideration in both periods relate to liabilities recorded in connection with the termination of the Sanofi-Pasteur MSD joint venture in 2016.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at September 30, 2020, was $32.6 billion compared with a carrying value of $28.7 billion and at December 31, 2019, was $28.8 billion compared with a carrying value of $26.3 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the United States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.1 billion and $2.7 billion of accounts receivable in the third quarter of 2020 and the fourth quarter of 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $34 million at December 31, 2019. The obligation to return such collateral is recorded in Accrued and other current liabilities. No cash collateral was advanced by the Company to counterparties as of September 30, 2020 or December 31, 2019.
- 20 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
6.    Inventories
Inventories consisted of:
($ in millions)September 30, 2020December 31, 2019
Finished goods$2,038 $1,772 
Raw materials and work in process6,073 5,650 
Supplies197 207 
Total (approximates current cost)8,308 7,629 
Decrease to LIFO cost(99)(171)
 $8,209 $7,458 
Recognized as:
Inventories$6,128 $5,978 
Other assets2,081 1,480 
Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At September 30, 2020 and December 31, 2019, these amounts included $1.8 billion and $1.3 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $288 million and $168 million at September 30, 2020 and December 31, 2019, respectively, of inventories produced in preparation for product launches.
7.    Other Intangibles
During the third quarter and first nine months of 2019, the Company recorded $612 million and $693 million, respectively, of intangible asset impairment charges related to marketed products within Cost of sales. During the third quarter of 2019, the Company recorded an impairment charge of $612 million related to Sivextro (tedizolid phosphate), a product for the treatment of acute bacterial skin and skin structure infections caused by susceptible isolates of certain Gram-positive microorganisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of Sivextro in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for Sivextro, which indicated that the Sivextro intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to Sivextro that, when compared with its related carrying value, resulted in the impairment charge noted above.
8.    Long-Term Debt
In June 2020, the Company issued $4.5 billion principal amount of senior unsecured notes consisting of $1.0 billion of 0.75% notes due 2026, $1.25 billion of 1.45% notes due 2030, $1.0 billion of 2.35% notes due 2040 and $1.25 billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities.
9.    Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
- 21 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Fosamax
As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving Fosamax (Fosamax Litigation). As of September 30, 2020, approximately 3,590 cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.
All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, Glynn v. Merck, the jury returned a verdict in Merck’s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck’s motion for judgment as a matter of law in the Glynn case and held that the plaintiff’s failure to warn claim was preempted by federal law.
In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court’s preemption decision in the Glynn case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court.
Accordingly, as of September 30, 2020, approximately 970 cases were actively pending in the Femur Fracture MDL.
As of September 30, 2020, approximately 2,340 cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.
As of September 30, 2020, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California.
Additionally, there are four Femur Fracture cases pending in other state courts.
Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits.
Januvia/Janumet
As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving Januvia and/or Janumet. As of September 30, 2020, Merck is aware of approximately 1,465 product users alleging that Januvia and/or Janumet caused the development of pancreatic cancer and other injuries.
Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court).
In November 2015, the MDL and California State Court–in separate opinions–granted summary judgment to defendants on grounds of federal preemption.
Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceedings agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment
- 22 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
and Daubert motions. Under the stipulated case management schedule, the hearings for Daubert and summary judgment motions took place on October 20, 2020.
As of September 30, 2020, six product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck’s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in Merck Sharp & Dohme Corp. v. Albrecht (relating to the Fosamax matter discussed above). Merck filed the opinion in Albrecht with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with Albrecht, that preemption presents a legal question to be resolved by the court.
In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against these lawsuits.
Vioxx
As previously disclosed, Merck is a defendant in a lawsuit brought by the Attorney General of Utah alleging that Merck misrepresented the safety of Vioxx. The lawsuit is pending in Utah state court. Utah seeks damages and penalties under the Utah False Claims Act. A bench trial in this matter has been rescheduled for April 6, 2021.
Governmental Proceedings
As previously disclosed, the Company’s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants’ motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants’ motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants’ motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. The Merck Defendants moved to dismiss the new allegations in both complaints. In October 2019, the magistrate judge issued a report and recommendation recommending that the district judge grant the motions in their entirety. In December 2019, the district court adopted this report and recommendation in part. The district court granted the Merck Defendants’ motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. On June 18, 2020, the magistrate judge issued a report and recommendation recommending that the district judge grant in part the direct purchasers’ motion for class certification and certify a class of 35 direct purchasers. On August 21, 2020, the district court adopted the report and recommendation in full, and on November 2, 2020, the U.S. Court of Appeals for the Fourth Circuit granted defendants’ motion for permission to appeal the district court’s order. Also, on August 14, 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. The Merck Defendants objected to this report and recommendation and are awaiting a decision from the district court.
- 23 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
On August 10, 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court will likely hold a hearing on the competing motions. Trial in this matter has been adjourned.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.
Bridion — Between January and March 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March and April 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier.
Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants. The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion. All New Jersey actions against all defendants have been consolidated.
Januvia, Janumet, Janumet XR — In February 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of a patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of Januvia, Janumet, and Janumet XR following expiration of key patent protection in 2022, but prior to the expiration of the later-granted patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026 (2026 salt/polymorph patent), and a later granted patent owned by the Company covering the Janumet formulation which expires in 2028. Par Pharmaceutical dismissed its case in the U.S. District Court for the District of New Jersey against the Company and will litigate the action in the U.S. District Court for the District of Delaware. The Company filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single three-day trial on invalidity issues in October 2021. The Court will schedule separate one-day trials on infringement issues if necessary. In the Company’s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues. In February 2020, the Company amended its complaint against one defendant, Teva Pharmaceuticals USA, Inc., to add patent infringement claims related to a patent that expires in 2025 and covers certain processes for manufacturing sitagliptin. In July 2020, the Company amended its complaints against two defendants, Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc., to add patent infringement claims related to a patent that also expires in 2026 and covers certain amorphous forms of sitagliptin.
The Company has settled with five generic companies such that these generic companies can bring their products to the market in November 2026 or earlier under certain circumstances.
In October 2019, Mylan filed a petition for Inter Partes Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2026 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial is scheduled for February 2021 and a final decision is expected in May 2021. After institution, three additional IPR petitions were filed by Teva Pharmaceuticals USA, Inc., Dr. Reddy’s Laboratories, Inc., and Sun Pharmaceutical Industries Ltd., as well as related entities, which requested joinder with Mylan’s IPR proceedings. If the challenges are successful, the unchallenged claims of the 2026 salt/polymorph patent will remain valid, subject to the court proceedings described above.
- 24 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
In Germany, two generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for Janumet. If the generic companies are successful, Janumet could lose market exclusivity in Germany as early as July 2022. Challenges to the Janumet SPC have also occurred in Portugal and Finland, and could occur in other European countries.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September 30, 2020 and December 31, 2019 of approximately $255 million and $240 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.

10.    Equity
Three Months Ended September 30,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at July 1, 20193,577 $1,788 $39,484 $45,295 $(5,362)1,010 $(53,570)$102 $27,737 
Net income attributable to Merck & Co., Inc.— — — 1,901 — — — — 1,901 
Other comprehensive loss, net of taxes— — — — (28)— — — (28)
Cash dividends declared on common stock ($0.55 per share)
— — — (1,392)— — — — (1,392)
Treasury stock shares purchased— — — — — 17 (1,405)— (1,405)
Share-based compensation plans and other— — 77 — — (1)50 — 127 
Net income attributable to noncontrolling interests
— — — — — — — 6 6 
Distributions attributable to noncontrolling interests
— — — — — — — (21)(21)
Balance at September 30, 20193,577 $1,788 $39,561 $45,804 $(5,390)1,026 $(54,925)$87 $26,925 
Balance at July 1, 20203,577 $1,788 $39,373 $49,724 $(6,393)1,048 $(56,850)$102 $27,744 
Net income attributable to Merck & Co., Inc.— — — 2,941 — — — — 2,941 
Other comprehensive income, net of taxes— — — — 10 — — — 10 
Cash dividends declared on common stock ($0.61 per share)
— — — (1,558)— — — — (1,558)
Share-based compensation plans and other— — 116 — — (1)35 — 151 
Net income attributable to noncontrolling interests
— — — — — — — 4 4 
Distributions attributable to noncontrolling interests
— — — — — — — (22)(22)
Balance at September 30, 20203,577 $1,788 $39,489 $51,107 $(6,383)1,047 $(56,815)$84 $29,270 
- 25 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Nine Months Ended September 30,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 20193,577 $1,788 $38,808 $42,579 $(5,545)985 $(50,929)$181 $26,882 
Net income attributable to Merck & Co., Inc.— — — 7,487 — — — — 7,487 
Other comprehensive income, net of taxes— — — — 155 — — — 155 
Cash dividends declared on common stock ($1.65 per share)
— — — (4,262)— — — — (4,262)
Treasury stock shares purchased— — 1,000 — — 54 (4,730)— (3,730)
Share-based compensation plans and other— — (247)— — (13)734 — 487 
Net loss attributable to noncontrolling interests
— — — — — — — (73)(73)
Distributions attributable to noncontrolling
 interests
— — — — — — — (21)(21)
Balance at September 30, 20193,577 1,788 39,561 45,804 (5,390)1,026 (54,925)87 26,925 
Balance at January 1, 20203,577 $1,788 $39,660 $46,602 $(6,193)1,038 $(55,950)$94 $26,001 
Net income attributable to Merck & Co., Inc.— — — 9,161 — — — — 9,161 
Other comprehensive loss, net of taxes— — — — (190)— — — (190)
Cash dividends declared on common stock ($1.83 per share)
— — — (4,656)— — — — (4,656)
Treasury stock shares purchased— — — — — 16 (1,281)— (1,281)
Share-based compensation plans and other— — (171)— — (7)416 — 245 
Net income attributable to noncontrolling interests
— — — — — — — 12 12 
Distributions attributable to noncontrolling
 interests
— — — — — — — (22)(22)
Balance at September 30, 20203,577 $1,788 $39,489 $51,107 $(6,383)1,047 $(56,815)$84 $29,270 

11.    Share-Based Compensation Plans
The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant.
The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Pretax share-based compensation expense$126 $101 $354 $306 
Income tax benefit(17)(14)(48)(42)
Total share-based compensation expense, net of taxes$109 $87 $306 $264 
During the first nine months of 2020, the Company granted 7 million RSUs with a weighted-average grant date fair value of $77.83 per RSU and during the first nine months of 2019 granted 5 million RSUs with a weighted-average grant date fair value of $80.03 per RSU. During the first nine months of 2020, the Company granted 773 thousand PSUs with a weighted-average grant date fair value of $75.22 per PSU and during the first nine months of 2019 granted 609 thousand PSUs with a weighted-average grant date fair value of $90.50 per PSU.
During the first nine months of 2020, the Company granted 4 million stock options with a weighted-average exercise price of $77.67 per option and during the first nine months of 2019 granted 3 million stock options with a weighted-average exercise price of $80.05 per option. The weighted-average fair value of options granted during the first nine months of 2020 and 2019 was $9.93 and $10.63 per option, respectively, and was determined using the following assumptions:
- 26 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
  Nine Months Ended
September 30,
20202019
Expected dividend yield3.1 %3.2 %
Risk-free interest rate0.4 %2.4 %
Expected volatility22.1 %18.7 %
Expected life (years)5.85.9
At September 30, 2020, there was $800 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted-average period of 2.1 years. For segment reporting, share-based compensation costs are unallocated expenses.
12.    Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components: 
  Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
($ in millions)U.S.InternationalU.S.InternationalU.S.InternationalU.S.International
Service cost$96 $77 $76 $58 $270 $225 $221 $178 
Interest cost107 35 115 44 323 103 343 133 
Expected return on plan assets(193)(104)(202)(106)(581)(310)(613)(320)
Amortization of unrecognized prior service credit
(12)(3)(12)(3)(37)(9)(37)(9)
Net loss amortization75 32 43 16 228 94 113 47 
Termination benefits1 1 3 — 5 2 7 1 
Curtailments1 — 5 — 4 (1)6 — 
Settlements2 — — — 11 2 — — 
 $77 $38 $28 $9 $223 $106 $40 $30 
The Company anticipates that in 2020 it will contribute approximately $200 million and $375 million to its U.S. and international pension plans, respectively, of which $184 million and $123 million, respectively, was contributed in the first nine months of the year.
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Service cost$13 $12 $39 $36 
Interest cost14 17 43 52 
Expected return on plan assets(19)(18)(56)(54)
Amortization of unrecognized prior service credit(18)(20)(54)(59)
Net gain amortization(5)(3)(13)(7)
Termination benefits— 1 — 1 
Curtailments— (3)(1)(4)
 $(15)$(14)$(42)$(35)
In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring actions, curtailments were recorded on pension and other postretirement benefit plans and settlements were recorded on certain U.S. and international pension plans as reflected in the tables above.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 13), with the exception of certain amounts for termination benefits, curtailments and
- 27 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
settlements, which are recorded in Restructuring costs if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions as noted above.
13.    Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Interest income$(9)$(61)$(48)$(225)
Interest expense203 231 624 674 
Exchange losses10 38 89 166 
Income from investments in equity securities, net (1)
(360)(16)(964)(50)
Net periodic defined benefit plan (credit) cost other than service cost(88)(128)(259)(409)
Other, net(68)(29)(72)206 
 $(312)$35 $(630)$362 
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag.
The decline in interest income in the third quarter and first nine months of 2020 reflects lower investments and lower interest rates. The lower exchange losses in the first nine months of 2020 reflect losses on forward exchange contracts in 2019 related to the acquisition of Antelliq. The increase in income from investments in equity securities, net, in both the third quarter and first nine months of 2020 was driven primarily by the recognition of unrealized gains on certain investments, most of which relate to Moderna, Inc.
Other, net (as reflected in the table above) in the first nine months of 2019 includes $162 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment.
Interest paid for the nine months ended September 30, 2020 and 2019 was $605 million and $629 million, respectively.
14.    Taxes on Income
The effective income tax rates of 14.1% and 18.7% for the third quarter of 2020 and 2019, respectively, and 14.9% and 14.5% for the first nine months of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. The effective income tax rates in the third quarter and first nine months of 2019 also reflect the unfavorable impact of a charge for the acquisition of Peloton for which no tax benefit was recognized and the favorable impact of product mix on the estimated 2019 full-year tax rate. In addition, the effective income tax rate for the first nine months of 2019 reflects the favorable impact of a $360 million net tax benefit related to the settlement of certain federal income tax matters.
In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million. The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $360 million net tax benefit in the first nine months of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.

- 28 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
15.    Earnings Per Share
The calculations of earnings per share are as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ and shares in millions except per share amounts)2020201920202019
Net income attributable to Merck & Co., Inc.
$2,941 $1,901 $9,161 $7,487 
Average common shares outstanding2,529 2,558 2,530 2,572 
Common shares issuable (1)
9 14 11 15 
Average common shares outstanding assuming dilution 2,538 2,572 2,541 2,587 
Basic earnings per common share attributable to Merck & Co., Inc. common shareholders
$1.16 $0.74 $3.62 $2.91 
Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders
$1.16 $0.74 $3.61 $2.89 
(1)Issuable primarily under share-based compensation plans.
For the third quarter of 2020 and 2019, 5 million and 3 million, respectively, and for the first nine months of 2020 and 2019, 5 million and 2 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.
16.    Other Comprehensive Income (Loss)
Changes in AOCI by component are as follows:
Three Months Ended September 30,
($ in millions)DerivativesInvestmentsEmployee
Benefit
Plans		Cumulative
Translation
Adjustment		Accumulated Other
Comprehensive
Income (Loss)
Balance July 1, 2019, net of taxes$66 $48 $(3,530)$(1,946)$(5,362)
Other comprehensive income (loss) before reclassification adjustments, pretax186 8 (4)(84)106 
Tax(39)— — (33)(72)
Other comprehensive income (loss) before reclassification adjustments, net of taxes147 8 (4)(117)34 
Reclassification adjustments, pretax(71)
(1)
(25)
(2)
21 
(3)
— (75)
Tax15 — (2)— 13 
Reclassification adjustments, net of taxes(56)

(25)

19 

— (62)
Other comprehensive income (loss), net of taxes91 (17)15 (117)(28)
Balance September 30, 2019, net of taxes$157 $31 $(3,515)$(2,063)$(5,390)
Balance July 1, 2020, net of taxes$15 $— $(4,162)$(2,246)$(6,393)
Other comprehensive income (loss) before reclassification adjustments, pretax(195)— 2 50 (143)
Tax41 — 1 35 77 
Other comprehensive income (loss) before reclassification adjustments, net of taxes(154)— 3 85 (66)
Reclassification adjustments, pretax22 
(1)
— 72 
(3)
— 94 
Tax(5)— (13)— (18)
Reclassification adjustments, net of taxes17 

— 

59 

— 76 
Other comprehensive income (loss), net of taxes(137)— 62 85 10 
Balance September 30, 2020, net of taxes$(122)$— $(4,100)$(2,161)$(6,383)
- 29 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Nine Months Ended September 30,
($ in millions)DerivativesInvestmentsEmployee
Benefit
Plans		Cumulative
Translation
Adjustment		Accumulated Other
Comprehensive
Income (Loss)
Balance January 1, 2019, net of taxes$166 $(78)$(3,556)$(2,077)$(5,545)
Other comprehensive income (loss) before reclassification adjustments, pretax183 139 (5)47 364 
Tax(38)— 6 (33)(65)
Other comprehensive income (loss) before reclassification adjustments, net of taxes145 139 1 14 299 
Reclassification adjustments, pretax(195)
(1)
(30)
(2)
49 
(3)
— (176)
Tax41 — (9)— 32 
Reclassification adjustments, net of taxes(154)(30)40 — (144)
Other comprehensive income (loss), net of taxes(9)109 41 14 155 
Balance September 30, 2019, net of taxes$157 $31 $(3,515)$(2,063)$(5,390)
Balance January 1, 2020, net of taxes$31 $18 $(4,261)$(1,981)$(6,193)
Other comprehensive income (loss) before reclassification adjustments, pretax(126)3 (19)(220)(362)
Tax27 — 12 40 79 
Other comprehensive income (loss) before reclassification adjustments, net of taxes(99)3 (7)(180)(283)
Reclassification adjustments, pretax(68)
(1)
(21)
(2)
210 
(3)
— 121 
Tax14 — (42)— (28)
Reclassification adjustments, net of taxes(54)(21)168 — 93 
Other comprehensive income (loss), net of taxes(153)(18)161 (180)(190)
Balance September 30, 2020, net of taxes$(122)$— $(4,100)$(2,161)$(6,383)
(1) Relates to foreign currency cash flow hedges that were reclassified from AOCI to Sales.
(2) Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from AOCI to Other (income) expense, net.
(3) Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 12).
17.    Segment Reporting
The Company’s operations are principally managed on a products basis and include three operating segments, which are the Pharmaceutical, Animal Health and Healthcare Services segments. The Pharmaceutical and Animal Health segments are the only reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers.
The Healthcare Services segment provided services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company has been in the process of divesting the businesses in the Healthcare Services segment. The remaining businesses were divested during the first quarter of 2020.

- 30 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Sales of the Company’s products were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$2,157 $1,559 $3,715 $1,743 $1,327 $3,070 $6,106 $4,281 $10,387 $4,525 $3,448 $7,973 
Alliance revenue - Lynparza (1)
107 89 196 71 53 123 297 223 519 186 126 313 
Alliance revenue - Lenvima (1)
82 60 142 65 44 109 270 152 421 169 112 280 
Emend8 31 39 42 56 98 18 96 115 173 163 336 
Vaccines
Gardasil/Gardasil 9
579 608 1,187 761 558 1,320 1,209 1,732 2,941 1,579 1,464 3,044 
ProQuad/M-M-R II/Varivax
437 139 576 482 141 623 1,033 356 1,390 1,325 469 1,794 
Pneumovax 23
276 99 375 179 58 237 478 270 748 428 164 592 
RotaTeq114 96 210 102 78 180 355 246 601 360 203 564 
Vaqta32 19 51 36 26 62 79 60 139 103 65 167 
Hospital Acute Care
Bridion162 157 320 133 151 284 412 431 843 381 437 817 
Noxafil13 66 79 77 100 177 27 220 247 268 291 560 
Prevymis32 46 77 22 23 45 87 113 200 60 55 115 
Primaxin1 73 74 2 75 77 2 187 189 2 204 207 
Invanz1 50 51 (1)58 57 7 152 159 30 176 206 
Cancidas1 49 50 — 62 62 2 147 148 5 187 191 
Cubicin11 28 39 14 38 52 36 80 116 78 129 207 
Zerbaxa20 23 43 20 15 35 57 54 112 45 43 88 
Immunology
Simponi— 209 209 — 203 203 — 615 615 — 625 625 
Remicade— 82 82 — 101 101 — 242 242 — 322 322 
Neuroscience
Belsomra18 63 81 23 57 80 67 177 244 68 155 223 
Virology
Isentress/Isentress HD
92 113 205 102 149 250 243 403 646 304 449 752 
Zepatier6 22 28 24 59 83 38 83 122 96 208 304 
Cardiovascular
Zetia(1)103 103 5 142 147 (4)389 384 11 432 443 
Vytorin3 44 47 5 52 57 9 130 139 11 219 231 
Atozet— 111 111 — 97 97 — 348 348 — 283 283 
Alliance revenue - Adempas (2)
78 5 83 48 2 50 200 16 216 137 7 144 
Adempas— 55 55 — 57 57 — 167 167 — 158 158 
Diabetes
Januvia342 479 821 367 440 807 1,110 1,339 2,449 1,223 1,317 2,539 
Janumet105 400 506 129 375 503 361 1,138 1,499 462 1,105 1,567 
Women’s Health
Implanon/Nexplanon137 52 189 136 62 199 374 142 515 421 160 581 
NuvaRing24 34 58 202 39 241 85 98 184 593 107 700 
Diversified Brands
Singulair4 78 82 11 140 152 14 324 338 24 479 503 
Cozaar/Hyzaar5 86 91 6 110 116 17 275 292 16 313 329 
Arcoxia— 68 68 — 72 72 — 204 204 — 221 221 
Nasonex— 41 41 4 55 58 9 152 161 2 224 226 
Follistim AQ20 31 50 27 35 62 60 76 136 80 102 182 
Other pharmaceutical (3)
352 834 1,186 343 804 1,149 1,144 2,334 3,478 1,037 2,394 3,431 
Total Pharmaceutical segment sales
5,218 6,102 11,320 5,180 5,914 11,095 14,202 17,452 31,654 14,202 17,016 31,218 
Animal Health:
Livestock164 594 758 144 582 726 448 1,697 2,145 406 1,601 2,007 
Companion Animals234 228 462 193 203 396 676 714 1,390 560 704 1,264 
Total Animal Health segment sales
398 822 1,220 337 785 1,122 1,124 2,411 3,535 966 2,305 3,271 
Other segment sales (4)
— — — 46 — 46 23 — 23 133 1 133 
Total segment sales5,616 6,924 12,540 5,563 6,699 12,263 15,349 19,863 35,212 15,301 19,322 34,622 
Other (5)
9 2 11 10 125 134 47 221 267 19 330 350 
 $5,625 $6,926 $12,551 $5,573 $6,824 $12,397 $15,396 $20,084 $35,479 $15,320 $19,652 $34,972 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2)    Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(3)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(4)    Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020.
(5)    Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.
- 31 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.4 billion and $3.0 billion for the three months ended September 30, 2020 and 2019, respectively, and $9.6 billion and $8.6 billion for the nine months ended September 30, 2020 and 2019, respectively.
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
United States$5,625 $5,573 $15,396 $15,320 
Europe, Middle East and Africa3,454 3,189 10,059 9,452 
China1,016 914 2,715 2,423 
Japan828 919 2,506 2,639 
Asia Pacific (other than China and Japan)735 756 2,129 2,217 
Latin America604 671 1,670 1,889 
Other289 375 1,004 1,032 
 $12,551 $12,397 $35,479 $34,972 
A reconciliation of segment profits to Income before taxes is as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Segment profits:
Pharmaceutical segment$7,974 $7,747 $22,010 $21,437 
Animal Health segment451 423 1,336 1,243 
Other segment(1)(2)1 (2)
Total segment profits8,424 8,168 23,347 22,678 
Other profits(12)101 188 226 
Unallocated:
Interest income9 61 48 225 
Interest expense(203)(231)(624)(674)
Depreciation and amortization(395)(382)(1,173)(1,169)
Research and development(3,272)(3,110)(7,364)(7,045)
Amortization of purchase accounting adjustments(285)(329)(879)(1,105)
Restructuring costs(114)(232)(269)(444)
Other unallocated, net(724)(1,699)(2,490)(4,019)
 $3,428 $2,347 $10,784 $8,673 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.
- 32 -
Notes to Condensed Consolidated Financial Statements (unaudited) (continued)
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Planned Spin-Off of Women’s Health, Biosimilars and Established Brands into New Company
In February 2020, Merck announced its intention to spin-off products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including Zetia (ezetimibe) and Vytorin (ezetimibe and simvastatin), as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the second quarter of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women’s health, biosimilars and established brands businesses will be reflected as discontinued operations in the Company’s consolidated financial statements.
Recent Developments
Management
In October 2020, Merck announced that Dr. Roger M. Perlmutter will be retiring as Executive Vice President and President, Merck Research Laboratories (MRL). Dr. Perlmutter will be succeeded by Dr. Dean Y. Li, effective January 1, 2021. Dr. Perlmutter will remain as Non-Executive Chairman, MRL through June 30, 2021 to facilitate a seamless transition.
Business Developments
Below is a summary of significant 2020 business development activity. See Note 2 to the condensed consolidated financial statements for additional information.
In November 2020, Merck and VelosBio, Inc. (VelosBio) announced that the companies had entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion, subject to certain customary adjustments. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate targeting ROR1 that is currently being evaluated in a Phase 1 and a Phase 2 clinical trial for the treatment of patients with hematologic malignancies and solid tumors, respectively. The closing of the transaction, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected by the end of 2020.
In September 2020, Merck and Seagen Inc. (Seagen, formerly known as Seattle Genetics, Inc.) announced an oncology collaboration to globally develop and commercialize Seagen’s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600 million and a $1.0 billion equity investment in 5 million shares of Seagen common stock at a price of $200 per share. The closing of the equity investment occurred in October 2020. Seagen is also eligible to receive future contingent milestone payments dependent upon the achievement of certain developmental and sales-based milestones.
Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Under the terms of the agreement, Merck made upfront payments aggregating $210 million. Seagen is also eligible to receive future contingent regulatory approval milestones and will receive tiered royalties on sales of Tukysa in Merck’s territories.
Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for €256 million ($302 million).
In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410 million. Sentinel products provide protection against common parasites in dogs.
Also, in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482, formerly known as EIDD-2801), an orally available antiviral candidate currently in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones, as well as a share of the net profits of molnupiravir and related molecules, if approved.
- 33 -

In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer for $366 million. Merck may make additional contingent payments dependent upon the achievement of certain developmental, regulatory approval and commercial milestones. The acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform and is expected to accelerate the development of the COVID-19 vaccine candidate (V591), which is currently in Phase 1 clinical development.
In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a new collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19, which is currently in Phase 1 clinical development. Under the terms of the agreement, Merck made an upfront payment of $6.5 million and may make additional contingent payments dependent upon the achievement of certain sales-based milestones, as well as royalties.
In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases, for total consideration of $2.7 billion. ArQule’s lead investigational candidate, MK-1026 (formerly known as ARQ 531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.
Coronavirus Disease 2019 (COVID-19) Update
Overall, in response to the COVID-19 pandemic, Merck is focused on protecting the safety of its employees, ensuring that its supply of medicines and vaccines reaches its patients, contributing its scientific expertise to the development of vaccine and antiviral approaches, and supporting health care providers and Merck’s communities. Although COVID-19-related disruptions to patients’ ability to access health care providers negatively affected results for the third quarter and first nine months of 2020, Merck remains confident in the fundamental underlying demand for its products and its prospects for long-term growth.
In the third quarter of 2020, the negative impact of the COVID-19 pandemic to Merck’s Pharmaceutical sales was estimated to be approximately $475 million. The negative impact to Animal Health sales was immaterial. The negative impact to sales in the first nine months of 2020 was approximately $2.0 billion for the Pharmaceutical segment and $50 million for the Animal Health segment. Merck assumes that the majority of the negative impact from the COVID-19 pandemic occurred in the second quarter of 2020. However, the Company expects some residual negative impacts in the fourth quarter, largely in Europe and certain emerging markets. In addition, the phasing of the recovery of Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant) demand is slower than originally anticipated, in particular in the United States due to lower back-to-school demand. Accordingly, for the full-year 2020, including the impact for the first nine months, Merck expects an unfavorable impact to sales of approximately $2.35 billion (excluding the impact of foreign exchange) due to the COVID-19 pandemic, comprised of approximately $2.3 billion for Pharmaceutical revenue and approximately $50 million for Animal Health revenue.
Roughly two-thirds of Merck’s Pharmaceutical revenue is comprised of physician-administered products, which, despite strong underlying demand, were affected by social distancing measures, fewer well visits and delays in elective surgeries due to the COVID-19 pandemic. These impacts, as well as the prioritization of COVID-19 patients at health care providers, have resulted in reduced administration of many of the Company’s human health products, in particular for its vaccines, including Gardasil 9, as well as for Keytruda (pembrolizumab) and Implanon/Nexplanon (etonogestrel implant). Access to healthcare providers remains reduced, although improved from the second quarter. Merck anticipates reduced demand for its physician-administered products while pandemic-related access measures remain in place. In addition, declines in elective surgeries negatively affected the demand for Bridion (sugammadex) Injection in the year-to-date period. Sales of Pneumovax 23 (pneumococcal vaccine polyvalent) increased due to heightened awareness of pneumococcal vaccination during the COVID-19 pandemic and ahead of flu season.
Operating expenses were positively affected in the third quarter and first nine months of 2020 by approximately $115 million and $540 million, respectively, primarily driven by lower promotional and selling costs, as well as lower research and development expenses, net of investments in COVID-19-related antiviral and vaccine research programs. For the full-year 2020, Merck expects a net favorable impact to operating expenses of approximately $625 million reflecting continued lower spending due to the COVID-19 pandemic, partially offset by spending on COVID-19-related antiviral and vaccine research programs.
Pricing
Global efforts toward health care cost containment continue to exert pressure on product pricing and market access worldwide. In the United States, pricing pressure continues on many of the Company’s products. Changes to the U.S. health care system as part of health care reform, as well as increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, have contributed to pricing pressure. In several international markets, government-mandated pricing actions have reduced prices of generic and patented drugs. In addition, the Company’s revenue
- 34 -

performance in the first nine months of 2020 was negatively affected by other cost-reduction measures taken by governments and other third-parties to lower health care costs. The Company anticipates all of these actions and additional actions in the future will continue to negatively affect revenue performance.
Operating Results
Sales
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20202019% Change20202019% Change
United States$5,625 $5,573 1 %1 %$15,396 $15,320 — %— %
International6,926 6,824 1 %4 %20,084 19,652 2 %5 %
Total$12,551 $12,397 1 %2 %$35,479 $34,972 1 %3 %
U.S. plus international may not equal total due to rounding.

Worldwide sales were $12.6 billion and $35.5 billion for the third quarter and first nine months of 2020, respectively, representing growth of 1% compared with the same prior year periods. Sales growth in both periods was primarily driven by higher sales in the oncology franchise reflecting strong growth of Keytruda, as well as increased alliance revenue from Lynparza (olaparib) and Lenvima (lenvatinib). Also contributing to revenue growth were higher sales of certain vaccines, including Pneumovax 23, and higher sales of certain hospital acute care products, including Prevymis (letermovir) and Bridion. Higher sales of Animal Health products also contributed to revenue growth in the third quarter and first nine months of 2020.
Sales growth in both periods was partially offset by the ongoing effects of generic competition for certain products including women’s health product NuvaRing (etonogestrel/ethinyl estradiol vaginal ring), hospital acute care product Noxafil (posaconazole), oncology products Emend (aprepitant)/Emend (fosaprepitant dimeglumine) for Injection, cardiovascular products Zetia and Vytorin, as well as products within the diversified brands franchise. The diversified brands franchise includes certain products that are approaching the expiration of their marketing exclusivity or that are no longer protected by patents in developed markets. Lower sales of certain vaccines including human papillomavirus (HPV) vaccines Gardasil (Human Papillomavirus Quadrivalent [Types 6,11,16 and 18] Vaccine, Recombinant)/Gardasil 9 and pediatric vaccines ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live), M-M-R II (Measles, Mumps and Rubella Virus Vaccine Live) and Varivax (Varicella Virus Vaccine Live), as well as lower sales of virology products Zepatier (elbasvir and grazoprevir) and Isentress/Isentress HD (raltegravir) also partially offset revenue growth in the third quarter and first nine months of 2020. As discussed above, the COVID-19 pandemic unfavorably affected sales in the third quarter and first nine months of 2020.
See Note 17 to the condensed consolidated financial statements for details on sales of the Company’s products. A discussion of performance for select products in the franchises follows.
Pharmaceutical Segment
Oncology
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20202019% Change20202019% Change
Keytruda$3,715 $3,070 21 %21 %$10,387 $7,973 30 %31 %
Alliance Revenue - Lynparza (1)
196 123 59 %58 %519 313 66 %67 %
Alliance Revenue - Lenvima (1)
142 109 30 %29 %421 280 50 %50 %
Emend39 98 (60)%(59)%115 336 (66)%(65)%
(1) Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).
Keytruda is an anti-PD-1 (programmed death receptor-1) therapy that has been approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma (cHL), cutaneous squamous cell carcinoma (cSCC), esophageal cancer, gastric or gastroesophageal junction adenocarcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), non-small-cell lung cancer (NSCLC), small-cell lung cancer (SCLC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient cancer, primary mediastinal large B-cell lymphoma (PMBCL), and urothelial carcinoma. Keytruda is also approved for the treatment of certain patients in combination with chemotherapy for metastatic squamous and nonsquamous NSCLC, in combination with chemotherapy for HNSCC, in combination with axitinib for renal cell carcinoma (RCC), and in combination with Lenvima for endometrial
- 35 -

carcinoma. The Keytruda clinical development program includes studies across a broad range of cancer types (see “Research and Development” below).
In January 2020, the U.S. Food and Drug Administration (FDA) approved Keytruda as monotherapy for the treatment of certain patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) based on the results of the KEYNOTE-057 trial.
In April 2020, the FDA granted accelerated approval for an additional recommended dosage of 400 mg every six weeks (Q6W) for Keytruda across all adult indications, including monotherapy and combination therapy. This new dosage option is available in addition to the current dose of 200 mg every three weeks (Q3W).
In June 2020, the FDA granted accelerated approval for Keytruda as monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) (≥10 mutations/megabase) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options based in part on the results of the KEYNOTE-158 trial.
Also in June 2020, the FDA approved Keytruda as monotherapy both for the treatment of patients with recurrent or metastatic cSCC that is not curable by surgery or radiation based on data from the Phase 2 KEYNOTE-629 trial and for the first-line treatment of patients with unresectable or metastatic MSI-H or mismatch repair deficient colorectal cancer based on results from the Phase 3 KEYNOTE-177 trial.
In October 2020, the FDA approved an expanded label for Keytruda as monotherapy for the treatment of adult patients with relapsed or refractory cHL. The approval is based on results from the Phase 3 KEYNOTE-204 trial in which Keytruda significantly reduced the risk of disease progression or death compared to brentuximab vedotin. The FDA also approved an updated pediatric indication for Keytruda for the treatment of pediatric patients with refractory cHL or cHL that has relapsed after two or more lines of therapy. Keytruda was previously approved under the FDA’s accelerated approval process for the treatment of adult and pediatric patients with refractory cHL, or who have relapsed after three or more prior lines of therapy based on data from the KEYNOTE-087 trial. In accordance with accelerated approval regulations, continued approval was contingent upon verification and description of clinical benefit; these accelerated approval requirements have been fulfilled with the data from KEYNOTE-204.
In June 2020, Keytruda was approved by the National Medical Products Administration (NMPA) in China as monotherapy for the second-line treatment of patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (Combined Positive Score [CPS] ≥10). This indication was granted based on the Phase 3 KEYNOTE-181 trial, including data from an extension of the global study in Chinese patients.
In August 2020, Keytruda was approved by the Japan Pharmaceuticals and Medical Devices Agency (PMDA) as monotherapy for the treatment of patients whose tumors are PD-L1-positive, and have radically unresectable, advanced or recurrent ESCC who have progressed after chemotherapy. The approval was based on results from the Phase 3 KEYNOTE-181 trial. Additionally, Keytruda was approved by the Japan PMDA for use at an additional recommended dosage of 400 mg Q6W, including monotherapy and combination therapy. This new dosage option is available in addition to the current dose of 200 mg Q3W.
Global sales of Keytruda grew 21% and 30% in the third quarter and first nine months of 2020, respectively. Sales growth in both periods was driven by higher demand as the Company continues to launch Keytruda with multiple new indications globally, although the COVID-19 pandemic had a dampening effect on growing demand. Sales in the United States continue to build across the multiple approved indications, in particular for the treatment of NSCLC as monotherapy, and in combination with chemotherapy for both nonsquamous and squamous metastatic NSCLC, along with uptake in the RCC, adjuvant melanoma, HNSCC, bladder cancer and endometrial carcinoma indications. Uptake of the Q6W dosing regimen in the United States benefited sales in 2020. Keytruda sales growth in international markets was driven by continued uptake in approved indications, particularly in the European Union (EU). Sales growth in the third quarter and first nine months of 2020 was partially offset by declines in Japan due to pricing. Pursuant to a re-pricing rule, the Japanese government reduced the price of Keytruda by 17.5% effective February 2020. Additionally, Keytruda was subject to another price reduction of 20.9% in April 2020 under a provision of the Japanese pricing rules.
Lynparza, an oral poly (ADP-ribose) polymerase (PARP) inhibitor being developed as part of a collaboration with AstraZeneca PLC (AstraZeneca) (see Note 3 to the condensed consolidated financial statements), is approved for the treatment of certain types of advanced ovarian, breast, pancreatic and prostate cancers. Alliance revenue related to Lynparza increased 59% and 66% in the third quarter and first nine months of 2020, respectively. Sales growth in both periods was largely driven by continued uptake across the multiple approved indications in the United States, the EU and China. In May 2020, the FDA approved Lynparza in combination with bevacizumab as a first-line maintenance treatment of certain adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy based on the results from the Phase 3 PAOLA-1 trial. In November 2020, Lynparza was
- 36 -

approved in the EU for the maintenance treatment of adult patients with advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or parital response following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either a breast cancer susceptibility gene 1/2 (BRCA1/2) mutation and/or genomic instability based on the results from the PAOLA-1 trial. Also in May 2020, the FDA approved Lynparza for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone based on positive results from the Phase 3 PROfound trial. In November 2020, Lynparza was approved in the EU as monotherapy for the treatment of adult patients with mCRPC and BRCA1/2 mutations (germline and/or somatic) who have progressed following a prior therapy that included a new hormonal agent based on the PROfound trial. In July 2020, Lynparza was approved in the EU as a monotherapy for the maintenance treatment of adult patients with germline BRCA1/2 mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen based on the results from the Phase 3 POLO trial.
Lenvima, an oral receptor tyrosine kinase inhibitor being developed as part of a collaboration with Eisai Co., Ltd. (Eisai) (see Note 3 to the condensed consolidated financial statements), is approved for the treatment of certain types of thyroid cancer, HCC, in combination with everolimus for certain patients with RCC, and in combination with Keytruda for the treatment of certain patients with endometrial carcinoma. Alliance revenue related to Lenvima grew 30% and 50% in the third quarter and first nine months of 2020, respectively. Sales growth in both periods was primarily due to higher demand in the United States, China and the EU.
Global sales of Emend, for the prevention of chemotherapy-induced nausea and vomiting, declined 60% and 66% in the third quarter and first nine months of 2020, respectively. The sales declines were primarily driven by lower demand and pricing in the United States due to generic competition, including recent generic competition for Emend for Injection following U.S. patent expiry in September 2019. Also contributing to the sales declines in the third quarter and first nine months of 2020 was lower demand in the EU as a result of generic competition for the oral formulation of Emend following loss of market exclusivity in May 2019. U.S. market exclusivity for the oral formulation of Emend previously expired in 2015. Generic competition for Emend for Injection in Japan following loss of exclusivity also contributed to the sales declines in the third quarter and first nine months of 2020. Emend for Injection lost market exclusivity in major European markets in August 2020. The Company anticipates that sales of Emend for Injection in these markets will decline significantly in future periods.
In April 2020, the FDA approved Koselugo (selumetinib) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). The FDA approval is based on positive results from the National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP)-sponsored Phase 2 SPRINT Stratum 1 trial coordinated by the NCI’s Center for Cancer Research, Pediatric Oncology Branch. This is the first regulatory approval of a medicine for the treatment of NF1 PN, a rare and debilitating genetic condition. Koselugo is being jointly developed and commercialized with AstraZeneca globally (see Note 3 to the condensed consolidated financial statements).
Vaccines
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20202019% Change20202019% Change
Gardasil/Gardasil 9$1,187 $1,320 (10)%(10)%$2,941 $3,044 (3)%(2)%
ProQuad218 232 (6)%(6)%507 588 (14)%(14)%
M-M-R II
115 121 (5)%(6)%287 443 (35)%(35)%
Varivax243 270 (10)%(9)%595 763 (22)%(21)%
Pneumovax 23
375 237 58 %58 %748 592 26 %27 %
Worldwide sales of Gardasil/Gardasil 9, vaccines to help prevent certain cancers and other diseases caused by certain types of HPV, declined 10% and 3% in the third quarter and first nine months of 2020, respectively, primarily due to lower demand in the United States and Hong Kong, SAR, PRC attributable to the COVID-19 pandemic, partially offset by higher volumes in China and in the EU.
The Company anticipates that in the fourth quarter of 2020 it will replenish the doses of Gardasil 9 borrowed from the U.S. Centers for Disease Control and Prevention (CDC) Pediatric Vaccine Stockpile in the fourth quarter of 2019. The replenishment will result in the recognition of approximately $120 million in sales and a reversal of the related liability.
In June 2020, the FDA approved an expanded indication for Gardasil 9 for the prevention of oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58. The oropharyngeal and head and neck
- 37 -

cancer indication was approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease.
In July 2020, Silgard 9 aqueous suspension for intramuscular injection syringes (recombinant adsorbed 9-valent Human Papillomavirus virus-like particles vaccine) were approved for use in women and girls by the Ministry of Health, Labor and Welfare in Japan.
Global sales of ProQuad, a pediatric combination vaccine to help protect against measles, mumps, rubella and varicella, declined 6% and 14% in the third quarter and first nine months of 2020, respectively, primarily due to lower demand in the United States resulting from the COVID-19 pandemic, partially offset by higher pricing.
Worldwide sales of M‑M‑R II, a vaccine to help protect against measles, mumps and rubella, declined 35% in the first nine months of 2020 primarily driven by lower demand in the United States resulting from fewer measles outbreaks in 2020 compared with 2019, coupled with the unfavorable impact of the COVID-19 pandemic, partially offset by higher pricing. Additionally, the sales decline in the first nine months of 2020 reflects lower demand in Brazil.
Global sales of Varivax, a vaccine to help prevent chickenpox (varicella), declined 10% and 22% in the third quarter and first nine months of 2020, respectively. The sales declines reflect lower demand in the United States resulting from the COVID-19 pandemic, partially offset by higher pricing. The sales decline in the first nine months of 2020 was also attributable to lower government tenders in Brazil.
Worldwide sales of Pneumovax 23, a vaccine to help prevent pneumococcal disease, grew 58% and 26% in the third quarter and first nine months of 2020, respectively, primarily due to higher volumes in the United States and in the EU attributable in part to heightened awareness of pneumococcal vaccination during the COVID-19 pandemic and ahead of flu season. Higher pricing in the United States also contributed to sales growth in the third quarter and first nine months of 2020.
Hospital Acute Care
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20202019% Change20202019% Change
Bridion$320 $284 13 %13 %$843 $817 3 %4 %
Noxafil79 177 (55)%(55)%247 560 (56)%(55)%
Prevymis77 45 72 %69 %200 115 74 %74 %
Cubicin39 52 (26)%(25)%116 207 (44)%(43)%
Worldwide sales of Bridion, for the reversal of two types of neuromuscular blocking agents used during surgery, grew 13% and 3% in the third quarter and first nine months of 2020, respectively, primarily attributable to higher demand in the United States. Fewer elective surgeries as a result of the COVID-19 pandemic unfavorably affected demand in 2020.
Global sales of Noxafil, for the prevention of invasive fungal infections, declined 55% and 56% in the third quarter and first nine months of 2020, respectively, primarily due to generic competition in the United States and in the EU. The patents that provided U.S. market exclusivity for certain forms of Noxafil representing the majority of U.S. Noxafil sales expired in July 2019. Additionally, the patent for Noxafil expired in a number of major European markets in December 2019. Accordingly, the Company is experiencing volume and pricing declines in Noxafil sales in these markets as a result of generic competition and expects the declines to continue.
Worldwide sales of Prevymis, a medicine for prophylaxis (prevention) of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogenic hematopoietic stem cell transplant, grew 72% and 74% in the third quarter and first nine months of 2020, respectively, due to continued uptake since launch in the EU and in the United States.
Global sales of Cubicin (daptomycin for injection), an I.V. antibiotic for complicated skin and skin structure infections or bacteremia when caused by designated susceptible organisms, declined 26% and 44% in the third quarter and first nine months of 2020, respectively, primarily due to ongoing generic competition in the EU and in the United States.
In June 2020, the FDA approved a supplemental New Drug Application (NDA) for Recarbrio (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by certain susceptible Gram-negative microorganisms.
Zerbaxa (ceftolozane and tazobactam) is indicated for the treatment of HABP/VABP caused by certain susceptible Gram-negative microorganisms, and for the treatment of certain complicated urinary tract and intra-abdominal infections. The COVID-19 pandemic is unfavorably affecting sales of Zerbaxa, particularly in the United States. An increased focus on more stringent cleaning protocols at hospitals, along with visitor restrictions, have reduced patients’ exposure to developing HABP/
- 38 -

VABP, resulting in a smaller population of patients that need to be treated with Zerbaxa. These factors resulted in lower cash flow forecasts for Zerbaxa in the United States, which constituted a triggering event requiring the evaluation of the Zerbaxa intangible asset for impairment. Although the “step one” impairment test that was performed indicated that the intangible asset related to Zerbaxa remains recoverable, in the event that these trends depress sales of Zerbaxa to a greater extent than anticipated by the Company, or in the event other circumstances arise that further reduce global cash flow projections for Zerbaxa, the Company may record an intangible asset impairment charge in the future and such charge could be material. The carrying value of Zerbaxa was $2.2 billion at September 30, 2020.
Immunology
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20202019% Change20202019% Change
Simponi$209 $203 3 %— %$615 $625 (2)%(1)%
Remicade82 101 (19)%(20)%242 322 (25)%(24)%
Sales of Simponi (golimumab), a once-monthly subcutaneous treatment for certain inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), declined 2% in the first nine month of 2020 primarily driven by lower demand in the EU due to the uptake of biosimilars for a competing product, partially offset by the timing of shipments in Russia.
Sales of Remicade (infliximab), a treatment for inflammatory diseases (marketed by the Company in Europe, Russia and Turkey), declined 19% and 25% in the third quarter and first nine months of 2020, respectively, driven by ongoing biosimilar competition in the Company’s marketing territories in Europe. The Company lost market exclusivity for Remicade in major European markets in 2015 and no longer has market exclusivity in any of its marketing territories. The Company is experiencing pricing and volume declines in these markets as a result of biosimilar competition and expects the declines to continue.
Virology
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20202019% Change20202019% Change
Isentress/Isentress HD$205 $250 (18)%(18)%$646 $752 (14)%(12)%
Zepatier28 83 (67)%(67)%122 304 (60)%(59)%
Global combined sales of Isentress/Isentress HD, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, declined 18% and 14% in the third quarter and first nine months of 2020, respectively, primarily driven by competitive pressure in the United States and in the EU, as well as the timing of shipments in Brazil.
Global sales of Zepatier, a treatment for adult patients with chronic hepatitis C virus genotype (GT) 1 or GT4 infection, declined 67% and 60% in the third quarter and first nine months of 2020, respectively, driven by lower demand globally due to competition and declining patient volumes, coupled with the impact of the COVID-19 pandemic.
Cardiovascular
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20202019% Change20202019% Change
Zetia/Vytorin$150 $204 (27)%(26)%$523 $674 (22)%(21)%
Atozet111 97 14 %12 %348 283 23 %25 %
Rosuzet32 32 1 %— %94 97 (3)%(1)%
Alliance Revenue - Adempas (1)
83 50 67 %67 %216 144 50 %50 %
Adempas55 57 (5)%(7)%167 158 6 %6 %
(1) Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3 to the condensed consolidated financial statements).
Combined global sales of Zetia (marketed in most countries outside the United States as Ezetrol) and Vytorin (marketed outside the United States as Inegy), medicines for lowering LDL cholesterol, declined 27% in the third quarter of 2020, primarily due to lower sales of Ezetrol in Japan. The patent that provided market exclusivity for Ezetrol in Japan expired in September 2019 and generic competition began in June 2020. Accordingly, the Company is experiencing a rapid and
- 39 -

substantial decline in Ezetrol sales in Japan and expects the decline to continue. Higher demand for Ezetrol in China partially offset the sales decline in the third quarter of 2020. Combined global sales of Zetia and Vytorin declined 22% in the first nine months of 2020 primarily due to generic competition for Ezetrol and Inegy in the EU and Ezetrol in Japan. The EU patents for Ezetrol and Inegy expired in April 2018 and April 2019, respectively. The sales decline in the first nine months of 2020 was also attributable to lower pricing following loss of exclusivity in Australia in 2018. Higher demand for Ezetrol in China partially offset the sales decline in the first nine months of 2020.
Sales of Atozet (ezetimibe and atorvastatin) (marketed outside of the United States), a medicine for lowering LDL cholesterol, grew 14% and 23% in the third quarter and first nine months of 2020, respectively, primarily due to higher demand in most markets, particularly in the EU, Japan and other countries in the Asia Pacific region.
Adempas (riociguat), a cardiovascular drug for the treatment of pulmonary arterial hypertension, is part of a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Adempas (see Note 3 to the condensed consolidated financial statements). Revenue from Adempas includes Merck’s share of profits from the sale of Adempas in Bayer’s marketing territories, which grew 67% and 50% in the third quarter and first nine months of 2020, respectively, as well as sales in Merck’s marketing territories, which declined 5% in the third quarter and grew 6% in the first nine months of 2020.
Diabetes
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20202019% Change20202019% Change
Januvia/Janumet$1,327 $1,311 1 %2 %$3,948 $4,106 (4)%(3)%
Worldwide combined sales of Januvia (sitagliptin) and Janumet (sitagliptin/metformin HCl), medicines that help lower blood sugar levels in adults with type 2 diabetes, grew 1% in the third quarter of 2020 driven primarily by higher demand in certain international markets, particularly in China, partially offset by continued pricing pressure in the United States. Global combined sales of Januvia and Janumet declined 4% in the first nine months of 2020. The decline was primarily due to continued pricing pressure in the United States and lower demand in the EU, partially offset by higher demand in certain international markets, particularly in China. The Company expects U.S. pricing pressure to continue. The patents that provide market exclusivity for Januvia and Janumet in the United States expire in July 2022 (although six-month pediatric exclusivity may extend this date). The patent that provides market exclusivity for Januvia in the EU expires in July 2022 (although pediatric exclusivity has recently been granted which may extend this date to September 2022 and the Company is applying in individual countries for the extensions). The supplementary patent certificate that provides market exclusivity for Janumet in the EU expires in April 2023. The Company anticipates sales of Januvia and Janumet in these markets will decline substantially after these patent expiries.
Women’s Health 
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20202019% Change20202019% Change
Implanon/Nexplanon$189 $199 (5)%(4)%$515 $581 (11)%(10)%
NuvaRing58 241 (76)%(76)%184 700 (74)%(73)%
Global sales of Implanon/Nexplanon, a single-rod subdermal contraceptive implant, declined 5% in the third quarter of 2020 primarily driven by lower demand in Latin America. Worldwide sales of Implanon/Nexplanon declined 11% in the first nine months of 2020 primarily due to lower demand in the United States and in the EU resulting from the COVID-19 pandemic.
Worldwide sales of NuvaRing, a vaginal contraceptive product, declined 76% and 74% in the third quarter and first nine months of 2020, respectively, due to generic competition in the United States. The patent that provided U.S. market exclusivity for NuvaRing expired in April 2018 and generic competition began in December 2019. Accordingly, the Company is experiencing a rapid and substantial decline in U.S. NuvaRing sales and expects the decline to continue.
Biosimilars 
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20202019% Change20202019% Change
Biosimilars$99 $68 45 %44 %$227 $189 20 %21 %
- 40 -

Biosimilar products are marketed by the Company pursuant to an agreement with Samsung Bioepis Co., Ltd. (Samsung) to develop and commercialize multiple pre-specified biosimilar candidates. Currently, the Company markets Renflexis (infliximab-abda), a biosimilar to Remicade (infliximab) for the treatment of certain inflammatory diseases; Ontruzant (trastuzumab-dttb), a biosimilar to Herceptin (trastuzumab) for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer and HER2 overexpressing gastric cancer; and Brenzys (etanercept biosimilar), a biosimilar to Enbrel for the treatment of certain inflammatory diseases. Merck’s commercialization territories under the agreement vary by product. Sales of biosimilars grew 45% and 20% in the third quarter and first nine months of 2020, respectively, primarily due to the launch of Ontruzant in Brazil in August 2020 and continued post-launch uptake of Renflexis in the United States and Canada. Sales growth in the first nine months of 2020 was partially offset by lower sales of Brenzys in Brazil.
In August 2020, the EC granted marketing authorization for Aybintio (bevacizumab) for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, NSCLC, advanced and/or metastatic RCC, epithelial ovarian, fallopian tube and primary peritoneal cancer and cervical cancer. An application seeking approval of Aybintio in the United States was filed in September 2019.
Animal Health Segment
Three Months Ended
September 30,		% Change
Excluding
Foreign
Exchange		Nine Months Ended
September 30,		% Change
Excluding
Foreign
Exchange
($ in millions)20202019% Change20202019% Change
Livestock$758 $726 5 %8 %$2,145 $2,007 7 %11 %
Companion Animal462 396 17 %18 %1,390 1,264 10 %12 %
Sales of livestock products grew 5% and 7% in the third quarter and first nine months of 2020, respectively, primarily driven by higher demand for ruminant, swine and poultry products. Sales growth in the first nine months of 2020 was also driven by the April 2019 acquisition of Antelliq Corporation (Antelliq) (see Note 2 to the condensed consolidated financial statements). Sales of companion animal products grew 17% in the third quarter of 2020 and 10% in the first nine months of 2020 primarily driven by higher demand for the Bravecto (fluralaner) line of products, as well as higher demand for companion animal vaccines.
Costs, Expenses and Other
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)20202019% Change20202019% Change
Cost of sales$3,481 $3,990 (13)%$9,952 $10,443 (5)%
Selling, general and administrative2,450 2,589 (5)%7,383 7,726 (4)%
Research and development3,390 3,204 6 %7,721 7,324 5 %
Restructuring costs114 232 (51)%269 444 (39)%
Other (income) expense, net(312)35 *(630)362 *
$9,123 $10,050 (9)%24,695 26,299 (6)%
* Greater than 100%.
Cost of Sales
Cost of sales declined 13% and 5% in the third quarter and first nine months of 2020, respectively. Cost of sales includes the amortization of intangible assets recorded in connection with business acquisitions, which totaled $270 million and $320 million in the third quarter of 2020 and 2019, respectively, and $843 million and $1.1 billion in the first nine months of 2020 and 2019, respectively. Cost of sales also includes the amortization of amounts capitalized in connection with collaborations of $117 million and $81 million in the third quarter of 2020 and 2019, respectively, and $509 million and $307 million in the first nine months of 2020 and 2019, respectively. Additionally, costs include intangible asset impairment charges of $612 million and $693 million in the third quarter and first nine months of 2019, respectively, related to marketed products. The Company may recognize additional impairment charges in the future related to intangible assets that were measured at fair value and capitalized in connection with business acquisitions and such charges could be material. Also included in cost of sales are expenses associated with restructuring activities which amounted to $38 million and $62 million in the third quarter of 2020 and 2019, respectively, and $131 million and $161 million in the first nine months of 2020 and 2019, respectively, including accelerated depreciation and asset write-offs related to the planned sale or closure of manufacturing facilities. Separation costs associated with manufacturing-related headcount reductions have been incurred and are reflected in Restructuring costs as discussed below.
- 41 -

Gross margin was 72.3% in the third quarter of 2020 compared with 67.8% in the third quarter of 2019. The gross margin improvement reflects lower intangible asset impairment charges (noted above), the favorable effect of product mix and lower restructuring costs, partially offset by the unfavorable effects of pricing pressure, inventory write-offs and foreign exchange. Gross margin was 71.9% in the first nine months of 2020 compared with 70.1% in the first nine months of 2019. The gross margin improvement was primarily driven by lower impairment charges and amortization related to intangible assets (noted above), as well as the favorable effect of product mix and lower restructuring costs, partially offset by the unfavorable effects of pricing pressure, royalties, manufacturing variances, and inventory write-offs.
Selling, General and Administrative
Selling, general and administrative (SG&A) expenses declined 5% and 4% in the third quarter and first nine months of 2020, respectively, primarily due to lower administrative and selling costs, including reduced travel and fewer meetings, due in part to the COVID-19 pandemic, and the favorable effect of foreign exchange, partially offset by costs related to the planned spin-off of Organon. Transaction costs related to the acquisition of ArQule also partially offset the decline in SG&A expenses in the first nine months of 2020 (see Note 2 to the condensed consolidated financial statements).
Research and Development
Research and development (R&D) expenses grew 6% and 5% in the third quarter and first nine months of 2020, respectively, primarily driven by higher upfront payments related to collaborations and license agreements (see Note 2 to the condensed consolidated financial statements), increased clinical development, discovery research and early drug development spending, as well as higher restructuring costs, partially offset by a charge in 2019 for the acquisition of Peloton Therapeutics, Inc. (Peloton) (see Note 2 to the condensed consolidated financial statements), lower costs associated with the COVID-19 pandemic (net of spending on COVID-19-related vaccine and antiviral research programs), and the favorable effect of foreign exchange.
R&D expenses are comprised of the costs directly incurred by MRL, the Company’s research and development division that focuses on human health-related activities, which were $1.6 billion in both the third quarter of 2020 and 2019, and $4.7 billion and $4.4 billion in the first nine months of 2020 and 2019, respectively. Also included in R&D expenses are Animal Health research costs, licensing costs and costs incurred by other divisions in support of R&D activities, including depreciation, production and general and administrative, which in the aggregate were approximately $645 million and $655 million for the third quarter of 2020 and 2019, respectively, and were $1.9 billion in both the first nine months of 2020 and 2019. In addition, R&D expenses include expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration recorded in connection with business acquisitions. The Company recorded a net reduction in expenses of $48 million and $36 million in the first nine months of 2020 and 2019, respectively, related to the changes in these estimates. R&D expenses also reflect $19 million and $67 million of accelerated depreciation costs in connection with restructuring activities in the third quarter and first nine months of 2020, respectively.
Restructuring Costs
In early 2019, Merck approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $2.5 billion. The Company expects to record charges of approximately $800 million in 2020 related to the Restructuring Program. The Company anticipates the actions under the Restructuring Program to result in annual net cost savings of approximately $900 million by the end of 2023. Actions under previous global restructuring programs have been substantially completed.
Restructuring costs, primarily representing separation and other related costs associated with these restructuring activities, were $114 million and $232 million for the third quarter of 2020 and 2019, respectively, and $269 million and $444 million in the first nine months of 2020 and 2019, respectively. Separation costs incurred were associated with actual headcount reductions, as well as estimated expenses under existing severance programs for headcount reductions that were probable and could be reasonably estimated. Also included in restructuring costs are asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation plan costs. For segment reporting, restructuring costs are unallocated expenses.
Additional costs associated with the Company’s restructuring activities are included in Cost of sales, Selling, general and administrative expenses and Research and development costs. The Company recorded aggregate pretax costs of
- 42 -

$186 million and $296 million in the third quarter of 2020 and 2019, respectively, and $504 million and $642 million in the first nine months of 2020 and 2019, respectively, related to restructuring program activities (see Note 4 to the condensed consolidated financial statements).
Other (Income) Expense, Net
For details on the components of Other (income) expense, net see Note 13 to the condensed consolidated financial statements.
Segment Profits
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Pharmaceutical segment profits$7,974 $7,747 $22,010 $21,437 
Animal Health segment profits451 423 1,336 1,243 
Other non-reportable segment profits(1)(2)1 (2)
Other(4,996)(5,821)(12,563)(14,005)
Income before taxes$3,428 $2,347 $10,784 $8,673 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as SG&A expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as SG&A expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred by MRL, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. Also excluded from the determination of segment profits are costs related to restructuring activities and acquisition and divestiture-related costs, including the amortization of purchase accounting adjustments, intangible asset impairment charges, and changes in the estimated fair value measurement of liabilities for contingent consideration. Additionally, segment profits do not reflect other expenses from corporate and manufacturing cost centers and other miscellaneous income or expense. These unallocated items are reflected in “Other” in the above table. Also included in “Other” are miscellaneous corporate profits (losses), as well as operating profits (losses) related to third-party manufacturing sales.
Pharmaceutical segment profits grew 3% in both the third quarter and first nine months of 2020 driven primarily by higher sales, as well as lower administrative and selling costs. Animal Health segment profits grew 6% and 7% in the third quarter and first nine months of 2020, respectively, reflecting higher sales and lower promotional costs, partially offset by higher R&D costs and the unfavorable effect of foreign exchange.
Taxes on Income
The effective income tax rates of 14.1% and 18.7% for the third quarter of 2020 and 2019, respectively, and 14.9% and 14.5% for the first nine months of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. The effective income tax rates in the third quarter and first nine months of 2019 also reflect the unfavorable impact of a charge for the acquisition of Peloton for which no tax benefit was recognized and the favorable impact of product mix on the estimated 2019 full-year tax rate. In addition, the effective income tax rate for the first nine months of 2019 reflects the favorable impact of a $360 million net tax benefit related to the settlement of certain federal income tax matters.
In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million. The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $360 million net tax benefit in the first nine months of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.
Net Loss Attributable to Noncontrolling Interests
Net loss attributable to noncontrolling interests of $73 million for the first nine months of 2019 includes the portion of goodwill impairment charges related to certain businesses in the Healthcare Services segment that are attributable to noncontrolling interests.

- 43 -

Net Income and Earnings per Common Share
Net income attributable to Merck & Co., Inc. was $2.9 billion for the third quarter of 2020 compared with $1.9 billion for the third quarter of 2019 and was $9.2 billion for the first nine months of 2020 compared with $7.5 billion for the first nine months of 2019. Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders (EPS) for the third quarter of 2020 were $1.16 compared with $0.74 in the third quarter of 2019 and were $3.61 for the first nine months of 2020 compared with $2.89 for the first nine months of 2019.
Non-GAAP Income and Non-GAAP EPS
Non-GAAP income and non-GAAP EPS are alternative views of the Company’s performance that Merck is providing because management believes this information enhances investors’ understanding of the Company’s results as it permits investors to understand how management assesses performance. Non-GAAP income and non-GAAP EPS exclude certain items because of the nature of these items and the impact that they have on the analysis of underlying business performance and trends. The excluded items (which should not be considered non-recurring) consist of acquisition and divestiture-related costs, restructuring costs and certain other items. These excluded items are significant components in understanding and assessing financial performance. Non-GAAP income and non-GAAP EPS are important internal measures for the Company. Senior management receives a monthly analysis of operating results that includes non-GAAP EPS. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the Company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. Since non-GAAP income and non-GAAP EPS are not measures determined in accordance with GAAP, they have no standardized meaning prescribed by GAAP and, therefore, may not be comparable to the calculation of similar measures of other companies. The information on non-GAAP income and non-GAAP EPS should be considered in addition to, but not as a substitute for or superior to, net income and EPS prepared in accordance with generally accepted accounting principles in the United States (GAAP).
A reconciliation between GAAP financial measures and non-GAAP financial measures is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions except per share amounts)2020201920202019
Income before taxes as reported under GAAP$3,428 $2,347 $10,784 $8,673 
Increase (decrease) for excluded items:
Acquisition and divestiture-related costs
508 975 1,551 2,183 
Restructuring costs
186 296 504 642 
Other items:
Charges for collaborations and acquisitions (1)
1,082 982 1,082 982 
Other(1)— (17)48 
Non-GAAP income before taxes5,203 4,600 13,904 12,528 
Taxes on income as reported under GAAP483 440 1,611 1,259 
Estimated tax benefit on excluded items (2)
356 281 616 555 
Adjustment to tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition(67)— (67)— 
Net tax benefit from the settlement of certain federal income tax matters
— — — 360 
Tax charge related to finalization of treasury regulations for the Tax Cuts and Job Act of 2017
— — — (67)
Non-GAAP taxes on income772 721 2,160 2,107 
Non-GAAP net income4,431 3,879 11,744 10,421 
Less: Net income (loss) attributable to noncontrolling interests as reported under GAAP
4 6 12 (73)
    Acquisition and divestiture-related costs attributable to noncontrolling interests
— — — 89 
Non-GAAP net income attributable to noncontrolling interests4 6 12 16 
Non-GAAP net income attributable to Merck & Co., Inc.$4,427 $3,873 $11,732 $10,405 
EPS assuming dilution as reported under GAAP$1.16 $0.74 $3.61 $2.89 
EPS difference0.58 0.77 1.01 1.13 
Non-GAAP EPS assuming dilution$1.74 $1.51 $4.62 $4.02 
(1)    Amount in 2020 includes $832 million related to transactions with Seagen. Amount in 2019 represents a charge for the acquisition of Peloton. See Note 2 to the condensed consolidated financial statements.
(2) The estimated tax impact on the excluded items is determined by applying the statutory rate of the originating territory of the non-GAAP adjustments.
- 44 -

Acquisition and Divestiture-Related Costs
Non-GAAP income and non-GAAP EPS exclude the impact of certain amounts recorded in connection with business acquisitions and divestitures. These amounts include the amortization of intangible assets and amortization of purchase accounting adjustments to inventories, as well as intangible asset impairment charges, and expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration. Also excluded are integration, transaction, and certain other costs associated with business acquisitions and divestitures.
Restructuring Costs
Non-GAAP income and non-GAAP EPS exclude costs related to restructuring actions (see Note 4 to the condensed consolidated financial statements). These amounts include employee separation costs and accelerated depreciation associated with facilities to be closed or divested. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. Restructuring costs also include asset abandonment, facility shut-down and other related costs, as well as employee-related costs such as curtailment, settlement and termination charges associated with pension and other postretirement benefit plans and share-based compensation costs.
Certain Other Items
Non-GAAP income and non-GAAP EPS exclude certain other items. These items are adjusted for after evaluating them on an individual basis, considering their quantitative and qualitative aspects. Typically, these consist of items that are unusual in nature, significant to the results of a particular period or not indicative of future operating results. Excluded from non-GAAP income and non-GAAP EPS in 2020 are upfront payments related to licensing arrangements and collaborations, including the transactions with Seagen (see Note 2 to the condensed consolidated financial statements), and an adjustment to tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition. Excluded from non-GAAP income and non-GAAP EPS in 2019 is a charge for the acquisition of Peloton (see Note 2 to the condensed consolidated financial statements), a net tax benefit related to the settlement of certain federal income tax matters (see Note 14 to the condensed consolidated financial statements) and a tax charge related to the finalization of U.S. treasury regulations related to the Tax Cuts and Jobs Act of 2017.
Research and Development Update
In July 2020, the FDA accepted for priority review the NDA for vericiguat, an orally administered sGC stimulator, to reduce the risk of cardiovascular death and heart failure hospitalization following a worsening heart failure event in patients with symptomatic chronic heart failure with reduced ejection fraction, in combination with other heart failure therapies. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action, date of January 20, 2021. Vericiguat is being jointly developed with Bayer (see Note 3 to the condensed consolidated financial statements). The application is based on results from the Phase 3 VICTORIA trial, which is the first contemporary outcomes study focused exclusively on a population with worsening chronic heart failure who are at high risk for cardiovascular mortality and repeated heart failure hospitalizations. Data from VICTORIA were presented at the virtual American College of Cardiology’s 69th Annual Scientific Session together with World Congress of Cardiology and published in The New England Journal of Medicine. Vericiguat is also under review in the EU and in Japan. Merck and Bayer plan to share VICTORIA data with regulatory authorities worldwide.
Koselugo is under review in the EU for the treatment of pediatric patients two years of age and older with NF1 who have symptomatic, inoperable PN based on positive results from the NCI CTEP-sponsored Phase 2 SPRINT Stratum 1 trial. Koselugo was approved by the FDA in April 2020. Koselugo is being jointly developed and commercialized with AstraZeneca globally (see Note 3 to the condensed consolidated financial statements).
Keytruda is an anti-PD-1 therapy approved for the treatment of many cancers that is in clinical development for expanded indications. These approvals were the result of a broad clinical development program that currently consists of more than 1,300 clinical trials, including more than 900 trials that combine Keytruda with other cancer treatments. These studies encompass more than 30 cancer types including: biliary tract, cervical, colorectal, cutaneous squamous cell, endometrial, esophageal, gastric, glioblastoma, head and neck, hepatocellular, Hodgkin lymphoma, non-Hodgkin lymphoma, melanoma, mesothelioma, nasopharyngeal, non-small-cell lung, ovarian, prostate, renal, small-cell lung, triple-negative breast and urothelial, many of which are currently in Phase 3 clinical development. Further trials are being planned for other cancers.
In July 2020, the FDA accepted and granted Priority Review for a supplemental Biologics License Application (BLA) seeking accelerated approval for Keytruda in combination with chemotherapy for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors express PD-L1 (CPS ≥10). The application was based on data from the KEYNOTE-355 trial in which Keytruda plus chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with chemotherapy alone in patients whose tumors expressed PD-L1 at CPS ≥10. In patients whose tumors expressed PD-L1 with
- 45 -

CPS ≥1, Keytruda plus chemotherapy improved PFS versus chemotherapy alone, however these results did not meet statistical significance. These data were presented at the virtual scientific program of the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting. As previously announced, the trial will continue without changes to evaluate the other dual primary endpoint of overall survival (OS). The FDA set a PDUFA date of November 28, 2020. In October 2020, Merck announced the submission of KEYNOTE-355 to the Japan PMDA.
Also in July 2020, the FDA accepted for standard review a supplemental BLA for Keytruda for the treatment of patients with high-risk, early-stage TNBC, in combination with chemotherapy as neoadjuvant treatment, and then as a single agent as adjuvant treatment after surgery. The application was based on data from the KEYNOTE-522 trial in which neoadjuvant Keytruda plus chemotherapy resulted in a statistically significant increase in pathologic complete response in patients with early-stage TNBC, regardless of PD-L1 expression. The Keytruda regimen also demonstrated a favorable trend for the other dual primary endpoint of event-free survival. An interim analysis for this study was conducted by the Independent Data Monitoring Committee (DMC). Based on the recommendation of the DMC, the study continues to evaluate event-free survival. Data from the KEYNOTE-522 trial were presented at the European Society for Medical Oncology 2019 Congress. As previously announced, Keytruda plus chemotherapy was granted Breakthrough Therapy designation by the FDA in September 2019 for the neoadjuvant treatment of patients with high-risk, early-stage TNBC. The PDUFA date for this application is March 29, 2021.
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) announced the start of a procedure to extend the currently approved therapeutic indication for the treatment of relapsed or refractory cHL in adults to an earlier line of therapy based on the pivotal Phase 3 KEYNOTE-204 trial, in which Keytruda demonstrated a significant improvement in PFS compared to brentuximab vedotin (BV), a current standard of care in this patient population. Data from KEYNOTE-204 were presented during the virtual scientific program of the 2020 ASCO Annual Meeting. Keytruda was approved for this indication by the FDA in October 2020. The procedure also seeks to extend the indication to include pediatric patients.
Keytruda is also under review in the EU and in Japan for the first-line treatment of patients with MSI-H or mismatch repair deficient unresectable or metastatic colorectal cancer based on the results from the Phase 3 KEYNOTE-177 trial. Keytruda was approved for this indication by the FDA in June 2020.
In addition to the Breakthrough Therapy designation from the FDA for the combination of Keytruda with neoadjuvant chemotherapy for the treatment of high-risk, early-stage TNBC noted above, Keytruda also received Breakthrough Therapy designation from the FDA in February 2020 for the combination of Keytruda with PADCEV (enfortumab vedotin-ejfv), in the first-line setting for the treatment of patients with unresectable locally advanced or metastatic urothelial cancer who are not eligible for cisplatin-containing chemotherapy. The FDA’s Breakthrough Therapy designation is intended to expedite the development and review of a candidate that is planned for use, alone or in combination, to treat a serious or life-threatening disease or condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints.
In August 2020, Merck announced first-time data from the pivotal Phase 3 KEYNOTE-590 trial evaluating Keytruda in combination with platinum-based chemotherapy for the first-line treatment of patients with locally advanced or metastatic esophageal and gastroesophageal junction cancer. In the study, Keytruda in combination with chemotherapy significantly improved OS and PFS versus chemotherapy in all randomized patients; it was demonstrated that the risk of death was reduced by 27% versus chemotherapy as first-line treatment for locally advanced or metastatic esophageal cancer. With these results, Keytruda is the first anti-PD-1 therapy in combination with chemotherapy to show superior OS, PFS and objective response rate (ORR) versus chemotherapy, the current standard of care, for these patients regardless of histology or PD-L1 expression status. These data were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. Merck will be sharing these data with regulatory authorities worldwide.
In June 2020, Merck announced that the Phase 3 KEYNOTE-361 trial evaluating Keytruda in combination with chemotherapy for the first-line treatment of patients with advanced or metastatic urothelial carcinoma (bladder cancer) did not meet its pre-specified dual primary endpoints of OS or PFS, compared with standard of care chemotherapy. In the final analysis of the study, there was an improvement in OS and PFS for patients treated with Keytruda in combination with chemotherapy compared to chemotherapy alone; however, these results did not meet statistical significance per the pre-specified statistical plan. The monotherapy arm of the study was not formally tested, since superiority was not reached for OS or PFS in the Keytruda combination arm. Keytruda has three FDA-approved bladder cancer indications across multiple stages of bladder cancer. Additionally, Merck has an extensive clinical development program in bladder cancer and is continuing to evaluate Keytruda as monotherapy and in combination with other anti-cancer therapies across several disease settings (i.e., metastatic, muscle invasive bladder cancer, and non-muscle invasive bladder cancer).
In May 2020, Merck announced positive results from two studies from the Company’s lung cancer research program. Initial results from the Phase 2 KEYNOTE-799 trial evaluating Keytruda plus concurrent chemoradiation therapy
- 46 -

demonstrated an ORR of 67.0% in Cohort A (squamous and nonsquamous NSCLC patients who received paclitaxel plus carboplatin) and 56.6% in Cohort B (nonsquamous NSCLC patients who received cisplatin plus pemetrexed) in untreated patients with unresectable, locally advanced stage III NSCLC.
Additionally in May 2020, Merck and Eisai presented data from analyses of two trials evaluating Keytruda plus Lenvima at the 2020 ASCO Annual Meeting, in which the Keytruda plus Lenvima combination demonstrated clinically meaningful ORR: the KEYNOTE-524/Study 116 trial in patients with unresectable HCC with no prior systemic therapy and the KEYNOTE-146/Study 111 trial in patients with metastatic clear cell renal cell carcinoma (ccRCC) who progressed following immune checkpoint inhibitor therapy.
In July 2020, Merck and Eisai announced that the FDA issued a Complete Response Letter (CRL) regarding Merck’s and Eisai’s applications seeking accelerated approval of Keytruda plus Lenvima for the first-line treatment of patients with unresectable HCC based on data from the Phase 1b KEYNOTE-524/Study 116 trial, which showed clinically meaningful efficacy in the single-arm setting. These data supported a Breakthrough Therapy designation granted by the FDA in July 2019. Ahead of the PDUFA action dates of Merck’s and Eisai’s applications, another combination therapy was approved based on a randomized, controlled trial that demonstrated improvement in OS versus standard-of-care treatment. Consequently, the CRL stated that Merck’s and Eisai’s applications do not provide evidence that Keytruda in combination with Lenvima represents a meaningful advantage over available therapies for the treatment of unresectable or metastatic HCC with no prior systemic therapy for advanced disease. Since the applications for KEYNOTE-524/Study 116 no longer meet the criteria for accelerated approval, both companies plan to work with the FDA to take appropriate next steps, which include conducting a well-controlled clinical trial that demonstrates substantial evidence of effectiveness and the clinical benefit of the combination. As such, LEAP-002, the Phase 3 trial evaluating the Keytruda plus Lenvima combination as a first-line treatment for advanced HCC, is currently underway and fully enrolled. The CRL does not impact the current approved indications for Keytruda or for Lenvima.
In July 2020, the FDA granted Breakthrough Therapy designation to the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482, a novel investigational candidate for the treatment of patients with von Hippel-Lindau (VHL) disease-associated RCC with nonmetastatic RCC tumors less than three centimeters in size, unless immediate surgery is required. The FDA also granted orphan drug designation to MK-6482 for VHL disease. These designations are based on data from a Phase 2 trial evaluating MK-6482 in patients with VHL-associated ccRCC, which were presented at the 2020 ASCO Annual Meeting. Additionally, Phase 2 data showing anti-tumor responses in VHL disease patients with ccRCC and other tumors were presented at the ESMO Virtual Congress 2020.
In September 2020, Merck and Seagen announced a collaboration to globally develop and commercialize Seagen’s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Keytruda in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. Seagen also granted Merck an exclusive license and entered into a co-development agreement with Merck to accelerate the global reach of Tukysa (MK-7119), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. See Note 2 to the condensed consolidated financial statements.
Lynparza is an oral PARP inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers being co-developed for multiple cancer types as part of a collaboration with AstraZeneca (see Note 3 to the condensed consolidated financial statements).
In May 2020, the results from the Phase 3 GY004 trial, led by NRG Oncology and sponsored by the U.S. NCI, were presented at the 2020 ASCO Annual Meeting. This follows the March 2020, Merck and AstraZeneca announcement of the high-level results from the Phase 3 GY004 trial that examined primarily the efficacy and safety of investigational medicine cediranib in combination with Lynparza versus platinum-based chemotherapy in patients with platinum-sensitive relapsed ovarian cancer. The trial did not meet the primary endpoint in the intent-to-treat population of a statistically significant improvement in PFS with cediranib in combination with Lynparza vs. platinum-based chemotherapy.
In September 2020, Merck announced the results from two ongoing pivotal Phase 3 trials (COUGH-1 and COUGH-2) evaluating the efficacy and safety of gefapixant (MK-7264), an investigational, orally administered, selective P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough. In these studies, adult patients treated with gefapixant 45 mg twice daily demonstrated a statistically significant reduction in 24-hour cough frequency versus placebo at 12 weeks (COUGH-1) and 24 weeks (COUGH-2). The gefapixant 15 mg twice daily treatment arms did not meet the primary efficacy endpoint in either Phase 3 study. These results were presented at the Virtual European Respiratory Society International Congress 2020. Merck plans to share data from COUGH-1 and COUGH-2 with regulatory authorities worldwide.
- 47 -

In October 2020, Merck announced Week 96 data from the Phase 2b trial (NCT03272347) evaluating the efficacy and safety of islatravir, the company’s investigational oral nucleoside reverse transcriptase translocation inhibitor (NRTTI), in combination with doravirine (Pifeltro), in treatment-naïve adults with HIV-1 infection. Week 96 findings demonstrated that the combination of islatravir and doravirine maintained virologic suppression (as measured by the number of study participants achieving HIV-1 RNA levels <50 copies/mL, similar to Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate)), and the findings were consistent with Week 48 results. Additional Week 96 data from the study show low rates of participants meeting the definition of protocol-defined virologic failure in both the islatravir plus doravirine and the Delstrigo treatment arms, and no participants in either arm met the criteria for resistance testing. These data were presented at the virtual 2020 International Congress on Drug Therapy in HIV Infection (HIV Glasglow).
In October 2020, Merck announced findings from two Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114, the Company’s investigational 15-valent pneumococcal conjugate vaccine. In the PNEU-PATH (V114-016) study, healthy adults 50 years of age and older received V114 or PCV13 followed by Pneumovax 23 one year later. Immune responses following vaccination with Pneumovax 23 were comparable in both vaccination groups for the 15 serotypes in V114. Results also showed that at 30 days post vaccination with either V114 or PCV13, immune responses were comparable for both groups across the 13 serotypes shared by the conjugate vaccines and higher in the V114 group for serotypes 22F and 33F, the two serotypes not included in PCV13. In PNEU-DAY (V114-017), a Phase 3 study in immunocompetent adults 18 to 49 years of age with underlying medical conditions associated with increased risk for pneumococcal disease, V114 generated immune responses generally comparable to PCV13 for the 13 shared serotypes and higher immune responses for serotypes 22F and 33F at 30 days post-vaccination.
In September 2020, Merck announced that two Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114 met their primary immunogenicity objectives. The pivotal PNEU-AGE (V114-019) study in healthy adults 50 years of age or older demonstrated that V114 is non-inferior to the currently available 13-valent pneumococcal conjugate vaccine (PCV13) for the 13 serotypes targeted by both vaccines and superior for serotypes 22F and 33F, the two serotypes targeted by V114 but not PCV13. The PNEU-AGE study also met the key secondary immunogenicity objective, demonstrating superiority of V114 compared to PCV13 for serotype 3, a leading cause of invasive pneumococcal disease globally. In another Phase 3 study, PNEU-TRUE (V114-020), in healthy adults 50 years of age or older, V114 met its primary immunogenicity objective demonstrating equivalent immune response across all 15 serotypes for three different lots of V114.
In June 2020, Merck announced results from two initial Phase 3 studies evaluating the safety, tolerability and immunogenicity of V114. Results from the PNEU-WAY (V114-018) study in adults 18 years of age or older living with HIV showed that V114 elicited an immune response to all 15 serotypes included in the vaccine, including serotypes 22F and 33F. Results from the PNEU-FLU (V114-021) study in healthy adults 50 years of age or older showed that V114 can be given concomitantly with the quadrivalent influenza vaccine. These data were announced and published in the International Symposium on Pneumococci and Pneumococcal Diseases digital library in lieu of an in-person meeting.
The V114 Phase 3 clinical development program is comprised of 16 trials investigating the safety, tolerability and immunogenicity of V114 in a variety of populations who are at increased risk for pneumococcal disease including both healthy older adult and healthy pediatric populations, as well as people who are immunocompromised or have certain chronic conditions. Findings from the V114 Phase 3 clinical program, including the studies above, will be presented at a future scientific congress and will form the basis for global regulatory licensure applications, beginning with the FDA before the end of the year.
In June 2020, Merck and Pfizer Inc. announced the presentation of results from the Phase 3 VERTIS CV cardiovascular (CV) outcomes trial that evaluated Steglatro (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, versus placebo, added to background standard of care treatment, in patients with type 2 diabetes and atherosclerotic CV disease. The study met the primary endpoint of non-inferiority on major adverse CV events (MACE), which is a composite of CV death, nonfatal myocardial infarction or nonfatal stroke, compared to placebo. The key secondary endpoints of superiority for Steglatro versus placebo for time to the first occurrence of the composite of CV death or hospitalization for heart failure, time to CV death alone and time to the first occurrence of the composite of renal death, dialysis/transplant or doubling of serum creatinine from baseline were not met. While not a pre-specified hypothesis for statistical testing, a reduction in hospitalization for heart failure was observed with Steglatro.
In July 2020, the FDA granted V181, the Company’s investigational dengue vaccine in Phase 1 development, Fast Track designation.
The chart below reflects the Company’s research pipeline as of November 2, 2020. Candidates shown in Phase 3 include specific products and the date such candidate entered into Phase 3 development. Candidates shown in Phase 2 include the most advanced compound with a specific mechanism or, if listed compounds have the same mechanism, they are each currently intended for commercialization in a given therapeutic area. Small molecules and biologics are given MK-number designations and vaccine candidates are given V-number designations. Except as otherwise noted, candidates in Phase 1,
- 48 -

additional indications in the same therapeutic area (other than with respect to cancer) and additional claims, line extensions or formulations for in-line products are not shown.
Phase 2Phase 3 (Phase 3 entry date)Under Review
Antiviral COVID-19
MK-4482 (molnupiravir)(1)
Cancer
MK-1026
     Hematological Malignancies
MK-1308 (quavonlimab)(2)
Melanoma
Non-Small-Cell Lung
MK-1454(2)
Head and Neck
MK-3475 Keytruda
Advanced Solid Tumors
MK-4280(2)
     Hematological Malignancies
     Non-Small-Cell Lung
MK-5890(2)
     Non-Small-Cell Lung
MK-6440 (ladiratuzumab vedotin)(1)(3)
Advanced Solid Tumors
Breast
MK-7119 Tukysa(1)
Colorectal
MK-7339 Lynparza(1)(3)
Advanced Solid Tumors
MK-7684 (vibostolimab)(2)
    Melanoma
Non-Small-Cell Lung
MK-7902 Lenvima(1)(2)
Advanced Solid Tumors
Biliary Tract
Colorectal
Gastric
Glioblastoma
V937
Breast
Cutaneous Squamous Cell
Melanoma
Head and Neck
Chikungunya virus
V184
Cytomegalovirus
V160
HIV-1 Prevention
MK-8591 (islatravir)
Overgrowth Syndrome
MK-7075 (miransertib)
Pneumococcal Vaccine Adult
V116
Respiratory Syncytial Virus
MK-1654
Schizophrenia
MK-8189

Cancer
MK-3475 Keytruda
Biliary Tract (September 2019)
Breast (October 2015) (EU)
Cervical (October 2018) (EU)
Cutaneous Squamous Cell (August 2019) (EU)
Endometrial (August 2019) (EU)
Esophageal (December 2015) (EU)
Gastric (May 2015) (EU)
Hepatocellular (May 2016) (EU)
Mesothelioma (May 2018)
Nasopharyngeal (April 2016)
Ovarian (December 2018)
Prostate (May 2019)
Small-Cell Lung (May 2017) (EU)
MK-6482
Renal Cell (February 2020)
MK-7119 Tukysa(1)
Breast (October 2019)
MK-7339 Lynparza(1)(2)
Colorectal (August 2020)
Non-Small-Cell Lung (June 2019)
MK-7902 Lenvima(1)(2)
Bladder (May 2019)
Endometrial (June 2018) (EU)
Head and Neck (February 2020)
Melanoma (March 2019)
Non-Small-Cell Lung (March 2019)
Cough
MK-7264 (gefapixant) (March 2018)
HIV-1 Infection
     MK-8591A (doravirine/islatravir) (February 2020)
Pneumoconjugate Vaccine
V114 (June 2018)
New Molecular Entities/Vaccines
Heart Failure
MK-1242 (vericiguat)(1) (U.S.) (EU) (JPN)
Pediatric Neurofibromatosis Type 1
MK-5618 (selumetinib)(1) (EU)


Certain Supplemental Filings
Cancer
MK-3475 Keytruda
• Metastatic Triple-Negative Breast Cancer
         (KEYNOTE-355) (U.S.) (JPN)
• Early-Stage Triple-Negative Breast Cancer
         (KEYNOTE-522) (U.S.)
• Refractory Classical Hodgkin Lymphoma
         (KEYNOTE-204) (EU)
• Unresectable or Metastatic MSI-H or dMMR Colorectal
         Cancer (KEYNOTE-177) (EU) (JPN)
MK-7902 Lenvima(1)
• First-Line Metastatic Hepatocellular Carcinoma
         (KEYNOTE-524) (U.S.)(2)(4)
• Thymic Carcinoma (NCCH1508/REMORA) (JPN)

Footnotes:
(1) Being developed in a collaboration
(2) Being developed in combination with Keytruda.
(3) Being developed as monotherapy and in combination with Keytruda.
(4) In July 2020, the FDA issued a CRL for Merck’s and Eisai’s applications. Merck and Eisai are reviewing the letter and will submit data to the FDA.


Liquidity and Capital Resources
($ in millions)September 30, 2020December 31, 2019
Cash and investments$8,728 $11,919 
Working capital6,172 5,263 
Total debt to total liabilities and equity32.0 %31.2 %
Cash provided by operating activities was $6.2 billion in the first nine months of 2020 compared with $8.6 billion in the first nine months of 2019. Cash provided by operating activities in the first nine months of 2020 includes $2.1 billion of payments related to collaborations compared with $505 million in the first nine months of 2019. Cash provided by operating activities continues to be the Company’s primary source of funds to finance operating needs, capital expenditures, treasury stock purchases and dividends paid to shareholders.
Cash used in investing activities was $4.7 billion in the first nine months of 2020 compared with $1.9 billion in the first nine months of 2019. The increase was driven primarily by lower proceeds from sales of securities and other investments and higher capital expenditures, partially offset by lower purchases of securities and other investments and lower use of cash for acquisitions.
- 49 -

Cash used in financing activities was $4.2 billion in the first nine months of 2020 compared with $6.9 billion in the first nine months of 2019. The lower use of cash in financing activities was driven primarily by a net increase in short-term borrowings in 2020 compared with a net decrease in short-term borrowing in 2019, as well as lower purchases of treasury stock, partially offset by higher payments on debt (see below), lower proceeds from the issuance of debt (see below), higher dividends paid to shareholders, and lower proceeds from the exercise of stock options.
Capital expenditures totaled $3.2 billion and $2.3 billion for the first nine months of 2020 and 2019, respectively. The increased capital expenditures reflect investment in new capital projects focused primarily on increasing manufacturing capacity for Merck’s key products, as well as the purchase of a manufacturing facility in Dunboyne, Ireland to support upcoming product launches (see Note 2 to the condensed consolidated financial statements).
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.1 billion and $2.7 billion of accounts receivable in the third quarter of 2020 and the fourth quarter of 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Condensed Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Condensed Consolidated Statement of Cash Flows.
Dividends paid to stockholders were $4.7 billion and $4.3 billion for the first nine months of 2020 and 2019, respectively. In May 2020, the Board of Directors declared a quarterly dividend of $0.61 per share on the Company’s common stock for the third quarter that was paid in July 2020. In July 2020, the Board of Directors declared a quarterly dividend of $0.61 per share on the Company’s common stock for the fourth quarter that was paid in October 2020.
In February 2020, the Company’s $1.25 billion, 1.85% notes and $700 million floating-rate notes matured in accordance with their terms and were repaid.
In June 2020, the Company issued $4.5 billion principal amount of senior unsecured notes consisting of $1.0 billion of 0.75% notes due 2026, $1.25 billion of 1.45% notes due 2030, $1.0 billion of 2.35% notes due 2040 and $1.25 billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities.
In March 2019, the Company issued $5.0 billion principal amount of senior unsecured notes consisting of $750 million of 2.90% notes due 2024, $1.75 billion of 3.40% notes due 2029, $1.0 billion of 3.90% notes due 2039, and $1.5 billion of 4.00% notes due 2049. The Company used the net proceeds from the offering of $5.0 billion for general corporate purposes, including the repayment of outstanding commercial paper borrowings.
In 2018, Merck’s Board of Directors authorized purchases of up to $10 billion of Merck’s common stock for its treasury. The treasury stock purchase authorization has no time limit and will be made over time in open-market transactions, block transactions on or off an exchange, or in privately negotiated transactions. During the first nine months of 2020, the Company purchased $1.3 billion (16 million shares) of its common stock for its treasury under this share repurchase program. As of September 30, 2020, the Company’s remaining share repurchase authorization was $5.9 billion. In March 2020, the Company temporarily suspended its share repurchase program.
The Company has a $6.0 billion credit facility that matures in June 2024. The facility provides backup liquidity for the Company’s commercial paper borrowing facility and is to be used for general corporate purposes. The Company has not drawn funding from this facility.
Critical Accounting Policies
The Company’s significant accounting policies, which include management’s best estimates and judgments, are included in Note 2 to the consolidated financial statements for the year ended December 31, 2019 included in Merck’s Form 10‑K filed on February 26, 2020. Certain of these accounting policies are considered critical as disclosed in the Critical Accounting Policies section of Management’s Discussion and Analysis of Financial Condition and Results of Operations included in Merck’s Form 10-K because of the potential for a significant impact on the financial statements due to the inherent uncertainty in such estimates. There have been no significant changes in the Company’s critical accounting policies since December 31, 2019. See Note 1 to the condensed consolidated financial statements for information on the adoption of new accounting standards during 2020.

- 50 -

Recently Issued Accounting Standards
For a discussion of recently issued accounting standards, see Note 1 to the condensed consolidated financial statements.
Item 4. Controls and Procedures
Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of the Company’s disclosure controls and procedures over financial reporting. Based on their evaluation, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that as of September 30, 2020, the Company’s disclosure controls and procedures are effective. For the third quarter of 2020, there were no changes in internal control over financial reporting that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.
CAUTIONARY FACTORS THAT MAY AFFECT FUTURE RESULTS
This report and other written reports and oral statements made from time to time by the Company may contain so-called “forward-looking statements,” all of which are based on management’s current expectations and are subject to risks and uncertainties which may cause results to differ materially from those set forth in the statements. One can identify these forward-looking statements by their use of words such as “anticipates,” “expects,” “plans,” “will,” “estimates,” “forecasts,” “projects” and other words of similar meaning, or negative variations of any of the foregoing. One can also identify them by the fact that they do not relate strictly to historical or current facts. These statements are likely to address the Company’s growth strategy, financial results, product development, product approvals, product potential and development programs. One must carefully consider any such statement and should understand that many factors could cause actual results to differ materially from the Company’s forward-looking statements. These factors include inaccurate assumptions and a broad variety of other risks and uncertainties, including the impact of the global outbreak of COVID-19 and other risks and uncertainties some that are known and some that are not. No forward-looking statement can be guaranteed and actual future results may vary materially.
The Company does not assume the obligation to update any forward-looking statement. One should carefully evaluate such statements in light of factors, including risk factors, described in the Company’s filings with the Securities and Exchange Commission, especially on Forms 10-K, 10-Q and 8-K. In Item 1A. “Risk Factors” of the Company’s Annual Report on Form 10‑K for the year ended December 31, 2019, as filed on February 26, 2020, in the Company’s Form 10-Q for the quarterly period ended March 31, 2020, as filed on May 6, 2020, in the Company’s Form 10-Q for the quarterly period ended June 30, 2020, as filed on August 5, 2020, and in this Form 10-Q, the Company discusses in more detail various important risk factors that could cause actual results to differ from expected or historic results. The Company notes these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. One should understand that it is not possible to predict or identify all such factors. Consequently, the reader should not consider any such list to be a complete statement of all potential risks or uncertainties.
PART II - Other Information
Item 1. Legal Proceedings
The information called for by this Item is incorporated herein by reference to Note 9 included in Part I, Item 1, Financial Statements (unaudited) — Notes to Condensed Consolidated Financial Statements.
Item 1A. Risk Factors
For a discussion of risks that affect the Company’s business, please refer to Part I, Item IA, “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. There have been no material changes to the risk factors as previously disclosed in the Company’s Annual Report on Form 10-K, except as follows:
The global COVID-19 pandemic is having an adverse impact on the Company’s business, operations and financial performance. The Company is unable to predict the full extent to which the pandemic and related impacts will continue to adversely impact its business, operations, financial performance, results of operations, and financial condition.
The Company’s business and financial results have been negatively impacted by the outbreak of Coronavirus Disease 2019 (COVID-19). The duration, spread and severity of the COVID-19 pandemic is uncertain, rapidly changing and difficult to predict. The degree to which COVID-19 impacts the Company’s results will depend on future developments, beyond the Company’s knowledge or control, including, but not limited to, the duration and spread of the outbreak, its
- 51 -

severity, the actions taken to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.
Merck assumes that the majority of the negative impact from the COVID-19 pandemic occurred in the second quarter of 2020. However, the Company expects some residual negative impacts in the fourth quarter, largely in Europe and certain emerging markets. In addition, the phasing of the recovery of Gardasil 9 demand is slower than originally anticipated, in particular in the United States due to lower back-to-school demand. To the extent these assumptions prove to be incorrect, the Company’s results may differ materially from the estimates set forth herein.
Thus far in 2020, the COVID-19 pandemic has impacted the Company’s business and the Company continues to expect that it will impact the business in numerous ways, including but not limited to those outlined below:
In the third quarter of 2020, the negative impact of the COVID-19 pandemic to Merck’s Pharmaceutical sales was estimated to be approximately $475 million. The negative impact to Animal Health sales was immaterial. The negative impact to sales in the first nine months of 2020 was approximately $2.0 billion for the Pharmaceutical segment and $50 million for the Animal Health segment. For the full-year 2020, including the impact for the first nine months, Merck expects an unfavorable impact to sales of approximately $2.35 billion (excluding the impact of foreign exchange) due to the COVID-19 pandemic, comprised of approximately $2.3 billion for Pharmaceutical revenue and approximately $50 million for Animal Health revenue.
Roughly two-thirds of Merck’s Pharmaceutical revenue is comprised of physician-administered products, which, despite strong underlying demand, were affected by social distancing measures, fewer well visits and delays in elective surgeries due to the COVID-19 pandemic. These impacts, as well as the prioritization of COVID-19 patients at health care providers, have resulted in reduced administration of many of the Company’s human health products, in particular for its vaccines, including Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), as well as for Keytruda (pembrolizumab) and Implanon/Nexplanon (etonogestrel implant). Access to healthcare providers remains reduced, although improved from the second quarter. Merck anticipates reduced demand for its physician-administered products while pandemic-related access measures remain in place. In addition, declines in elective surgeries negatively affected the demand for Bridion (sugammadex) Injection in the year-to-date period. Sales of Pneumovax 23 (pneumococcal vaccine polyvalent) increased due to heightened awareness of pneumococcal vaccination during the COVID-19 pandemic and ahead of flu season.
Operating expenses were positively affected in the third quarter and first nine months of 2020 by approximately $115 million and $540 million, respectively, primarily driven by lower promotional and selling costs, as well as lower research and development expenses, net of investments in COVID-19-related antiviral and vaccine research programs. For the full-year 2020, Merck expects a net favorable impact to operating expenses of approximately $625 million reflecting continued lower spending due to the COVID-19 pandemic, partially offset by spending on COVID-19-related antiviral and vaccine research programs.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Issuer purchases of equity securities for the three months ended September 30, 2020 were as follows:
ISSUER PURCHASES OF EQUITY SECURITIES
($ in millions)
Period
Total Number
of Shares
Purchased (1)
Average Price
Paid Per
Share
Approximate Dollar Value of Shares
That May Yet Be Purchased
Under the Plans or Programs (1)
July 1 - July 31— $0.00$5,888
August 1 - August 31— $0.00$5,888
September 1 - September 30— $0.00$5,888
Total— $0.00$5,888
(1) The Company did not purchase any shares during the three months ended September 30, 2020 under the plan approved by the Board of Directors in October 2018 to purchase up to $10 billion of Merck’s common stock for its treasury.









- 52 -

Item 6. Exhibits
Number  Description
3.1—
3.2—
31.1 —
31.2 —
32.1 —
32.2 —
101.INS—XBRL Instance Document - The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document.
101.SCH—XBRL Taxonomy Extension Schema Document.
101.CAL—XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF—XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB—XBRL Taxonomy Extension Label Linkbase Document.
101.PRE—XBRL Taxonomy Extension Presentation Linkbase Document.
104 —Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
- 53 -




Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
 MERCK & CO., INC.
Date: November 5, 2020 /s/ Jennifer Zachary
 JENNIFER ZACHARY
 Executive Vice President, General Counsel and Corporate Secretary
Date: November 5, 2020 /s/ Rita A. Karachun
 RITA A. KARACHUN
 Senior Vice President Finance - Global Controller
- 54 -
 EX-31.1 2 exhibit311-rule13ax14a.htm EX-31.1 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CEO 3Q20 Document

Exhibit 31.1
CERTIFICATION
I, Kenneth C. Frazier, certify that:
1.    I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 5, 2020
 
By:     /s/ Kenneth C. Frazier
KENNETH C. FRAZIER
Chairman, President and Chief Executive Officer

 EX-31.2 3 exhibit312-rule13ax14a.htm EX-31.2 RULE 13A-14(A)/15D-14(A) CERTIFICATION OF CFO 3Q20 Document

Exhibit 31.2
CERTIFICATION
I, Robert M. Davis, certify that:
1.    I have reviewed this quarterly report on Form 10-Q of Merck & Co., Inc.;
2.    Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.    Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.    The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)    Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)    Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)    Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)    Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.    The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)    All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)    Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:   November 5, 2020
By:      /s/ Robert M. Davis
ROBERT M. DAVIS
Executive Vice President, Global Services
and Chief Financial Officer

 EX-32.1 4 exhibit321-section1350.htm EX-32.1 SECTION 1350 CERTIFICATION OF CEO 3Q20 Document

Exhibit 32.1
Section 1350
Certification of Chief Executive Officer
 
 
 
Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: November 5, 2020/s/ Kenneth C. Frazier
Name:
Title:		KENNETH C. FRAZIER
Chairman, President and Chief Executive Officer



 EX-32.2 5 exhibit322-section1350.htm EX-32.2 SECTION 1350 CERTIFICATION OF CFO 3Q20 Document

Exhibit 32.2
Section 1350
Certification of Chief Financial Officer



Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: November 5, 2020/s/ Robert M. Davis
Name:
Title:		ROBERT M. DAVIS
Executive Vice President, Global Services
and Chief Financial Officer




 EX-101.SCH 6 mrk-20200930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink 1001002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME link:presentationLink link:calculationLink link:definitionLink 1002003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET link:presentationLink link:calculationLink link:definitionLink 1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 2101101 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2202201 - Disclosure - Basis of Presentation (Policies) link:presentationLink link:calculationLink link:definitionLink 2103102 - Disclosure - Acquisitions, Research Collaborations and License Agreements link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 2405401 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details) link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details) link:presentationLink link:calculationLink link:definitionLink 2107103 - Disclosure - Collaborative Arrangements link:presentationLink link:calculationLink link:definitionLink 2308302 - Disclosure - Collaborative Arrangements (Tables) link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Collaborative Arrangements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2410404 - Disclosure - Collaborative Arrangements - Schedule of Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2111104 - Disclosure - Restructuring link:presentationLink link:calculationLink link:definitionLink 2312303 - Disclosure - Restructuring (Tables) link:presentationLink link:calculationLink link:definitionLink 2413405 - Disclosure - Restructuring - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2414406 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) link:presentationLink link:calculationLink link:definitionLink 2415407 - Disclosure - Restructuring - Activities by Program (Details) link:presentationLink link:calculationLink link:definitionLink 2116105 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 2317304 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 2418408 - Disclosure - Financial Instruments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2419409 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 2420410 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details) link:presentationLink link:calculationLink link:definitionLink 2421411 - Disclosure - Financial Instruments - Fair Value Hedges (Details) link:presentationLink link:calculationLink link:definitionLink 2422412 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2423413 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2424414 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 2425415 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 2426416 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details) link:presentationLink link:calculationLink link:definitionLink 2427417 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link:presentationLink link:calculationLink link:definitionLink 2428418 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 2129106 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 2330305 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 2431419 - Disclosure - Inventories - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2431419 - Disclosure - Inventories - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 2432420 - Disclosure - Inventories - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2133107 - Disclosure - Other Intangibles link:presentationLink link:calculationLink link:definitionLink 2434421 - Disclosure - Other Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 2135108 - Disclosure - Long-Term Debt link:presentationLink link:calculationLink link:definitionLink 2436422 - Disclosure - Long-Term Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2137109 - Disclosure - Contingencies link:presentationLink link:calculationLink link:definitionLink 2438423 - Disclosure - Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2139110 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2340306 - Disclosure - Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 2441424 - Disclosure - Equity - Rollforward Reconciliations (Details) link:presentationLink link:calculationLink link:definitionLink 2142111 - Disclosure - Share-Based Compensation Plans link:presentationLink link:calculationLink link:definitionLink 2343307 - Disclosure - Share-Based Compensation Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2444425 - Disclosure - Share-Based Compensation Plans - Expense Allocations (Details) link:presentationLink link:calculationLink link:definitionLink 2445426 - Disclosure - Share-Based Compensation Plans - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2446427 - Disclosure - Share-Based Compensation Plans - Assumptions Used for Options Granted (Details) link:presentationLink link:calculationLink link:definitionLink 2147112 - Disclosure - Pension and Other Postretirement Benefit Plans link:presentationLink link:calculationLink link:definitionLink 2348308 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) link:presentationLink link:calculationLink link:definitionLink 2449428 - Disclosure - Pension and Other Postretirement Benefit Plans (Details) link:presentationLink link:calculationLink link:definitionLink 2450429 - Disclosure - Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans (Narrative) (Details) link:presentationLink link:calculationLink link:definitionLink 2151113 - Disclosure - Other (Income) Expense, Net link:presentationLink link:calculationLink link:definitionLink 2352309 - Disclosure - Other (Income) Expense, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 2453430 - Disclosure - Other (Income) Expense, Net (Details) link:presentationLink link:calculationLink link:definitionLink 2454431 - Disclosure - Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2155114 - Disclosure - Taxes on Income link:presentationLink link:calculationLink link:definitionLink 2456432 - Disclosure - Taxes on Income (Details) link:presentationLink link:calculationLink link:definitionLink 2157115 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 2358310 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2459433 - Disclosure - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2160116 - Disclosure - Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 2361311 - Disclosure - Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 2462434 - Disclosure - Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 2163117 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 2364312 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 2465435 - Disclosure - Segment Reporting - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2466436 - Disclosure - Segment Reporting - Sales of Company's Products (Details) link:presentationLink link:calculationLink link:definitionLink 2467437 - Disclosure - Segment Reporting - Revenues by Geographic Area (Details) link:presentationLink link:calculationLink link:definitionLink 2468438 - Disclosure - Segment Reporting - Profits to Income Before Taxes (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mrk-20200930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 mrk-20200930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 mrk-20200930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Shares granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Other (income) expense, net Other (income) expense, net Other Nonoperating Income (Expense) Payments of contingent consideration Payments Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Contingencies Commitments and Contingencies Disclosure [Text Block]   Treasury Stock Treasury Stock [Member] Deferred income tax liabilities Deferred income tax liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Implanon/Nexplanon Implanon/Nexplanon [Member] Implanon/Nexplanon [Member]. Segments [Axis] Segments [Axis] Pension and Other Postretirement Benefit Plans Retirement Benefits [Text Block] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Collaborative Arrangements [Abstract] Changes in AOCI by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] China CHINA Level 3 Fair Value, Inputs, Level 3 [Member] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Other current assets Other Current Assets [Member] Fair Value of Derivative, Asset Gross amounts recognized in the consolidated balance sheet, asset Derivative assets Derivative Asset Statistical Measurement [Domain] Statistical Measurement [Domain] Liabilities and Equity Liabilities and Equity [Abstract] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Distributions attributable to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Deferred Income Taxes Deferred Income Tax Liabilities, Net Current Fiscal Year End Date Current Fiscal Year End Date Other Intangibles, Net Intangible Assets, Net (Excluding Goodwill) Proceeds from issuance of debt Proceeds from Issuance of Long-term Debt Entity Address, Postal Zip Code Entity Address, Postal Zip Code Primary weighted average life of collateral Investments, Primary Weighted Average Life of Collateral Investments, Primary Weighted Average Life of Collateral Total current liabilities Payables, current Liabilities, Current Cash collateral received from counterparties Cash collateral received, asset Derivative, Collateral, Obligation to Return Cash Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Performance Share Units (PSUs) Performance Shares [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Purchases of treasury stock Payments for Repurchase of Common Stock Assets Assets [Abstract] Bayer AG Bayer AG [Member] Bayer AG [Member] Acquisition of ArQule, Inc., net of cash acquired Payments to Acquire Business Two, Net of Cash Acquired Entity Shell Company Entity Shell Company Cover [Abstract] Cover [Abstract] Trade accounts payable Accounts Payable, Current Document Type Document Type Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Retained earnings Retained Earnings (Accumulated Deficit) Weighted average useful life of acquired finite-lived intangible assets Acquired Finite-lived Intangible Assets, Weighted Average Useful Life ArQule ArQule [Member] ArQule [Member] Treasury stock shares purchased (in shares) Treasury Stock, Shares, Acquired Income taxes paid Income Taxes Paid Property, plant and equipment Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment Forecasted transactions Foreign Exchange Future [Member] Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Cases Company Agreed To Toll Statute Of Limitations Cases Company Agreed ToToll Statute Of Limitations [Member] Cases Company Agreed To Toll Statute Of Limitations[Member] Legal Defense Costs Legal Defense Costs [Member] Legal Defense Costs [Member] Accumulated Other Comprehensive Income (Loss) [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Amount of Derivative Pretax (Gain) Loss Recognized in Income Amount of Derivative Pretax (Gain) Loss Recognized in Income Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net Hedging Designation [Domain] Hedging Designation [Domain] Other Comprehensive Income (Loss) Net of Taxes: Other Comprehensive Income (Loss), Net of Tax [Abstract] Document Quarterly Report Document Quarterly Report Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Sales discounts Sales Discounts Sales Discounts Other Noncurrent Liabilities Other liabilities, noncurrent Other Liabilities, Noncurrent Antelliq Antelliq [Member] Antelliq [Member] Other Payments for (Proceeds from) Other Investing Activities Short-term investments Marketable Securities, Current AstraZeneca AstraZeneca [Member] AstraZeneca [Member] Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Unallocated Segment Reconciling Items [Member] Inventories (excludes inventories of $2,081 in 2020 and $1,480 in 2019 classified in Other assets - see Note 6) Inventories Inventory, Net Measurement Frequency [Domain] Measurement Frequency [Domain] Inventory [Line Items] Inventory [Line Items] Share price (in dollars per share) Share Price Entity File Number Entity File Number Business Acquisition [Axis] Business Acquisition [Axis] Geographical [Domain] Geographical [Domain] Settlements Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement Defined Benefit Plan Disclosure [Line Items] Defined Benefit Plan Disclosure [Line Items] Inventory [Axis] Inventory [Axis] Forecast Forecast [Member] Class of Stock [Domain] Class of Stock [Domain] Pretax net unrealized losses on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred Derivative Instruments and Hedging Activities Disclosures [Line Items] Derivative Instruments and Hedging Activities Disclosures [Line Items] Document Fiscal Period Focus Document Fiscal Period Focus Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Total Animal Health segment sales Animal Health segment Animal Health segment [Member] Animal Health segment [Member] Measurement Input Type [Domain] Measurement Input Type [Domain] Interest cost Defined Benefit Plan, Interest Cost Type of Restructuring [Domain] Type of Restructuring [Domain] Statistical Measurement [Axis] Statistical Measurement [Axis] Fair value of loans payable and long-term debt, including current portion Debt Instrument, Fair Value Disclosure Alliance revenue - Koselugo Alliance revenue - Koselugo [Member] Alliance revenue - Koselugo Other net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other U.S. government and agency securities US Government Agencies Debt Securities [Member] Carrying Amount of Hedged Liabilities Hedged Liability, Fair Value Hedge Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Business Combinations [Abstract] Business Combinations [Abstract] Latin America Latin America [Member] Alliance revenue - Adempas (2) Alliance Revenue - Adempas [Member] Alliance Revenue - Adempas [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Derivative Instruments and Hedging Activities Disclosures [Table] Derivative Instruments and Hedging Activities Disclosures [Table] Long-Term Debt Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Collaborative Arrangement Collaborative Arrangement [Member] Raw materials and work in process Inventory, Work in Process and Raw Materials Selling, general and administrative Selling, general and administrative Selling, General and Administrative Expenses [Member] Calculations of Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Share-based compensation payments attributable to precombination service Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Total pretax restructuring costs Expense Restructuring and Related Cost, Incurred Cost Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Business Acquisition, Contingent Consideration [Line Items] Business Acquisition, Contingent Consideration [Line Items] Fair Value of Assets Acquired and Liabilities Assumed Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Other Other profits Corporate, Non-Segment [Member] Amendment Flag Amendment Flag Milestone payments made to collaborative partner Milestone Payments Made to Collaborative Partner Milestone Payments Made to Collaborative Partner Inventories Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory Reclassification adjustments, net of taxes Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Increase (decrease) in Sales as a result of AOCI reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax Present value discount rate Intangible Asset, Measurement Input Intangible Asset, Measurement Input Sanofi Pasteur Sanofi Pasteur [Member] Sanofi Pasteur [Member] Net Cash Provided by Operating Activities Net Cash Provided by (Used in) Operating Activities Restructuring Restructuring and Related Activities Disclosure [Text Block] Measurement Frequency [Axis] Measurement Frequency [Axis] Januvia Januvia [Member] Januvia [Member] . Derivatives Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] Sentinel Sentinel [Member] Sentinel [Member] Financial Instruments Financial Instruments [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Expected return on plan assets Defined Benefit Plan, Expected Return (Loss) on Plan Assets Alliance revenue - profit sharing Collaborative Arrangement, Profit Sharing Collaborative Arrangement, Profit Sharing Amount of gain recognized in Other (income) expense, net on derivatives Derivative, Gain (Loss) on Derivative, Net Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Cash equivalents Cash Equivalents, at Carrying Value Geographical [Axis] Geographical [Axis] Tax Reclassification from AOCI, Current Period, Tax Local Phone Number Local Phone Number Other state courts Other State Court [Member] Other state court. Segments [Domain] Segments [Domain] Net periodic defined benefit plan (credit) cost other than service cost Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component Debt securities, amortized cost Debt Securities, Available-for-sale, Amortized Cost Debt securities, unrealized gains Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] 2.40% notes due 2022 2.40% Notes Due 2022 [Member] 2.40% Notes Due 2022 [Member] Healthcare Services Segment Healthcare Services Segment [Member] Healthcare Services segment [Member] Common shares issuable (1) Weighted Average Number Diluted Shares Outstanding Adjustment Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease) RotaTeq Rotateq [Member] RotaTeq [Member] Sales of Company's products Revenue from External Customers by Products and Services [Table Text Block] Income Statement Location [Axis] Income Statement Location [Axis] Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Income Statement Location [Domain] Income Statement Location [Domain] Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Cash Flows from Financing Activities Net Cash Provided by (Used in) Financing Activities [Abstract] Information on Investments in Debt and Equity Securities Schedule of Available-for-sale Securities Reconciliation [Table Text Block] Selling, general and administrative Selling, General and Administrative Expense Total swap notional amount U.S Dollar Notional Amount Derivative, Notional Amount Consolidated revenues by geographic area Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Foreign exchange contracts Foreign Exchange Contract [Member] Entity Current Reporting Status Entity Current Reporting Status Other pharmaceutical (3) Other Pharmaceutical [Member] Other pharmaceutical. Treasury lock Treasury Lock [Member] Other assets Other Assets, Noncurrent Legal Costs, Policy Legal Costs, Policy [Policy Text Block] Acquisition of Antelliq Corporation, net of cash acquired Payments to Acquire Business Three, Net of Cash Acquired NuvaRing Nuvaring [Member] NuvaRing [Member]. Segment Reporting Segment Reporting Disclosure [Text Block] Long-Term Debt Long Term Debt Excluding Current Maturities [Member] Long Term Debt Excluding Current Maturities [Member] Receivables Receivables, Net, Current Investments Marketable Securities, Noncurrent Total Assets Assets Scenario [Axis] Scenario [Axis] Foreign government bonds Debt Security, Government, Non-US [Member] Basis of Presentation Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] IPR&D Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets Retirement Plan Sponsor Location [Axis] Retirement Plan Sponsor Location [Axis] Belsomra Belsomra [Member] Belsomra [Member] Income from investments in equity securities, net (1) Equity Securities, FV-NI, Gain (Loss) Pneumovax 23 Pneumovax 23 [Member] Pneumovax 23[Member]. Amortization of unrecognized prior service credit Defined Benefit Plan, Amortization of Prior Service Cost (Credit) Finite-lived intangible assets Finite-Lived Intangible Assets, Net Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Income taxes payable Accrued Income Taxes, Current Subsequent Event Type [Axis] Subsequent Event Type [Axis] 0.500% Notes due 2024 0.500% Notes due 2024 [Member] 0.500% Notes due 2024 [Member] Entity Small Business Entity Small Business Lenvima Alliance revenue - Lenvima (1) Lenvima [Member] Lenvima [Member] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Cost of sales Cost of sales Cost of Sales [Member] Interest expense Interest expense Interest Expense Share-based compensation plans and other Stockholders' Equity, Other Depreciation and amortization Depreciation and amortization Depreciation, Depletion and Amortization Entity Filer Category Entity Filer Category Unrealized net losses (gains) Equity Securities, FV-NI, Unrealized Gain (Loss) Other intangible assets Other Intangible Assets [Member] Cash and cash equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Cubicin Cubicin [Member] Cubicin [Member] Product and Service [Axis] Product and Service [Axis] Liabilities Liabilities Entity Address, City or Town Entity Address, City or Town Derivatives designated as hedging instruments Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments 1.875% Notes due 2026 1.875% Notes due 2026 [Member] 1.875% Notes due 2026 [Member] Singulair Singulair [Member] Singulair [Member]. Revenue Sales Sales [Member] Stockholders Equity [Line Items] Stockholders Equity [Line Items] [Line Items] for Stockholders Equity [Table] Other Assets Other Noncurrent Assets [Member] Emend Emend [Member] Emend [Member]. Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Retirement Plan Type [Axis] Retirement Plan Type [Axis] Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Other Other Restructuring [Member] Other segment sales (4) Other segment Other Segments [Member] Zepatier Zepatier [Member] Zepatier [Member] Loss contingency, claims on appeal, number (in legal matters) Loss Contingency, Claims on Appeal, Number Loss Contingency, Claims on Appeal, Number 2.45% notes due 2050 2.45% notes due 2050 [Member] 2.45% notes due 2050 [Member] Probable contingent payments collaborative arrangement Probable Contingent Payments Collaborative Arrangement Probable Contingent Payments Collaborative Arrangement Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Level 1 Fair Value, Inputs, Level 1 [Member] Amount of (loss) gain recognized in OCI on derivatives Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Legal Entity Type of Counterparty [Domain] Legal Entity Type of Counterparty [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Document Fiscal Year Focus Document Fiscal Year Focus Isentress/Isentress HD Isentress/Isentress HD [Member] Isentress/Isentress HD [Member]. Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset Derivative Asset, Not Offset, Policy Election Deduction Immune Design Immune Design [Member] Immune Design [Member] Other Paid-In Capital Additional Paid-in Capital [Member] Debt Instrument [Axis] Debt Instrument [Axis] Atozet Atozet [Member] Atozet [Member] Other (Income) Expense, Net Schedule of Other Nonoperating Income (Expense) [Table Text Block] Inventory [Table] Inventory [Table] Inventory [Table] Total (approximates current cost) Inventory, Gross Operating Segments Total segment profits Operating Segments [Member] Contingent Consideration by Type [Axis] Contingent Consideration by Type [Axis] Japan JAPAN Treasury stock shares purchased Treasury Stock, Value, Acquired, Cost Method Net changes in assets and liabilities Increase (Decrease) in Operating Capital Fair Value of Derivative, Liability Gross amounts recognized in the consolidated balance sheet, liability Derivative liabilities Derivative Liability Adjustments to reconcile net income to net cash provided by operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Litigation Case [Axis] Litigation Case [Axis] Accounts payable and accrued liabilities Accounts Payable and Accrued Liabilities [Member] Net unrealized (loss) gain on investments, net of reclassifications Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Recognized as: Recognized As [Abstract] Recognized as. Component of Other Income / Expense of Nonoperating [Table] Component of Other Income / Expense of Nonoperating [Table] Component of Other Income / Expense of Nonoperating [Table] Income Before Taxes Profits Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Acquisition of Peloton Therapeutics, Inc., net of cash acquired Payments to Acquire Business Four, Net of Cash Acquired Payments to Acquire Business Four, Net of Cash Acquired Research and development Research and development Research and Development Expense Primaxin Primaxin [Member] Primaxin [Member]. License option payment related to collaborative arrangement License option payment related to collaborative arrangement License option payment related to collaborative arrangement Debt assumed and paid Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt Subsequent Event Subsequent Event [Member] Upfront and milestone payments Upfront And Milestone Payments Made To Collaborative Partner Upfront and milestone payments made to partner as part of collaborative arrangement. Domestic Tax Authority Domestic Tax Authority [Member] Other acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Common stock, shares authorized (shares) Common Stock, Shares Authorized Debt, carrying amount Debt, Long-term and Short-term, Combined Amount Proceeds from exercise of stock options Proceeds from Stock Options Exercised Estimate of cumulative pre tax costs that will result in cash outlays Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense). Vaqta Vaqta [Member] Vaqta [Member] Currency options Foreign Exchange Option [Member] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Additions Business Combination, Consideration Transferred, Liabilities Incurred Document Period End Date Document Period End Date Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Entity Registrant Name Entity Registrant Name Income Statement [Abstract] Income Statement [Abstract] Accumulated Other Comprehensive Loss Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Development Milestones Development Milestones [Member] Development Milestones [Member] Noxafil Noxafil [Member] Noxafil [Member]. IPR&D Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Interest paid Interest Paid, Including Capitalized Interest, Operating and Investing Activities Current Assets Assets, Current [Abstract] Interest income Interest income Investment Income, Interest Income Tax Authority [Domain] Income Tax Authority [Domain] Comprehensive Income Attributable to Merck & Co., Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Patents [Member] Patents [Member] ProQuad/M-M-R II/Varivax ProQuad MMR II Varivax [Member] ProQuad/M-M-R II/Varivax [Member]. Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Sivextro [Member] Sivextro [Member] Sivextro Scenario [Domain] Scenario [Domain] Asia Pacific (other than China and Japan) Asia Pacific [Member] Other comprehensive income (loss) before reclassification adjustments, net of taxes OCI, before Reclassifications, Net of Tax, Attributable to Parent Counterparty Name [Domain] Counterparty Name [Domain] Consolidation Items [Domain] Consolidation Items [Domain] Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis Offsetting Assets And Liabilities [Table Text Block] Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis. Income Tax Authority [Axis] Income Tax Authority [Axis] Entity Tax Identification Number Entity Tax Identification Number Contingent consideration Fair value, beginning balance Fair value, ending balance Business Combination, Contingent Consideration, Liability Estimate of cumulative pre tax costs that will be noncash Estimate Of Cumulative Pre Tax Costs That Will Be Noncash Estimate of cumulative pre tax costs that will be noncash. Simponi Simponi [Member] Simponi [Member]. Total debt and publicly traded equity securities, fair value Debt Securities and Equity Securities, FV-NI Debt Securities and Equity Securities, FV-NI Net Income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Trading Symbol Trading Symbol Hedging Designation [Axis] Hedging Designation [Axis] Entity Information [Line Items] Entity Information [Line Items] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] Loans payable and current portion of long-term debt Long Term Debt, Current Maturities [Member] Long Term Debt, Current Maturities [Member] Schedule of Inventories Schedule of Inventory, Current [Table Text Block] Investments Debt Securities, Trading, and Equity Securities, FV-NI Nasonex Cozaar Hyzaar [Member] Cozaar/Hyzaar [Member]. Tax Other Comprehensive Income (Loss) before Reclassifications, Tax Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Share-based compensation Pretax share-based compensation expense Share-based Payment Arrangement, Noncash Expense Net change in short-term borrowings Proceeds from (Repayments of) Short-term Debt Capital expenditures Payments to Acquire Productive Assets Payments to Acquire Productive Assets Publicly traded equity securities, fair value Publicly traded equity securities Equity Securities, FV-NI Fosamax Fosamax [Member] Fosamax [Member]. Loss contingency, claims dismissed, number (in legal matters) Loss Contingency, Claims Dismissed, Number Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax Other, net Other Nonoperating Income Expense, Other Other nonoperating income and expense items not separately disclosed. Other Proceeds from (Payments for) Other Financing Activities Derivatives Designated as Hedging Instruments Designated as Hedging Instrument [Member] Inventories classified in Other assets Other assets Inventory, Noncurrent Charges Related to Restructuring Program Activities by Type of Cost Restructuring and Related Costs [Table Text Block] Measurement Input Type [Axis] Measurement Input Type [Axis] Non-cash activity Restructuring Reserve Noncash Activity Noncash activity affecting the restructuring reserve, including accelerated depreciation. Cumulative unrealized losses on investments Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Keytruda Keytruda [Member] Keytruda [Member] Income Statement Effects of Derivatives Not Designated as Hedging Instruments Derivatives Not Designated as Hedging Instruments [Table Text Block] Other Intangibles Intangible Assets Disclosure [Text Block] Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Maximum average period of maturities of contracts in years (less than) Derivative, Average Remaining Maturity Service cost Defined Benefit Plan, Service Cost Restricted cash Restricted Cash and Cash Equivalents Other (Income) Expense, Net Other Income and Other Expense Disclosure [Text Block] City Area Code City Area Code Cost of sales Cost of Goods and Services Sold Debt securities, fair value Investments Debt Securities, Available-for-sale Equity Components [Axis] Equity Components [Axis] Title of 12(b) Security Title of 12(b) Security Loss contingency, pending claims, number (in legal matters) Loss Contingency, Pending Claims, Number Sales-Based Milestones Sales-Based Milestones [Member] Sales-Based Milestones [Member] Accounts receivable Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Minimum Minimum [Member] Legal Entity of Counterparty, Type [Axis] Legal Entity of Counterparty, Type [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Revenue from External Customer [Line Items] Revenue from External Customer [Line Items] Income Tax Authority, Name [Domain] Income Tax Authority, Name [Domain] Themis Themis [Member] Themis [Member] Less: Net Income (Loss) Attributable to Noncontrolling Interests Net income (loss) attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Location and Amount of Pretax (Gains) Losses of Derivatives Derivative Instruments, Gain (Loss) [Table Text Block] Net loss amortization Defined Benefit Plan, Amortization of Gain (Loss) Assumptions Used to Determine Weighted-Average Fair Value of Options Granted Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Asset-backed securities Asset-backed Securities [Member] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Net periodic benefit cost Defined Benefit Plan, Net Periodic Benefit Cost (Credit) U.S. United States UNITED STATES Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Cash Flows from Operating Activities Net Cash Provided by (Used in) Operating Activities [Abstract] Equity Stockholders' Equity Note Disclosure [Text Block] Share-based compensation plans and other (in shares) Stockholders' Equity, Other Shares Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] Interest rate swap contracts Interest rate swap contracts Interest Rate Swap [Member] IAVI IAVI [Member] IAVI [Member] Lynparza Lynparza [Member] Lynparza [Member] Other paid-in capital Additional Paid in Capital, Common Stock Subsequent Event Type [Domain] Subsequent Event Type [Domain] Total current and noncurrent inventories Inventory Net And Inventory Noncurrent Total of current and noncurrent inventories. Derivative [Table] Derivative [Table] Acquisitions Research Collaborations And License Agreements Transactions [Line Items] Business Acquisition [Line Items] Assets Assets, Fair Value Disclosure [Abstract] Income Tax Examination [Line Items] Income Tax Examination [Line Items] Reconciliation of segment profits to income before taxes Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block] Zetia antitrust litigation [Member] Zetia antitrust litigation [Member] Zetia antitrust litigation [Member] Acquisitions, Research Collaborations and License Agreements Acquisitions Research Collaborations And License Agreements [Text Block] Information related to acquisitions, divestitures, research collaborations and license agreements. Changes in estimated fair value Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Other Nonoperating Income (Expense) [Abstract] Other Nonoperating Income (Expense) [Abstract] Retirement Plan Type [Domain] Retirement Plan Type [Domain] Dividends paid to stockholders Payments of Ordinary Dividends, Common Stock 1.375% Notes due 2036 1.375% Notes due 2036 [Member] 1.375% Notes due 2036 [Member] Consolidation Items [Axis] Consolidation Items [Axis] Cumulative unrealized gains on investments Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount Research and development Research and development Research and Development Expense [Member] Forward Contracts Forward Contracts [Member] 1.85% Notes Due 2020 1.85% Notes Due 2020 [Member] 1.85% Notes Due 2020 [Member] Derivatives Not Designated as Hedging Instruments Not Designated as Hedging Instrument [Member] Publicly traded equity securities Equity Securities [Member] Accrued and other current liabilities Accrued Liabilities [Member] Goodwill, Impairment Loss Goodwill, Impairment Loss Accounts receivable (net of allowance for doubtful accounts of $89 in 2020 and $86 in 2019) Accounts Receivable, after Allowance for Credit Loss, Current Finished goods Inventory, Finished Goods, Gross International Foreign Plan [Member] Restructuring reserve, beginning balance Restructuring reserve, ending balance Restructuring Reserve Separation Costs One-time Termination Benefits [Member] Restructuring costs Restructuring Charges [Member] Cancidas Cancidas [Member] Cancidas [Member]. Debt securities, unrealized losses Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax Peloton Peloton [Member] Peloton Supplies Other Inventory, Supplies, Gross Restructuring Type [Axis] Restructuring Type [Axis] Cumulative translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent (Payments) receipts, net Payments for Restructuring Goodwill Goodwill Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-sale [Line Items] Other comprehensive income (loss), net of taxes Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Total Costs, Expenses and Other Costs Expenses And Other Total of cost of sales, operating expenses and nonoperating income or expense. Income Tax Examination [Table] Income Tax Examination [Table] Current liability Business Combination, Contingent Consideration, Liability, Current Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Transaction costs Business Acquisition, Transaction Costs Regulatory Milestones Regulatory Milestones [Member] Regulatory Milestones [Member] Cash dividends declared on common stock (in dollars per share) Common Stock, Dividends, Per Share, Declared Face amount of debt Par Value of Debt Debt Instrument, Face Amount Level 2 Fair Value, Inputs, Level 2 [Member] Royalty Rate, Percentage Royalty Rate, Percentage Royalty Rate, Percentage Contingent consideration, measurement input, discount rate (as percent) Business Combination, Contingent Consideration, Liability, Measurement Input Liabilities Liabilities, Fair Value Disclosure [Abstract] Dunboyne Dunboyne [Member] Dunboyne Decrease to LIFO cost Inventory, LIFO Reserve Entities [Table] Entities [Table] Equity [Abstract] Equity [Abstract] Total assets Assets, Fair Value Disclosure Europe, Middle East and Africa EMEA [Member] Femur Fracture Litigation Femur Fracture Litigation [Member] Femur Fracture litigation. 1.125% Notes due 2021 1.125% Notes due 2021 [Member] 1.125% Notes due 2021 [Member] Entity Central Index Key Entity Central Index Key Entity Emerging Growth Company Entity Emerging Growth Company Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Average common shares outstanding assuming dilution Weighted Average Number of Shares Outstanding, Diluted Derivative Contract [Domain] Derivative Contract [Domain] Litigation Case [Domain] Litigation Case [Domain] Forward contract, shares Forward Contract Indexed to Issuer's Equity, Indexed Shares Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) Basic earnings per common share attributable to Merck & Co., Inc. common shareholders Earnings Per Share, Basic Other Other Countries [Member] Other Countries [Member] Other Income and Expenses [Abstract] Other Income and Expenses [Abstract] Number of operating segments Number of Operating Segments Expected life (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Curtailments Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment Debt Disclosure [Abstract] Debt Disclosure [Abstract] Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax Net amounts, asset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Net amounts, liability Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Acquired rights Finite-lived Intangible Assets Acquired Net Cash Used in Financing Activities Net Cash Provided by (Used in) Financing Activities Payments on debt Repayments of Long-term Debt Termination benefits Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits Investments AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member] Cozaar/Hyzaar Nasonex [Member] Nasonex [Member]. Balance Sheet Location [Axis] Balance Sheet Location [Axis] Counterparty Name [Axis] Counterparty Name [Axis] Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019 Common Stock, Value, Issued Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Intangible asset impairment charges Impairment of Intangible Assets, Finite-lived Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] VelosBio [Member] VelosBio [Member] VelosBio Deferred tax assets Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets Commercial paper Commercial Paper [Member] Income tax benefit Share-based Payment Arrangement, Expense, Tax Benefit Unrealized gains recognized on investments in equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount Tax benefit recognized related to settlement Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities Loans payable and current portion of long-term debt Debt, Current Expected restructuring and related cost Restructuring and Related Cost, Expected Cost Retirement Benefits [Abstract] Retirement Benefits [Abstract] Foreign currency Currency Swap [Member] Stockholders' equity before deduction for treasury stock Stockholders' Equity before Treasury Stock Prevymis Prevymis [Member] Prevymis [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Total identifiable net assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net Noncontrolling Interests Stockholders' Equity Attributable to Noncontrolling Interest Weighted-average fair value per share granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Collaborative Arrangements Collaborative Arrangement Disclosure [Text Block] Cash Flows from Investing Activities Net Cash Provided by (Used in) Investing Activities [Abstract] Common stock, shares issued (in shares) Shares, beginning balance (in shares) Shares, ending balance (in shares) Common Stock, Shares, Issued Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Federal Federal [Member] Federal. Legal defense costs reserve Estimated Litigation Liability 2.500% Notes due 2034 2.500% Notes due 2034 [Member] 2.500% Notes due 2034 [Member] Schedule of Defined Benefit Plans Disclosures [Table] Schedule of Defined Benefit Plans Disclosures [Table] Vytorin Vytorin [Member] Vytorin [Member] . Long-Term Debt Long-term Debt, Excluding Current Maturities Segment Reporting [Abstract] Segment Reporting [Abstract] 0.75% notes due 2026 0.75% notes due 2026 [Member] 0.75% notes due 2026 Debt Instrument [Line Items] Debt Instrument [Line Items] Total Merck & Co., Inc. stockholders’ equity Stockholders' Equity Attributable to Parent Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Accounts Receivable, Sale Accounts Receivable, Sale Liabilities and Equity Liabilities and Equity Loss Contingencies [Line Items] Loss Contingencies [Line Items] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Taxes on Income Income Tax Disclosure [Text Block] Payables, Noncurrent Liabilities, Noncurrent Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Summary of Interest Rate Swaps Held Schedule of Interest Rate Derivatives [Table Text Block] Consideration transferred Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Other Assets Other Assets [Member] Financial Instrument Financial Instrument [Axis] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table] Common shares issuable under share-based compensation plans excluded from diluted earnings per common share because the effect would have been antidilutive (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Proceeds from sales of securities and other investments Proceeds from Sale, Maturity and Collection of Investments Euro-denominated notes Euro-dominated Notes [Member] Euro-dominated Notes [Member] California state court California State Court [Member] California state court. Other Other Noncash Income (Expense) Equity Component [Domain] Equity Component [Domain] Charge for acquisition of Peloton Therapeutics, Inc. Research and Development in Process Entity Address, Address Line One Entity Address, Address Line One Loss Contingency, Claims Settled, Number Loss Contingency, Claims Settled, Number Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,572 in 2020 and $17,686 in 2019 Property, Plant and Equipment, Net Bridion Bridion [Member] Bridion [Member]. Share-Based Compensation Plans Share-based Payment Arrangement [Text Block] Interest rate swap contracts Interest Rate Contract [Member] Net Income Attributable to Merck & Co., Inc. Net Income Attributable to Merck & Co., Inc. Net income attributable to Merck & Co., Inc. Net Income (Loss) Attributable to Parent Entity Address, State or Province Entity Address, State or Province Accrued and other current liabilities Other Liabilities, Current Eisai Eisai [Member] Eisai [Member] Other comprehensive income (loss), net of taxes Other Comprehensive Income (Loss), Net of Tax Inventories Inventory Disclosure [Text Block] Other assets and liabilities, net Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net Seagen Seagen [Member] Seagen International International [Member] International [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Total current assets Assets, Current Number of interest rate swaps held (in interest rate swaps) Number of Interest Rate Swaps Held (in interest rate swaps) Number of Interest Rate Derivatives Held Retirement Plan Sponsor Location [Domain] Retirement Plan Sponsor Location [Domain] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Income Tax Authority, Name [Axis] Income Tax Authority, Name [Axis] Restructuring costs Restructuring costs Restructuring Charges Follistim AQ Follistim Aq [Member] Follistim AQ [Member]. Other current assets Deferred Income Taxes and Other Assets, Current Employee Benefit Plans Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] Reclassification adjustments, pretax Reclassification from AOCI, Current Period, before Tax, Attributable to Parent Total Pharmaceutical segment sales Pharmaceutical segment Pharmaceutical segment [Member] Pharmaceutical segment. Merck & Co., Inc. Stockholders’ Equity Stockholders' Equity Attributable to Parent [Abstract] Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Technology Rights Developed Technology Rights [Member] Entity Interactive Data Current Entity Interactive Data Current Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Intangible asset impairment charges Goodwill and Intangible Asset Impairment Benefit plan net gain and prior service credit, net of amortization Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Contributions by employer Defined Benefit Plan, Plan Assets, Contributions by Employer Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Cumulative costs since program inception Restructuring and Related Cost, Cost Incurred to Date Equity Schedule of Stockholders Equity [Table Text Block] Amounts of Share-Based Compensation Cost Recorded in Consolidated Statement of Income Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]    Common Stock Common Stock [Member] Cumulative Translation Adjustment Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Product and Service [Domain] Product and Service [Domain] Net unrealized (loss) gain on derivatives, net of reclassifications Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Collaboration Arrangements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Inventories Produced in Preparation for Product Launches Inventories Produced in Preparation for Product Launches [Member] Inventories Produced in Preparation for Product Launches [Member] Inventory [Domain] Inventory [Domain] Zetia Zetia [Member] Zetia [Member] . Unrealized losses recognized on investments in equity securities without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount Gardasil/Gardasil 9 Gardasil/Gardasil 9 [Member] Gardasil/Gardasil 9 [Member]. Other (income) expense, net Other Nonoperating Income (Expense) [Member] Expected future employer contributions, current fiscal year Defined Benefit Plan, Expected Future Employer Contributions, Current Fiscal Year Stated interest rate (as percent) Debt Instrument, Interest Rate, Stated Percentage Dividends payable Dividends Payable, Current Other Assets Deferred Income Taxes and Other Assets, Noncurrent Remicade Remicade [Member] Remicade [Member]. Accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Stockholders Equity [Table] Stockholders Equity [Table] Stockholders Equity [Table] Net Decrease in Cash, Cash Equivalents and Restricted Cash Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Janumet Janumet [Member] Janumet [Member]. Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Hedged items Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge Average common shares outstanding Weighted Average Number of Shares Outstanding, Basic Costs, Expenses and Other Costs and Expenses [Abstract] Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Amounts Recorded on Balance Sheet Related to Fair Value Hedges Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block] Treasury Stock, Shares Treasury Stock, Shares 2.35% notes due 2040 2.35% notes due 2040 [Member] 2.35% notes due 2040 [Member] Zerbaxa Zerbaxa [Member] Zerbaxa [Member] Loss Contingencies [Table] Loss Contingencies [Table] Component of Other Income / Expense of Nonoperating [Line Items] Component of Other Income / Expense of Nonoperating [Line Items] [Line Items] for Component of Other Income / Expense of Nonoperating [Table] Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability Derivative Liability, Not Offset, Policy Election Deduction Amortization of purchase accounting adjustments Amortization Of Purchase Accounting Adjustments Amortization of purchase accounting adjustments. Equity investments without readily determinable fair values Equity Securities without Readily Determinable Fair Value, Amount Tukysa Tukysa [Member] Tukysa Total equity Equity, beginning balance Equity, ending balance Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest New Jersey state court New Jersey State Court [Member] New Jersey state court member. Sales Revenues Exchange losses Foreign Currency Transaction Gain (Loss), before Tax Class of Stock [Axis] Class of Stock [Axis] Taxes on Income Income Tax Expense (Benefit) Accelerated Depreciation Accelerated Depreciation [Member] Accelerated Depreciation [Member] Adempas Adempas [Member] Adempas Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 at January 1, 2020 included in Other Assets) Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $45 at September 30, 2020 included in Other Assets) Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-sale [Table] Purchases of securities and other investments Payments to Acquire Marketable Securities Total liabilities Financial and Nonfinancial Liabilities, Fair Value Disclosure Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders Earnings Per Share, Diluted Alliance revenue - Lynparza (1) Alliance revenue - Lynparza [Member] Alliance revenue - Lynparza [Member] Payment to acquire business Payments to Acquire Businesses, Gross Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Livestock Livestock [Member] Livestock [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Derivative [Line Items] Derivative [Line Items] Information About the Changes in Liabilities for Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Other unallocated, net Segment Reporting Unallocated Other Expenses Net Other net expenses not allocated to segments. Commercial Milestone Commercial Milestone [Member] Commercial Milestone Inventories Not Expected to be Sold Within One Year Inventory Not Expected to be Sold Within One Year [Member] Inventory Not Expected to be Sold Within One Year [Member] Total share-based compensation expense, net of taxes Share-based Payment Arrangement, Expense, after Tax Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Contingent consideration, maximum Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High Deferred income taxes Deferred Income Tax Expense (Benefit) Internal Revenue Service (IRS) Internal Revenue Service (IRS) [Member] Award Type [Axis] Award Type [Axis] Maximum Maximum [Member] Security Exchange Name Security Exchange Name Non- controlling Interests Noncontrolling Interest [Member] Cash dividends declared on common stock Dividends, Common Stock, Cash Retained Earnings Retained Earnings [Member] 2.35% notes due 2022 2.35% Notes Due 2022 [Member] 2.35% Notes Due 2022 [Member] Effective income tax rate (as percent) Effective Income Tax Rate Reconciliation, Percent Components of net cost of defined benefit plans Schedule of Net Benefit Costs [Table Text Block] Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Payments to Acquire Investments Payments to Acquire Investments Net Cash Used in Investing Activities Net Cash Provided by (Used in) Investing Activities Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Award Type [Domain] Award Type [Domain] Document Transition Report Document Transition Report Companion Animals Companion Animals [Member] Companion Animals [Member] Other Postretirement Benefit Plans Other Postretirement Benefits Plan [Member] Corporate notes and bonds Corporate Debt Securities [Member] Charges and Spending Relating to Restructuring Activities by Program Schedule of Restructuring Reserve by Type of Cost [Table Text Block] 1.45% notes due 2030 1.45% notes due 2030 [Member] 1.45% notes due 2030 [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Other comprehensive income (loss) before reclassification adjustments, pretax OCI, before Reclassifications, before Tax, Attributable to Parent Contingent milestone payments collaborative arrangement Contingent Payments Collaborative Arrangement Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement. Schedule of Revenues from External Customers and Long-Lived Assets [Table] Schedule of Revenues from External Customers and Long-Lived Assets [Table] Invanz Invanz [Member] Invanz [Member]. Less treasury stock, at cost: 1,047,343,390 shares in 2020 and 1,038,087,496 shares in 2019 Treasury Stock, Value 3.875% notes due 2021 3.875% Notes Due 2021 [Member] 3.875% Notes Due 2021 Earnings Per Share Earnings Per Share [Text Block] Pension Plans Pension Plan [Member] Cash collateral advanced to counterparties Cash collateral received, liability Derivative, Collateral, Right to Reclaim Cash Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Financial Instruments Financial Instruments Disclosure [Text Block] Pension and Other Postretirement Benefit Plans (Narrative) [Abstract] Pension and Other Postretirement Benefit Plans (Narrative) [Abstract] Pension and Other Postretirement Benefit Plans (Narrative) [Abstract] Current Liabilities Liabilities, Current [Abstract] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Arcoxia Arcoxia [Member] Arcoxia [Member]. Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Collaborative Arrangement, Sales, Net Collaborative Arrangement, Sales, Net Collaborative Arrangement, Sales, Net Recently Adopted and Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Measurement Input, Discount Rate Measurement Input, Discount Rate [Member] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] EX-101.PRE 10 mrk-20200930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 mrk-20200930_htm.xml IDEA: XBRL DOCUMENT 0000310158 2020-01-01 2020-09-30 0000310158 us-gaap:CommonStockMember 2020-01-01 2020-09-30 0000310158 mrk:A1.125Notesdue2021Member 2020-01-01 2020-09-30 0000310158 mrk:A0.500Notesdue2024Member 2020-01-01 2020-09-30 0000310158 mrk:A1.875Notesdue2026Member 2020-01-01 2020-09-30 0000310158 mrk:A2.500Notesdue2034Member 2020-01-01 2020-09-30 0000310158 mrk:A1.375Notesdue2036Member 2020-01-01 2020-09-30 0000310158 2020-10-31 0000310158 2020-07-01 2020-09-30 0000310158 2019-07-01 2019-09-30 0000310158 2019-01-01 2019-09-30 0000310158 2020-09-30 0000310158 2019-12-31 0000310158 2018-12-31 0000310158 2019-09-30 0000310158 srt:ScenarioForecastMember mrk:VelosBioMember 2020-11-01 2020-11-30 0000310158 mrk:SeagenMember 2020-09-01 2020-09-30 0000310158 mrk:SeagenMember 2020-09-30 0000310158 us-gaap:ForwardContractsMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0000310158 us-gaap:ForwardContractsMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:SubsequentEventMember 2020-10-01 2020-10-31 0000310158 mrk:SeagenMember mrk:RegulatoryMilestonesMember 2020-09-01 2020-09-30 0000310158 mrk:SeagenMember mrk:SalesBasedMilestonesMember 2020-09-01 2020-09-30 0000310158 mrk:SeagenMember mrk:TukysaMember 2020-09-01 2020-09-30 0000310158 mrk:SeagenMember mrk:TukysaMember mrk:RegulatoryMilestonesMember 2020-09-01 2020-09-30 0000310158 mrk:SeagenMember mrk:TukysaMember srt:MinimumMember 2020-09-01 2020-09-30 0000310158 mrk:SeagenMember mrk:TukysaMember srt:MaximumMember 2020-09-01 2020-09-30 0000310158 mrk:DunboyneMember 2020-09-01 2020-09-30 0000310158 mrk:DunboyneMember 2020-09-30 0000310158 mrk:SentinelMember 2020-07-01 2020-07-31 0000310158 mrk:SentinelMember us-gaap:DevelopedTechnologyRightsMember 2020-07-01 2020-07-31 0000310158 mrk:SentinelMember us-gaap:DevelopedTechnologyRightsMember 2020-07-31 0000310158 mrk:SentinelMember us-gaap:DevelopedTechnologyRightsMember 2020-07-01 2020-07-31 0000310158 mrk:ThemisMember 2020-06-01 2020-06-30 0000310158 mrk:ThemisMember 2020-06-30 0000310158 mrk:ThemisMember mrk:DevelopmentMilestonesMember 2020-06-30 0000310158 mrk:ThemisMember mrk:RegulatoryMilestonesMember 2020-06-30 0000310158 mrk:ThemisMember mrk:SalesBasedMilestonesMember 2020-06-30 0000310158 mrk:IAVIMember 2020-05-01 2020-05-31 0000310158 mrk:ArQuleMember 2020-01-16 2020-01-16 0000310158 mrk:ArQuleMember 2020-01-16 0000310158 mrk:ArQuleMember us-gaap:MeasurementInputDiscountRateMember 2020-01-16 0000310158 mrk:PelotonMember 2019-07-01 2019-07-31 0000310158 mrk:PelotonMember mrk:RegulatoryMilestonesMember 2019-07-31 0000310158 mrk:PelotonMember mrk:CommercialMilestoneMember 2019-07-31 0000310158 mrk:PelotonMember mrk:SalesBasedMilestonesMember 2019-07-31 0000310158 mrk:PelotonMember 2019-07-31 0000310158 mrk:AntelliqMember 2019-04-01 2019-04-01 0000310158 mrk:AntelliqMember 2019-04-01 0000310158 mrk:AntelliqMember srt:MinimumMember us-gaap:DevelopedTechnologyRightsMember 2019-04-01 2019-04-01 0000310158 mrk:AntelliqMember srt:MaximumMember us-gaap:DevelopedTechnologyRightsMember 2019-04-01 2019-04-01 0000310158 mrk:AntelliqMember us-gaap:MeasurementInputDiscountRateMember 2019-04-01 0000310158 mrk:ImmuneDesignMember 2019-04-01 2019-04-30 0000310158 mrk:ImmuneDesignMember 2019-04-30 0000310158 mrk:AstraZenecaMember 2017-07-01 2017-07-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2020-04-01 2020-06-30 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2020-06-30 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2017-08-01 2019-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2019-01-01 2019-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-09-30 0000310158 mrk:AstraZenecaMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-09-30 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2020-04-01 2020-06-30 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2019-01-01 2019-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:AstraZenecaMember mrk:LynparzaMember mrk:RegulatoryMilestonesMember 2020-01-01 2020-09-30 0000310158 mrk:LynparzaMember us-gaap:OtherNoncurrentAssetsMember 2020-09-30 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:AstraZenecaMember mrk:AlliancerevenueLynparzaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:AstraZenecaMember mrk:AllianceRevenueKoselugoMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:AstraZenecaMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:AstraZenecaMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:AstraZenecaMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2020-09-30 0000310158 mrk:AstraZenecaMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2020-09-30 0000310158 mrk:AstraZenecaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:EisaiMember 2018-03-01 2018-03-31 0000310158 mrk:EisaiMember srt:ScenarioForecastMember 2018-03-01 2021-03-31 0000310158 mrk:EisaiMember 2019-03-01 2019-03-31 0000310158 mrk:EisaiMember 2020-03-01 2020-03-31 0000310158 mrk:EisaiMember srt:ScenarioForecastMember 2021-03-01 2021-03-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2020-04-01 2020-06-30 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2020-06-30 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2018-04-01 2019-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2019-01-01 2019-12-31 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-09-30 0000310158 mrk:EisaiMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-09-30 0000310158 mrk:EisaiMember mrk:LenvimaMember mrk:RegulatoryMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:EisaiMember mrk:RegulatoryMilestonesMember 2020-01-01 2020-09-30 0000310158 mrk:LenvimaMember us-gaap:OtherNoncurrentAssetsMember 2020-09-30 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:EisaiMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:EisaiMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:EisaiMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:EisaiMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2020-09-30 0000310158 mrk:EisaiMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2020-09-30 0000310158 mrk:EisaiMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:EisaiMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2020-09-30 0000310158 mrk:EisaiMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:BayerAGMember mrk:SalesBasedMilestonesMember 2019-01-01 2019-12-31 0000310158 mrk:BayerAGMember mrk:SalesBasedMilestonesMember 2018-01-01 2018-12-31 0000310158 mrk:BayerAGMember mrk:SalesBasedMilestonesMember 2020-01-01 2020-09-30 0000310158 mrk:AdempasMember us-gaap:OtherIntangibleAssetsMember 2020-09-30 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:BayerAGMember us-gaap:SalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:BayerAGMember us-gaap:CostOfSalesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:BayerAGMember us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-07-01 2020-09-30 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-07-01 2019-09-30 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2020-01-01 2020-09-30 0000310158 mrk:BayerAGMember us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:CollaborativeArrangementMember 2019-01-01 2019-09-30 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2020-09-30 0000310158 mrk:BayerAGMember us-gaap:OtherCurrentAssetsMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 mrk:BayerAGMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2020-09-30 0000310158 mrk:BayerAGMember us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:CollaborativeArrangementMember 2019-12-31 0000310158 srt:ScenarioForecastMember 2020-12-31 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2020-07-01 2020-09-30 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2020-07-01 2020-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2020-07-01 2020-09-30 0000310158 us-gaap:CostOfSalesMember 2020-07-01 2020-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-09-30 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2020-01-01 2020-09-30 0000310158 us-gaap:CostOfSalesMember 2020-01-01 2020-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2020-07-01 2020-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2020-07-01 2020-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2020-07-01 2020-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-07-01 2020-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2020-01-01 2020-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2020-07-01 2020-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2020-07-01 2020-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2020-07-01 2020-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2020-07-01 2020-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2020-01-01 2020-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2020-07-01 2020-09-30 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2020-07-01 2020-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2020-07-01 2020-09-30 0000310158 us-gaap:RestructuringChargesMember 2020-07-01 2020-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-09-30 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2020-01-01 2020-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2020-01-01 2020-09-30 0000310158 us-gaap:RestructuringChargesMember 2020-01-01 2020-09-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2020-07-01 2020-09-30 0000310158 mrk:AcceleratedDepreciationMember 2020-07-01 2020-09-30 0000310158 us-gaap:OtherRestructuringMember 2020-07-01 2020-09-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2020-01-01 2020-09-30 0000310158 mrk:AcceleratedDepreciationMember 2020-01-01 2020-09-30 0000310158 us-gaap:OtherRestructuringMember 2020-01-01 2020-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2019-07-01 2019-09-30 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2019-07-01 2019-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2019-07-01 2019-09-30 0000310158 us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-09-30 0000310158 us-gaap:CostOfSalesMember mrk:AcceleratedDepreciationMember 2019-01-01 2019-09-30 0000310158 us-gaap:CostOfSalesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-09-30 0000310158 us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2019-07-01 2019-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2019-07-01 2019-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2019-07-01 2019-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-07-01 2019-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember mrk:AcceleratedDepreciationMember 2019-01-01 2019-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-09-30 0000310158 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2019-07-01 2019-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2019-07-01 2019-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2019-07-01 2019-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember mrk:AcceleratedDepreciationMember 2019-01-01 2019-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:OtherRestructuringMember 2019-01-01 2019-09-30 0000310158 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2019-07-01 2019-09-30 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2019-07-01 2019-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2019-07-01 2019-09-30 0000310158 us-gaap:RestructuringChargesMember 2019-07-01 2019-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-09-30 0000310158 us-gaap:RestructuringChargesMember mrk:AcceleratedDepreciationMember 2019-01-01 2019-09-30 0000310158 us-gaap:RestructuringChargesMember us-gaap:OtherRestructuringMember 2019-01-01 2019-09-30 0000310158 us-gaap:RestructuringChargesMember 2019-01-01 2019-09-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2019-07-01 2019-09-30 0000310158 mrk:AcceleratedDepreciationMember 2019-07-01 2019-09-30 0000310158 us-gaap:OtherRestructuringMember 2019-07-01 2019-09-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2019-01-01 2019-09-30 0000310158 mrk:AcceleratedDepreciationMember 2019-01-01 2019-09-30 0000310158 us-gaap:OtherRestructuringMember 2019-01-01 2019-09-30 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2019-12-31 0000310158 mrk:AcceleratedDepreciationMember 2019-12-31 0000310158 us-gaap:OtherRestructuringMember 2019-12-31 0000310158 us-gaap:OneTimeTerminationBenefitsMember 2020-09-30 0000310158 mrk:AcceleratedDepreciationMember 2020-09-30 0000310158 us-gaap:OtherRestructuringMember 2020-09-30 0000310158 srt:MaximumMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-01-01 2020-09-30 0000310158 srt:MaximumMember us-gaap:NondesignatedMember 2020-01-01 2020-09-30 0000310158 us-gaap:ForeignExchangeContractMember 2020-07-01 2020-09-30 0000310158 us-gaap:ForeignExchangeContractMember 2019-07-01 2019-09-30 0000310158 us-gaap:ForeignExchangeContractMember 2020-01-01 2020-09-30 0000310158 us-gaap:ForeignExchangeContractMember 2019-01-01 2019-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-07-01 2020-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000310158 mrk:EurodominatedNotesMember 2020-07-01 2020-09-30 0000310158 mrk:EurodominatedNotesMember 2019-07-01 2019-09-30 0000310158 mrk:EurodominatedNotesMember 2020-01-01 2020-09-30 0000310158 mrk:EurodominatedNotesMember 2019-01-01 2019-09-30 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-07-01 2020-09-30 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-09-30 0000310158 mrk:EurodominatedNotesMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000310158 us-gaap:InterestRateSwapMember 2020-02-29 0000310158 mrk:A1.85NotesDue2020Member 2020-02-29 0000310158 us-gaap:InterestRateSwapMember 2020-09-30 0000310158 us-gaap:InterestRateSwapMember mrk:A3.875NotesDue2021Member 2020-09-30 0000310158 us-gaap:InterestRateSwapMember mrk:A2.40NotesDue2022Member 2020-09-30 0000310158 us-gaap:InterestRateSwapMember mrk:A2.35NotesDue2022Member 2020-09-30 0000310158 mrk:LongTermDebtCurrentMaturitiesMember 2020-09-30 0000310158 mrk:LongTermDebtCurrentMaturitiesMember 2019-12-31 0000310158 mrk:LongTermDebtExcludingCurrentMaturitiesMember 2020-09-30 0000310158 mrk:LongTermDebtExcludingCurrentMaturitiesMember 2019-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000310158 us-gaap:OtherAssetsMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:InterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000310158 us-gaap:OtherAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000310158 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2020-09-30 0000310158 us-gaap:DesignatedAsHedgingInstrumentMember 2019-12-31 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-09-30 0000310158 us-gaap:OtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2020-09-30 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NondesignatedMember 2019-12-31 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2020-09-30 0000310158 us-gaap:AccruedLiabilitiesMember us-gaap:ForwardContractsMember us-gaap:NondesignatedMember 2019-12-31 0000310158 us-gaap:NondesignatedMember 2020-09-30 0000310158 us-gaap:NondesignatedMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-07-01 2020-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-07-01 2020-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-07-01 2019-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2020-01-01 2020-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2019-01-01 2019-09-30 0000310158 us-gaap:InterestRateSwapMember 2020-07-01 2020-09-30 0000310158 us-gaap:InterestRateSwapMember 2019-07-01 2019-09-30 0000310158 us-gaap:InterestRateSwapMember 2020-01-01 2020-09-30 0000310158 us-gaap:InterestRateSwapMember 2019-01-01 2019-09-30 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-07-01 2020-09-30 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-09-30 0000310158 us-gaap:CurrencySwapMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2020-07-01 2020-09-30 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2019-07-01 2019-09-30 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2020-01-01 2020-09-30 0000310158 us-gaap:ForeignExchangeFutureMember us-gaap:SalesMember 2019-01-01 2019-09-30 0000310158 us-gaap:TreasuryLockMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-07-01 2020-09-30 0000310158 us-gaap:TreasuryLockMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000310158 us-gaap:TreasuryLockMember us-gaap:OtherNonoperatingIncomeExpenseMember 2020-01-01 2020-09-30 0000310158 us-gaap:TreasuryLockMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000310158 us-gaap:ForwardContractsMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0000310158 us-gaap:ForwardContractsMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-09-30 0000310158 us-gaap:ForwardContractsMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:CommercialPaperMember 2020-09-30 0000310158 us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:AssetBackedSecuritiesMember 2020-09-30 0000310158 us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:ForeignGovernmentDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeContractMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateSwapMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForeignExchangeOptionMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:ForwardContractsMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForwardContractsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:ForwardContractsMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:InterestRateContractMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000310158 us-gaap:AssetBackedSecuritiesMember 2020-01-01 2020-09-30 0000310158 us-gaap:FairValueInputsLevel2Member 2020-09-30 0000310158 us-gaap:FairValueInputsLevel2Member 2019-12-31 0000310158 mrk:SanofiPasteurMember 2020-09-30 0000310158 mrk:SanofiPasteurMember 2019-12-31 0000310158 mrk:SanofiPasteurMember us-gaap:MeasurementInputDiscountRateMember 2020-09-30 0000310158 2019-10-01 2019-12-31 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2020-09-30 0000310158 mrk:InventoryNotExpectedtobeSoldWithinOneYearMember 2019-12-31 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2020-09-30 0000310158 mrk:InventoriesProducedinPreparationforProductLaunchesMember 2019-12-31 0000310158 mrk:SivextroMember 2019-07-01 2019-09-30 0000310158 2020-06-30 0000310158 mrk:A0.75notesdue2026Member 2020-06-30 0000310158 mrk:A1.45notesdue2030Member 2020-06-30 0000310158 mrk:A2.35notesdue2040Member 2020-06-30 0000310158 mrk:A2.45notesdue2050Member 2020-06-30 0000310158 mrk:FosamaxMember 2020-09-30 0000310158 mrk:FederalMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2014-03-01 2014-03-31 0000310158 mrk:FederalMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2020-09-30 0000310158 mrk:NewJerseyStateCourtMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2020-09-30 0000310158 mrk:CaliforniaStateCourtMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2020-09-30 0000310158 mrk:OtherStateCourtMember mrk:FosamaxMember mrk:FemurFractureLitigationMember 2020-09-30 0000310158 mrk:JanuviaMember 2020-09-30 0000310158 mrk:OtherStateCourtMember mrk:JanuviaMember 2020-09-30 0000310158 mrk:JanuviaMember mrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember 2020-09-30 0000310158 mrk:ZetiaantitrustlitigationMember 2020-09-30 0000310158 us-gaap:PatentsMember 2020-01-01 2020-09-30 0000310158 us-gaap:PatentsMember 2020-09-30 0000310158 mrk:LegalDefenseCostsMember 2020-09-30 0000310158 mrk:LegalDefenseCostsMember 2019-12-31 0000310158 us-gaap:CommonStockMember 2019-06-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000310158 us-gaap:RetainedEarningsMember 2019-06-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000310158 us-gaap:TreasuryStockMember 2019-06-30 0000310158 us-gaap:NoncontrollingInterestMember 2019-06-30 0000310158 2019-06-30 0000310158 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000310158 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000310158 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0000310158 us-gaap:CommonStockMember 2019-09-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000310158 us-gaap:RetainedEarningsMember 2019-09-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000310158 us-gaap:TreasuryStockMember 2019-09-30 0000310158 us-gaap:NoncontrollingInterestMember 2019-09-30 0000310158 us-gaap:CommonStockMember 2020-06-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000310158 us-gaap:RetainedEarningsMember 2020-06-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000310158 us-gaap:TreasuryStockMember 2020-06-30 0000310158 us-gaap:NoncontrollingInterestMember 2020-06-30 0000310158 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-01 2020-09-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0000310158 us-gaap:TreasuryStockMember 2020-07-01 2020-09-30 0000310158 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0000310158 us-gaap:CommonStockMember 2020-09-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0000310158 us-gaap:RetainedEarningsMember 2020-09-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-09-30 0000310158 us-gaap:TreasuryStockMember 2020-09-30 0000310158 us-gaap:NoncontrollingInterestMember 2020-09-30 0000310158 us-gaap:CommonStockMember 2018-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000310158 us-gaap:RetainedEarningsMember 2018-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000310158 us-gaap:TreasuryStockMember 2018-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2018-12-31 0000310158 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0000310158 us-gaap:TreasuryStockMember 2019-01-01 2019-09-30 0000310158 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-09-30 0000310158 us-gaap:CommonStockMember 2019-12-31 0000310158 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000310158 us-gaap:RetainedEarningsMember 2019-12-31 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000310158 us-gaap:TreasuryStockMember 2019-12-31 0000310158 us-gaap:NoncontrollingInterestMember 2019-12-31 0000310158 us-gaap:RetainedEarningsMember 2020-01-01 2020-09-30 0000310158 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-09-30 0000310158 us-gaap:TreasuryStockMember 2020-01-01 2020-09-30 0000310158 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-09-30 0000310158 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-09-30 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-09-30 0000310158 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0000310158 us-gaap:PerformanceSharesMember 2020-01-01 2020-09-30 0000310158 us-gaap:PerformanceSharesMember 2019-01-01 2019-09-30 0000310158 us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000310158 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000310158 us-gaap:ForeignPlanMember us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000310158 country:US 2020-09-30 0000310158 us-gaap:ForeignPlanMember 2020-09-30 0000310158 country:US 2020-01-01 2020-09-30 0000310158 us-gaap:ForeignPlanMember 2020-01-01 2020-09-30 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-01-01 2020-09-30 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2020-07-01 2020-09-30 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-07-01 2019-09-30 0000310158 us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-09-30 0000310158 mrk:HealthcareServicesSegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2019-01-01 2019-09-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-06-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-06-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-06-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-07-01 2019-09-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-09-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-09-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-06-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-06-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-06-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2020-06-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-07-01 2020-09-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-07-01 2020-09-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-09-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-09-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-09-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2020-09-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2018-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-01-01 2019-09-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-12-31 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2019-12-31 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-12-31 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2019-12-31 0000310158 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2020-01-01 2020-09-30 0000310158 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2020-01-01 2020-09-30 0000310158 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:AccumulatedTranslationAdjustmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:KeytrudaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AlliancerevenueLynparzaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LenvimaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:EmendMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:GardasilGardasil9Member mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ProQuadMMRIIVarivaxMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:Pneumovax23Member mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RotateqMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VaqtaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BridionMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NoxafilMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrevymisMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PrimaxinMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InvanzMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CancidasMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CubicinMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZerbaxaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SimponiMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:RemicadeMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:BelsomraMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:IsentressIsentressHDMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZepatierMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ZetiaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:VytorinMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AtozetMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AllianceRevenueAdempasMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AdempasMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanuviaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:JanumetMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ImplanonNexplanonMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NuvaringMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:SingulairMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:NasonexMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:ArcoxiaMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CozaarHyzaarMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:FollistimAqMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:OtherPharmaceuticalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:PharmaceuticalsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember country:US mrk:AnimalHealthsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:LivestockMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember country:US mrk:AnimalHealthsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:CompanionAnimalsMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US mrk:AnimalHealthsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:AnimalHealthsegmentMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US us-gaap:AllOtherSegmentsMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember us-gaap:AllOtherSegmentsMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember us-gaap:AllOtherSegmentsMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember 2020-07-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember 2020-01-01 2020-09-30 0000310158 us-gaap:OperatingSegmentsMember country:US 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember mrk:InternationalMember 2019-01-01 2019-09-30 0000310158 us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000310158 us-gaap:CorporateNonSegmentMember country:US 2020-07-01 2020-09-30 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2020-07-01 2020-09-30 0000310158 us-gaap:CorporateNonSegmentMember 2020-07-01 2020-09-30 0000310158 us-gaap:CorporateNonSegmentMember country:US 2019-07-01 2019-09-30 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2019-07-01 2019-09-30 0000310158 us-gaap:CorporateNonSegmentMember 2019-07-01 2019-09-30 0000310158 us-gaap:CorporateNonSegmentMember country:US 2020-01-01 2020-09-30 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2020-01-01 2020-09-30 0000310158 us-gaap:CorporateNonSegmentMember 2020-01-01 2020-09-30 0000310158 us-gaap:CorporateNonSegmentMember country:US 2019-01-01 2019-09-30 0000310158 us-gaap:CorporateNonSegmentMember mrk:InternationalMember 2019-01-01 2019-09-30 0000310158 us-gaap:CorporateNonSegmentMember 2019-01-01 2019-09-30 0000310158 country:US 2020-07-01 2020-09-30 0000310158 mrk:InternationalMember 2020-07-01 2020-09-30 0000310158 country:US 2019-07-01 2019-09-30 0000310158 mrk:InternationalMember 2019-07-01 2019-09-30 0000310158 country:US 2020-01-01 2020-09-30 0000310158 mrk:InternationalMember 2020-01-01 2020-09-30 0000310158 country:US 2019-01-01 2019-09-30 0000310158 mrk:InternationalMember 2019-01-01 2019-09-30 0000310158 us-gaap:EMEAMember 2020-07-01 2020-09-30 0000310158 us-gaap:EMEAMember 2019-07-01 2019-09-30 0000310158 us-gaap:EMEAMember 2020-01-01 2020-09-30 0000310158 us-gaap:EMEAMember 2019-01-01 2019-09-30 0000310158 country:CN 2020-07-01 2020-09-30 0000310158 country:CN 2019-07-01 2019-09-30 0000310158 country:CN 2020-01-01 2020-09-30 0000310158 country:CN 2019-01-01 2019-09-30 0000310158 country:JP 2020-07-01 2020-09-30 0000310158 country:JP 2019-07-01 2019-09-30 0000310158 country:JP 2020-01-01 2020-09-30 0000310158 country:JP 2019-01-01 2019-09-30 0000310158 srt:AsiaPacificMember 2020-07-01 2020-09-30 0000310158 srt:AsiaPacificMember 2019-07-01 2019-09-30 0000310158 srt:AsiaPacificMember 2020-01-01 2020-09-30 0000310158 srt:AsiaPacificMember 2019-01-01 2019-09-30 0000310158 srt:LatinAmericaMember 2020-07-01 2020-09-30 0000310158 srt:LatinAmericaMember 2019-07-01 2019-09-30 0000310158 srt:LatinAmericaMember 2020-01-01 2020-09-30 0000310158 srt:LatinAmericaMember 2019-01-01 2019-09-30 0000310158 mrk:OtherCountriesMember 2020-07-01 2020-09-30 0000310158 mrk:OtherCountriesMember 2019-07-01 2019-09-30 0000310158 mrk:OtherCountriesMember 2020-01-01 2020-09-30 0000310158 mrk:OtherCountriesMember 2019-01-01 2019-09-30 0000310158 us-gaap:MaterialReconcilingItemsMember 2020-07-01 2020-09-30 0000310158 us-gaap:MaterialReconcilingItemsMember 2019-07-01 2019-09-30 0000310158 us-gaap:MaterialReconcilingItemsMember 2020-01-01 2020-09-30 0000310158 us-gaap:MaterialReconcilingItemsMember 2019-01-01 2019-09-30 shares iso4217:USD iso4217:USD shares pure iso4217:EUR mrk:interest_rate_swap mrk:Case mrk:Claim mrk:segment false 2020 Q3 0000310158 --12-31 10-Q true 2020-09-30 false 1-6571 Merck & Co., Inc. NJ 22-1918501 2000 Galloping Hill Road Kenilworth NJ 07033 (908) 740-4000 Yes Yes Large Accelerated Filer false false false Common Stock ($0.50 par value) MRK NYSE 1.125% Notes due 2021 MRK/21 NYSE 0.500% Notes due 2024 MRK 24 NYSE 1.875% Notes due 2026 MRK/26 NYSE 2.500% Notes due 2034 MRK/34 NYSE 1.375% Notes due 2036 MRK 36A NYSE 2530034437 12551000000 12397000000 35479000000 34972000000 3481000000 3990000000 9952000000 10443000000 2450000000 2589000000 7383000000 7726000000 3390000000 3204000000 7721000000 7324000000 114000000 232000000 269000000 444000000 312000000 -35000000 630000000 -362000000 9123000000 10050000000 24695000000 26299000000 3428000000 2347000000 10784000000 8673000000 483000000 440000000 1611000000 1259000000 2945000000 1907000000 9173000000 7414000000 4000000 6000000 12000000 -73000000 2941000000 1901000000 9161000000 7487000000 1.16 0.74 3.62 2.91 1.16 0.74 3.61 2.89 2941000000 1901000000 9161000000 7487000000 -137000000 91000000 -153000000 -9000000 0 -17000000 -18000000 109000000 -62000000 -15000000 -161000000 -41000000 85000000 -117000000 -180000000 14000000 10000000 -28000000 -190000000 155000000 2951000000 1873000000 8971000000 7642000000 7356000000 9676000000 0 774000000 89000000 86000000 8422000000 6778000000 2081000000 1480000000 6128000000 5978000000 4671000000 4277000000 26577000000 27483000000 1372000000 1469000000 18572000000 17686000000 16919000000 15053000000 20248000000 19425000000 16677000000 14196000000 8007000000 6771000000 89800000000 84397000000 2420000000 3610000000 3744000000 3738000000 11690000000 12549000000 984000000 736000000 1567000000 1587000000 20405000000 22220000000 26321000000 22736000000 1777000000 1470000000 12027000000 11970000000 0.50 0.50 6500000000 6500000000 3577103522 3577103522 1788000000 1788000000 39489000000 39660000000 51107000000 46602000000 -6383000000 -6193000000 86001000000 81857000000 1047343390 1038087496 56815000000 55950000000 29186000000 25907000000 84000000 94000000 29270000000 26001000000 89800000000 84397000000 9173000000 7414000000 2721000000 2716000000 35000000 864000000 0 982000000 47000000 -386000000 354000000 306000000 445000000 -219000000 5638000000 3469000000 6247000000 8646000000 3170000000 2336000000 78000000 2380000000 1894000000 7459000000 2545000000 0 0 3620000000 0 1040000000 907000000 269000000 -141000000 -320000000 -4665000000 -1866000000 -311000000 -3892000000 1954000000 0 4419000000 4958000000 1281000000 3730000000 4673000000 4290000000 68000000 344000000 -472000000 -240000000 -4204000000 -6850000000 89000000 -26000000 -2533000000 -96000000 258000000 9934000000 7967000000 45000000 7401000000 7871000000 Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of Merck &amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2020.The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. Basis of Presentation<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements of Merck &amp; Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Planned Spin-Off of Women’s Health, Biosimilars and Established Brands into New Company </span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, Merck announced its intention to spin-off products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon &amp; Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ezetimibe) and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vytorin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ezetimibe and simvastatin), as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the second quarter of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women’s health, biosimilars and established brands businesses will be reflected as discontinued operations in the Company’s consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company’s collaborative arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by: removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company’s consolidated financial statements upon adoption.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company’s collaborative arrangements.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards Not Yet Adopted</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by: removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.</span></div> Acquisitions, Research Collaborations and License Agreements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Merck and VelosBio, Inc. (VelosBio) announced that the companies had entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion, subject to certain customary adjustments. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate targeting ROR1 that is currently being evaluated in a Phase 1 and a Phase 2 clinical trial for the treatment of patients with hematologic malignancies and solid tumors, respectively. The closing of the transaction, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected by the end of 2020.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Merck and Seagen Inc. (Seagen, formerly known as Seattle Genetics, Inc.) announced an oncology collaboration to globally develop and commercialize Seagen’s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600 million and a $1.0 billion equity investment in 5 million shares of Seagen common stock at a price of $200 per share. Merck recorded $622 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2020 related to this transaction reflecting the upfront payment as well as a $22 million mark-to-market loss on the purchase commitment (forward contract) relating to the equity shares (calculated based on the closing price of Seagen common stock on September 30, 2020). The closing of the equity investment occurred in October 2020 and resulted in the recognition of a $6 million reduction to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6 billion, including $850 million in development milestones and $1.75 billion in sales milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210 million, which were recorded as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the third quarter and first nine months of 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65 million and will receive tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck’s territories.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for €256 million ($302 million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289 million and other net assets of $13 million. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410 million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401 million related to currently marketed products and inventory of $9 million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482, formerly known as EIDD-2801), an orally </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">available antiviral candidate currently in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones, as well as a share of the net profits of molnupiravir and related molecules, if approved. Merck and Ridgeback are committed to ensure that any medicines developed for SARS-CoV-2 (the causative agent of COVID-19) will be accessible and affordable globally.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer for $366 million. Merck may make additional contingent payments of up to $740 million, including up to $80 million for development milestones, up to $260 million for regulatory approval milestones, and up to $400 million for commercial milestones. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur and licensed exclusively to Themis for select viral indications. The acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform and is expected to accelerate the development of the COVID-19 vaccine candidate (V591), which is currently in Phase 1 clinical development. The transaction was accounted for as an acquisition of a business. The Company determined the fair value of the contingent consideration was $97 million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payment. Merck recognized intangible assets for in-process research and development (IPR&amp;D) of $136 million, cash of $59 million, deferred tax assets of $71 million and other net liabilities of $32 million. The excess of the consideration transferred over the fair value of net assets acquired of $229 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. In connection with the transaction, Merck has entered into a memorandum of understanding that reflects the parties’ commitments to address the COVID-19 pandemic by developing, manufacturing and distributing the vaccine on a global basis and with pricing that makes the vaccine both available around the world and accessible to those who need it.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a new collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis for Merck’s approved Ebola Zaire virus vaccine, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ervebo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Ebola Zaire Vaccine, Live), which was the first rVSV vaccine approved for use in humans. Under the terms of the agreement, Merck made an upfront payment of $6.5 million and may make additional contingent payments of up to $100 million for sales-based milestones, as well as royalty payments. Merck has also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the United States Department of Health and Human Services, to provide initial funding support for this effort. Under the agreement, IAVI and Merck will work together to advance the development and global clinical evaluation of a SARS-CoV-2 vaccine candidate designed and engineered by IAVI scientists. The vaccine candidate is currently in Phase 1 clinical development. Merck will lead regulatory filings globally. Both organizations will work together to develop the vaccine and make it accessible and affordable globally, if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138 million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95 million of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2020. ArQule’s lead investigational candidate, MK-1026 (formerly known as ARQ 531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D MK-1026 (formerly ARQ 531) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangement for ARQ 087</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible asset related to IPR&amp;D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, Merck acquired Peloton Therapeutics, Inc. (Peloton), a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. Peloton’s lead candidate, MK-6482 (formerly known as PT2977), is a novel investigational oral HIF-2α inhibitor in late-stage development for renal cell carcinoma. Merck made an upfront payment of $1.2 billion; additionally, former Peloton shareholders will be eligible to receive $50 million upon U.S. regulatory approval, $50 million upon first commercial sale in the United States, and up to $1.05 billion of sales-based milestones. The transaction was accounted for as an acquisition of an asset. Merck recorded cash of $157 million, deferred tax liabilities of $64 million, and other net liabilities of $6 million at the acquisition date and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses of $982 million in the third quarter and first nine months of 2019 related to the transaction.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $2.3 billion to acquire all outstanding shares of Antelliq and spent $1.3 billion to repay Antelliq’s debt. The transaction was accounted for as an acquisition of a business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.981%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets (useful lives ranging from 18-24 years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s results for the first nine months of 2019 include five months of activity for Antelliq. The Company incurred $47 million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, general and administrative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses in the first nine months of 2019.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> approaches to enable the body’s immune system to fight disease, for $301 million in cash. The transaction was accounted for as an acquisition of a business. Merck recognized intangible assets of $156 million, cash of $83 million and other net assets of $42 million. The excess of the consideration transferred over the fair value of net assets acquired of $20 </span></div>million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&amp;D were determined using an income approach. Actual cash flows are likely to be different than those assumed. 2750000000 600000000 1000000000.0 5000000 200 622000000 -22000000 6000000 2600000000 850000000 1750000000 210000000 65000000 0.20 0.33 256000000 302000000 289000000 13000000 410000000 401000000 9000000 P15Y 366000000 740000000 80000000 260000000 400000000 97000000 136000000 59000000 71000000 -32000000 229000000 6500000 100000000 2700000000 138000000 95000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:84.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.542%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 16, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D MK-1026 (formerly ARQ 531) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,280 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Licensing arrangement for ARQ 087</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(389)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair value of the identifiable intangible asset related to IPR&amp;D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:83.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.981%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 1, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identifiable intangible assets (useful lives ranging from 18-24 years) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,689 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(589)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets and liabilities, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total identifiable net assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,275 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consideration transferred</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,651 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.</span></div> 145000000 2280000000 80000000 389000000 34000000 2150000000 540000000 2690000000 0.125 1200000000 50000000 50000000 1050000000.00 157000000 64000000 6000000 982000000 2300000000 1300000000 31000000 73000000 93000000 60000000 P18Y P24Y 2689000000 589000000 -82000000 2275000000 1376000000 3651000000 0.115 47000000 301000000 156000000 83000000 42000000 20000000 Collaborative Arrangements<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AstraZeneca</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Imfinzi. The companies will also jointly develop and commercialize AstraZeneca’s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple indications. In April 2020, Koselugo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in combination with Lynparza or Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the agreement, Merck made an upfront payment to AstraZeneca of $1.6 billion in 2017 and made payments of $750 million over a multi-year period for certain license options. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, Merck determined it was probable that sales of Lynparza in the future would trigger $400 million of sales-based milestone payments from Merck to AstraZeneca. Accordingly, Merck recorded a $400 million liability and a corresponding increase to the intangible asset related to Lynparza. Prior to 2020, Merck accrued sales-based milestone payments aggregating $1.0 billion related to Lynparza, of which $200 million and $250 million was paid to AstraZeneca in 2019 and 2018, respectively, and $250 million was paid in the first nine months of 2020. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of $135 million from Merck to AstraZeneca. In 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of $60 million and $140 million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.4 billion remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.3 billion at September 30, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Eisai</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Keytruda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development, including for studies evaluating Lenvima as monotherapy, are shared equally by the two companies and reflected in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and development </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expenses. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Merck made an upfront payment to Eisai of $750 million and agreed to make payments of up to $650 million for certain option rights through 2021 (of which $325 million was paid in March 2019, $200 million was paid in March 2020 and $125 million is expected to be paid in March 2021). In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2020, Merck determined it was probable that sales of Lenvima in the future would trigger sales-based milestone payments aggregating $370 million from Merck to Eisai. Accordingly, Merck recorded a $370 million liability and a corresponding increase to the intangible asset related to Lenvima. Prior to 2020, Merck accrued sales-based milestone payments aggregating $950 million. Of these amounts, $50 million was paid to Eisai in 2019 and an additional $500 million was paid in the first nine months of 2020. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of $250 million in the aggregate from Merck to Eisai. Potential future regulatory milestone payments of $135 million remain under the agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $1.1 billion at September 30, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone and future option payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer AG</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer’s vericiguat, which is in development for the potential treatment of worsening heart failure. Vericiguat is currently under review by regulatory authorities in the United States, the EU and Japan. Under the agreement, Bayer leads commercialization of Adempas in the Americas, while Merck leads commercialization in the rest of the world. For vericiguat, if approved, Bayer will lead commercialization in the rest of world and Merck will lead in the Americas. Both companies share in development costs and profits on sales and have the right to co-promote in territories where they are not the lead. Merck records sales of Adempas in its marketing territories, as well as alliance revenue, which is Merck’s share of profits from the sale of Adempas in Bayer’s marketing territories. In addition, the agreement provides for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to 2020, Merck accrued $725 million of sales-based milestone payments for this collaboration, of which $350 million was paid to Bayer in 2018. There is an additional $400 million potential future sales-based milestone payment that has not yet been accrued as it is not deemed by the Company to be probable at this time.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was $838 million at September 30, 2020 and is included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Intangibles, Net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payment.</span></div> 1600000000 750000000 400000000 400000000 1000000000.0 200000000 250000000 250000000 2700000000 135000000 60000000 140000000 1400000000 1300000000 <div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Koselugo</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total alliance revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">522 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">577 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to AstraZeneca included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:61.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Eisai included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">570 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents amortization of capitalized milestone payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone and future option payments.</span></div><div style="margin-top:2pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes accrued milestone payments.</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized financial information related to this collaboration is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alliance revenue - Adempas</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net sales of Adempas recorded by Merck</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables from Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other current assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payables to Bayer included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes amortization of intangible assets.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents accrued milestone payment.</span></div> 196000000 123000000 519000000 313000000 3000000 0 3000000 0 199000000 123000000 522000000 313000000 41000000 28000000 205000000 120000000 40000000 36000000 112000000 96000000 20000000 44000000 93000000 122000000 197000000 128000000 309000000 577000000 400000000 0 750000000 650000000 325000000 200000000 125000000 370000000 370000000 950000000 50000000 500000000 2700000000 250000000 135000000 1100000000 142000000 109000000 421000000 280000000 46000000 23000000 215000000 97000000 18000000 21000000 48000000 59000000 48000000 37000000 168000000 146000000 170000000 150000000 325000000 700000000 570000000 525000000 725000000 350000000 400000000 838000000 83000000 50000000 216000000 144000000 55000000 57000000 167000000 158000000 138000000 107000000 383000000 302000000 29000000 28000000 85000000 86000000 19000000 12000000 42000000 31000000 12000000 31000000 53000000 94000000 70000000 49000000 375000000 375000000 Restructuring<div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In early 2019, Merck approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $2.5 billion. The Company estimates that approximately 60% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 40% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately $800 million in 2020 related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded total pretax costs of $186 million and $296 million in the third quarter of 2020 and 2019, respectively, and $504 million and $642 million for the first nine months of 2020 and 2019, respectively, related to restructuring program activities. Since inception of the Restructuring Program through September 30, 2020, Merck has recorded total pretax accumulated costs of approximately $1.4 billion. For segment reporting, restructuring charges are unallocated expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:21.886%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other activity in 2020 and 2019 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 12) and share-based compensation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves January 1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves September 30, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The remaining cash outlays are expected to be substantially completed by the end of 2023. 2500000000 0.60 0.40 800000000 186000000 296000000 504000000 642000000 1400000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the charges related to restructuring program activities by type of cost:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:21.886%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.543%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.556%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">358 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 0 33000000 5000000 38000000 0 89000000 42000000 131000000 0 15000000 0 15000000 0 37000000 0 37000000 0 18000000 1000000 19000000 0 66000000 1000000 67000000 61000000 0 53000000 114000000 143000000 0 126000000 269000000 61000000 66000000 59000000 186000000 143000000 192000000 169000000 504000000 0 41000000 21000000 62000000 0 139000000 22000000 161000000 0 1000000 0 1000000 0 33000000 0 33000000 0 -1000000 2000000 1000000 0 1000000 3000000 4000000 205000000 0 27000000 232000000 358000000 0 86000000 444000000 205000000 41000000 50000000 296000000 358000000 173000000 111000000 642000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September 30, 2020:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Separation<br/>Costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated<br/>Depreciation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves January 1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">504 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Payments) receipts, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(237)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-cash activity</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserves September 30, 2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">438 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)The remaining cash outlays are expected to be substantially completed by the end of 2023. 690000000 0 69000000 759000000 143000000 192000000 169000000 504000000 395000000 0 237000000 632000000 0 192000000 -39000000 153000000 438000000 0 40000000 478000000 Financial Instruments<div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Derivative Instruments and Hedging Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Risk Management</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated other comprehensive income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) and reclassified into </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The forward contracts are not designated as hedges and are marked to market through </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and remain in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCI into income related to the sale of a subsidiary.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Risk Management</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, five interest rate swaps with notional amounts of $250 million each matured. These swaps effectively converted the Company’s $1.25 billion, 1.85% fixed-rate notes due 2020 to variable rate debt. At September 30, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.875% notes due 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.35% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.073%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,309 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,409 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:20.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.301%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,881 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,096 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,654 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,245 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,938 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,151 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,666 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:64.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:17.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.974%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35,479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">34,972 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges against rising treasury rates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, the Company estimates $155 million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The amount ultimately reclassified to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments in Debt and Equity Securities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,768 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,785 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,553 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net (gains) losses recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at September 30, 2020 were $(43) million and $(512) million in the third quarter and first nine months of 2020, respectively. Unrealized net losses (gains) recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at September 30, 2019 were $25 million and $(41) million in the third quarter and first nine months of 2019, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020 and September 30, 2019, the Company also had $508 million and $393 million, respectively, of equity investments without readily determinable fair values included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and recognizes unrealized losses based on unfavorable observable price changes. During the first nine months of 2020, the Company recognized unrealized gains of $21 million and unrealized losses of $3 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to these equity investments held at September 30, 2020. During the first nine months of 2019, the Company recognized unrealized gains of $4 million and unrealized losses of $12 million in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> related to these investments held at September 30, 2019. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values still held at September 30, 2020 were $128 million and $24 million, respectively. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Quoted prices (unadjusted) in active markets for identical assets or liabilities; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:20.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.717%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,792 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,013 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,127 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">864 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily all of the asset-backed securities were highly rated (Standard &amp; Poor’s rating of AAA and Moody’s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily 5 years or less. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020 and December 31, 2019, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and cash equivalents</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included $6.6 billion and $8.9 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy). </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:80.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value September 30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Balance at September 30, 2020 includes $140 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> At September 30, 2020 and December 31, 2019, $637 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The additions to contingent consideration in 2020 relate to the acquisition of Themis (see Note 2). The payments of contingent consideration in both periods relate to liabilities recorded in connection with the termination of the Sanofi-Pasteur MSD joint venture in 2016.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Measurements</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of loans payable and long-term debt (including current portion) at September 30, 2020, was $32.6 billion compared with a carrying value of $28.7 billion and at December 31, 2019, was $28.8 billion compared with a carrying value of $26.3 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentrations of Credit Risk</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s accounts receivable arise from product sales in the United States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.1 billion and $2.7 billion of accounts receivable in the third quarter of 2020 and the fourth quarter of 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">de minimis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $34 million at December 31, 2019. The obligation to return such collateral is recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued and other current liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. No cash collateral was advanced by the Company to counterparties as of September 30, 2020 or December 31, 2019.</span></div> P2Y P1Y <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effects of the Company’s net investment hedges on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and the Consolidated Statement of Income are shown below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:34.039%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.368%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Pretax (Gain) Loss Recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> for Amounts Excluded from Effectiveness Testing</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro-denominated notes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(152)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> No amounts were reclassified from AOCI into income related to the sale of a subsidiary.</span></div> -10000000 -1000000 -15000000 -8000000 4000000 8000000 15000000 23000000 -162000000 150000000 -182000000 152000000 0 0 0 0 5 250000000 1250000000 0.0185 At September 30, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value of Debt</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Number of Interest Rate Swaps Held</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Swap Notional Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.875% notes due 2021</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.40% notes due 2022</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.35% notes due 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 14 0.03875 1150000000 5 1150000000 0.0240 1000000000 4 1000000000 0.0235 1250000000 5 1250000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:48.606%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.070%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.776%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.073%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Carrying Amount of Hedged Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Line Item in which Hedged Item is Included</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loans payable and current portion of long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,249 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long-Term Debt</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,309 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,409 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 1155000000 1249000000 5000000 -1000000 2309000000 3409000000 62000000 14000000 <div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:20.107%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.301%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair Value of Derivative</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Dollar<br/>Notional</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance Sheet Caption</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,150 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,250 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,400 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,120 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,881 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,096 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other Noncurrent Liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12,654 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,728 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,455 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,245 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">171 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,042 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,693 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;text-indent:-4.5pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,497 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,938 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,151 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30,666 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6000000 1150000000 0 0 63000000 2250000000 15000000 3400000000 0 0 1000000 1250000000 30000000 4120000000 152000000 6117000000 59000000 1881000000 55000000 2160000000 104000000 3096000000 22000000 1748000000 1000000 157000000 1000000 53000000 158000000 105000000 12654000000 222000000 24000000 14728000000 81000000 5455000000 66000000 7245000000 171000000 8042000000 73000000 8693000000 22000000 1000000000 0 0 81000000 193000000 14497000000 66000000 73000000 15938000000 239000000 298000000 27151000000 288000000 97000000 30666000000 The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:64.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.105%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.282%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts recognized in the condensed consolidated balance sheet</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash collateral received</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net amounts</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 239000000 298000000 288000000 97000000 140000000 140000000 84000000 84000000 0 0 34000000 0 99000000 158000000 170000000 13000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"/><td style="width:17.686%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.965%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.539%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.974%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">12,397 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">35,479 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">34,972 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(Gain) loss on fair value hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate swap contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Hedged items</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Derivatives designated as hedging instruments</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Impact of cash flow hedging relationships</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of (loss) gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Increase (decrease) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> reclassifications</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">70 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(189)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Interest rate contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of gain recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Amount of loss recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">OCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> on derivatives</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Interest expense is a component of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net.</span></div> 12551000000 12397000000 312000000 -35000000 10000000 -28000000 35479000000 34972000000 630000000 -362000000 -190000000 155000000 14000000 -13000000 -54000000 -101000000 0 6000000 76000000 74000000 -195000000 186000000 -126000000 183000000 -23000000 70000000 23000000 -70000000 65000000 189000000 -65000000 -189000000 -1000000 -1000000 -3000000 -3000000 -1000000 -1000000 -3000000 -6000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:34.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.281%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.310%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.874%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amount of Derivative Pretax (Gain) Loss Recognized in Income</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivative contracts serve as economic hedges of forecasted transactions.</span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> These derivatives serve as economic hedges against rising treasury rates.</span></div> 7000000 8000000 138000000 -112000000 -7000000 11000000 -4000000 7000000 0 0 -9000000 0 -22000000 0 -22000000 0 -155000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information on investments in debt and equity securities is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:30.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.294%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.705%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.558%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.712%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gross Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair<br/>Value</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">266 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,768 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,785 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total debt and publicly traded equity securities</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,553 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,623 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Unrealized net (gains) losses recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at September 30, 2020 were $(43) million and $(512) million in the third quarter and first nine months of 2020, respectively. Unrealized net losses (gains) recognized in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> on equity securities still held at September 30, 2019 were $25 million and $(41) million in the third quarter and first nine months of 2019, respectively.</span></div> 74000000 0 0 74000000 266000000 3000000 0 269000000 2000000 0 0 2000000 0 0 0 0 0 0 0 0 668000000 0 0 668000000 0 0 0 0 608000000 13000000 0 621000000 0 0 0 0 226000000 1000000 0 227000000 76000000 0 0 76000000 1768000000 17000000 0 1785000000 1477000000 838000000 1553000000 2623000000 43000000 512000000 -25000000 41000000 508000000 393000000 21000000 3000000 4000000 12000000 128000000 24000000 <div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial assets and liabilities measured at fair value on a recurring basis are summarized below:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.122%"><tr><td style="width:1.0%"/><td style="width:20.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.717%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.307%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Fair Value Measurements Using</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign government bonds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate notes and bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">621 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,370 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,372 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">518 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,725 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,243 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government and agency securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Publicly traded equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">380 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased currency options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">239 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">288 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,551 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,792 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">898 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,013 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Derivative liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward exchange contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Forward contract related to Seagen common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Written currency options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,127 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">864 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Primarily all of the asset-backed securities were highly rated (Standard &amp; Poor’s rating of AAA and Moody’s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily 5 years or less. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.</span></div> 0 2000000 0 2000000 0 0 0 0 0 0 0 0 0 668000000 0 668000000 0 0 0 0 0 621000000 0 621000000 0 0 0 0 0 227000000 0 227000000 0 0 0 0 0 209000000 0 209000000 1370000000 0 0 1370000000 518000000 0 0 518000000 1370000000 2000000 0 1372000000 518000000 1725000000 0 2243000000 74000000 0 0 74000000 60000000 0 0 60000000 107000000 0 0 107000000 320000000 0 0 320000000 181000000 0 0 181000000 380000000 0 0 380000000 0 116000000 0 116000000 0 169000000 0 169000000 0 69000000 0 69000000 0 15000000 0 15000000 0 54000000 0 54000000 0 104000000 0 104000000 0 239000000 0 239000000 0 288000000 0 288000000 1551000000 241000000 0 1792000000 898000000 2013000000 0 2911000000 0 0 829000000 829000000 0 0 767000000 767000000 0 275000000 0 275000000 0 95000000 0 95000000 0 22000000 0 22000000 0 0 0 0 0 1000000 0 1000000 0 1000000 0 1000000 0 0 0 0 0 1000000 0 1000000 0 298000000 0 298000000 0 97000000 0 97000000 0 298000000 829000000 1127000000 0 97000000 767000000 864000000 P5Y 6600000000 8900000000 <div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:80.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.846%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value January 1</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">767 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value September 30 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)(3)</span></div></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">829 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">755 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> Recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cost of sales, Research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> expenses, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Includes cumulative translation adjustments.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Balance at September 30, 2020 includes $140 million recorded as a current liability for amounts expected to be paid within the next 12 months.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> At September 30, 2020 and December 31, 2019, $637 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.</span></div> 767000000 788000000 97000000 0 71000000 52000000 106000000 85000000 829000000 755000000 140000000 637000000 625000000 0.115 0.08 32600000000 28700000000 28800000000 26300000000 2100000000 2700000000 34000000 0 0 Inventories<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,308 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,629 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,209 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,458 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,081 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts recognized as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are comprised almost entirely of raw materials and work in process inventories. At September 30, 2020 and December 31, 2019, these amounts included $1.8 billion and $1.3 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $288 million and $168 million at September 30, 2020 and December 31, 2019, respectively, of inventories produced in preparation for product launches.</span></div> <div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,772 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,073 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,650 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total (approximates current cost)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,308 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,629 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease to LIFO cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,209 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,458 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized as:</span></td><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,128 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,978 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,081 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 2038000000 1772000000 6073000000 5650000000 197000000 207000000 8308000000 7629000000 99000000 171000000 8209000000 7458000000 6128000000 5978000000 2081000000 1480000000 1800000000 1300000000 288000000 168000000 <div style="margin-top:15pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.    Other Intangibles</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter and first nine months of 2019, the Company recorded $612 million and $693 million, respectively, of intangible asset impairment charges related to marketed products within </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. During the third quarter of 2019, the Company recorded an impairment charge of $612 million related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (tedizolid phosphate), a product for the treatment of acute bacterial skin and skin structure infections caused by susceptible isolates of certain Gram-positive microorganisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which indicated that the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sivextro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> that, when compared with its related carrying value, resulted in the impairment charge noted above.</span></div> 612000000 693000000 612000000 Long-Term DebtIn June 2020, the Company issued $4.5 billion principal amount of senior unsecured notes consisting of $1.0 billion of 0.75% notes due 2026, $1.25 billion of 1.45% notes due 2030, $1.0 billion of 2.35% notes due 2040 and $1.25 billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities. 4500000000 1000000000.0 0.0075 1250000000 0.0145 1000000000.0 0.0235 1250000000 0.0245 Contingencies<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Liability Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Litigation). As of September 30, 2020, approximately 3,590 cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn v. Merck</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the jury returned a verdict in Merck’s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck’s motion for judgment as a matter of law in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case and held that the plaintiff’s failure to warn claim was preempted by federal law.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court’s preemption decision in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Glynn</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, as of September 30, 2020, approximately 970 cases were actively pending in the Femur Fracture MDL.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, approximately 2,340 cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there are four Femur Fracture cases pending in other state courts.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia/Janumet</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of September 30, 2020, Merck is aware of approximately 1,465 product users alleging that </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and/or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> caused the development of pancreatic cancer and other injuries. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court). </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2015, the MDL and California State Court–in separate opinions–granted summary judgment to defendants on grounds of federal preemption.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceedings agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment </span></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Daubert </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">motions. Under the stipulated case management schedule, the hearings for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Daubert</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and summary judgment motions took place on October 20, 2020.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2020, six product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck’s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Merck Sharp &amp; Dohme Corp. v. Albrecht </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(relating to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fosamax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> matter discussed above). Merck filed the opinion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Albrecht</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that preemption presents a legal question to be resolved by the court.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against these lawsuits.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, Merck is a defendant in a lawsuit brought by the Attorney General of Utah alleging that Merck misrepresented the safety of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vioxx</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The lawsuit is pending in Utah state court. Utah seeks damages and penalties under the Utah False Claims Act. A bench trial in this matter has been rescheduled for April 6, 2021.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governmental Proceedings</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, the Company’s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial and Other Litigation</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:174%">Antitrust Litigation</span></div><div style="text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Zetia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants’ motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants’ motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants’ motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. The Merck Defendants moved to dismiss the new allegations in both complaints. In October 2019, the magistrate judge issued a report and recommendation recommending that the district judge grant the motions in their entirety. In December 2019, the district court adopted this report and recommendation in part. The district court granted the Merck Defendants’ motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. On June 18, 2020, the magistrate judge issued a report and recommendation recommending that the district judge grant in part the direct purchasers’ motion for class certification and certify a class of 35 direct purchasers. On August 21, 2020, the district court adopted the report and recommendation in full, and on November 2, 2020, the U.S. Court of Appeals for the Fourth Circuit granted defendants’ motion for permission to appeal the district court’s order. Also, on August 14, 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. The Merck Defendants objected to this report and recommendation and are awaiting a decision from the district court. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 10, 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court will likely hold a hearing on the competing motions. Trial in this matter has been adjourned.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Between January and March 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bridion</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (sugammadex) Injection. In March and April 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants. The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion. All New Jersey actions against all defendants have been consolidated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia, Janumet, Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — In February 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of a patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Januvia</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet XR</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> following expiration of key patent protection in 2022, but prior to the expiration of the later-granted patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026 (2026 salt/polymorph patent), and a later granted patent owned by the Company covering the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> formulation which expires in 2028. Par Pharmaceutical dismissed its case in the U.S. District Court for the District of New Jersey against the Company and will litigate the action in the U.S. District Court for the District of Delaware. The Company filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single three-day trial on invalidity issues in October 2021. The Court will schedule separate one-day trials on infringement issues if necessary. In the Company’s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues. In February 2020, the Company amended its complaint against one defendant, Teva Pharmaceuticals USA, Inc., to add patent infringement claims related to a patent that expires in 2025 and covers certain processes for manufacturing sitagliptin. In July 2020, the Company amended its complaints against two defendants, Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc., to add patent infringement claims related to a patent that also expires in 2026 and covers certain amorphous forms of sitagliptin.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has settled with five generic companies such that these generic companies can bring their products to the market in November 2026 or earlier under certain circumstances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In October 2019, Mylan filed a petition for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Inter Partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2026 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial is scheduled for February 2021 and a final decision is expected in May 2021. After institution, three additional IPR petitions were filed by Teva Pharmaceuticals USA, Inc., Dr. Reddy’s Laboratories, Inc., and Sun Pharmaceutical Industries Ltd., as well as related entities, which requested joinder with Mylan’s IPR proceedings. If the challenges are successful, the unchallenged claims of the 2026 salt/polymorph patent will remain valid, subject to the court proceedings described above. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In Germany, two generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. If the generic companies are successful, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janumet</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> could lose market exclusivity in Germany as early as July 2022. Challenges to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Janumet </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">SPC have also occurred in Portugal and Finland, and could occur in other European countries.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Defense Reserves</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September 30, 2020 and December 31, 2019 of approximately $255 million and $240 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.</span></div> Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. 3590 650 515 970 2340 275 4 1465 6 50 35 5 3 255000000 240000000 Equity<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53,570)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,737 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.55 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,925)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,373 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,724 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,393)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,850)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,744 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.61 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,489 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,107 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,815)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,270 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,579 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,929)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,882 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($1.65 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,925)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,660 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,602 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55,950)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,001 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($1.83 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,489 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,107 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,815)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,270 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> <table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,484 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,295 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,010 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(53,570)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,737 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.55 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,392)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,405)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,925)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at July 1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,373 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49,724 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,393)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,850)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27,744 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($0.61 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,558)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,489 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,107 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,815)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,270 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.795%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other<br/>Paid-In<br/>Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury Stock</span></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-<br/>controlling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38,808 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42,579 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50,929)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,882 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($1.65 per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,262)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">734 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">487 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,561 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45,804 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54,925)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,925 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,660 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46,602 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,038 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(55,950)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26,001 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,161 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared on common stock ($1.83 per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,656)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Treasury stock shares purchased</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,281)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation plans and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(171)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">245 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distributions attributable to noncontrolling</span></div><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,577 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,788 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39,489 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51,107 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,047 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56,815)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29,270 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 3577000000 1788000000 39484000000 45295000000 -5362000000 1010000000 -53570000000 102000000 27737000000 1901000000 1901000000 -28000000 -28000000 0.55 1392000000 1392000000 17000000 1405000000 1405000000 -77000000 1000000 -50000000 -127000000 6000000 6000000 21000000 21000000 3577000000 1788000000 39561000000 45804000000 -5390000000 1026000000 -54925000000 87000000 26925000000 3577000000 1788000000 39373000000 49724000000 -6393000000 1048000000 -56850000000 102000000 27744000000 2941000000 2941000000 10000000 10000000 0.61 1558000000 1558000000 -116000000 1000000 -35000000 -151000000 4000000 4000000 22000000 22000000 3577000000 1788000000 39489000000 51107000000 -6383000000 1047000000 -56815000000 84000000 29270000000 3577000000 1788000000 38808000000 42579000000 -5545000000 985000000 -50929000000 181000000 26882000000 7487000000 7487000000 155000000 155000000 1.65 4262000000 4262000000 -1000000000 54000000 4730000000 3730000000 247000000 13000000 -734000000 -487000000 -73000000 -73000000 21000000 21000000 3577000000 1788000000 39561000000 45804000000 -5390000000 1026000000 -54925000000 87000000 26925000000 3577000000 1788000000 39660000000 46602000000 -6193000000 1038000000 -55950000000 94000000 26001000000 9161000000 9161000000 -190000000 -190000000 1.83 4656000000 4656000000 16000000 1281000000 1281000000 171000000 7000000 -416000000 -245000000 12000000 12000000 22000000 22000000 3577000000 1788000000 39489000000 51107000000 -6383000000 1047000000 -56815000000 84000000 29270000000 Share-Based Compensation Plans<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first nine months of 2020, the Company granted 7 million RSUs with a weighted-average grant date fair value of $77.83 per RSU and during the first nine</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months of 2019 granted 5 million RSUs with a weighted-average grant date fair value of $80.03 per RSU. During the first nine months of 2020, the Company granted 773 thousand PSUs with a weighted-average grant date fair value of $75.22 per PSU and during the first nine</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months of 2019 granted 609 thousand PSUs with a weighted-average grant date fair value of $90.50 per PSU. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first nine months of 2020, the Company granted 4 million stock options with a weighted-average exercise price of $77.67 per option and during the first nine months of 2019 granted 3 million stock options with a weighted-average exercise price of $80.05 per option. The weighted-average fair value of options granted during the first nine months of 2020 and 2019 was $9.93 and $10.63 per option, respectively, and was determined using the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September 30, 2020, there was $800 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted-average period of 2.1 years. For segment reporting, share-based compensation costs are unallocated expenses.</span></div> <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.699%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax share-based compensation expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">354 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense, net of taxes</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 126000000 101000000 354000000 306000000 17000000 14000000 48000000 42000000 109000000 87000000 306000000 264000000 7000000 77.83 5000000 80.03 773000 75.22 609000 90.50 During the first nine months of 2020, the Company granted 4 million stock options with a weighted-average exercise price of $77.67 per option and during the first nine months of 2019 granted 3 million stock options with a weighted-average exercise price of $80.05 per option. The weighted-average fair value of options granted during the first nine months of 2020 and 2019 was $9.93 and $10.63 per option, respectively, and was determined using the following assumptions:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.932%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.017%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.018%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td></tr></table> 4000000 77.67 3000000 80.05 9.93 10.63 0.031 0.032 0.004 0.024 0.221 0.187 P5Y9M18D P5Y10M24D 800000000 P2Y1M6D Pension and Other Postretirement Benefit Plans<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:27.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.140%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that in 2020 it will contribute approximately $200 million and $375 million to its U.S. and international pension plans, respectively, of which $184 million and $123 million, respectively, was contributed in the first nine months of the year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring actions, curtailments were recorded on pension and other postretirement benefit plans and settlements were recorded on certain U.S. and international pension plans as reflected in the tables above.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of net periodic benefit cost (credit) other than the service cost component are included in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (see Note 13), with the exception of certain amounts for termination benefits, curtailments and </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">settlements, which are recorded in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions as noted above.</span> <div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:27.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.140%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">International</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(202)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(106)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(581)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(613)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(320)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 96000000 77000000 76000000 58000000 270000000 225000000 221000000 178000000 107000000 35000000 115000000 44000000 323000000 103000000 343000000 133000000 193000000 104000000 202000000 106000000 581000000 310000000 613000000 320000000 -12000000 -3000000 -12000000 -3000000 -37000000 -9000000 -37000000 -9000000 -75000000 -32000000 -43000000 -16000000 -228000000 -94000000 -113000000 -47000000 1000000 1000000 3000000 0 5000000 2000000 7000000 1000000 -1000000 0 -5000000 0 -4000000 1000000 -6000000 0 -2000000 0 0 0 -11000000 -2000000 0 0 77000000 38000000 28000000 9000000 223000000 106000000 40000000 30000000 200000000 375000000 184000000 123000000 <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">  </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of unrecognized prior service credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net gain amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Termination benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 13000000 12000000 39000000 36000000 14000000 17000000 43000000 52000000 19000000 18000000 56000000 54000000 -18000000 -20000000 -54000000 -59000000 5000000 3000000 13000000 7000000 0 1000000 0 1000000 0 3000000 1000000 4000000 -15000000 -14000000 -42000000 -35000000 Other (Income) Expense, Net<div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from investments in equity securities, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(964)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decline in interest income in the third quarter and first nine months of 2020 reflects lower investments and lower interest rates. The lower exchange losses in the first nine months of 2020 reflect losses on forward exchange contracts in 2019 related to the acquisition of Antelliq. The increase in income from investments in equity securities, net, in both the third quarter and first nine months of 2020 was driven primarily by the recognition of unrealized gains on certain investments, most of which relate to Moderna, Inc. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other, net (as reflected in the table above) in the first nine months of 2019 includes $162 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest paid for the nine months ended September 30, 2020 and 2019 was $605 million and $629 million, respectively.</span></div> <div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income) expense, net, consisted of:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.857%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.710%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.888%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">674 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exchange losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from investments in equity securities, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(360)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(964)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic defined benefit plan (credit) cost other than service cost</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(259)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(409)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(312)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(630)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. 9000000 61000000 48000000 225000000 203000000 231000000 624000000 674000000 -10000000 -38000000 -89000000 -166000000 360000000 16000000 964000000 50000000 -88000000 -128000000 -259000000 -409000000 68000000 29000000 72000000 -206000000 312000000 -35000000 630000000 -362000000 162000000 605000000 629000000 Taxes on Income<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective income tax rates of 14.1% and 18.7% for the third quarter of 2020 and 2019, respectively, and 14.9% and 14.5% for the first nine months of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. The effective income tax rates in the third quarter and first nine months of 2019 also reflect the unfavorable impact of a charge for the acquisition of Peloton for which no tax benefit was recognized and the favorable impact of product mix on the estimated 2019 full-year tax rate. In addition, the effective income tax rate for the first nine months of 2019 reflects the favorable impact of a $360 million net tax benefit related to the settlement of certain federal income tax matters. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million. The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $360 million net tax benefit in the first nine months of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.</span></div> 0.141 0.187 0.149 0.145 360000000 107000000 360000000 Earnings Per Share<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:61.972%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,529 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,538 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.89 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Issuable primarily under share-based compensation plans.</span></div>For the third quarter of 2020 and 2019, 5 million and 3 million, respectively, and for the first nine months of 2020 and 2019, 5 million and 2 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive. <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculations of earnings per share are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.976%"><tr><td style="width:1.0%"/><td style="width:61.972%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.319%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ and shares in millions except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to Merck &amp; Co., Inc.</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,487 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,529 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,558 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,530 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common shares issuable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average common shares outstanding assuming dilution </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,538 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,572 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,541 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,587 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic earnings per common share attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.62 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91 </span></td><td style="background-color:#cceeff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share assuming dilution attributable to Merck &amp; Co., Inc. common shareholders</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.16 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.74 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.61 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.89 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.94pt">Issuable primarily under share-based compensation plans.</span></div> 2941000000 1901000000 9161000000 7487000000 2529000000 2558000000 2530000000 2572000000 9000000 14000000 11000000 15000000 2538000000 2572000000 2541000000 2587000000 1.16 0.74 3.62 2.91 1.16 0.74 3.61 2.89 5000000 3000000 5000000 2000000 Other Comprehensive Income (Loss)<div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by component are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,530)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,946)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,162)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,246)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,393)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,100)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,161)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,556)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,100)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,161)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 12).</span></div> <div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> by component are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,530)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,946)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(75)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(56)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(62)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(117)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance July 1, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,162)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,246)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,393)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,100)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,161)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.187%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivatives</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee<br/>Benefit<br/>Plans</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative<br/>Translation<br/>Adjustment</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other<br/>Comprehensive<br/>Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,556)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,077)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,545)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(33)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">299 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(195)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(154)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2019, net of taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,515)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,063)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance January 1, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,981)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,193)</span></td><td style="background-color:#ffffff;border-top:2pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(220)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(362)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(283)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, pretax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reclassification adjustments, net of taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(190)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance September 30, 2020, net of taxes</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(122)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,100)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,161)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,383)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Relates to foreign currency cash flow hedges that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Sales</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">AOCI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">to</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other (income) expense, net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="margin-top:3pt;padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 12).</span></div> 66000000 48000000 -3530000000 -1946000000 -5362000000 186000000 8000000 -4000000 -84000000 106000000 39000000 0 0 33000000 72000000 147000000 8000000 -4000000 -117000000 34000000 71000000 25000000 -21000000 0 75000000 15000000 0 -2000000 0 13000000 56000000 25000000 -19000000 0 62000000 91000000 -17000000 15000000 -117000000 -28000000 157000000 31000000 -3515000000 -2063000000 -5390000000 15000000 0 -4162000000 -2246000000 -6393000000 -195000000 0 2000000 50000000 -143000000 -41000000 0 -1000000 -35000000 -77000000 -154000000 0 3000000 85000000 -66000000 -22000000 0 -72000000 0 -94000000 -5000000 0 -13000000 0 -18000000 -17000000 0 -59000000 0 -76000000 -137000000 0 62000000 85000000 10000000 -122000000 0 -4100000000 -2161000000 -6383000000 166000000 -78000000 -3556000000 -2077000000 -5545000000 183000000 139000000 -5000000 47000000 364000000 38000000 0 -6000000 33000000 65000000 145000000 139000000 1000000 14000000 299000000 195000000 30000000 -49000000 0 176000000 41000000 0 -9000000 0 32000000 154000000 30000000 -40000000 0 144000000 -9000000 109000000 41000000 14000000 155000000 157000000 31000000 -3515000000 -2063000000 -5390000000 31000000 18000000 -4261000000 -1981000000 -6193000000 -126000000 3000000 -19000000 -220000000 -362000000 -27000000 0 -12000000 -40000000 -79000000 -99000000 3000000 -7000000 -180000000 -283000000 68000000 21000000 -210000000 0 -121000000 14000000 0 -42000000 0 -28000000 54000000 21000000 -168000000 0 -93000000 -153000000 -18000000 161000000 -180000000 -190000000 -122000000 0 -4100000000 -2161000000 -6383000000 Segment Reporting<div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s operations are principally managed on a products basis and include three operating segments, which are the Pharmaceutical, Animal Health and Healthcare Services segments. The Pharmaceutical and Animal Health segments are the only reportable segments. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.</span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Healthcare Services segment provided services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company has been in the process of divesting the businesses in the Healthcare Services segment. The remaining businesses were divested during the first quarter of 2020.</span></div><div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.617%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"> ($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,743 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Emend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cubicin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zepatier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zetia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vytorin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Atozet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,539 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Women’s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Implanon/Nexplanon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">NuvaRing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diversified Brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Singulair</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cozaar/Hyzaar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Arcoxia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Nasonex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Follistim AQ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,914 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,095 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,654 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,016 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,411 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,535 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,305 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,924 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,263 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,863 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,212 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,301 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,322 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34,622 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,625 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,926 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,551 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,573 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,824 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,397 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,396 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,084 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,479 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,320 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,652 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34,972 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020. </span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(5)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. </span></div><div style="margin-top:5pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.4 billion and $3.0 billion for the three months ended September 30, 2020 and 2019, respectively, and $9.6 billion and $8.6 billion for the nine months ended September 30, 2020 and 2019, respectively. </span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,573 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,551 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,479 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,972 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income before taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,347 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,272)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of purchase accounting adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,428 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,347 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,784 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,673 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.</span></div> 3 <div style="text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company’s products were as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.315%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.601%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.617%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%"> ($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Int’l</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Pharmaceutical:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Keytruda</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,157 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,559 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,743 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,327 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,070 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,106 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,281 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10,387 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4,525 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7,973 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lynparza</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">196 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">53 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">123 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">297 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">519 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">126 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Lenvima</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">169 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">280 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Emend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">42 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">56 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">173 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">163 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">336 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Vaccines</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Gardasil/Gardasil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">608 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,187 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">761 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">558 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,209 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,732 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,579 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,464 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,044 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">ProQuad/M-M-R </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">II</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">/Varivax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">437 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">576 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">482 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">141 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">623 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,033 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">356 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,390 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,325 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">469 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,794 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Pneumovax </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">276 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">99 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">237 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">270 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">748 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">428 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">RotaTeq</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">114 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">210 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">180 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">355 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">360 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vaqta</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">65 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Hospital Acute Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Bridion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">162 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">157 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">151 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">284 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">412 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">843 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">381 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">817 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Noxafil</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">13 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">66 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">220 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">247 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">291 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Prevymis</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">115 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Primaxin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">73 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">74 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">75 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">77 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Invanz</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">51 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">159 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">30 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">176 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">206 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cancidas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">49 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">148 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">187 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">191 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cubicin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">36 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">207 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zerbaxa</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">112 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">45 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">88 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Simponi</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">615 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">625 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Remicade</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">242 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">322 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Belsomra</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">18 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">63 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">81 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">67 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">244 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">155 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Virology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Isentress/Isentress</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">HD</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">92 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">205 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">250 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">243 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">403 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">646 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">449 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">752 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zepatier</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">22 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">28 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">59 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">38 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">122 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">96 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">208 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">304 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cardiovascular</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Zetia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">103 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">147 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">389 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">384 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">432 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">443 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Vytorin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">44 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">130 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">139 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">219 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">231 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Atozet</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">111 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">97 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">348 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">283 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Alliance revenue - Adempas </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">83 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">200 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">216 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Adempas</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">57 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">167 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">158 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diabetes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Januvia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">342 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">821 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">367 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">440 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">807 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,110 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,339 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,449 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,223 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,539 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Janumet</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">129 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">361 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,138 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,499 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Women’s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Implanon/Nexplanon</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">137 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">52 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">199 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">142 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">421 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">160 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">581 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">NuvaRing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">39 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">241 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">85 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">184 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">593 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">107 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">700 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diversified Brands</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Singulair</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">78 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">82 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">324 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">24 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">479 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Cozaar/Hyzaar</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">86 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">91 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">110 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">116 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">275 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">292 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">16 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">313 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">329 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Arcoxia</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">68 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">72 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">204 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Nasonex</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">41 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">55 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">58 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">152 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">161 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">224 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:100%">Follistim AQ</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">50 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">27 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">62 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">60 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">76 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">80 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">102 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">182 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">834 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,186 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">804 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,149 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,144 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,334 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,478 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,037 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,394 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,431 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Pharmaceutical segment sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,102 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,180 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,914 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11,095 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,452 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,654 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">14,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">17,016 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">31,218 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Animal Health:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Livestock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">164 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">594 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">758 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">144 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">582 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">726 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">448 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,697 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,601 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,007 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Companion Animals</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">234 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">228 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">462 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">193 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">203 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">676 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">714 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">560 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,264 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total Animal Health segment sales</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">398 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">822 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,220 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">337 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">785 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,122 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,124 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,411 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,535 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">966 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2,305 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">3,271 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other segment sales </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">46 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">23 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">133 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total segment sales</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,616 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,924 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,540 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,563 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,699 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,263 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,349 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,863 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,212 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,301 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,322 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34,622 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.44pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">11 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">10 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">125 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">134 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">47 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">221 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">267 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">330 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">350 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,625 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,926 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,551 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">5,573 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">6,824 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">12,397 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,396 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">20,084 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">35,479 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">15,320 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">19,652 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">34,972 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">U.S. plus international may not equal total due to rounding.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(2)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(3)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.</span></div><div style="margin-top:3pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(4)    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020. </span></div>(5)    Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales. 2157000000 1559000000 3715000000 1743000000 1327000000 3070000000 6106000000 4281000000 10387000000 4525000000 3448000000 7973000000 107000000 89000000 196000000 71000000 53000000 123000000 297000000 223000000 519000000 186000000 126000000 313000000 82000000 60000000 142000000 65000000 44000000 109000000 270000000 152000000 421000000 169000000 112000000 280000000 8000000 31000000 39000000 42000000 56000000 98000000 18000000 96000000 115000000 173000000 163000000 336000000 579000000 608000000 1187000000 761000000 558000000 1320000000 1209000000 1732000000 2941000000 1579000000 1464000000 3044000000 437000000 139000000 576000000 482000000 141000000 623000000 1033000000 356000000 1390000000 1325000000 469000000 1794000000 276000000 99000000 375000000 179000000 58000000 237000000 478000000 270000000 748000000 428000000 164000000 592000000 114000000 96000000 210000000 102000000 78000000 180000000 355000000 246000000 601000000 360000000 203000000 564000000 32000000 19000000 51000000 36000000 26000000 62000000 79000000 60000000 139000000 103000000 65000000 167000000 162000000 157000000 320000000 133000000 151000000 284000000 412000000 431000000 843000000 381000000 437000000 817000000 13000000 66000000 79000000 77000000 100000000 177000000 27000000 220000000 247000000 268000000 291000000 560000000 32000000 46000000 77000000 22000000 23000000 45000000 87000000 113000000 200000000 60000000 55000000 115000000 1000000 73000000 74000000 2000000 75000000 77000000 2000000 187000000 189000000 2000000 204000000 207000000 1000000 50000000 51000000 -1000000 58000000 57000000 7000000 152000000 159000000 30000000 176000000 206000000 1000000 49000000 50000000 0 62000000 62000000 2000000 147000000 148000000 5000000 187000000 191000000 11000000 28000000 39000000 14000000 38000000 52000000 36000000 80000000 116000000 78000000 129000000 207000000 20000000 23000000 43000000 20000000 15000000 35000000 57000000 54000000 112000000 45000000 43000000 88000000 0 209000000 209000000 0 203000000 203000000 0 615000000 615000000 0 625000000 625000000 0 82000000 82000000 0 101000000 101000000 0 242000000 242000000 0 322000000 322000000 18000000 63000000 81000000 23000000 57000000 80000000 67000000 177000000 244000000 68000000 155000000 223000000 92000000 113000000 205000000 102000000 149000000 250000000 243000000 403000000 646000000 304000000 449000000 752000000 6000000 22000000 28000000 24000000 59000000 83000000 38000000 83000000 122000000 96000000 208000000 304000000 -1000000 103000000 103000000 5000000 142000000 147000000 -4000000 389000000 384000000 11000000 432000000 443000000 3000000 44000000 47000000 5000000 52000000 57000000 9000000 130000000 139000000 11000000 219000000 231000000 0 111000000 111000000 0 97000000 97000000 0 348000000 348000000 0 283000000 283000000 78000000 5000000 83000000 48000000 2000000 50000000 200000000 16000000 216000000 137000000 7000000 144000000 0 55000000 55000000 0 57000000 57000000 0 167000000 167000000 0 158000000 158000000 342000000 479000000 821000000 367000000 440000000 807000000 1110000000 1339000000 2449000000 1223000000 1317000000 2539000000 105000000 400000000 506000000 129000000 375000000 503000000 361000000 1138000000 1499000000 462000000 1105000000 1567000000 137000000 52000000 189000000 136000000 62000000 199000000 374000000 142000000 515000000 421000000 160000000 581000000 24000000 34000000 58000000 202000000 39000000 241000000 85000000 98000000 184000000 593000000 107000000 700000000 4000000 78000000 82000000 11000000 140000000 152000000 14000000 324000000 338000000 24000000 479000000 503000000 5000000 86000000 91000000 6000000 110000000 116000000 17000000 275000000 292000000 16000000 313000000 329000000 0 68000000 68000000 0 72000000 72000000 0 204000000 204000000 0 221000000 221000000 0 41000000 41000000 4000000 55000000 58000000 9000000 152000000 161000000 2000000 224000000 226000000 20000000 31000000 50000000 27000000 35000000 62000000 60000000 76000000 136000000 80000000 102000000 182000000 352000000 834000000 1186000000 343000000 804000000 1149000000 1144000000 2334000000 3478000000 1037000000 2394000000 3431000000 5218000000 6102000000 11320000000 5180000000 5914000000 11095000000 14202000000 17452000000 31654000000 14202000000 17016000000 31218000000 164000000 594000000 758000000 144000000 582000000 726000000 448000000 1697000000 2145000000 406000000 1601000000 2007000000 234000000 228000000 462000000 193000000 203000000 396000000 676000000 714000000 1390000000 560000000 704000000 1264000000 398000000 822000000 1220000000 337000000 785000000 1122000000 1124000000 2411000000 3535000000 966000000 2305000000 3271000000 0 0 0 46000000 0 46000000 23000000 0 23000000 133000000 1000000 133000000 5616000000 6924000000 12540000000 5563000000 6699000000 12263000000 15349000000 19863000000 35212000000 15301000000 19322000000 34622000000 9000000 2000000 11000000 10000000 125000000 134000000 47000000 221000000 267000000 19000000 330000000 350000000 5625000000 6926000000 12551000000 5573000000 6824000000 12397000000 15396000000 20084000000 35479000000 15320000000 19652000000 34972000000 3400000000 3000000000.0 9600000000 8600000000 <div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated sales by geographic area where derived are as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.882%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.956%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,625 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,573 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,396 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,320 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe, Middle East and Africa</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,454 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,189 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,059 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">China</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,016 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">914 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">919 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,639 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia Pacific (other than China and Japan)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">735 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">756 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Latin America</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">671 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,670 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,889 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,032 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,551 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,397 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,479 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,972 </span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 5625000000 5573000000 15396000000 15320000000 3454000000 3189000000 10059000000 9452000000 1016000000 914000000 2715000000 2423000000 828000000 919000000 2506000000 2639000000 735000000 756000000 2129000000 2217000000 604000000 671000000 1670000000 1889000000 289000000 375000000 1004000000 1032000000 12551000000 12397000000 35479000000 34972000000 <div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of segment profits to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income before taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is as follows:</span></div><div style="margin-bottom:5pt;margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.150%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.538%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.540%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Nine Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">($ in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment profits:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical segment</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,974 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,747 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,010 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,437 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Animal Health segment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,243 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other segment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total segment profits</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,424 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,168 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,347 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other profits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">188 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unallocated:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(231)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(624)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(395)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(382)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,173)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,169)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,272)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,110)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,364)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,045)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of purchase accounting adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(329)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(879)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(114)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(444)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other unallocated, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(724)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,699)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,019)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,428 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,347 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,784 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,673 </span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 7974000000 7747000000 22010000000 21437000000 451000000 423000000 1336000000 1243000000 -1000000 -2000000 1000000 -2000000 8424000000 8168000000 23347000000 22678000000 -12000000 101000000 188000000 226000000 9000000 61000000 48000000 225000000 203000000 231000000 624000000 674000000 395000000 382000000 1173000000 1169000000 3272000000 3110000000 7364000000 7045000000 285000000 329000000 879000000 1105000000 114000000 232000000 269000000 444000000 724000000 1699000000 2490000000 4019000000 3428000000 2347000000 10784000000 8673000000 XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page - shares
 9 Months Ended
Sep. 30, 2020
Oct. 31, 2020
Entity Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2020  
Document Transition Report false  
Entity File Number 1-6571  
Entity Registrant Name Merck & Co., Inc.  
Entity Incorporation, State or Country Code NJ  
Entity Tax Identification Number 22-1918501  
Entity Address, Address Line One 2000 Galloping Hill Road  
Entity Address, City or Town Kenilworth  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07033  
City Area Code (908)  
Local Phone Number 740-4000  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   2,530,034,437
Amendment Flag false  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q3  
Entity Central Index Key 0000310158  
Current Fiscal Year End Date --12-31  
   Common Stock    
Entity Information [Line Items]    
Title of 12(b) Security Common Stock ($0.50 par value)  
Trading Symbol MRK  
Security Exchange Name NYSE  
1.125% Notes due 2021    
Entity Information [Line Items]    
Title of 12(b) Security 1.125% Notes due 2021  
Trading Symbol MRK/21  
Security Exchange Name NYSE  
0.500% Notes due 2024    
Entity Information [Line Items]    
Title of 12(b) Security 0.500% Notes due 2024  
Trading Symbol MRK 24  
Security Exchange Name NYSE  
1.875% Notes due 2026    
Entity Information [Line Items]    
Title of 12(b) Security 1.875% Notes due 2026  
Trading Symbol MRK/26  
Security Exchange Name NYSE  
2.500% Notes due 2034    
Entity Information [Line Items]    
Title of 12(b) Security 2.500% Notes due 2034  
Trading Symbol MRK/34  
Security Exchange Name NYSE  
1.375% Notes due 2036    
Entity Information [Line Items]    
Title of 12(b) Security 1.375% Notes due 2036  
Trading Symbol MRK 36A  
Security Exchange Name NYSE  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENT OF INCOME - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Statement [Abstract]        
Sales $ 12,551 $ 12,397 $ 35,479 $ 34,972
Costs, Expenses and Other        
Cost of sales 3,481 3,990 9,952 10,443
Selling, general and administrative 2,450 2,589 7,383 7,726
Research and development 3,390 3,204 7,721 7,324
Restructuring costs 114 232 269 444
Other (income) expense, net (312) 35 (630) 362
Total Costs, Expenses and Other 9,123 10,050 24,695 26,299
Income Before Taxes 3,428 2,347 10,784 8,673
Taxes on Income 483 440 1,611 1,259
Net Income 2,945 1,907 9,173 7,414
Less: Net Income (Loss) Attributable to Noncontrolling Interests 4 6 12 (73)
Net Income Attributable to Merck & Co., Inc. $ 2,941 $ 1,901 $ 9,161 $ 7,487
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.16 $ 0.74 $ 3.62 $ 2.91
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) $ 1.16 $ 0.74 $ 3.61 $ 2.89
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Statement of Comprehensive Income [Abstract]        
Net Income Attributable to Merck & Co., Inc. $ 2,941 $ 1,901 $ 9,161 $ 7,487
Other Comprehensive Income (Loss) Net of Taxes:        
Net unrealized (loss) gain on derivatives, net of reclassifications (137) 91 (153) (9)
Net unrealized (loss) gain on investments, net of reclassifications 0 (17) (18) 109
Benefit plan net gain and prior service credit, net of amortization 62 15 161 41
Cumulative translation adjustment 85 (117) (180) 14
Other comprehensive income (loss), net of taxes 10 (28) (190) 155
Comprehensive Income Attributable to Merck & Co., Inc. $ 2,951 $ 1,873 $ 8,971 $ 7,642
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Current Assets    
Cash and cash equivalents $ 7,356 $ 9,676
Short-term investments 0 774
Accounts receivable (net of allowance for doubtful accounts of $89 in 2020 and $86 in 2019) 8,422 6,778
Inventories (excludes inventories of $2,081 in 2020 and $1,480 in 2019 classified in Other assets - see Note 6) 6,128 5,978
Other current assets 4,671 4,277
Total current assets 26,577 27,483
Investments 1,372 1,469
Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,572 in 2020 and $17,686 in 2019 16,919 15,053
Goodwill 20,248 19,425
Other Intangibles, Net 16,677 14,196
Other Assets 8,007 6,771
Total Assets 89,800 84,397
Current Liabilities    
Loans payable and current portion of long-term debt 2,420 3,610
Trade accounts payable 3,744 3,738
Accrued and other current liabilities 11,690 12,549
Income taxes payable 984 736
Dividends payable 1,567 1,587
Total current liabilities 20,405 22,220
Long-Term Debt 26,321 22,736
Deferred Income Taxes 1,777 1,470
Other Noncurrent Liabilities 12,027 11,970
Merck & Co., Inc. Stockholders’ Equity    
Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019 1,788 1,788
Other paid-in capital 39,489 39,660
Retained earnings 51,107 46,602
Accumulated other comprehensive loss (6,383) (6,193)
Stockholders' equity before deduction for treasury stock 86,001 81,857
Less treasury stock, at cost: 1,047,343,390 shares in 2020 and 1,038,087,496 shares in 2019 56,815 55,950
Total Merck & Co., Inc. stockholders’ equity 29,186 25,907
Noncontrolling Interests 84 94
Total equity 29,270 26,001
Liabilities and Equity $ 89,800 $ 84,397
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Statement of Financial Position [Abstract]    
Allowance for doubtful accounts $ 89 $ 86
Inventories classified in Other assets 2,081 1,480
Accumulated depreciation $ 18,572 $ 17,686
Common stock, par value (in dollars per share) $ 0.50 $ 0.50
Common stock, shares authorized (shares) 6,500,000,000 6,500,000,000
Common stock, shares issued (in shares) 3,577,103,522 3,577,103,522
Treasury Stock, Shares 1,047,343,390 1,038,087,496
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash Flows from Operating Activities    
Net income $ 9,173 $ 7,414
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 2,721 2,716
Intangible asset impairment charges 35 864
Charge for acquisition of Peloton Therapeutics, Inc. 0 982
Deferred income taxes 47 (386)
Share-based compensation 354 306
Other (445) 219
Net changes in assets and liabilities (5,638) (3,469)
Net Cash Provided by Operating Activities 6,247 8,646
Cash Flows from Investing Activities    
Capital expenditures (3,170) (2,336)
Purchases of securities and other investments (78) (2,380)
Proceeds from sales of securities and other investments 1,894 7,459
Acquisition of ArQule, Inc., net of cash acquired (2,545) 0
Acquisition of Antelliq Corporation, net of cash acquired 0 (3,620)
Acquisition of Peloton Therapeutics, Inc., net of cash acquired 0 (1,040)
Other acquisitions, net of cash acquired (907) (269)
Other 141 320
Net Cash Used in Investing Activities (4,665) (1,866)
Cash Flows from Financing Activities    
Net change in short-term borrowings (311) (3,892)
Payments on debt (1,954) 0
Proceeds from issuance of debt 4,419 4,958
Purchases of treasury stock (1,281) (3,730)
Dividends paid to stockholders (4,673) (4,290)
Proceeds from exercise of stock options 68 344
Other (472) (240)
Net Cash Used in Financing Activities (4,204) (6,850)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash 89 (26)
Net Decrease in Cash, Cash Equivalents and Restricted Cash (2,533) (96)
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 at January 1, 2020 included in Other Assets) 9,934 7,967
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $45 at September 30, 2020 included in Other Assets) $ 7,401 $ 7,871
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.2
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Statement of Cash Flows [Abstract]    
Restricted cash $ 45 $ 258
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2020.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Planned Spin-Off of Women’s Health, Biosimilars and Established Brands into New Company
In February 2020, Merck announced its intention to spin-off products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consist of dermatology, non-opioid pain management, respiratory, and select cardiovascular products including Zetia (ezetimibe) and Vytorin (ezetimibe and simvastatin), as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs will continue to be owned and developed within Merck as planned. Organon will have development capabilities initially focused on late-stage development and life-cycle management and is expected over time to develop research capabilities in selected therapeutic areas. The spin-off is expected to be completed in the second quarter of 2021, subject to market and certain other conditions. Subsequent to the spin-off, the historical results of the women’s health, biosimilars and established brands businesses will be reflected as discontinued operations in the Company’s consolidated financial statements.
Recently Adopted Accounting Standards
In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company’s collaborative arrangements.
Recently Issued Accounting Standards Not Yet Adopted
In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by: removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions, Research Collaborations and License Agreements
 9 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
Acquisitions, Research Collaborations and License Agreements Acquisitions, Research Collaborations and License Agreements
The Company continues to pursue acquisitions and the establishment of external alliances such as research collaborations and licensing agreements to complement its internal research capabilities. These arrangements often include upfront payments, as well as expense reimbursements or payments to the third party, and milestone, royalty or profit share arrangements, contingent upon the occurrence of certain future events linked to the success of the asset in development. The Company also reviews its marketed products and pipeline to examine candidates which may provide more value through out-licensing and, as part of its portfolio assessment process, may also divest certain assets. Pro forma financial information for acquired businesses is not presented if the historical financial results of the acquired entity are not significant when compared with the Company’s financial results.
In November 2020, Merck and VelosBio, Inc. (VelosBio) announced that the companies had entered into a definitive agreement pursuant to which Merck, through a subsidiary, will acquire all outstanding shares of VelosBio for $2.75 billion, subject to certain customary adjustments. VelosBio is a privately held clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate targeting ROR1 that is currently being evaluated in a Phase 1 and a Phase 2 clinical trial for the treatment of patients with hematologic malignancies and solid tumors, respectively. The closing of the transaction, which is subject to approval under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions, is expected by the end of 2020.
In September 2020, Merck and Seagen Inc. (Seagen, formerly known as Seattle Genetics, Inc.) announced an oncology collaboration to globally develop and commercialize Seagen’s ladiratuzumab vedotin (MK-6440), an investigational antibody-drug conjugate targeting LIV-1, which is currently in Phase 2 clinical trials for breast cancer and other solid tumors. The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Keytruda (pembrolizumab) in triple-negative breast cancer, hormone receptor-positive breast cancer and other LIV-1-expressing solid tumors. The companies will equally share profits worldwide. Under the terms of the agreement, Merck made an upfront payment of $600 million and a $1.0 billion equity investment in 5 million shares of Seagen common stock at a price of $200 per share. Merck recorded $622 million in Research and development expenses in the third quarter and first nine months of 2020 related to this transaction reflecting the upfront payment as well as a $22 million mark-to-market loss on the purchase commitment (forward contract) relating to the equity shares (calculated based on the closing price of Seagen common stock on September 30, 2020). The closing of the equity investment occurred in October 2020 and resulted in the recognition of a $6 million reduction to Research and development expenses based on the price of Seagen common stock on the closing date. Seagen is also eligible to receive future contingent milestone payments of up to $2.6 billion, including $850 million in development milestones and $1.75 billion in sales milestones.
Concurrent with the above transaction, Seagen granted Merck an exclusive license to commercialize Tukysa (tucatinib), a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America and other regions outside of the United States, Canada and Europe. Merck will be responsible for marketing applications seeking approval in its territories, supported by the positive results from the HER2CLIMB clinical trial. Merck will also co-fund a portion of the Tukysa global development plan, which encompasses several ongoing and planned trials across HER2-positive cancers, including breast, colorectal, gastric and other cancers set forth in a global product development plan. Merck will solely fund and conduct country-specific clinical trials necessary to support anticipated regulatory applications in its territories. Under the terms of the agreement, Merck made upfront payments aggregating $210 million, which were recorded as Research and development expenses in the third quarter and first nine months of 2020. Seagen is also eligible to receive future contingent regulatory approval milestones of up to $65 million and will receive tiered royalties ranging from 20% to 33% based on annual sales levels of Tukysa in Merck’s territories.
Additionally in September 2020, Merck acquired a biologics manufacturing facility located in Dunboyne, Ireland from Takeda Pharmaceutical Company Limited for €256 million ($302 million). The transaction was accounted for as an acquisition of an asset. Merck recorded property, plant and equipment of $289 million and other net assets of $13 million. There are no future contingent payments associated with the acquisition.
In July 2020, Merck acquired the U.S. rights to Sentinel Flavor Tabs and Sentinel Spectrum Chews from Virbac Corporation for $410 million. Sentinel products provide protection against common parasites in dogs. The transaction was accounted for as an acquisition of an asset. Merck recognized intangible assets of $401 million related to currently marketed products and inventory of $9 million at the acquisition date. The estimated fair values of the identifiable intangible assets related to currently marketed products were determined using an income approach. Actual cash flows are likely to be different than those assumed. The intangible assets related to currently marketed products will be amortized over their estimated useful lives of 15 years. There are no future contingent payments associated with the acquisition.
Also, in July 2020, Merck and Ridgeback Biotherapeutics LP (Ridgeback Bio), a closely held biotechnology company, closed a collaboration agreement to develop molnupiravir (MK-4482, formerly known as EIDD-2801), an orally
available antiviral candidate currently in clinical development for the treatment of patients with COVID-19. Merck gained exclusive worldwide rights to develop and commercialize molnupiravir and related molecules. Under the terms of the agreement, Ridgeback Bio received an upfront payment and also is eligible to receive future contingent payments dependent upon the achievement of certain developmental and regulatory approval milestones, as well as a share of the net profits of molnupiravir and related molecules, if approved. Merck and Ridgeback are committed to ensure that any medicines developed for SARS-CoV-2 (the causative agent of COVID-19) will be accessible and affordable globally.
In June 2020, Merck acquired privately held Themis Bioscience GmbH (Themis), a company focused on vaccines and immune-modulation therapies for infectious diseases and cancer for $366 million. Merck may make additional contingent payments of up to $740 million, including up to $80 million for development milestones, up to $260 million for regulatory approval milestones, and up to $400 million for commercial milestones. Themis has a broad pipeline of vaccine candidates and immune-modulatory therapies developed using its innovative measles virus vector platform based on a vector originally developed by scientists at the Institut Pasteur and licensed exclusively to Themis for select viral indications. The acquisition builds upon an ongoing collaboration between the two companies to develop vaccine candidates using the measles virus vector platform and is expected to accelerate the development of the COVID-19 vaccine candidate (V591), which is currently in Phase 1 clinical development. The transaction was accounted for as an acquisition of a business. The Company determined the fair value of the contingent consideration was $97 million at the acquisition date utilizing a probability-weighted estimated cash flow stream using an appropriate discount rate dependent on the nature and timing of the milestone payment. Merck recognized intangible assets for in-process research and development (IPR&D) of $136 million, cash of $59 million, deferred tax assets of $71 million and other net liabilities of $32 million. The excess of the consideration transferred over the fair value of net assets acquired of $229 million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&D were determined using an income approach. Actual cash flows are likely to be different than those assumed. In connection with the transaction, Merck has entered into a memorandum of understanding that reflects the parties’ commitments to address the COVID-19 pandemic by developing, manufacturing and distributing the vaccine on a global basis and with pricing that makes the vaccine both available around the world and accessible to those who need it.
In May 2020, Merck and the International AIDS Vaccine Initiative, Inc. (IAVI), a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announced a new collaboration to develop V590, an investigational vaccine against SARS-CoV-2 being studied for the prevention of COVID-19. This vaccine candidate will use the recombinant vesicular stomatitis virus (rVSV) technology that is the basis for Merck’s approved Ebola Zaire virus vaccine, Ervebo (Ebola Zaire Vaccine, Live), which was the first rVSV vaccine approved for use in humans. Under the terms of the agreement, Merck made an upfront payment of $6.5 million and may make additional contingent payments of up to $100 million for sales-based milestones, as well as royalty payments. Merck has also signed an agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response within an agency of the United States Department of Health and Human Services, to provide initial funding support for this effort. Under the agreement, IAVI and Merck will work together to advance the development and global clinical evaluation of a SARS-CoV-2 vaccine candidate designed and engineered by IAVI scientists. The vaccine candidate is currently in Phase 1 clinical development. Merck will lead regulatory filings globally. Both organizations will work together to develop the vaccine and make it accessible and affordable globally, if approved.
In January 2020, Merck acquired ArQule, Inc. (ArQule), a publicly traded biopharmaceutical company focused on kinase inhibitor discovery and development for the treatment of patients with cancer and other diseases. Total consideration paid of $2.7 billion included $138 million of share-based compensation payments to settle equity awards attributable to precombination service and cash paid for transaction costs on behalf of ArQule. The Company incurred $95 million of transaction costs directly related to the acquisition of ArQule, consisting almost entirely of share-based compensation payments to settle non-vested equity awards attributable to postcombination service. These costs were included in Selling, general and administrative expenses in the first nine months of 2020. ArQule’s lead investigational candidate, MK-1026 (formerly known as ARQ 531), is a novel, oral Bruton’s tyrosine kinase (BTK) inhibitor currently being evaluated for the treatment of B-cell malignancies.
The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:
($ in millions)January 16, 2020
Cash and cash equivalents$145 
IPR&D MK-1026 (formerly ARQ 531) (1)
2,280 
Licensing arrangement for ARQ 08780 
Deferred income tax liabilities(389)
Other assets and liabilities, net34 
Total identifiable net assets
2,150 
Goodwill (2)
540 
Consideration transferred$2,690 
(1)    The estimated fair value of the identifiable intangible asset related to IPR&D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.
In July 2019, Merck acquired Peloton Therapeutics, Inc. (Peloton), a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases. Peloton’s lead candidate, MK-6482 (formerly known as PT2977), is a novel investigational oral HIF-2α inhibitor in late-stage development for renal cell carcinoma. Merck made an upfront payment of $1.2 billion; additionally, former Peloton shareholders will be eligible to receive $50 million upon U.S. regulatory approval, $50 million upon first commercial sale in the United States, and up to $1.05 billion of sales-based milestones. The transaction was accounted for as an acquisition of an asset. Merck recorded cash of $157 million, deferred tax liabilities of $64 million, and other net liabilities of $6 million at the acquisition date and Research and development expenses of $982 million in the third quarter and first nine months of 2019 related to the transaction.
On April 1, 2019, Merck acquired Antelliq Corporation (Antelliq), a leader in digital animal identification, traceability and monitoring solutions. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. Merck paid $2.3 billion to acquire all outstanding shares of Antelliq and spent $1.3 billion to repay Antelliq’s debt. The transaction was accounted for as an acquisition of a business.
The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:
($ in millions)April 1, 2019
Cash and cash equivalents$31 
Accounts receivable73 
Inventories93 
Property, plant and equipment60 
Identifiable intangible assets (useful lives ranging from 18-24 years) (1)
2,689 
Deferred income tax liabilities(589)
Other assets and liabilities, net(82)
Total identifiable net assets
2,275 
Goodwill (2)
1,376 
Consideration transferred$3,651 
(1)    The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.

The Company’s results for the first nine months of 2019 include five months of activity for Antelliq. The Company incurred $47 million of transaction costs directly related to the acquisition of Antelliq, consisting largely of advisory fees, which are reflected in Selling, general and administrative expenses in the first nine months of 2019.
Also in April 2019, Merck acquired Immune Design, a late-stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease, for $301 million in cash. The transaction was accounted for as an acquisition of a business. Merck recognized intangible assets of $156 million, cash of $83 million and other net assets of $42 million. The excess of the consideration transferred over the fair value of net assets acquired of $20
million was recorded as goodwill that was allocated to the Pharmaceutical segment and is not deductible for tax purposes. The fair values of the identifiable intangible assets related to IPR&D were determined using an income approach. Actual cash flows are likely to be different than those assumed.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborative Arrangements
 9 Months Ended
Sep. 30, 2020
Collaborative Arrangements [Abstract]  
Collaborative Arrangements Collaborative Arrangements
Merck has entered into collaborative arrangements that provide the Company with varying rights to develop, produce and market products together with its collaborative partners. Both parties in these arrangements are active participants and exposed to significant risks and rewards dependent on the commercial success of the activities of the collaboration. Merck’s more significant collaborative arrangements are discussed below.
AstraZeneca
In July 2017, Merck and AstraZeneca PLC (AstraZeneca) entered into a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s Lynparza (olaparib) for multiple cancer types. Lynparza is an oral poly (ADP-ribose) polymerase (PARP) inhibitor currently approved for certain types of advanced ovarian, breast, pancreatic and prostate cancers. The companies are jointly developing and commercializing Lynparza, both as monotherapy and in combination trials with other potential medicines. Independently, Merck and AstraZeneca will develop and commercialize Lynparza in combinations with their respective PD-1 and PD-L1 medicines, Keytruda and Imfinzi. The companies will also jointly develop and commercialize AstraZeneca’s Koselugo (selumetinib), an oral, selective inhibitor of MEK, part of the mitogen-activated protein kinase (MAPK) pathway, currently being developed for multiple indications. In April 2020, Koselugo was approved by the U.S. Food and Drug Administration (FDA) for the treatment of pediatric patients two years of age and older with neurofibromatosis type 1 who have symptomatic, inoperable plexiform neurofibromas. Under the terms of the agreement, AstraZeneca and Merck will share the development and commercialization costs for Lynparza and Koselugo monotherapy and non-PD-L1/PD-1 combination therapy opportunities.
Profits from Lynparza and Koselugo product sales generated through monotherapies or combination therapies are shared equally. Merck will fund all development and commercialization costs of Keytruda in combination with Lynparza or Koselugo. AstraZeneca will fund all development and commercialization costs of Imfinzi in combination with Lynparza or Koselugo. AstraZeneca is the principal on Lynparza and Koselugo sales transactions. Merck records its share of Lynparza and Koselugo product sales, net of cost of sales and commercialization costs, as alliance revenue and its share of development costs associated with the collaboration as part of Research and development expenses. Reimbursements received from AstraZeneca for research and development expenses are recognized as reductions to Research and development costs.
As part of the agreement, Merck made an upfront payment to AstraZeneca of $1.6 billion in 2017 and made payments of $750 million over a multi-year period for certain license options. In addition, the agreement provides for additional contingent payments from Merck to AstraZeneca related to the successful achievement of sales-based and regulatory milestones.
In the second quarter of 2020, Merck determined it was probable that sales of Lynparza in the future would trigger $400 million of sales-based milestone payments from Merck to AstraZeneca. Accordingly, Merck recorded a $400 million liability and a corresponding increase to the intangible asset related to Lynparza. Prior to 2020, Merck accrued sales-based milestone payments aggregating $1.0 billion related to Lynparza, of which $200 million and $250 million was paid to AstraZeneca in 2019 and 2018, respectively, and $250 million was paid in the first nine months of 2020. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
In the second quarter of 2020, Lynparza received regulatory approvals triggering capitalized milestone payments of $135 million from Merck to AstraZeneca. In 2019 and 2018, Lynparza received regulatory approvals triggering capitalized milestone payments of $60 million and $140 million, respectively, in the aggregate from Merck to AstraZeneca. Potential future regulatory milestone payments of $1.4 billion remain under the agreement.
The intangible asset balance related to Lynparza (which includes capitalized sales-based and regulatory milestone payments) was $1.3 billion at September 30, 2020 and is included in Other Intangibles, Net on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2028 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Alliance revenue - Lynparza$196 $123 $519 $313 
Alliance revenue - Koselugo3 — 3 — 
Total alliance revenue$199 $123 $522 $313 
Cost of sales (1)
41 28 205 120 
Selling, general and administrative40 36 112 96 
Research and development20 44 93 122 
($ in millions)September 30, 2020December 31, 2019
Receivables from AstraZeneca included in Other current assets
$197 $128 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
309 577 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
400 — 
(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone payments.
Eisai
In March 2018, Merck and Eisai Co., Ltd. (Eisai) announced a strategic collaboration for the worldwide co-development and co-commercialization of Lenvima (lenvatinib), an orally available tyrosine kinase inhibitor discovered by Eisai. Lenvima is currently approved for the treatment of certain types of thyroid cancer, hepatocellular carcinoma, in combination with everolimus for certain patients with renal cell carcinoma, and in combination with Keytruda for the treatment of certain patients with endometrial carcinoma. Under the agreement, Merck and Eisai will develop and commercialize Lenvima jointly, both as monotherapy and in combination with Keytruda. Eisai records Lenvima product sales globally (Eisai is the principal on Lenvima sales transactions), and Merck and Eisai share profits equally. Merck records its share of Lenvima product sales, net of cost of sales and commercialization costs, as alliance revenue. Expenses incurred during co-development, including for studies evaluating Lenvima as monotherapy, are shared equally by the two companies and reflected in Research and development expenses.
Under the agreement, Merck made an upfront payment to Eisai of $750 million and agreed to make payments of up to $650 million for certain option rights through 2021 (of which $325 million was paid in March 2019, $200 million was paid in March 2020 and $125 million is expected to be paid in March 2021). In addition, the agreement provides for additional contingent payments from Merck to Eisai related to the successful achievement of sales-based and regulatory milestones.
In the second quarter of 2020, Merck determined it was probable that sales of Lenvima in the future would trigger sales-based milestone payments aggregating $370 million from Merck to Eisai. Accordingly, Merck recorded a $370 million liability and a corresponding increase to the intangible asset related to Lenvima. Prior to 2020, Merck accrued sales-based milestone payments aggregating $950 million. Of these amounts, $50 million was paid to Eisai in 2019 and an additional $500 million was paid in the first nine months of 2020. Potential future sales-based milestone payments of $2.7 billion have not yet been accrued as they are not deemed by the Company to be probable at this time.
In 2018, Lenvima received regulatory approvals triggering capitalized milestone payments of $250 million in the aggregate from Merck to Eisai. Potential future regulatory milestone payments of $135 million remain under the agreement.
The intangible asset balance related to Lenvima (which includes capitalized sales-based and regulatory milestone payments) was $1.1 billion at September 30, 2020 and is included in Other Intangibles, Net on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2026 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Alliance revenue - Lenvima$142 $109 $421 $280 
Cost of sales (1)
46 23 215 97 
Selling, general and administrative18 21 48 59 
Research and development48 37 168 146 
($ in millions)September 30, 2020December 31, 2019
Receivables from Eisai included in Other current assets
$170 $150 
Payables to Eisai included in Accrued and other current liabilities (2)
325 700 
Payables to Eisai included in Other Noncurrent Liabilities (3)
570 525 
(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone and future option payments.
(3) Includes accrued milestone payments.
Bayer AG
In 2014, the Company entered into a worldwide clinical development collaboration with Bayer AG (Bayer) to market and develop soluble guanylate cyclase (sGC) modulators including Bayer’s Adempas (riociguat), which is approved to treat pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The two companies have implemented a joint development and commercialization strategy. The collaboration also includes clinical development of Bayer’s vericiguat, which is in development for the potential treatment of worsening heart failure. Vericiguat is currently under review by regulatory authorities in the United States, the EU and Japan. Under the agreement, Bayer leads commercialization of Adempas in the Americas, while Merck leads commercialization in the rest of the world. For vericiguat, if approved, Bayer will lead commercialization in the rest of world and Merck will lead in the Americas. Both companies share in development costs and profits on sales and have the right to co-promote in territories where they are not the lead. Merck records sales of Adempas in its marketing territories, as well as alliance revenue, which is Merck’s share of profits from the sale of Adempas in Bayer’s marketing territories. In addition, the agreement provides for contingent payments from Merck to Bayer related to the successful achievement of sales-based milestones.
Prior to 2020, Merck accrued $725 million of sales-based milestone payments for this collaboration, of which $350 million was paid to Bayer in 2018. There is an additional $400 million potential future sales-based milestone payment that has not yet been accrued as it is not deemed by the Company to be probable at this time.
The intangible asset balance related to this collaboration (which includes the acquired intangible asset balance, as well as capitalized sales-based milestone payments) was $838 million at September 30, 2020 and is included in Other Intangibles, Net on the Consolidated Balance Sheet. The amount is being amortized over its estimated useful life through 2027 as supported by projected future cash flows, subject to impairment testing.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Alliance revenue - Adempas$83 $50 $216 $144 
Net sales of Adempas recorded by Merck55 57 167 158 
Total sales$138 $107 $383 $302 
Cost of sales (1)
29 28 85 86 
Selling, general and administrative19 12 42 31 
Research and development12 31 53 94 
($ in millions)September 30, 2020December 31, 2019
Receivables from Bayer included in Other current assets
$70 $49 
Payables to Bayer included in Other Noncurrent Liabilities (2)
375 375 
(1) Includes amortization of intangible assets.
(2) Represents accrued milestone payment.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring
 9 Months Ended
Sep. 30, 2020
Restructuring and Related Activities [Abstract]  
Restructuring Restructuring
In early 2019, Merck approved a new global restructuring program (Restructuring Program) as part of a worldwide initiative focused on further optimizing the Company’s manufacturing and supply network, as well as reducing its global real estate footprint. This program is a continuation of the Company’s plant rationalization, builds on prior restructuring programs and does not include any actions associated with the planned spin-off of Organon. As the Company continues to evaluate its global footprint and overall operating model, it subsequently identified additional actions under the Restructuring Program, and could identify further actions over time. The actions currently contemplated under the Restructuring Program are expected to be substantially completed by the end of 2023, with the cumulative pretax costs to be incurred by the Company to implement the program estimated to be approximately $2.5 billion. The Company estimates that approximately 60% of the cumulative pretax costs will result in cash outlays, primarily related to employee separation expense and facility shut-down costs. Approximately 40% of the cumulative pretax costs will be non-cash, relating primarily to the accelerated depreciation of facilities to be closed or divested. The Company expects to record charges of approximately $800 million in 2020 related to the Restructuring Program. Actions under previous global restructuring programs have been substantially completed.
The Company recorded total pretax costs of $186 million and $296 million in the third quarter of 2020 and 2019, respectively, and $504 million and $642 million for the first nine months of 2020 and 2019, respectively, related to restructuring program activities. Since inception of the Restructuring Program through September 30, 2020, Merck has recorded total pretax accumulated costs of approximately $1.4 billion. For segment reporting, restructuring charges are unallocated expenses.
The following tables summarize the charges related to restructuring program activities by type of cost:
 Three Months Ended September 30, 2020Nine Months Ended September 30, 2020
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotalSeparation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $33 $5 $38 $— $89 $42 $131 
Selling, general and administrative— 15 — 15 — 37 — 37 
Research and development— 18 1 19 — 66 1 67 
Restructuring costs61 — 53 114 143 — 126 269 
$61 $66 $59 $186 $143 $192 $169 $504 
 Three Months Ended September 30, 2019Nine Months Ended September 30, 2019
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotalSeparation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $41 $21 $62 $— $139 $22 $161 
Selling, general and administrative— 1 — 1 — 33 — 33 
Research and development— (1)2 1 — 1 3 4 
Restructuring costs205 — 27 232 358 — 86 444 
$205 $41 $50 $296 $358 $173 $111 $642 
Separation costs are associated with actual headcount reductions, as well as those headcount reductions which were probable and could be reasonably estimated.
Accelerated depreciation costs primarily relate to manufacturing, research and administrative facilities and equipment to be sold or closed as part of the programs. Accelerated depreciation costs represent the difference between the depreciation expense to be recognized over the revised useful life of the asset, based upon the anticipated date the site will be closed or divested or the equipment disposed of, and depreciation expense as determined utilizing the useful life prior to the restructuring actions. All the sites have and will continue to operate up through the respective closure dates and, since future undiscounted cash flows are sufficient to recover the respective book values, Merck is recording accelerated depreciation over the revised useful life of the site assets. Anticipated site closure dates, particularly related to manufacturing locations, have been and may continue to be adjusted to reflect changes resulting from regulatory or other factors.
Other activity in 2020 and 2019 includes asset abandonment, facility shut-down and other related costs, as well as pretax gains and losses resulting from the sales of facilities and related assets. Additionally, other activity includes certain employee-related costs associated with pension and other postretirement benefit plans (see Note 12) and share-based compensation.
The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September 30, 2020:
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Restructuring reserves January 1, 2020$690 $— $69 $759 
Expense143 192 169 504 
(Payments) receipts, net(395)— (237)(632)
Non-cash activity— (192)39 (153)
Restructuring reserves September 30, 2020 (1)
$438 $— $40 $478 
(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments
 9 Months Ended
Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Financial Instruments Financial Instruments
Derivative Instruments and Hedging Activities
The Company manages the impact of foreign exchange rate movements and interest rate movements on its earnings, cash flows and fair values of assets and liabilities through operational means and through the use of various financial instruments, including derivative instruments.
A significant portion of the Company’s revenues and earnings in foreign affiliates is exposed to changes in foreign exchange rates. The objectives and accounting related to the Company’s foreign currency risk management program, as well as its interest rate risk management activities are discussed below.
Foreign Currency Risk Management
The Company has established revenue hedging, balance sheet risk management and net investment hedging programs to protect against volatility of future foreign currency cash flows and changes in fair value caused by changes in foreign exchange rates.
The objective of the revenue hedging program is to reduce the variability caused by changes in foreign exchange rates that would affect the U.S. dollar value of future cash flows derived from foreign currency denominated sales, primarily the euro, Japanese yen and Chinese renminbi. To achieve this objective, the Company will hedge a portion of its forecasted foreign currency denominated third-party and intercompany distributor entity sales (forecasted sales) that are expected to occur over its planning cycle, typically no more than two years into the future. The Company will layer in hedges over time, increasing the portion of forecasted sales hedged as it gets closer to the expected date of the forecasted sales. The portion of forecasted sales hedged is based on assessments of cost-benefit profiles that consider natural offsetting exposures, revenue and exchange rate volatilities and correlations, and the cost of hedging instruments. The Company manages its anticipated transaction exposure principally with purchased local currency put options, forward contracts and purchased collar options.
The fair values of these derivative contracts are recorded as either assets (gain positions) or liabilities (loss positions) in the Condensed Consolidated Balance Sheet. Changes in the fair value of derivative contracts are recorded each period in either current earnings or Other comprehensive income (OCI), depending on whether the derivative is designated as part of a hedge transaction and, if so, the type of hedge transaction. For derivatives that are designated as cash flow hedges, the unrealized gains or losses on these contracts are recorded in Accumulated other comprehensive income (AOCI) and reclassified into Sales when the hedged anticipated revenue is recognized. For those derivatives which are not designated as cash flow hedges, but serve as economic hedges of forecasted sales, unrealized gains or losses are recorded in Sales each period. The cash flows from both designated and non-designated contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows. The Company does not enter into derivatives for trading or speculative purposes.
The Company manages operating activities and net asset positions at each local subsidiary in order to mitigate the effects of exchange on monetary assets and liabilities. The Company also uses a balance sheet risk management program to mitigate the exposure of net monetary assets that are denominated in a currency other than a subsidiary’s functional currency from the effects of volatility in foreign exchange. In these instances, Merck principally utilizes forward exchange contracts to offset the effects of exchange on exposures denominated in developed country currencies, primarily the euro and Japanese yen. For exposures in developing country currencies, the Company will enter into forward contracts to partially offset the effects of exchange on exposures when it is deemed economical to do so based on a cost-benefit analysis that considers the magnitude of the exposure, the volatility of the exchange rate and the cost of the hedging instrument. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
Monetary assets and liabilities denominated in a currency other than the functional currency of a given subsidiary are remeasured at spot rates in effect on the balance sheet date with the effects of changes in spot rates reported in Other (income) expense, net. The forward contracts are not designated as hedges and are marked to market through Other (income) expense, net. Accordingly, fair value changes in the forward contracts help mitigate the changes in the value of the remeasured
assets and liabilities attributable to changes in foreign currency exchange rates, except to the extent of the spot-forward differences. These differences are not significant due to the short-term nature of the contracts, which typically have average maturities at inception of less than one year.
The Company also uses forward exchange contracts to hedge a portion of its net investment in foreign operations against movements in exchange rates. The forward contracts are designated as hedges of the net investment in a foreign operation. The unrealized gains or losses on these contracts are recorded in foreign currency translation adjustment within OCI and remain in AOCI until either the sale or complete or substantially complete liquidation of the subsidiary. The Company excludes certain portions of the change in fair value of its derivative instruments from the assessment of hedge effectiveness (excluded components). Changes in fair value of the excluded components are recognized in OCI. The Company recognizes in earnings the initial value of the excluded components on a straight-line basis over the life of the derivative instrument, rather than using the mark-to-market approach. The cash flows from these contracts are reported as investing activities in the Condensed Consolidated Statement of Cash Flows.
Foreign exchange risk is also managed through the use of foreign currency debt. The Company’s senior unsecured euro-denominated notes have been designated as, and are effective as, economic hedges of the net investment in a foreign operation. Accordingly, foreign currency transaction gains or losses due to spot rate fluctuations on the euro-denominated debt instruments are included in foreign currency translation adjustment within OCI.
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended September 30,Nine Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)20202019202020192020201920202019
Net Investment Hedging Relationships
Foreign exchange contracts
$10 $1 $15 $8 $(4)$(8)$(15)$(23)
Euro-denominated notes162 (150)182 (152)— — — — 
(1) No amounts were reclassified from AOCI into income related to the sale of a subsidiary.
Interest Rate Risk Management
The Company may use interest rate swap contracts on certain investing and borrowing transactions to manage its net exposure to interest rate changes and to reduce its overall cost of borrowing. The Company does not use leveraged swaps and, in general, does not leverage any of its investment activities that would put principal capital at risk.
In February 2020, five interest rate swaps with notional amounts of $250 million each matured. These swaps effectively converted the Company’s $1.25 billion, 1.85% fixed-rate notes due 2020 to variable rate debt. At September 30, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.
September 30, 2020
($ in millions)Par Value of DebtNumber of Interest Rate Swaps HeldTotal Swap Notional Amount
3.875% notes due 2021
$1,150 5 $1,150 
2.40% notes due 2022
1,000 4 1,000 
2.35% notes due 2022
1,250 5 1,250 
The interest rate swap contracts are designated hedges of the fair value changes in the notes attributable to changes in the benchmark London Interbank Offered Rate (LIBOR) swap rate. The fair value changes in the notes attributable to changes in the LIBOR swap rate are recorded in interest expense along with the offsetting fair value changes in the swap contracts. The cash flows from these contracts are reported as operating activities in the Condensed Consolidated Statement of Cash Flows.
The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
Carrying Amount of Hedged LiabilitiesCumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount
($ in millions)September 30, 2020December 31, 2019September 30, 2020December 31, 2019
Balance Sheet Line Item in which Hedged Item is Included
Loans payable and current portion of long-term debt$1,155 $1,249 $5 $(1)
Long-Term Debt2,309 3,409 62 14 
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  September 30, 2020December 31, 2019
  Fair Value of DerivativeU.S. Dollar
Notional		Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)Balance Sheet CaptionAssetLiabilityAssetLiability
Derivatives Designated as Hedging Instruments
Interest rate swap contractsOther current assets$6 $— $1,150 $— $— $— 
Interest rate swap contractsOther Assets63 — 2,250 15 — 3,400 
Interest rate swap contractsAccrued and other current liabilities— — — — 1 1,250 
Foreign exchange contractsOther current assets30 — 4,120 152 — 6,117 
Foreign exchange contractsOther Assets59 — 1,881 55 — 2,160 
Foreign exchange contractsAccrued and other current liabilities— 104 3,096 — 22 1,748 
Foreign exchange contractsOther Noncurrent Liabilities— 1 157 — 1 53 
  $158 $105 $12,654 $222 $24 $14,728 
Derivatives Not Designated as Hedging Instruments
       
Foreign exchange contractsOther current assets$81 $— $5,455 $66 $— $7,245 
Foreign exchange contractsAccrued and other current liabilities— 171 8,042 — 73 8,693 
Forward contract related to Seagen common stockAccrued and other current liabilities— 22 1,000 — — — 
  $81 $193 $14,497 $66 $73 $15,938 
  $239 $298 $27,151 $288 $97 $30,666 
As noted above, the Company records its derivatives on a gross basis in the Condensed Consolidated Balance Sheet. The Company has master netting agreements with several of its financial institution counterparties (see Concentrations of Credit Risk below). The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 September 30, 2020December 31, 2019
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$239 $298 $288 $97 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet
(140)(140)(84)(84)
Cash collateral received— — (34)— 
Net amounts$99 $158 $170 $13 
The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:
Sales
Other (income) expense, net (1)
Other comprehensive income (loss)Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
Three Months Ended September 30,Three Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,
($ in millions)202020192020201920202019202020192020201920202019
Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded$12,551 $12,397 $(312)$35 $10 $(28)$35,479 $34,972 $(630)$362 $(190)$155 
(Gain) loss on fair value hedging relationships
Interest rate swap contracts
Hedged items
— — (14)13 — — — — 54 101 — — 
Derivatives designated as hedging instruments
— — — (6)— — — — (76)(74)— — 
Impact of cash flow hedging relationships
Foreign exchange contracts
Amount of (loss) gain recognized in OCI on derivatives
— — — — (195)186 — — — — (126)183 
Increase (decrease) in Sales as a result of AOCI reclassifications
(23)70 — — 23 (70)65 189 — — (65)(189)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — (1)(1)— — — — (3)(3)— — 
Amount of loss recognized in OCI on derivatives
— — — — (1)(1)— — — — (3)(6)
(1) Interest expense is a component of Other (income) expense, net.
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended
September 30,		Nine Months Ended September 30,
($ in millions)Income Statement Caption2020201920202019
Derivatives Not Designated as Hedging Instruments
Foreign exchange contracts (1)
Other (income) expense, net$(7)$(8)$(138)$112 
Foreign exchange contracts (2)
Sales7 (11)4 (7)
Interest rate contracts (3)
Other (income) expense, net— — 9 — 
Forward contract related to Seagen common stockResearch and development expenses22 — 22 — 
(1) These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2) These derivative contracts serve as economic hedges of forecasted transactions.
(3) These derivatives serve as economic hedges against rising treasury rates.
At September 30, 2020, the Company estimates $155 million of pretax net unrealized losses on derivatives maturing within the next 12 months that hedge foreign currency denominated sales over that same period will be reclassified from AOCI to Sales. The amount ultimately reclassified to Sales may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity.
Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 September 30, 2020December 31, 2019
 Amortized
Cost		Gross UnrealizedFair
Value		Amortized
Cost		Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
U.S. government and agency securities$74 $— $— $74 $266 $3 $— $269 
Foreign government bonds2 — — 2 — — — — 
Commercial paper— — — — 668 — — 668 
Corporate notes and bonds— — — — 608 13 — 621 
Asset-backed securities— — — — 226 1 — 227 
Total debt securities$76 $— $— $76 $1,768 $17 $— $1,785 
Publicly traded equity securities (1)
1,477 838 
Total debt and publicly traded equity securities
$1,553 $2,623 
(1) Unrealized net (gains) losses recognized in Other (income) expense, net on equity securities still held at September 30, 2020 were $(43) million and $(512) million in the third quarter and first nine months of 2020, respectively. Unrealized net losses (gains) recognized in Other (income) expense, net on equity securities still held at September 30, 2019 were $25 million and $(41) million in the third quarter and first nine months of 2019, respectively.
At September 30, 2020 and September 30, 2019, the Company also had $508 million and $393 million, respectively, of equity investments without readily determinable fair values included in Other Assets. The Company recognizes unrealized gains on these equity investments based on favorable observable price changes from transactions involving similar investments of the same investee and recognizes unrealized losses based on unfavorable observable price changes. During the first nine months of 2020, the Company recognized unrealized gains of $21 million and unrealized losses of $3 million in Other (income) expense, net related to these equity investments held at September 30, 2020. During the first nine months of 2019, the Company recognized unrealized gains of $4 million and unrealized losses of $12 million in Other (income) expense, net related to these investments held at September 30, 2019. Cumulative unrealized gains and cumulative unrealized losses based on observable prices changes for investments in equity investments without readily determinable fair values still held at September 30, 2020 were $128 million and $24 million, respectively.
Fair Value Measurements
Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company uses a fair value hierarchy which maximizes the use of observable inputs and minimizes the use of unobservable inputs when measuring fair value. There are three levels of inputs used to measure fair value with Level 1 having the highest priority and Level 3 having the lowest: Level 1 - Quoted prices (unadjusted) in active markets for identical assets or liabilities; Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities; Level 3 - Unobservable inputs that are supported by little or no market activity. Level 3 assets or liabilities are those whose values are determined using pricing models, discounted cash flow methodologies, or similar techniques with significant unobservable inputs, as well as assets or liabilities for which the determination of fair value requires significant judgment or estimation. If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level input that is significant to the fair value measurement of the instrument.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)September 30, 2020December 31, 2019
Assets
Investments
Foreign government bonds$— $2 $— $2 $— $— $— $— 
Commercial paper— — — — — 668 — 668 
Corporate notes and bonds— — — — — 621 — 621 
Asset-backed securities (1)
— — — — — 227 — 227 
U.S. government and agency securities
— — — — — 209 — 209 
Publicly traded equity securities
1,370 — — 1,370 518 — — 518 
 1,370 2 — 1,372 518 1,725 — 2,243 
Other assets (2)
U.S. government and agency securities
74 — — 74 60 — — 60 
Publicly traded equity securities107 — — 107 320 — — 320 
181 — — 181 380 — — 380 
Derivative assets (3)
Forward exchange contracts— 116 — 116 — 169 — 169 
Interest rate swaps— 69 — 69 — 15 — 15 
Purchased currency options— 54 — 54 — 104 — 104 
 — 239 — 239 — 288 — 288 
Total assets$1,551 $241 $— $1,792 $898 $2,013 $— $2,911 
Liabilities
Other liabilities
Contingent consideration$— $— $829 $829 $— $— $767 $767 
Derivative liabilities (3)
Forward exchange contracts— 275 — 275 — 95 — 95 
Forward contract related to Seagen common stock— 22 — 22 — — — — 
Written currency options— 1 — 1 — 1 — 1 
Interest rate swaps— — — — — 1 — 1 
— 298 — 298 — 97 — 97 
Total liabilities$— $298 $829 $1,127 $— $97 $767 $864 
(1)Primarily all of the asset-backed securities were highly rated (Standard & Poor’s rating of AAA and Moody’s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily 5 years or less.
(2)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(3)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
As of September 30, 2020 and December 31, 2019, Cash and cash equivalents included $6.6 billion and $8.9 billion of cash equivalents, respectively (which would be considered Level 2 in the fair value hierarchy).
Contingent Consideration
Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:
Nine Months Ended September 30,
($ in millions)20202019
Fair value January 1$767 $788 
Additions97 — 
Changes in estimated fair value (1)
71 52 
Payments(106)(85)
Fair value September 30 (2)(3)
$829 $755 
(1) Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2) Balance at September 30, 2020 includes $140 million recorded as a current liability for amounts expected to be paid within the next 12 months.
(3) At September 30, 2020 and December 31, 2019, $637 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.
The additions to contingent consideration in 2020 relate to the acquisition of Themis (see Note 2). The payments of contingent consideration in both periods relate to liabilities recorded in connection with the termination of the Sanofi-Pasteur MSD joint venture in 2016.
Other Fair Value Measurements
Some of the Company’s financial instruments, such as cash and cash equivalents, receivables and payables, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature.
The estimated fair value of loans payable and long-term debt (including current portion) at September 30, 2020, was $32.6 billion compared with a carrying value of $28.7 billion and at December 31, 2019, was $28.8 billion compared with a carrying value of $26.3 billion. Fair value was estimated using recent observable market prices and would be considered Level 2 in the fair value hierarchy.
Concentrations of Credit Risk
On an ongoing basis, the Company monitors concentrations of credit risk associated with corporate and government issuers of securities and financial institutions with which it conducts business. Credit exposure limits are established to limit a concentration with any single issuer or institution. Cash and investments are placed in instruments that meet high credit quality standards as specified in the Company’s investment policy guidelines.
The majority of the Company’s accounts receivable arise from product sales in the United States, Europe and China and are primarily due from drug wholesalers and retailers, hospitals, government agencies, managed health care providers and pharmacy benefit managers. The Company monitors the financial performance and creditworthiness of its customers so that it can properly assess and respond to changes in their credit profile. The Company also continues to monitor global economic conditions, including the volatility associated with international sovereign economies, and associated impacts on the financial markets and its business.
The Company has accounts receivable factoring agreements with financial institutions in certain countries to sell accounts receivable. The Company factored $2.1 billion and $2.7 billion of accounts receivable in the third quarter of 2020 and the fourth quarter of 2019, respectively, under these factoring arrangements, which reduced outstanding accounts receivable. The cash received from the financial institutions is reported within operating activities in the Consolidated Statement of Cash Flows. In certain of these factoring arrangements, for ease of administration, the Company will collect customer payments related to the factored receivables, which it then remits to the financial institutions. The net cash flows relating to these collections are reported as financing activities in the Consolidated Statement of Cash Flows. The cost of factoring such accounts receivable was de minimis.
Derivative financial instruments are executed under International Swaps and Derivatives Association master agreements. The master agreements with several of the Company’s financial institution counterparties also include credit support annexes. These annexes contain provisions that require collateral to be exchanged depending on the value of the derivative assets and liabilities, the Company’s credit rating, and the credit rating of the counterparty. Cash collateral received by the Company from various counterparties was $34 million at December 31, 2019. The obligation to return such collateral is recorded in Accrued and other current liabilities. No cash collateral was advanced by the Company to counterparties as of September 30, 2020 or December 31, 2019.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories
 9 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of:
($ in millions)September 30, 2020December 31, 2019
Finished goods$2,038 $1,772 
Raw materials and work in process6,073 5,650 
Supplies197 207 
Total (approximates current cost)8,308 7,629 
Decrease to LIFO cost(99)(171)
 $8,209 $7,458 
Recognized as:
Inventories$6,128 $5,978 
Other assets2,081 1,480 
Amounts recognized as Other Assets are comprised almost entirely of raw materials and work in process inventories. At September 30, 2020 and December 31, 2019, these amounts included $1.8 billion and $1.3 billion, respectively, of inventories not expected to be sold within one year. In addition, these amounts included $288 million and $168 million at September 30, 2020 and December 31, 2019, respectively, of inventories produced in preparation for product launches.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Other Intangibles
 9 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]  
Other Intangibles
7.    Other Intangibles
During the third quarter and first nine months of 2019, the Company recorded $612 million and $693 million, respectively, of intangible asset impairment charges related to marketed products within Cost of sales. During the third quarter of 2019, the Company recorded an impairment charge of $612 million related to Sivextro (tedizolid phosphate), a product for the treatment of acute bacterial skin and skin structure infections caused by susceptible isolates of certain Gram-positive microorganisms. As part of a reorganization and reprioritization of its internal sales force, the Company made the decision to cease promotion of Sivextro in the U.S. market by the end of 2019. This decision resulted in reduced cash flow projections for Sivextro, which indicated that the Sivextro intangible asset value was not fully recoverable on an undiscounted cash flows basis. The Company utilized market participant assumptions to determine its best estimate of the fair value of the intangible asset related to Sivextro that, when compared with its related carrying value, resulted in the impairment charge noted above.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Debt
 9 Months Ended
Sep. 30, 2020
Debt Disclosure [Abstract]  
Long-Term Debt Long-Term DebtIn June 2020, the Company issued $4.5 billion principal amount of senior unsecured notes consisting of $1.0 billion of 0.75% notes due 2026, $1.25 billion of 1.45% notes due 2030, $1.0 billion of 2.35% notes due 2040 and $1.25 billion of 2.45% notes due 2050. Merck used the net proceeds from the offering for general corporate purposes, including without limitation the repayment of outstanding commercial paper borrowings and other indebtedness with upcoming maturities.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Contingencies
 9 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]  
Contingencies Contingencies
The Company is involved in various claims and legal proceedings of a nature considered normal to its business, including product liability, intellectual property, and commercial litigation, as well as certain additional matters including governmental and environmental matters. In the opinion of the Company, it is unlikely that the resolution of these matters will be material to the Company’s financial condition, results of operations or cash flows.
Given the nature of the litigation discussed below and the complexities involved in these matters, the Company is unable to reasonably estimate a possible loss or range of possible loss for such matters until the Company knows, among other factors, (i) what claims, if any, will survive dispositive motion practice, (ii) the extent of the claims, including the size of any potential class, particularly when damages are not specified or are indeterminate, (iii) how the discovery process will affect the litigation, (iv) the settlement posture of the other parties to the litigation and (v) any other factors that may have a material effect on the litigation.
The Company records accruals for contingencies when it is probable that a liability has been incurred and the amount can be reasonably estimated. These accruals are adjusted periodically as assessments change or additional information becomes available. For product liability claims, a portion of the overall accrual is actuarially determined and considers such factors as past experience, number of claims reported and estimates of claims incurred but not yet reported. Individually significant contingent losses are accrued when probable and reasonably estimable. Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
The Company’s decision to obtain insurance coverage is dependent on market conditions, including cost and availability, existing at the time such decisions are made. The Company has evaluated its risks and has determined that the cost of obtaining product liability insurance outweighs the likely benefits of the coverage that is available and, as such, has no insurance for most product liabilities.
Product Liability Litigation
Fosamax
As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving Fosamax (Fosamax Litigation). As of September 30, 2020, approximately 3,590 cases are pending against Merck in either federal or state court. Plaintiffs in the vast majority of these cases generally allege that they sustained femur fractures and/or other bone injuries (Femur Fractures) in association with the use of Fosamax.
All federal cases involving allegations of Femur Fractures have been or will be transferred to a multidistrict litigation in the District of New Jersey (Femur Fracture MDL). In the only bellwether case tried to date in the Femur Fracture MDL, Glynn v. Merck, the jury returned a verdict in Merck’s favor. In addition, in June 2013, the Femur Fracture MDL court granted Merck’s motion for judgment as a matter of law in the Glynn case and held that the plaintiff’s failure to warn claim was preempted by federal law.
In August 2013, the Femur Fracture MDL court entered an order requiring plaintiffs in the Femur Fracture MDL to show cause why those cases asserting claims for a femur fracture injury that took place prior to September 14, 2010, should not be dismissed based on the court’s preemption decision in the Glynn case. Pursuant to the show cause order, in March 2014, the Femur Fracture MDL court dismissed with prejudice approximately 650 cases on preemption grounds. Plaintiffs in approximately 515 of those cases appealed that decision to the U.S. Court of Appeals for the Third Circuit (Third Circuit). In March 2017, the Third Circuit issued a decision reversing the Femur Fracture MDL court’s preemption ruling and remanding the appealed cases back to the Femur Fracture MDL court. In May 2019, the U.S. Supreme Court decided that the Third Circuit had incorrectly concluded that the issue of preemption should be resolved by a jury, and accordingly vacated the judgment of the Third Circuit and remanded the proceedings back to the Third Circuit to address the issue in a manner consistent with the Supreme Court’s opinion. In November 2019, the Third Circuit remanded the cases back to the District Court in order to allow that court to determine in the first instance whether the plaintiffs’ state law claims are preempted by federal law under the standards described by the Supreme Court in its opinion. Briefing on the issue is closed, and the parties await the decision of the District Court.
Accordingly, as of September 30, 2020, approximately 970 cases were actively pending in the Femur Fracture MDL.
As of September 30, 2020, approximately 2,340 cases alleging Femur Fractures have been filed in New Jersey state court and are pending before Judge James Hyland in Middlesex County. The parties selected an initial group of cases to be reviewed through fact discovery, and Merck has continued to select additional cases to be reviewed.
As of September 30, 2020, approximately 275 cases alleging Femur Fractures have been filed and are pending in California state court. All of the Femur Fracture cases filed in California state court have been coordinated before a single judge in Orange County, California.
Additionally, there are four Femur Fracture cases pending in other state courts.
Discovery is presently stayed in the Femur Fracture MDL and in the state court in California. Merck intends to defend against these lawsuits.
Januvia/Janumet
As previously disclosed, Merck is a defendant in product liability lawsuits in the United States involving Januvia and/or Janumet. As of September 30, 2020, Merck is aware of approximately 1,465 product users alleging that Januvia and/or Janumet caused the development of pancreatic cancer and other injuries.
Most claims have been filed in multidistrict litigation before the U.S. District Court for the Southern District of California (MDL). Outside of the MDL, the majority of claims have been filed in coordinated proceedings before the Superior Court of California, County of Los Angeles (California State Court).
In November 2015, the MDL and California State Court–in separate opinions–granted summary judgment to defendants on grounds of federal preemption.
Plaintiffs appealed in both forums. In November 2017, the U.S. Court of Appeals for the Ninth Circuit vacated the judgment and remanded for further discovery. In November 2018, the California state appellate court reversed and remanded on similar grounds. In March 2019, the parties in the MDL and the California coordinated proceedings agreed to coordinate and adopt a schedule for completing discovery on general causation and preemption issues and for renewing summary judgment
and Daubert motions. Under the stipulated case management schedule, the hearings for Daubert and summary judgment motions took place on October 20, 2020.
As of September 30, 2020, six product users have claims pending against Merck in state courts other than California, including Illinois. In June 2017, the Illinois trial court denied Merck’s motion for summary judgment based on federal preemption. Merck appealed, and the Illinois appellate court affirmed in December 2018. Merck filed a petition for leave to appeal to the Illinois Supreme Court in February 2019. In April 2019, the Illinois Supreme Court stayed consideration of the pending petition to appeal until the U.S. Supreme Court issued its opinion in Merck Sharp & Dohme Corp. v. Albrecht (relating to the Fosamax matter discussed above). Merck filed the opinion in Albrecht with the Illinois Supreme Court in June 2019. The petition for leave to appeal was decided in September 2019, in which the Illinois Supreme Court directed the intermediate appellate court to reconsider its earlier ruling. The Illinois Appellate Court issued a favorable decision concluding, consistent with Albrecht, that preemption presents a legal question to be resolved by the court.
In addition to the claims noted above, the Company has agreed to toll the statute of limitations for approximately 50 additional claims. The Company intends to continue defending against these lawsuits.
Vioxx
As previously disclosed, Merck is a defendant in a lawsuit brought by the Attorney General of Utah alleging that Merck misrepresented the safety of Vioxx. The lawsuit is pending in Utah state court. Utah seeks damages and penalties under the Utah False Claims Act. A bench trial in this matter has been rescheduled for April 6, 2021.
Governmental Proceedings
As previously disclosed, the Company’s subsidiaries in China have received and may continue to receive inquiries regarding their operations from various Chinese governmental agencies. Some of these inquiries may be related to matters involving other multinational pharmaceutical companies, as well as Chinese entities doing business with such companies. The Company’s policy is to cooperate with these authorities and to provide responses as appropriate.
As previously disclosed, from time to time, the Company receives inquiries and is the subject of preliminary investigation activities from competition and other governmental authorities in markets outside the United States. These authorities may include regulators, administrative authorities, and law enforcement and other similar officials, and these preliminary investigation activities may include site visits, formal or informal requests or demands for documents or materials, inquiries or interviews and similar matters. Certain of these preliminary inquiries or activities may lead to the commencement of formal proceedings. Should those proceedings be determined adversely to the Company, monetary fines and/or remedial undertakings may be required.
Commercial and Other Litigation
Zetia Antitrust Litigation
As previously disclosed, Merck, MSD, Schering Corporation and MSP Singapore Company LLC (collectively, the Merck Defendants) are defendants in putative class action and opt-out lawsuits filed in 2018 on behalf of direct and indirect purchasers of Zetia alleging violations of federal and state antitrust laws, as well as other state statutory and common law causes of action. The cases have been consolidated for pretrial purposes in a federal multidistrict litigation before Judge Rebecca Beach Smith in the Eastern District of Virginia. In December 2018, the court denied the Merck Defendants’ motions to dismiss or stay the direct purchaser putative class actions pending bilateral arbitration. In August 2019, the district court adopted in full the report and recommendation of the magistrate judge with respect to the Merck Defendants’ motions to dismiss on non-arbitration issues, thereby granting in part and denying in part Merck Defendants’ motions to dismiss. In addition, in June 2019, the representatives of the putative direct purchaser class filed an amended complaint, and in August 2019, retailer opt-out plaintiffs filed an amended complaint. The Merck Defendants moved to dismiss the new allegations in both complaints. In October 2019, the magistrate judge issued a report and recommendation recommending that the district judge grant the motions in their entirety. In December 2019, the district court adopted this report and recommendation in part. The district court granted the Merck Defendants’ motion to dismiss to the extent the motion sought dismissal of claims for overcharges paid by entities that purchased generic ezetimibe from Par Pharmaceutical, Inc. (Par Pharmaceutical) and dismissed any claims for such overcharges. In November 2019, the direct purchaser plaintiffs and the indirect purchaser plaintiffs filed motions for class certification. On June 18, 2020, the magistrate judge issued a report and recommendation recommending that the district judge grant in part the direct purchasers’ motion for class certification and certify a class of 35 direct purchasers. On August 21, 2020, the district court adopted the report and recommendation in full, and on November 2, 2020, the U.S. Court of Appeals for the Fourth Circuit granted defendants’ motion for permission to appeal the district court’s order. Also, on August 14, 2020, the magistrate judge recommended that the court grant the motion for class certification filed by the putative indirect purchaser class. The Merck Defendants objected to this report and recommendation and are awaiting a decision from the district court.
On August 10, 2020, the Merck Defendants filed a motion for summary judgment and other motions, and plaintiffs filed a motion for partial summary judgment, and other motions. Those motions are now fully briefed, and the court will likely hold a hearing on the competing motions. Trial in this matter has been adjourned.
Patent Litigation
From time to time, generic manufacturers of pharmaceutical products file abbreviated New Drug Applications (NDAs) with the FDA seeking to market generic forms of the Company’s products prior to the expiration of relevant patents owned by the Company. To protect its patent rights, the Company may file patent infringement lawsuits against such generic companies. Similar lawsuits defending the Company’s patent rights may exist in other countries. The Company intends to vigorously defend its patents, which it believes are valid, against infringement by companies attempting to market products prior to the expiration of such patents. As with any litigation, there can be no assurance of the outcomes, which, if adverse, could result in significantly shortened periods of exclusivity for these products and, with respect to products acquired through acquisitions, potentially significant intangible asset impairment charges.
Bridion — Between January and March 2020, the Company received multiple Paragraph IV Certification Letters under the Hatch-Waxman Act notifying the Company that generic drug companies have filed applications to the FDA seeking pre-patent expiry approval to sell generic versions of Bridion (sugammadex) Injection. In March and April 2020, the Company filed patent infringement lawsuits in the U.S. District Courts for the District of New Jersey and the Northern District of West Virginia against those generic companies. These lawsuits, which assert one or more patents covering sugammadex and methods of using sugammadex, automatically stay FDA approval of the generic applications until June 2023 or until adverse court decisions, if any, whichever may occur earlier.
Mylan Pharmaceuticals Inc., Mylan API US LLC, and Mylan Inc. (Mylan) have filed motions to dismiss in the District of New Jersey for lack of venue and failure to state a claim against certain defendants, and in the Northern District of West Virginia for failure to state a claim against certain defendants. The New Jersey motion has not yet been decided, and the West Virginia action is stayed pending resolution of the New Jersey motion. All New Jersey actions against all defendants have been consolidated.
Januvia, Janumet, Janumet XR — In February 2019, Par Pharmaceutical filed suit against the Company in the U.S. District Court for the District of New Jersey, seeking a declaratory judgment of invalidity of a patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026. In response, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of Delaware against Par Pharmaceutical and additional companies that also indicated an intent to market generic versions of Januvia, Janumet, and Janumet XR following expiration of key patent protection in 2022, but prior to the expiration of the later-granted patent owned by the Company covering certain salt and polymorphic forms of sitagliptin that expires in 2026 (2026 salt/polymorph patent), and a later granted patent owned by the Company covering the Janumet formulation which expires in 2028. Par Pharmaceutical dismissed its case in the U.S. District Court for the District of New Jersey against the Company and will litigate the action in the U.S. District Court for the District of Delaware. The Company filed a patent infringement lawsuit against Mylan in the Northern District of West Virginia. The Judicial Panel of Multidistrict Litigation entered an order transferring the Company’s lawsuit against Mylan to the U.S. District Court for the District of Delaware for coordinated and consolidated pretrial proceedings with the other cases pending in that district. The U.S. District Court for the District of Delaware has scheduled the lawsuits for a single three-day trial on invalidity issues in October 2021. The Court will schedule separate one-day trials on infringement issues if necessary. In the Company’s case against Mylan, the U.S. District Court for the Northern District of West Virginia has conditionally scheduled a three-day trial in December 2021 on all issues. In February 2020, the Company amended its complaint against one defendant, Teva Pharmaceuticals USA, Inc., to add patent infringement claims related to a patent that expires in 2025 and covers certain processes for manufacturing sitagliptin. In July 2020, the Company amended its complaints against two defendants, Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc., to add patent infringement claims related to a patent that also expires in 2026 and covers certain amorphous forms of sitagliptin.
The Company has settled with five generic companies such that these generic companies can bring their products to the market in November 2026 or earlier under certain circumstances.
In October 2019, Mylan filed a petition for Inter Partes Review (IPR) at the United States Patent and Trademark Office (USPTO) seeking invalidity of some, but not all, of the claims of the 2026 salt/polymorph patent. The USPTO instituted IPR proceedings in May 2020, finding a reasonable likelihood that the challenged claims are not valid. A trial is scheduled for February 2021 and a final decision is expected in May 2021. After institution, three additional IPR petitions were filed by Teva Pharmaceuticals USA, Inc., Dr. Reddy’s Laboratories, Inc., and Sun Pharmaceutical Industries Ltd., as well as related entities, which requested joinder with Mylan’s IPR proceedings. If the challenges are successful, the unchallenged claims of the 2026 salt/polymorph patent will remain valid, subject to the court proceedings described above.
In Germany, two generic companies have sought the revocation of the Supplementary Protection Certificate (SPC) for Janumet. If the generic companies are successful, Janumet could lose market exclusivity in Germany as early as July 2022. Challenges to the Janumet SPC have also occurred in Portugal and Finland, and could occur in other European countries.
Other Litigation
There are various other pending legal proceedings involving the Company, principally product liability and intellectual property lawsuits. While it is not feasible to predict the outcome of such proceedings, in the opinion of the Company, either the likelihood of loss is remote or any reasonably possible loss associated with the resolution of such proceedings is not expected to be material to the Company’s financial condition, results of operations or cash flows either individually or in the aggregate.
Legal Defense Reserves
Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable. Some of the significant factors considered in the review of these legal defense reserves are as follows: the actual costs incurred by the Company; the development of the Company’s legal defense strategy and structure in light of the scope of its litigation; the number of cases being brought against the Company; the costs and outcomes of completed trials and the most current information regarding anticipated timing, progression, and related costs of pre-trial activities and trials in the associated litigation. The amount of legal defense reserves as of September 30, 2020 and December 31, 2019 of approximately $255 million and $240 million, respectively, represents the Company’s best estimate of the minimum amount of defense costs to be incurred in connection with its outstanding litigation; however, events such as additional trials and other events that could arise in the course of its litigation could affect the ultimate amount of legal defense costs to be incurred by the Company. The Company will continue to monitor its legal defense costs and review the adequacy of the associated reserves and may determine to increase the reserves at any time in the future if, based upon the factors set forth, it believes it would be appropriate to do so.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Equity
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Equity Equity
Three Months Ended September 30,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at July 1, 20193,577 $1,788 $39,484 $45,295 $(5,362)1,010 $(53,570)$102 $27,737 
Net income attributable to Merck & Co., Inc.— — — 1,901 — — — — 1,901 
Other comprehensive loss, net of taxes— — — — (28)— — — (28)
Cash dividends declared on common stock ($0.55 per share)
— — — (1,392)— — — — (1,392)
Treasury stock shares purchased— — — — — 17 (1,405)— (1,405)
Share-based compensation plans and other— — 77 — — (1)50 — 127 
Net income attributable to noncontrolling interests
— — — — — — — 6 6 
Distributions attributable to noncontrolling interests
— — — — — — — (21)(21)
Balance at September 30, 20193,577 $1,788 $39,561 $45,804 $(5,390)1,026 $(54,925)$87 $26,925 
Balance at July 1, 20203,577 $1,788 $39,373 $49,724 $(6,393)1,048 $(56,850)$102 $27,744 
Net income attributable to Merck & Co., Inc.— — — 2,941 — — — — 2,941 
Other comprehensive income, net of taxes— — — — 10 — — — 10 
Cash dividends declared on common stock ($0.61 per share)
— — — (1,558)— — — — (1,558)
Share-based compensation plans and other— — 116 — — (1)35 — 151 
Net income attributable to noncontrolling interests
— — — — — — — 4 4 
Distributions attributable to noncontrolling interests
— — — — — — — (22)(22)
Balance at September 30, 20203,577 $1,788 $39,489 $51,107 $(6,383)1,047 $(56,815)$84 $29,270 
Nine Months Ended September 30,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 20193,577 $1,788 $38,808 $42,579 $(5,545)985 $(50,929)$181 $26,882 
Net income attributable to Merck & Co., Inc.— — — 7,487 — — — — 7,487 
Other comprehensive income, net of taxes— — — — 155 — — — 155 
Cash dividends declared on common stock ($1.65 per share)
— — — (4,262)— — — — (4,262)
Treasury stock shares purchased— — 1,000 — — 54 (4,730)— (3,730)
Share-based compensation plans and other— — (247)— — (13)734 — 487 
Net loss attributable to noncontrolling interests
— — — — — — — (73)(73)
Distributions attributable to noncontrolling
 interests
— — — — — — — (21)(21)
Balance at September 30, 20193,577 1,788 39,561 45,804 (5,390)1,026 (54,925)87 26,925 
Balance at January 1, 20203,577 $1,788 $39,660 $46,602 $(6,193)1,038 $(55,950)$94 $26,001 
Net income attributable to Merck & Co., Inc.— — — 9,161 — — — — 9,161 
Other comprehensive loss, net of taxes— — — — (190)— — — (190)
Cash dividends declared on common stock ($1.83 per share)
— — — (4,656)— — — — (4,656)
Treasury stock shares purchased— — — — — 16 (1,281)— (1,281)
Share-based compensation plans and other— — (171)— — (7)416 — 245 
Net income attributable to noncontrolling interests
— — — — — — — 12 12 
Distributions attributable to noncontrolling
 interests
— — — — — — — (22)(22)
Balance at September 30, 20203,577 $1,788 $39,489 $51,107 $(6,383)1,047 $(56,815)$84 $29,270 
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation Plans
 9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
Share-Based Compensation Plans Share-Based Compensation Plans
The Company has share-based compensation plans under which the Company grants restricted stock units (RSUs) and performance share units (PSUs) to certain management level employees. In addition, employees and non-employee directors may be granted options to purchase shares of Company common stock at the fair market value at the time of grant.
The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Pretax share-based compensation expense$126 $101 $354 $306 
Income tax benefit(17)(14)(48)(42)
Total share-based compensation expense, net of taxes$109 $87 $306 $264 
During the first nine months of 2020, the Company granted 7 million RSUs with a weighted-average grant date fair value of $77.83 per RSU and during the first nine months of 2019 granted 5 million RSUs with a weighted-average grant date fair value of $80.03 per RSU. During the first nine months of 2020, the Company granted 773 thousand PSUs with a weighted-average grant date fair value of $75.22 per PSU and during the first nine months of 2019 granted 609 thousand PSUs with a weighted-average grant date fair value of $90.50 per PSU.
During the first nine months of 2020, the Company granted 4 million stock options with a weighted-average exercise price of $77.67 per option and during the first nine months of 2019 granted 3 million stock options with a weighted-average exercise price of $80.05 per option. The weighted-average fair value of options granted during the first nine months of 2020 and 2019 was $9.93 and $10.63 per option, respectively, and was determined using the following assumptions:
  Nine Months Ended
September 30,
20202019
Expected dividend yield3.1 %3.2 %
Risk-free interest rate0.4 %2.4 %
Expected volatility22.1 %18.7 %
Expected life (years)5.85.9
At September 30, 2020, there was $800 million of total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards which will be recognized over a weighted-average period of 2.1 years. For segment reporting, share-based compensation costs are unallocated expenses.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Pension and Other Postretirement Benefit Plans
 9 Months Ended
Sep. 30, 2020
Retirement Benefits [Abstract]  
Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans
The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components: 
  Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
($ in millions)U.S.InternationalU.S.InternationalU.S.InternationalU.S.International
Service cost$96 $77 $76 $58 $270 $225 $221 $178 
Interest cost107 35 115 44 323 103 343 133 
Expected return on plan assets(193)(104)(202)(106)(581)(310)(613)(320)
Amortization of unrecognized prior service credit
(12)(3)(12)(3)(37)(9)(37)(9)
Net loss amortization75 32 43 16 228 94 113 47 
Termination benefits1 1 3 — 5 2 7 1 
Curtailments1 — 5 — 4 (1)6 — 
Settlements2 — — — 11 2 — — 
 $77 $38 $28 $9 $223 $106 $40 $30 
The Company anticipates that in 2020 it will contribute approximately $200 million and $375 million to its U.S. and international pension plans, respectively, of which $184 million and $123 million, respectively, was contributed in the first nine months of the year.
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Service cost$13 $12 $39 $36 
Interest cost14 17 43 52 
Expected return on plan assets(19)(18)(56)(54)
Amortization of unrecognized prior service credit(18)(20)(54)(59)
Net gain amortization(5)(3)(13)(7)
Termination benefits— 1 — 1 
Curtailments— (3)(1)(4)
 $(15)$(14)$(42)$(35)
In connection with restructuring actions (see Note 4), termination charges were recorded on pension plans related to expanded eligibility for certain employees exiting Merck. Also, in connection with these restructuring actions, curtailments were recorded on pension and other postretirement benefit plans and settlements were recorded on certain U.S. and international pension plans as reflected in the tables above.
The components of net periodic benefit cost (credit) other than the service cost component are included in Other (income) expense, net (see Note 13), with the exception of certain amounts for termination benefits, curtailments and
settlements, which are recorded in Restructuring costs if the event giving rise to the termination benefits, curtailment or settlement is related to restructuring actions as noted above.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Other (Income) Expense, Net
 9 Months Ended
Sep. 30, 2020
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Interest income$(9)$(61)$(48)$(225)
Interest expense203 231 624 674 
Exchange losses10 38 89 166 
Income from investments in equity securities, net (1)
(360)(16)(964)(50)
Net periodic defined benefit plan (credit) cost other than service cost(88)(128)(259)(409)
Other, net(68)(29)(72)206 
 $(312)$35 $(630)$362 
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag.
The decline in interest income in the third quarter and first nine months of 2020 reflects lower investments and lower interest rates. The lower exchange losses in the first nine months of 2020 reflect losses on forward exchange contracts in 2019 related to the acquisition of Antelliq. The increase in income from investments in equity securities, net, in both the third quarter and first nine months of 2020 was driven primarily by the recognition of unrealized gains on certain investments, most of which relate to Moderna, Inc.
Other, net (as reflected in the table above) in the first nine months of 2019 includes $162 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment.
Interest paid for the nine months ended September 30, 2020 and 2019 was $605 million and $629 million, respectively.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Taxes on Income
 9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]  
Taxes on Income Taxes on Income
The effective income tax rates of 14.1% and 18.7% for the third quarter of 2020 and 2019, respectively, and 14.9% and 14.5% for the first nine months of 2020 and 2019, respectively, reflect the impacts of acquisition and divestiture-related costs and restructuring costs, partially offset by the beneficial impact of foreign earnings. The effective income tax rates in the third quarter and first nine months of 2019 also reflect the unfavorable impact of a charge for the acquisition of Peloton for which no tax benefit was recognized and the favorable impact of product mix on the estimated 2019 full-year tax rate. In addition, the effective income tax rate for the first nine months of 2019 reflects the favorable impact of a $360 million net tax benefit related to the settlement of certain federal income tax matters.
In the first quarter of 2019, the Internal Revenue Service (IRS) concluded its examinations of Merck’s 2012-2014 U.S. federal income tax returns. As a result, the Company was required to make a payment of $107 million. The Company’s reserves for unrecognized tax benefits for the years under examination exceeded the adjustments relating to this examination period and therefore the Company recorded a $360 million net tax benefit in the first nine months of 2019. This net benefit reflects reductions in reserves for unrecognized tax benefits for tax positions relating to the years that were under examination, partially offset by additional reserves for tax positions not previously reserved for.
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The calculations of earnings per share are as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ and shares in millions except per share amounts)2020201920202019
Net income attributable to Merck & Co., Inc.
$2,941 $1,901 $9,161 $7,487 
Average common shares outstanding2,529 2,558 2,530 2,572 
Common shares issuable (1)
9 14 11 15 
Average common shares outstanding assuming dilution 2,538 2,572 2,541 2,587 
Basic earnings per common share attributable to Merck & Co., Inc. common shareholders
$1.16 $0.74 $3.62 $2.91 
Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders
$1.16 $0.74 $3.61 $2.89 
(1)Issuable primarily under share-based compensation plans.
For the third quarter of 2020 and 2019, 5 million and 3 million, respectively, and for the first nine months of 2020 and 2019, 5 million and 2 million, respectively, of common shares issuable under share-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Other Comprehensive Income (Loss)
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Other Comprehensive Income (Loss) Other Comprehensive Income (Loss)
Changes in AOCI by component are as follows:
Three Months Ended September 30,
($ in millions)DerivativesInvestmentsEmployee
Benefit
Plans		Cumulative
Translation
Adjustment		Accumulated Other
Comprehensive
Income (Loss)
Balance July 1, 2019, net of taxes$66 $48 $(3,530)$(1,946)$(5,362)
Other comprehensive income (loss) before reclassification adjustments, pretax186 8 (4)(84)106 
Tax(39)— — (33)(72)
Other comprehensive income (loss) before reclassification adjustments, net of taxes147 8 (4)(117)34 
Reclassification adjustments, pretax(71)
(1)
(25)
(2)
21 
(3)
— (75)
Tax15 — (2)— 13 
Reclassification adjustments, net of taxes(56)

(25)

19 

— (62)
Other comprehensive income (loss), net of taxes91 (17)15 (117)(28)
Balance September 30, 2019, net of taxes$157 $31 $(3,515)$(2,063)$(5,390)
Balance July 1, 2020, net of taxes$15 $— $(4,162)$(2,246)$(6,393)
Other comprehensive income (loss) before reclassification adjustments, pretax(195)— 2 50 (143)
Tax41 — 1 35 77 
Other comprehensive income (loss) before reclassification adjustments, net of taxes(154)— 3 85 (66)
Reclassification adjustments, pretax22 
(1)
— 72 
(3)
— 94 
Tax(5)— (13)— (18)
Reclassification adjustments, net of taxes17 

— 

59 

— 76 
Other comprehensive income (loss), net of taxes(137)— 62 85 10 
Balance September 30, 2020, net of taxes$(122)$— $(4,100)$(2,161)$(6,383)
Nine Months Ended September 30,
($ in millions)DerivativesInvestmentsEmployee
Benefit
Plans		Cumulative
Translation
Adjustment		Accumulated Other
Comprehensive
Income (Loss)
Balance January 1, 2019, net of taxes$166 $(78)$(3,556)$(2,077)$(5,545)
Other comprehensive income (loss) before reclassification adjustments, pretax183 139 (5)47 364 
Tax(38)— 6 (33)(65)
Other comprehensive income (loss) before reclassification adjustments, net of taxes145 139 1 14 299 
Reclassification adjustments, pretax(195)
(1)
(30)
(2)
49 
(3)
— (176)
Tax41 — (9)— 32 
Reclassification adjustments, net of taxes(154)(30)40 — (144)
Other comprehensive income (loss), net of taxes(9)109 41 14 155 
Balance September 30, 2019, net of taxes$157 $31 $(3,515)$(2,063)$(5,390)
Balance January 1, 2020, net of taxes$31 $18 $(4,261)$(1,981)$(6,193)
Other comprehensive income (loss) before reclassification adjustments, pretax(126)3 (19)(220)(362)
Tax27 — 12 40 79 
Other comprehensive income (loss) before reclassification adjustments, net of taxes(99)3 (7)(180)(283)
Reclassification adjustments, pretax(68)
(1)
(21)
(2)
210 
(3)
— 121 
Tax14 — (42)— (28)
Reclassification adjustments, net of taxes(54)(21)168 — 93 
Other comprehensive income (loss), net of taxes(153)(18)161 (180)(190)
Balance September 30, 2020, net of taxes$(122)$— $(4,100)$(2,161)$(6,383)
(1) Relates to foreign currency cash flow hedges that were reclassified from AOCI to Sales.
(2) Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from AOCI to Other (income) expense, net.
(3) Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 12).
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Reporting
 9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Segment Reporting Segment Reporting
The Company’s operations are principally managed on a products basis and include three operating segments, which are the Pharmaceutical, Animal Health and Healthcare Services segments. The Pharmaceutical and Animal Health segments are the only reportable segments.
The Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers such as health maintenance organizations, pharmacy benefit managers and other institutions. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines, primarily administered at physician offices. The Company sells these human health vaccines primarily to physicians, wholesalers, physician distributors and government entities. A large component of pediatric and adolescent vaccine sales are made to the U.S. Centers for Disease Control and Prevention Vaccines for Children program, which is funded by the U.S. government. Additionally, the Company sells vaccines to the Federal government for placement into vaccine stockpiles.
The Animal Health segment discovers, develops, manufactures and markets a wide range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. The Company also offers an extensive suite of digitally connected identification, traceability and monitoring products. The Company sells its products to veterinarians, distributors and animal producers.
The Healthcare Services segment provided services and solutions that focus on engagement, health analytics and clinical services to improve the value of care delivered to patients. The Company has been in the process of divesting the businesses in the Healthcare Services segment. The remaining businesses were divested during the first quarter of 2020.
Sales of the Company’s products were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$2,157 $1,559 $3,715 $1,743 $1,327 $3,070 $6,106 $4,281 $10,387 $4,525 $3,448 $7,973 
Alliance revenue - Lynparza (1)
107 89 196 71 53 123 297 223 519 186 126 313 
Alliance revenue - Lenvima (1)
82 60 142 65 44 109 270 152 421 169 112 280 
Emend8 31 39 42 56 98 18 96 115 173 163 336 
Vaccines
Gardasil/Gardasil 9
579 608 1,187 761 558 1,320 1,209 1,732 2,941 1,579 1,464 3,044 
ProQuad/M-M-R II/Varivax
437 139 576 482 141 623 1,033 356 1,390 1,325 469 1,794 
Pneumovax 23
276 99 375 179 58 237 478 270 748 428 164 592 
RotaTeq114 96 210 102 78 180 355 246 601 360 203 564 
Vaqta32 19 51 36 26 62 79 60 139 103 65 167 
Hospital Acute Care
Bridion162 157 320 133 151 284 412 431 843 381 437 817 
Noxafil13 66 79 77 100 177 27 220 247 268 291 560 
Prevymis32 46 77 22 23 45 87 113 200 60 55 115 
Primaxin1 73 74 2 75 77 2 187 189 2 204 207 
Invanz1 50 51 (1)58 57 7 152 159 30 176 206 
Cancidas1 49 50 — 62 62 2 147 148 5 187 191 
Cubicin11 28 39 14 38 52 36 80 116 78 129 207 
Zerbaxa20 23 43 20 15 35 57 54 112 45 43 88 
Immunology
Simponi— 209 209 — 203 203 — 615 615 — 625 625 
Remicade— 82 82 — 101 101 — 242 242 — 322 322 
Neuroscience
Belsomra18 63 81 23 57 80 67 177 244 68 155 223 
Virology
Isentress/Isentress HD
92 113 205 102 149 250 243 403 646 304 449 752 
Zepatier6 22 28 24 59 83 38 83 122 96 208 304 
Cardiovascular
Zetia(1)103 103 5 142 147 (4)389 384 11 432 443 
Vytorin3 44 47 5 52 57 9 130 139 11 219 231 
Atozet— 111 111 — 97 97 — 348 348 — 283 283 
Alliance revenue - Adempas (2)
78 5 83 48 2 50 200 16 216 137 7 144 
Adempas— 55 55 — 57 57 — 167 167 — 158 158 
Diabetes
Januvia342 479 821 367 440 807 1,110 1,339 2,449 1,223 1,317 2,539 
Janumet105 400 506 129 375 503 361 1,138 1,499 462 1,105 1,567 
Women’s Health
Implanon/Nexplanon137 52 189 136 62 199 374 142 515 421 160 581 
NuvaRing24 34 58 202 39 241 85 98 184 593 107 700 
Diversified Brands
Singulair4 78 82 11 140 152 14 324 338 24 479 503 
Cozaar/Hyzaar5 86 91 6 110 116 17 275 292 16 313 329 
Arcoxia— 68 68 — 72 72 — 204 204 — 221 221 
Nasonex— 41 41 4 55 58 9 152 161 2 224 226 
Follistim AQ20 31 50 27 35 62 60 76 136 80 102 182 
Other pharmaceutical (3)
352 834 1,186 343 804 1,149 1,144 2,334 3,478 1,037 2,394 3,431 
Total Pharmaceutical segment sales
5,218 6,102 11,320 5,180 5,914 11,095 14,202 17,452 31,654 14,202 17,016 31,218 
Animal Health:
Livestock164 594 758 144 582 726 448 1,697 2,145 406 1,601 2,007 
Companion Animals234 228 462 193 203 396 676 714 1,390 560 704 1,264 
Total Animal Health segment sales
398 822 1,220 337 785 1,122 1,124 2,411 3,535 966 2,305 3,271 
Other segment sales (4)
— — — 46 — 46 23 — 23 133 1 133 
Total segment sales5,616 6,924 12,540 5,563 6,699 12,263 15,349 19,863 35,212 15,301 19,322 34,622 
Other (5)
9 2 11 10 125 134 47 221 267 19 330 350 
 $5,625 $6,926 $12,551 $5,573 $6,824 $12,397 $15,396 $20,084 $35,479 $15,320 $19,652 $34,972 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2)    Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(3)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(4)    Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020.
(5)    Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.
Product sales are recorded net of the provision for discounts, including chargebacks, which are customer discounts that occur when a contracted customer purchases through an intermediary wholesale purchaser, and rebates that are owed based upon definitive contractual agreements or legal requirements with private sector and public sector (Medicaid and Medicare Part D) benefit providers, after the final dispensing of the product by a pharmacy to a benefit plan participant. These discounts, in the aggregate, reduced U.S. sales by $3.4 billion and $3.0 billion for the three months ended September 30, 2020 and 2019, respectively, and $9.6 billion and $8.6 billion for the nine months ended September 30, 2020 and 2019, respectively.
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
United States$5,625 $5,573 $15,396 $15,320 
Europe, Middle East and Africa3,454 3,189 10,059 9,452 
China1,016 914 2,715 2,423 
Japan828 919 2,506 2,639 
Asia Pacific (other than China and Japan)735 756 2,129 2,217 
Latin America604 671 1,670 1,889 
Other289 375 1,004 1,032 
 $12,551 $12,397 $35,479 $34,972 
A reconciliation of segment profits to Income before taxes is as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Segment profits:
Pharmaceutical segment$7,974 $7,747 $22,010 $21,437 
Animal Health segment451 423 1,336 1,243 
Other segment(1)(2)1 (2)
Total segment profits8,424 8,168 23,347 22,678 
Other profits(12)101 188 226 
Unallocated:
Interest income9 61 48 225 
Interest expense(203)(231)(624)(674)
Depreciation and amortization(395)(382)(1,173)(1,169)
Research and development(3,272)(3,110)(7,364)(7,045)
Amortization of purchase accounting adjustments(285)(329)(879)(1,105)
Restructuring costs(114)(232)(269)(444)
Other unallocated, net(724)(1,699)(2,490)(4,019)
 $3,428 $2,347 $10,784 $8,673 
Pharmaceutical segment profits are comprised of segment sales less standard costs, as well as selling, general and administrative expenses directly incurred by the segment. Animal Health segment profits are comprised of segment sales, less all cost of sales, as well as selling, general and administrative expenses and research and development costs directly incurred by the segment. For internal management reporting presented to the chief operating decision maker, Merck does not allocate the remaining cost of sales not included in segment profits as described above, research and development expenses incurred in Merck Research Laboratories, the Company’s research and development division that focuses on human health-related activities, or general and administrative expenses, nor the cost of financing these activities. Separate divisions maintain responsibility for monitoring and managing these costs, including depreciation related to fixed assets utilized by these divisions and, therefore, they are not included in segment profits. In addition, costs related to restructuring activities, as well as the amortization of purchase accounting adjustments are not allocated to segments.
Other profits are primarily comprised of miscellaneous corporate profits, as well as operating profits related to third-party manufacturing sales.
Other unallocated, net, includes expenses from corporate and manufacturing cost centers, goodwill and other intangible asset impairment charges, gains or losses on sales of businesses, expense or income related to changes in the estimated fair value measurement of liabilities for contingent consideration, and other miscellaneous income or expense items.
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Basis of Presentation (Policies)
 9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation Basis of PresentationThe accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 26, 2020.The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Recently Adopted and Issued Accounting Standards
Recently Adopted Accounting Standards
In June 2016, the Financial Accounting Standards Board (FASB) issued new guidance on the accounting for credit losses on financial instruments. The new guidance introduces an expected loss model for estimating credit losses, replacing the incurred loss model. The new guidance also changes the impairment model for available-for-sale debt securities, requiring the use of an allowance to record estimated credit losses (and subsequent recoveries). The Company adopted the new guidance effective January 1, 2020. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2018, the FASB issued new guidance for collaborative arrangements intended to reduce diversity in practice by clarifying whether certain transactions between collaborative arrangement participants should be accounted for under revenue recognition guidance (ASC 606). The Company adopted the new guidance effective January 1, 2020, which resulted in minor changes to the presentation of information related to the Company’s collaborative arrangements.
Recently Issued Accounting Standards Not Yet Adopted
In December 2019, the FASB issued amended guidance on the accounting and reporting of income taxes. The guidance is intended to simplify the accounting for income taxes by: removing exceptions related to certain intraperiod tax allocations and deferred tax liabilities; clarifying guidance primarily related to evaluating the step-up tax basis for goodwill in a business combination; and reflecting enacted changes in tax laws or rates in the annual effective tax rate. The amended guidance is effective for interim and annual periods in 2021. Early adoption is permitted. The amendments in the new guidance are to be applied on a retrospective basis, on a modified retrospective basis through a cumulative-effect adjustment to retained earnings or prospectively, depending on the amendment. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In January 2020, the FASB issued new guidance intended to clarify certain interactions between accounting standards related to equity securities, equity method investments and certain derivatives. The guidance addresses accounting for the transition into and out of the equity method of accounting and measuring certain purchased options and forward contracts to acquire investments. The new guidance is effective for interim and annual periods in 2021 and is to be applied prospectively. Early adoption is permitted. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The guidance provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform. The optional guidance is effective upon issuance and can be applied on a prospective basis at any time between January 1, 2020 through December 31, 2022. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
Legal Costs, Policy Legal defense costs expected to be incurred in connection with a loss contingency are accrued when probable and reasonably estimable.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions, Research Collaborations and License Agreements (Tables)
 9 Months Ended
Sep. 30, 2020
Business Combinations [Abstract]  
Fair Value of Assets Acquired and Liabilities Assumed
The estimated fair value of assets acquired and liabilities assumed from ArQule is as follows:
($ in millions)January 16, 2020
Cash and cash equivalents$145 
IPR&D MK-1026 (formerly ARQ 531) (1)
2,280 
Licensing arrangement for ARQ 08780 
Deferred income tax liabilities(389)
Other assets and liabilities, net34 
Total identifiable net assets
2,150 
Goodwill (2)
540 
Consideration transferred$2,690 
(1)    The estimated fair value of the identifiable intangible asset related to IPR&D was determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 12.5%. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill was allocated to the Pharmaceutical segment and is not deductible for tax purposes.
The estimated fair value of assets acquired and liabilities assumed from Antelliq is as follows:
($ in millions)April 1, 2019
Cash and cash equivalents$31 
Accounts receivable73 
Inventories93 
Property, plant and equipment60 
Identifiable intangible assets (useful lives ranging from 18-24 years) (1)
2,689 
Deferred income tax liabilities(589)
Other assets and liabilities, net(82)
Total identifiable net assets
2,275 
Goodwill (2)
1,376 
Consideration transferred$3,651 
(1)    The estimated fair values of identifiable intangible assets relate primarily to trade names and were determined using an income approach. The future net cash flows were discounted to present value utilizing a discount rate of 11.5%. Actual cash flows are likely to be different than those assumed.
(2)    The goodwill recognized is largely attributable to anticipated synergies expected to arise after the acquisition and was allocated to the Animal Health segment. The goodwill is not deductible for tax purposes.
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborative Arrangements (Tables)
 9 Months Ended
Sep. 30, 2020
Collaborative Arrangements [Abstract]  
Collaboration Arrangements
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Alliance revenue - Lynparza$196 $123 $519 $313 
Alliance revenue - Koselugo3 — 3 — 
Total alliance revenue$199 $123 $522 $313 
Cost of sales (1)
41 28 205 120 
Selling, general and administrative40 36 112 96 
Research and development20 44 93 122 
($ in millions)September 30, 2020December 31, 2019
Receivables from AstraZeneca included in Other current assets
$197 $128 
Payables to AstraZeneca included in Accrued and other current liabilities (2)
309 577 
Payables to AstraZeneca included in Other Noncurrent Liabilities (2)
400 — 
(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Alliance revenue - Lenvima$142 $109 $421 $280 
Cost of sales (1)
46 23 215 97 
Selling, general and administrative18 21 48 59 
Research and development48 37 168 146 
($ in millions)September 30, 2020December 31, 2019
Receivables from Eisai included in Other current assets
$170 $150 
Payables to Eisai included in Accrued and other current liabilities (2)
325 700 
Payables to Eisai included in Other Noncurrent Liabilities (3)
570 525 
(1) Represents amortization of capitalized milestone payments.
(2) Includes accrued milestone and future option payments.
(3) Includes accrued milestone payments.
Summarized financial information related to this collaboration is as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Alliance revenue - Adempas$83 $50 $216 $144 
Net sales of Adempas recorded by Merck55 57 167 158 
Total sales$138 $107 $383 $302 
Cost of sales (1)
29 28 85 86 
Selling, general and administrative19 12 42 31 
Research and development12 31 53 94 
($ in millions)September 30, 2020December 31, 2019
Receivables from Bayer included in Other current assets
$70 $49 
Payables to Bayer included in Other Noncurrent Liabilities (2)
375 375 
(1) Includes amortization of intangible assets.
(2) Represents accrued milestone payment.
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring (Tables)
 9 Months Ended
Sep. 30, 2020
Restructuring and Related Activities [Abstract]  
Charges Related to Restructuring Program Activities by Type of Cost
The following tables summarize the charges related to restructuring program activities by type of cost:
 Three Months Ended September 30, 2020Nine Months Ended September 30, 2020
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotalSeparation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $33 $5 $38 $— $89 $42 $131 
Selling, general and administrative— 15 — 15 — 37 — 37 
Research and development— 18 1 19 — 66 1 67 
Restructuring costs61 — 53 114 143 — 126 269 
$61 $66 $59 $186 $143 $192 $169 $504 
 Three Months Ended September 30, 2019Nine Months Ended September 30, 2019
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotalSeparation
Costs		Accelerated
Depreciation		OtherTotal
Cost of sales$— $41 $21 $62 $— $139 $22 $161 
Selling, general and administrative— 1 — 1 — 33 — 33 
Research and development— (1)2 1 — 1 3 4 
Restructuring costs205 — 27 232 358 — 86 444 
$205 $41 $50 $296 $358 $173 $111 $642 
Charges and Spending Relating to Restructuring Activities by Program
The following table summarizes the charges and spending relating to restructuring program activities for the nine months ended September 30, 2020:
($ in millions)Separation
Costs		Accelerated
Depreciation		OtherTotal
Restructuring reserves January 1, 2020$690 $— $69 $759 
Expense143 192 169 504 
(Payments) receipts, net(395)— (237)(632)
Non-cash activity— (192)39 (153)
Restructuring reserves September 30, 2020 (1)
$438 $— $40 $478 
(1)The remaining cash outlays are expected to be substantially completed by the end of 2023.
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income
The effects of the Company’s net investment hedges on OCI and the Consolidated Statement of Income are shown below:
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income (1)
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing
Three Months Ended September 30,Nine Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,
($ in millions)20202019202020192020201920202019
Net Investment Hedging Relationships
Foreign exchange contracts
$10 $1 $15 $8 $(4)$(8)$(15)$(23)
Euro-denominated notes162 (150)182 (152)— — — — 
(1) No amounts were reclassified from AOCI into income related to the sale of a subsidiary.
Summary of Interest Rate Swaps Held At September 30, 2020, the Company was a party to 14 pay-floating, receive-fixed interest rate swap contracts designated as fair value hedges of fixed-rate notes in which the notional amounts match the amount of the hedged fixed-rate notes as detailed in the table below.
September 30, 2020
($ in millions)Par Value of DebtNumber of Interest Rate Swaps HeldTotal Swap Notional Amount
3.875% notes due 2021
$1,150 5 $1,150 
2.40% notes due 2022
1,000 4 1,000 
2.35% notes due 2022
1,250 5 1,250 
Amounts Recorded on Balance Sheet Related to Fair Value Hedges
The table below presents the location of amounts recorded on the Consolidated Balance Sheet related to cumulative basis adjustments for fair value hedges:
Carrying Amount of Hedged LiabilitiesCumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount
($ in millions)September 30, 2020December 31, 2019September 30, 2020December 31, 2019
Balance Sheet Line Item in which Hedged Item is Included
Loans payable and current portion of long-term debt$1,155 $1,249 $5 $(1)
Long-Term Debt2,309 3,409 62 14 
Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments
Presented in the table below is the fair value of derivatives on a gross basis segregated between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:
  September 30, 2020December 31, 2019
  Fair Value of DerivativeU.S. Dollar
Notional		Fair Value of DerivativeU.S. Dollar
Notional
($ in millions)Balance Sheet CaptionAssetLiabilityAssetLiability
Derivatives Designated as Hedging Instruments
Interest rate swap contractsOther current assets$6 $— $1,150 $— $— $— 
Interest rate swap contractsOther Assets63 — 2,250 15 — 3,400 
Interest rate swap contractsAccrued and other current liabilities— — — — 1 1,250 
Foreign exchange contractsOther current assets30 — 4,120 152 — 6,117 
Foreign exchange contractsOther Assets59 — 1,881 55 — 2,160 
Foreign exchange contractsAccrued and other current liabilities— 104 3,096 — 22 1,748 
Foreign exchange contractsOther Noncurrent Liabilities— 1 157 — 1 53 
  $158 $105 $12,654 $222 $24 $14,728 
Derivatives Not Designated as Hedging Instruments
       
Foreign exchange contractsOther current assets$81 $— $5,455 $66 $— $7,245 
Foreign exchange contractsAccrued and other current liabilities— 171 8,042 — 73 8,693 
Forward contract related to Seagen common stockAccrued and other current liabilities— 22 1,000 — — — 
  $81 $193 $14,497 $66 $73 $15,938 
  $239 $298 $27,151 $288 $97 $30,666 
Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis The following table provides information on the Company’s derivative positions subject to these master netting arrangements as if they were presented on a net basis, allowing for the right of offset by counterparty and cash collateral exchanged per the master agreements and related credit support annexes:
 September 30, 2020December 31, 2019
($ in millions)AssetLiabilityAssetLiability
Gross amounts recognized in the condensed consolidated balance sheet$239 $298 $288 $97 
Gross amounts subject to offset in master netting arrangements not offset in the condensed consolidated balance sheet
(140)(140)(84)(84)
Cash collateral received— — (34)— 
Net amounts$99 $158 $170 $13 
Location and Amount of Pretax (Gains) Losses of Derivatives
The table below provides information regarding the location and amount of pretax (gains) losses of derivatives designated in fair value or cash flow hedging relationships:
Sales
Other (income) expense, net (1)
Other comprehensive income (loss)Sales
Other (income) expense, net (1)
Other comprehensive income (loss)
Three Months Ended September 30,Three Months Ended September 30,Three Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,Nine Months Ended September 30,
($ in millions)202020192020201920202019202020192020201920202019
Financial Statement Line Items in which Effects of Fair Value or Cash Flow Hedges are Recorded$12,551 $12,397 $(312)$35 $10 $(28)$35,479 $34,972 $(630)$362 $(190)$155 
(Gain) loss on fair value hedging relationships
Interest rate swap contracts
Hedged items
— — (14)13 — — — — 54 101 — — 
Derivatives designated as hedging instruments
— — — (6)— — — — (76)(74)— — 
Impact of cash flow hedging relationships
Foreign exchange contracts
Amount of (loss) gain recognized in OCI on derivatives
— — — — (195)186 — — — — (126)183 
Increase (decrease) in Sales as a result of AOCI reclassifications
(23)70 — — 23 (70)65 189 — — (65)(189)
Interest rate contracts
Amount of gain recognized in Other (income) expense, net on derivatives
— — (1)(1)— — — — (3)(3)— — 
Amount of loss recognized in OCI on derivatives
— — — — (1)(1)— — — — (3)(6)
(1) Interest expense is a component of Other (income) expense, net.
Income Statement Effects of Derivatives Not Designated as Hedging Instruments
The table below provides information regarding the income statement effects of derivatives not designated as hedging instruments:
Amount of Derivative Pretax (Gain) Loss Recognized in Income
Three Months Ended
September 30,		Nine Months Ended September 30,
($ in millions)Income Statement Caption2020201920202019
Derivatives Not Designated as Hedging Instruments
Foreign exchange contracts (1)
Other (income) expense, net$(7)$(8)$(138)$112 
Foreign exchange contracts (2)
Sales7 (11)4 (7)
Interest rate contracts (3)
Other (income) expense, net— — 9 — 
Forward contract related to Seagen common stockResearch and development expenses22 — 22 — 
(1) These derivative contracts mitigate changes in the value of remeasured foreign currency denominated monetary assets and liabilities attributable to changes in foreign currency exchange rates.
(2) These derivative contracts serve as economic hedges of forecasted transactions.
(3) These derivatives serve as economic hedges against rising treasury rates.
Information on Investments in Debt and Equity Securities
Information on investments in debt and equity securities is as follows:
 September 30, 2020December 31, 2019
 Amortized
Cost		Gross UnrealizedFair
Value		Amortized
Cost		Gross UnrealizedFair
Value
($ in millions)GainsLossesGainsLosses
U.S. government and agency securities$74 $— $— $74 $266 $3 $— $269 
Foreign government bonds2 — — 2 — — — — 
Commercial paper— — — — 668 — — 668 
Corporate notes and bonds— — — — 608 13 — 621 
Asset-backed securities— — — — 226 1 — 227 
Total debt securities$76 $— $— $76 $1,768 $17 $— $1,785 
Publicly traded equity securities (1)
1,477 838 
Total debt and publicly traded equity securities
$1,553 $2,623 
(1) Unrealized net (gains) losses recognized in Other (income) expense, net on equity securities still held at September 30, 2020 were $(43) million and $(512) million in the third quarter and first nine months of 2020, respectively. Unrealized net losses (gains) recognized in Other (income) expense, net on equity securities still held at September 30, 2019 were $25 million and $(41) million in the third quarter and first nine months of 2019, respectively.
Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis
Financial assets and liabilities measured at fair value on a recurring basis are summarized below:
Fair Value Measurements UsingFair Value Measurements Using
 Level 1Level 2Level 3TotalLevel 1Level 2Level 3Total
($ in millions)September 30, 2020December 31, 2019
Assets
Investments
Foreign government bonds$— $2 $— $2 $— $— $— $— 
Commercial paper— — — — — 668 — 668 
Corporate notes and bonds— — — — — 621 — 621 
Asset-backed securities (1)
— — — — — 227 — 227 
U.S. government and agency securities
— — — — — 209 — 209 
Publicly traded equity securities
1,370 — — 1,370 518 — — 518 
 1,370 2 — 1,372 518 1,725 — 2,243 
Other assets (2)
U.S. government and agency securities
74 — — 74 60 — — 60 
Publicly traded equity securities107 — — 107 320 — — 320 
181 — — 181 380 — — 380 
Derivative assets (3)
Forward exchange contracts— 116 — 116 — 169 — 169 
Interest rate swaps— 69 — 69 — 15 — 15 
Purchased currency options— 54 — 54 — 104 — 104 
 — 239 — 239 — 288 — 288 
Total assets$1,551 $241 $— $1,792 $898 $2,013 $— $2,911 
Liabilities
Other liabilities
Contingent consideration$— $— $829 $829 $— $— $767 $767 
Derivative liabilities (3)
Forward exchange contracts— 275 — 275 — 95 — 95 
Forward contract related to Seagen common stock— 22 — 22 — — — — 
Written currency options— 1 — 1 — 1 — 1 
Interest rate swaps— — — — — 1 — 1 
— 298 — 298 — 97 — 97 
Total liabilities$— $298 $829 $1,127 $— $97 $767 $864 
(1)Primarily all of the asset-backed securities were highly rated (Standard & Poor’s rating of AAA and Moody’s Investors Service rating of Aaa), secured primarily by auto loan, credit card and student loan receivables, with weighted-average lives of primarily 5 years or less.
(2)    Investments included in other assets are restricted as to use, including for the payment of benefits under employee benefit plans.
(3)    The fair value determination of derivatives includes the impact of the credit risk of counterparties to the derivatives and the Company’s own credit risk, the effects of which were not significant.
Information About the Changes in Liabilities for Contingent Consideration
Summarized information about the changes in liabilities for contingent consideration associated with business acquisitions is as follows:
Nine Months Ended September 30,
($ in millions)20202019
Fair value January 1$767 $788 
Additions97 — 
Changes in estimated fair value (1)
71 52 
Payments(106)(85)
Fair value September 30 (2)(3)
$829 $755 
(1) Recorded in Cost of sales, Research and development expenses, and Other (income) expense, net. Includes cumulative translation adjustments.
(2) Balance at September 30, 2020 includes $140 million recorded as a current liability for amounts expected to be paid within the next 12 months.
(3) At September 30, 2020 and December 31, 2019, $637 million and $625 million, respectively, of the liabilities relate to the termination of the Sanofi-Pasteur MSD joint venture in 2016. As part of the termination, Merck recorded a liability for contingent future royalty payments of 11.5% on net sales of all Merck products that were previously sold by the joint venture through December 31, 2024. The fair value of this liability is determined utilizing the estimated amount and timing of projected cash flows using a risk-adjusted discount rate of 8% to present value the cash flows.
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories (Tables)
 9 Months Ended
Sep. 30, 2020
Inventory Disclosure [Abstract]  
Schedule of Inventories
Inventories consisted of:
($ in millions)September 30, 2020December 31, 2019
Finished goods$2,038 $1,772 
Raw materials and work in process6,073 5,650 
Supplies197 207 
Total (approximates current cost)8,308 7,629 
Decrease to LIFO cost(99)(171)
 $8,209 $7,458 
Recognized as:
Inventories$6,128 $5,978 
Other assets2,081 1,480 
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Equity (Tables)
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Equity
Three Months Ended September 30,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at July 1, 20193,577 $1,788 $39,484 $45,295 $(5,362)1,010 $(53,570)$102 $27,737 
Net income attributable to Merck & Co., Inc.— — — 1,901 — — — — 1,901 
Other comprehensive loss, net of taxes— — — — (28)— — — (28)
Cash dividends declared on common stock ($0.55 per share)
— — — (1,392)— — — — (1,392)
Treasury stock shares purchased— — — — — 17 (1,405)— (1,405)
Share-based compensation plans and other— — 77 — — (1)50 — 127 
Net income attributable to noncontrolling interests
— — — — — — — 6 6 
Distributions attributable to noncontrolling interests
— — — — — — — (21)(21)
Balance at September 30, 20193,577 $1,788 $39,561 $45,804 $(5,390)1,026 $(54,925)$87 $26,925 
Balance at July 1, 20203,577 $1,788 $39,373 $49,724 $(6,393)1,048 $(56,850)$102 $27,744 
Net income attributable to Merck & Co., Inc.— — — 2,941 — — — — 2,941 
Other comprehensive income, net of taxes— — — — 10 — — — 10 
Cash dividends declared on common stock ($0.61 per share)
— — — (1,558)— — — — (1,558)
Share-based compensation plans and other— — 116 — — (1)35 — 151 
Net income attributable to noncontrolling interests
— — — — — — — 4 4 
Distributions attributable to noncontrolling interests
— — — — — — — (22)(22)
Balance at September 30, 20203,577 $1,788 $39,489 $51,107 $(6,383)1,047 $(56,815)$84 $29,270 
Nine Months Ended September 30,
 
  
Common Stock
Other
Paid-In
Capital		Retained
Earnings		Accumulated
Other
Comprehensive
Loss
 
Treasury Stock
Non-
controlling
Interests		Total
($ and shares in millions except per share amounts)SharesPar ValueSharesCost
Balance at January 1, 20193,577 $1,788 $38,808 $42,579 $(5,545)985 $(50,929)$181 $26,882 
Net income attributable to Merck & Co., Inc.— — — 7,487 — — — — 7,487 
Other comprehensive income, net of taxes— — — — 155 — — — 155 
Cash dividends declared on common stock ($1.65 per share)
— — — (4,262)— — — — (4,262)
Treasury stock shares purchased— — 1,000 — — 54 (4,730)— (3,730)
Share-based compensation plans and other— — (247)— — (13)734 — 487 
Net loss attributable to noncontrolling interests
— — — — — — — (73)(73)
Distributions attributable to noncontrolling
 interests
— — — — — — — (21)(21)
Balance at September 30, 20193,577 1,788 39,561 45,804 (5,390)1,026 (54,925)87 26,925 
Balance at January 1, 20203,577 $1,788 $39,660 $46,602 $(6,193)1,038 $(55,950)$94 $26,001 
Net income attributable to Merck & Co., Inc.— — — 9,161 — — — — 9,161 
Other comprehensive loss, net of taxes— — — — (190)— — — (190)
Cash dividends declared on common stock ($1.83 per share)
— — — (4,656)— — — — (4,656)
Treasury stock shares purchased— — — — — 16 (1,281)— (1,281)
Share-based compensation plans and other— — (171)— — (7)416 — 245 
Net income attributable to noncontrolling interests
— — — — — — — 12 12 
Distributions attributable to noncontrolling
 interests
— — — — — — — (22)(22)
Balance at September 30, 20203,577 $1,788 $39,489 $51,107 $(6,383)1,047 $(56,815)$84 $29,270 
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation Plans (Tables)
 9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement [Abstract]  
Amounts of Share-Based Compensation Cost Recorded in Consolidated Statement of Income
The following table provides the amounts of share-based compensation cost recorded in the Condensed Consolidated Statement of Income:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Pretax share-based compensation expense$126 $101 $354 $306 
Income tax benefit(17)(14)(48)(42)
Total share-based compensation expense, net of taxes$109 $87 $306 $264 
Assumptions Used to Determine Weighted-Average Fair Value of Options Granted During the first nine months of 2020, the Company granted 4 million stock options with a weighted-average exercise price of $77.67 per option and during the first nine months of 2019 granted 3 million stock options with a weighted-average exercise price of $80.05 per option. The weighted-average fair value of options granted during the first nine months of 2020 and 2019 was $9.93 and $10.63 per option, respectively, and was determined using the following assumptions:
  Nine Months Ended
September 30,
20202019
Expected dividend yield3.1 %3.2 %
Risk-free interest rate0.4 %2.4 %
Expected volatility22.1 %18.7 %
Expected life (years)5.85.9
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Pension and Other Postretirement Benefit Plans (Tables)
 9 Months Ended
Sep. 30, 2020
Pension Plans  
Defined Benefit Plan Disclosure [Line Items]  
Components of net cost of defined benefit plans
The Company has defined benefit pension plans covering eligible employees in the United States and in certain of its international subsidiaries. The net periodic benefit cost of such plans consisted of the following components: 
  Three Months Ended
September 30,		Nine Months Ended
September 30,
2020201920202019
($ in millions)U.S.InternationalU.S.InternationalU.S.InternationalU.S.International
Service cost$96 $77 $76 $58 $270 $225 $221 $178 
Interest cost107 35 115 44 323 103 343 133 
Expected return on plan assets(193)(104)(202)(106)(581)(310)(613)(320)
Amortization of unrecognized prior service credit
(12)(3)(12)(3)(37)(9)(37)(9)
Net loss amortization75 32 43 16 228 94 113 47 
Termination benefits1 1 3 — 5 2 7 1 
Curtailments1 — 5 — 4 (1)6 — 
Settlements2 — — — 11 2 — — 
 $77 $38 $28 $9 $223 $106 $40 $30 
Other Postretirement Benefit Plans  
Defined Benefit Plan Disclosure [Line Items]  
Components of net cost of defined benefit plans
The Company provides medical benefits, principally to its eligible U.S. retirees and similar benefits to their dependents, through its other postretirement benefit plans. The net credit of such plans consisted of the following components: 
  Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Service cost$13 $12 $39 $36 
Interest cost14 17 43 52 
Expected return on plan assets(19)(18)(56)(54)
Amortization of unrecognized prior service credit(18)(20)(54)(59)
Net gain amortization(5)(3)(13)(7)
Termination benefits— 1 — 1 
Curtailments— (3)(1)(4)
 $(15)$(14)$(42)$(35)
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Other (Income) Expense, Net (Tables)
 9 Months Ended
Sep. 30, 2020
Other Income and Expenses [Abstract]  
Other (Income) Expense, Net
Other (income) expense, net, consisted of: 
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Interest income$(9)$(61)$(48)$(225)
Interest expense203 231 624 674 
Exchange losses10 38 89 166 
Income from investments in equity securities, net (1)
(360)(16)(964)(50)
Net periodic defined benefit plan (credit) cost other than service cost(88)(128)(259)(409)
Other, net(68)(29)(72)206 
 $(312)$35 $(630)$362 
(1)    Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag.
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share (Tables)
 9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]  
Calculations of Earnings Per Share
The calculations of earnings per share are as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ and shares in millions except per share amounts)2020201920202019
Net income attributable to Merck & Co., Inc.
$2,941 $1,901 $9,161 $7,487 
Average common shares outstanding2,529 2,558 2,530 2,572 
Common shares issuable (1)
9 14 11 15 
Average common shares outstanding assuming dilution 2,538 2,572 2,541 2,587 
Basic earnings per common share attributable to Merck & Co., Inc. common shareholders
$1.16 $0.74 $3.62 $2.91 
Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders
$1.16 $0.74 $3.61 $2.89 
(1)Issuable primarily under share-based compensation plans.
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Other Comprehensive Income (Loss) (Tables)
 9 Months Ended
Sep. 30, 2020
Equity [Abstract]  
Changes in AOCI by Component
Changes in AOCI by component are as follows:
Three Months Ended September 30,
($ in millions)DerivativesInvestmentsEmployee
Benefit
Plans		Cumulative
Translation
Adjustment		Accumulated Other
Comprehensive
Income (Loss)
Balance July 1, 2019, net of taxes$66 $48 $(3,530)$(1,946)$(5,362)
Other comprehensive income (loss) before reclassification adjustments, pretax186 8 (4)(84)106 
Tax(39)— — (33)(72)
Other comprehensive income (loss) before reclassification adjustments, net of taxes147 8 (4)(117)34 
Reclassification adjustments, pretax(71)
(1)
(25)
(2)
21 
(3)
— (75)
Tax15 — (2)— 13 
Reclassification adjustments, net of taxes(56)

(25)

19 

— (62)
Other comprehensive income (loss), net of taxes91 (17)15 (117)(28)
Balance September 30, 2019, net of taxes$157 $31 $(3,515)$(2,063)$(5,390)
Balance July 1, 2020, net of taxes$15 $— $(4,162)$(2,246)$(6,393)
Other comprehensive income (loss) before reclassification adjustments, pretax(195)— 2 50 (143)
Tax41 — 1 35 77 
Other comprehensive income (loss) before reclassification adjustments, net of taxes(154)— 3 85 (66)
Reclassification adjustments, pretax22 
(1)
— 72 
(3)
— 94 
Tax(5)— (13)— (18)
Reclassification adjustments, net of taxes17 

— 

59 

— 76 
Other comprehensive income (loss), net of taxes(137)— 62 85 10 
Balance September 30, 2020, net of taxes$(122)$— $(4,100)$(2,161)$(6,383)
Nine Months Ended September 30,
($ in millions)DerivativesInvestmentsEmployee
Benefit
Plans		Cumulative
Translation
Adjustment		Accumulated Other
Comprehensive
Income (Loss)
Balance January 1, 2019, net of taxes$166 $(78)$(3,556)$(2,077)$(5,545)
Other comprehensive income (loss) before reclassification adjustments, pretax183 139 (5)47 364 
Tax(38)— 6 (33)(65)
Other comprehensive income (loss) before reclassification adjustments, net of taxes145 139 1 14 299 
Reclassification adjustments, pretax(195)
(1)
(30)
(2)
49 
(3)
— (176)
Tax41 — (9)— 32 
Reclassification adjustments, net of taxes(154)(30)40 — (144)
Other comprehensive income (loss), net of taxes(9)109 41 14 155 
Balance September 30, 2019, net of taxes$157 $31 $(3,515)$(2,063)$(5,390)
Balance January 1, 2020, net of taxes$31 $18 $(4,261)$(1,981)$(6,193)
Other comprehensive income (loss) before reclassification adjustments, pretax(126)3 (19)(220)(362)
Tax27 — 12 40 79 
Other comprehensive income (loss) before reclassification adjustments, net of taxes(99)3 (7)(180)(283)
Reclassification adjustments, pretax(68)
(1)
(21)
(2)
210 
(3)
— 121 
Tax14 — (42)— (28)
Reclassification adjustments, net of taxes(54)(21)168 — 93 
Other comprehensive income (loss), net of taxes(153)(18)161 (180)(190)
Balance September 30, 2020, net of taxes$(122)$— $(4,100)$(2,161)$(6,383)
(1) Relates to foreign currency cash flow hedges that were reclassified from AOCI to Sales.
(2) Represents net realized (gains) losses on the sales of available-for-sale debt securities that were reclassified from AOCI to Other (income) expense, net.
(3) Includes net amortization of prior service cost and actuarial gains and losses included in net periodic benefit cost (see Note 12).
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Reporting (Tables)
 9 Months Ended
Sep. 30, 2020
Segment Reporting [Abstract]  
Sales of Company's products
Sales of the Company’s products were as follows:
Three Months Ended September 30,Nine Months Ended September 30,
2020201920202019
 ($ in millions)U.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotalU.S.Int’lTotal
Pharmaceutical:
Oncology
Keytruda$2,157 $1,559 $3,715 $1,743 $1,327 $3,070 $6,106 $4,281 $10,387 $4,525 $3,448 $7,973 
Alliance revenue - Lynparza (1)
107 89 196 71 53 123 297 223 519 186 126 313 
Alliance revenue - Lenvima (1)
82 60 142 65 44 109 270 152 421 169 112 280 
Emend8 31 39 42 56 98 18 96 115 173 163 336 
Vaccines
Gardasil/Gardasil 9
579 608 1,187 761 558 1,320 1,209 1,732 2,941 1,579 1,464 3,044 
ProQuad/M-M-R II/Varivax
437 139 576 482 141 623 1,033 356 1,390 1,325 469 1,794 
Pneumovax 23
276 99 375 179 58 237 478 270 748 428 164 592 
RotaTeq114 96 210 102 78 180 355 246 601 360 203 564 
Vaqta32 19 51 36 26 62 79 60 139 103 65 167 
Hospital Acute Care
Bridion162 157 320 133 151 284 412 431 843 381 437 817 
Noxafil13 66 79 77 100 177 27 220 247 268 291 560 
Prevymis32 46 77 22 23 45 87 113 200 60 55 115 
Primaxin1 73 74 2 75 77 2 187 189 2 204 207 
Invanz1 50 51 (1)58 57 7 152 159 30 176 206 
Cancidas1 49 50 — 62 62 2 147 148 5 187 191 
Cubicin11 28 39 14 38 52 36 80 116 78 129 207 
Zerbaxa20 23 43 20 15 35 57 54 112 45 43 88 
Immunology
Simponi— 209 209 — 203 203 — 615 615 — 625 625 
Remicade— 82 82 — 101 101 — 242 242 — 322 322 
Neuroscience
Belsomra18 63 81 23 57 80 67 177 244 68 155 223 
Virology
Isentress/Isentress HD
92 113 205 102 149 250 243 403 646 304 449 752 
Zepatier6 22 28 24 59 83 38 83 122 96 208 304 
Cardiovascular
Zetia(1)103 103 5 142 147 (4)389 384 11 432 443 
Vytorin3 44 47 5 52 57 9 130 139 11 219 231 
Atozet— 111 111 — 97 97 — 348 348 — 283 283 
Alliance revenue - Adempas (2)
78 5 83 48 2 50 200 16 216 137 7 144 
Adempas— 55 55 — 57 57 — 167 167 — 158 158 
Diabetes
Januvia342 479 821 367 440 807 1,110 1,339 2,449 1,223 1,317 2,539 
Janumet105 400 506 129 375 503 361 1,138 1,499 462 1,105 1,567 
Women’s Health
Implanon/Nexplanon137 52 189 136 62 199 374 142 515 421 160 581 
NuvaRing24 34 58 202 39 241 85 98 184 593 107 700 
Diversified Brands
Singulair4 78 82 11 140 152 14 324 338 24 479 503 
Cozaar/Hyzaar5 86 91 6 110 116 17 275 292 16 313 329 
Arcoxia— 68 68 — 72 72 — 204 204 — 221 221 
Nasonex— 41 41 4 55 58 9 152 161 2 224 226 
Follistim AQ20 31 50 27 35 62 60 76 136 80 102 182 
Other pharmaceutical (3)
352 834 1,186 343 804 1,149 1,144 2,334 3,478 1,037 2,394 3,431 
Total Pharmaceutical segment sales
5,218 6,102 11,320 5,180 5,914 11,095 14,202 17,452 31,654 14,202 17,016 31,218 
Animal Health:
Livestock164 594 758 144 582 726 448 1,697 2,145 406 1,601 2,007 
Companion Animals234 228 462 193 203 396 676 714 1,390 560 704 1,264 
Total Animal Health segment sales
398 822 1,220 337 785 1,122 1,124 2,411 3,535 966 2,305 3,271 
Other segment sales (4)
— — — 46 — 46 23 — 23 133 1 133 
Total segment sales5,616 6,924 12,540 5,563 6,699 12,263 15,349 19,863 35,212 15,301 19,322 34,622 
Other (5)
9 2 11 10 125 134 47 221 267 19 330 350 
 $5,625 $6,926 $12,551 $5,573 $6,824 $12,397 $15,396 $20,084 $35,479 $15,320 $19,652 $34,972 
U.S. plus international may not equal total due to rounding.
(1)    Alliance revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs (see Note 3).
(2)    Alliance revenue represents Merck’s share of profits from sales in Bayer’s marketing territories, which are product sales net of cost of sales and commercialization costs (see Note 3).
(3)    Other pharmaceutical primarily reflects sales of other human health pharmaceutical products, including products within the franchises not listed separately.
(4)    Represents sales for the Healthcare Services segment. All the businesses in the Healthcare Services segment were divested as of March 31, 2020.
(5)    Other is primarily comprised of miscellaneous corporate revenues, including revenue hedging activities, as well as third-party manufacturing sales.
Consolidated revenues by geographic area
Consolidated sales by geographic area where derived are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
United States$5,625 $5,573 $15,396 $15,320 
Europe, Middle East and Africa3,454 3,189 10,059 9,452 
China1,016 914 2,715 2,423 
Japan828 919 2,506 2,639 
Asia Pacific (other than China and Japan)735 756 2,129 2,217 
Latin America604 671 1,670 1,889 
Other289 375 1,004 1,032 
 $12,551 $12,397 $35,479 $34,972 
Reconciliation of segment profits to income before taxes
A reconciliation of segment profits to Income before taxes is as follows:
 Three Months Ended
September 30,		Nine Months Ended
September 30,
($ in millions)2020201920202019
Segment profits:
Pharmaceutical segment$7,974 $7,747 $22,010 $21,437 
Animal Health segment451 423 1,336 1,243 
Other segment(1)(2)1 (2)
Total segment profits8,424 8,168 23,347 22,678 
Other profits(12)101 188 226 
Unallocated:
Interest income9 61 48 225 
Interest expense(203)(231)(624)(674)
Depreciation and amortization(395)(382)(1,173)(1,169)
Research and development(3,272)(3,110)(7,364)(7,045)
Amortization of purchase accounting adjustments(285)(329)(879)(1,105)
Restructuring costs(114)(232)(269)(444)
Other unallocated, net(724)(1,699)(2,490)(4,019)
 $3,428 $2,347 $10,784 $8,673 
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details)
$ / shares in Units, shares in Thousands, € in Millions, $ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended
Jan. 16, 2020
USD ($)
Apr. 01, 2019
USD ($)
Nov. 30, 2020
USD ($)
Oct. 31, 2020
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2020
EUR (€)
Jul. 31, 2020
USD ($)
Jun. 30, 2020
USD ($)
May 31, 2020
USD ($)
Jul. 31, 2019
USD ($)
Apr. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
$ / shares
shares
Sep. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration         $ 829.0             $ 829.0 $ 755.0 $ 829.0 $ 755.0 $ 767.0 $ 788.0
Goodwill         20,248.0             20,248.0   20,248.0   19,425.0  
Research and development                       3,390.0 3,204.0 7,721.0 7,324.0    
Inventories         6,128.0             6,128.0   6,128.0   $ 5,978.0  
Payments to Acquire Productive Assets                           3,170.0 2,336.0    
Forward Contracts | Research and development                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Amount of Derivative Pretax (Gain) Loss Recognized in Income                       (22.0) $ 0.0 (22.0) $ 0.0    
Forward Contracts | Research and development | Subsequent Event                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Amount of Derivative Pretax (Gain) Loss Recognized in Income       $ 6.0                          
Sentinel                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business             $ 410.0                    
Dunboyne                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Other assets and liabilities, net         13.0             13.0   13.0      
Payments to Acquire Productive Assets         302.0 € 256                      
Property, plant and equipment         289.0             $ 289.0   $ 289.0      
Themis                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business               $ 366.0                  
Contingent consideration, maximum               740.0                  
Contingent consideration               97.0                  
IPR&D               136.0                  
Cash and cash equivalents               59.0                  
Goodwill               229.0                  
Deferred tax assets               71.0                  
Other assets and liabilities, net               (32.0)                  
ArQule                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business $ 2,700.0                                
IPR&D 2,280.0                                
Share-based compensation payments attributable to precombination service 138.0                                
Transaction costs 95.0                                
Cash and cash equivalents 145.0                                
Goodwill 540.0                                
Other assets and liabilities, net 34.0                                
Deferred income tax liabilities 389.0                                
Intangible assets $ 80.0                                
Peloton                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business                   $ 1,200.0              
Cash and cash equivalents                   157.0              
Other assets and liabilities, net                   6.0              
Research and development                   982.0              
Deferred income tax liabilities                   64.0              
Antelliq                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business   $ 2,300.0                              
Transaction costs   47.0                              
Cash and cash equivalents   31.0                              
Goodwill   1,376.0                              
Debt assumed and paid   1,300.0                              
Other assets and liabilities, net   (82.0)                              
Deferred income tax liabilities   589.0                              
Inventories   93.0                              
Intangible assets   2,689.0                              
Property, plant and equipment   $ 60.0                              
Immune Design                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business                     $ 301.0            
IPR&D                     156.0            
Cash and cash equivalents                     83.0            
Other net assets                     42.0            
Goodwill                     $ 20.0            
VelosBio [Member] | Forecast                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Payment to acquire business     $ 2,750.0                            
Development Milestones | Themis                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration, maximum               80.0                  
Sales-Based Milestones | Themis                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration, maximum               400.0                  
Sales-Based Milestones | Peloton                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration, maximum                   1,050.0              
Regulatory Milestones | Themis                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration, maximum               $ 260.0                  
Regulatory Milestones | Peloton                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration, maximum                   50.0              
Commercial Milestone | Peloton                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent consideration, maximum                   $ 50.0              
Seagen                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Upfront and milestone payments         $ 600.0                        
Share price (in dollars per share) | $ / shares         $ 200             $ 200   $ 200      
Contingent milestone payments collaborative arrangement         $ 2,600.0                        
Payments to Acquire Investments         1,000.0                        
Research and development         $ 622.0                        
Forward contract, shares | shares         5,000             5,000   5,000      
Seagen | Tukysa                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Upfront and milestone payments         $ 210.0                        
Seagen | Tukysa | Minimum                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Royalty Rate, Percentage         20.00% 20.00%                      
Seagen | Tukysa | Maximum                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Royalty Rate, Percentage         33.00% 33.00%                      
Seagen | Sales-Based Milestones                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent milestone payments collaborative arrangement         $ 1,750.0                        
Seagen | Regulatory Milestones                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent milestone payments collaborative arrangement         850.0                        
Seagen | Regulatory Milestones | Tukysa                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Contingent milestone payments collaborative arrangement         $ 65.0                        
IAVI                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Upfront and milestone payments                 $ 6.5                
Contingent milestone payments collaborative arrangement                 $ 100.0                
Technology Rights | Sentinel                                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                                  
Acquired rights             401.0                    
Inventories             $ 9.0                    
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details)
$ in Millions
 1 Months Ended
Apr. 01, 2019
USD ($)
Jul. 31, 2020
Sep. 30, 2020
USD ($)
Jan. 16, 2020
USD ($)
Dec. 31, 2019
USD ($)
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]          
Goodwill     $ 20,248   $ 19,425
Sentinel | Technology Rights          
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]          
Weighted average useful life of acquired finite-lived intangible assets   15 years      
Antelliq | Technology Rights | Minimum          
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]          
Weighted average useful life of acquired finite-lived intangible assets 18 years        
Antelliq | Technology Rights | Maximum          
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]          
Weighted average useful life of acquired finite-lived intangible assets 24 years        
ArQule          
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]          
Cash and cash equivalents       $ 145  
IPR&D       2,280  
Intangible assets       80  
Deferred income tax liabilities       (389)  
Other assets and liabilities, net       34  
Total identifiable net assets       2,150  
Goodwill       540  
Consideration transferred       $ 2,690  
Antelliq          
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]          
Cash and cash equivalents $ 31        
Accounts receivable 73        
Inventories 93        
Property, plant and equipment 60        
Intangible assets 2,689        
Deferred income tax liabilities (589)        
Other assets and liabilities, net (82)        
Total identifiable net assets 2,275        
Goodwill 1,376        
Consideration transferred $ 3,651        
Measurement Input, Discount Rate | ArQule          
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]          
Present value discount rate       0.125  
Measurement Input, Discount Rate | Antelliq          
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]          
Present value discount rate 0.115        
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborative Arrangements - Narrative (Details) - USD ($)
$ in Millions
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended 21 Months Ended 29 Months Ended 37 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2018
Jul. 31, 2017
Sep. 30, 2020
Jun. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2019
Dec. 31, 2019
Mar. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Research and development           $ 3,390   $ 3,204 $ 7,721 $ 7,324          
Other liabilities, noncurrent           12,027     12,027   $ 11,970   $ 11,970 $ 11,970  
Lynparza | Other Assets                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Finite-lived intangible assets           1,300     1,300            
Lenvima | Other Assets                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Finite-lived intangible assets           1,100     1,100            
Adempas | Other intangible assets                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Finite-lived intangible assets           $ 838     838            
AstraZeneca                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Upfront and milestone payments         $ 1,600                    
License option payment related to collaborative arrangement         $ 750                    
AstraZeneca | Sales-Based Milestones                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Contingent milestone payments collaborative arrangement                 2,700            
AstraZeneca | Sales-Based Milestones | Lynparza                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Probable contingent payments collaborative arrangement             $ 400             $ 1,000  
Liabilities             400                
Milestone payments made to collaborative partner                 250   200 $ 250      
AstraZeneca | Regulatory Milestones | Lynparza                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Milestone payments made to collaborative partner             135       60 140      
Contingent milestone payments collaborative arrangement                 1,400            
Eisai                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Upfront and milestone payments       $ 750                      
License option payment related to collaborative arrangement   $ 200 $ 325                        
Eisai | Forecast                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
License option payment related to collaborative arrangement $ 125                           $ 650
Eisai | Sales-Based Milestones                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Contingent milestone payments collaborative arrangement                 2,700            
Eisai | Sales-Based Milestones | Lenvima                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Probable contingent payments collaborative arrangement             370           $ 950    
Liabilities             $ 370                
Milestone payments made to collaborative partner                 500   50        
Eisai | Regulatory Milestones                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Contingent milestone payments collaborative arrangement                 135            
Eisai | Regulatory Milestones | Lenvima                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Milestone payments made to collaborative partner                       250      
Bayer AG | Sales-Based Milestones                              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                              
Probable contingent payments collaborative arrangement                     $ 725        
Milestone payments made to collaborative partner                       $ 350      
Contingent milestone payments collaborative arrangement                 $ 400            
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Collaborative Arrangements - Schedule of Transactions (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Sales $ 12,551 $ 12,397 $ 35,479 $ 34,972  
Cost of sales 3,481 3,990 9,952 10,443  
Selling, general and administrative 2,450 2,589 7,383 7,726  
Research and development 3,390 3,204 7,721 7,324  
Payables, current 20,405   20,405   $ 22,220
Other current assets | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables 197   197   128
Other current assets | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables 170   170   150
Other current assets | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Receivables 70   70   49
Accounts payable and accrued liabilities | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables, current 309   309   577
Payables, Noncurrent 400   400   0
Accounts payable and accrued liabilities | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables, current 325   325   700
Other Noncurrent Liabilities | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables, Noncurrent 570   570   525
Other Noncurrent Liabilities | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Payables, Noncurrent 375   375   $ 375
Revenue | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 199 123 522 313  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Lynparza (1)          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 196 123 519 313  
Revenue | AstraZeneca | Collaborative Arrangement | Alliance revenue - Koselugo          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 3 0 3 0  
Revenue | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 142 109 421 280  
Revenue | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Alliance revenue - profit sharing 83 50 216 144  
Collaborative Arrangement, Sales, Net 55 57 167 158  
Sales 138 107 383 302  
Cost of sales | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 41 28 205 120  
Cost of sales | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 46 23 215 97  
Cost of sales | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Cost of sales 29 28 85 86  
Selling, general and administrative | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 40 36 112 96  
Selling, general and administrative | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 18 21 48 59  
Selling, general and administrative | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Selling, general and administrative 19 12 42 31  
Research and development | AstraZeneca | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development 20 44 93 122  
Research and development | Eisai | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development 48 37 168 146  
Research and development | Bayer AG | Collaborative Arrangement          
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]          
Research and development $ 12 $ 31 $ 53 $ 94  
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2020
Restructuring Cost and Reserve [Line Items]          
Cumulative costs since program inception $ 1,400   $ 1,400    
Estimate of cumulative pre tax costs that will result in cash outlays     60.00%    
Estimate of cumulative pre tax costs that will be noncash     40.00%    
Expected restructuring and related cost 2,500   $ 2,500    
Total pretax restructuring costs $ 186 $ 296 $ 504 $ 642  
Forecast          
Restructuring Cost and Reserve [Line Items]          
Expected restructuring and related cost         $ 800
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring - Charges Activities by Type of Cost (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs $ 186 $ 296 $ 504 $ 642
Separation Costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 61 205 143 358
Accelerated Depreciation        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 66 41 192 173
Other        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 59 50 169 111
Cost of sales        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 38 62 131 161
Cost of sales | Separation Costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Cost of sales | Accelerated Depreciation        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 33 41 89 139
Cost of sales | Other        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 5 21 42 22
Selling, general and administrative        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 15 1 37 33
Selling, general and administrative | Separation Costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Selling, general and administrative | Accelerated Depreciation        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 15 1 37 33
Selling, general and administrative | Other        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Research and development        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 19 1 67 4
Research and development | Separation Costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Research and development | Accelerated Depreciation        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 18 (1) 66 1
Research and development | Other        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 1 2 1 3
Restructuring costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 114 232 269 444
Restructuring costs | Separation Costs        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 61 205 143 358
Restructuring costs | Accelerated Depreciation        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs 0 0 0 0
Restructuring costs | Other        
Restructuring Cost and Reserve [Line Items]        
Total pretax restructuring costs $ 53 $ 27 $ 126 $ 86
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Restructuring - Activities by Program (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     $ 759  
Expense $ 186 $ 296 504 $ 642
(Payments) receipts, net     (632)  
Non-cash activity     (153)  
Restructuring reserve, ending balance 478   478  
Separation Costs        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     690  
Expense 61 205 143 358
(Payments) receipts, net     (395)  
Non-cash activity     0  
Restructuring reserve, ending balance 438   438  
Accelerated Depreciation        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     0  
Expense 66 41 192 173
(Payments) receipts, net     0  
Non-cash activity     (192)  
Restructuring reserve, ending balance 0   0  
Other        
Restructuring Reserve [Roll Forward]        
Restructuring reserve, beginning balance     69  
Expense 59 $ 50 169 $ 111
(Payments) receipts, net     (237)  
Non-cash activity     39  
Restructuring reserve, ending balance $ 40   $ 40  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Narrative (Details)
 3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
interest_rate_swap
Dec. 31, 2019
USD ($)
Sep. 30, 2020
USD ($)
interest_rate_swap
Sep. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
Feb. 29, 2020
USD ($)
interest_rate_swap
Derivative [Line Items]            
Pretax net unrealized losses on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales     $ 155,000,000      
Equity investments without readily determinable fair values $ 508,000,000   508,000,000 $ 393,000,000    
Unrealized gains recognized on investments in equity securities without readily determinable fair value     21,000,000 4,000,000    
Unrealized losses recognized on investments in equity securities without readily determinable fair values     3,000,000 12,000,000    
Cumulative unrealized gains on investments 128,000,000   128,000,000      
Cumulative unrealized losses on investments 24,000,000   24,000,000      
Payments of contingent consideration     106,000,000 $ 85,000,000    
Fair value of loans payable and long-term debt, including current portion 32,600,000,000 $ 28,800,000,000 32,600,000,000      
Debt, carrying amount 28,700,000,000 26,300,000,000 28,700,000,000      
Accounts Receivable, Sale 2,100,000,000 2,700,000,000        
Cash collateral received from counterparties 0 34,000,000 0      
Cash collateral advanced to counterparties 0 0 0      
Total swap notional amount 27,151,000,000 30,666,000,000 27,151,000,000      
Face amount of debt         $ 4,500,000,000  
Level 2            
Derivative [Line Items]            
Cash equivalents 6,600,000,000 8,900,000,000 6,600,000,000      
Derivatives Designated as Hedging Instruments            
Derivative [Line Items]            
Total swap notional amount 12,654,000,000 14,728,000,000 $ 12,654,000,000      
Derivatives Designated as Hedging Instruments | Maximum            
Derivative [Line Items]            
Maximum average period of maturities of contracts in years (less than)     2 years      
Derivatives Not Designated as Hedging Instruments            
Derivative [Line Items]            
Total swap notional amount $ 14,497,000,000 $ 15,938,000,000 $ 14,497,000,000      
Derivatives Not Designated as Hedging Instruments | Maximum            
Derivative [Line Items]            
Maximum average period of maturities of contracts in years (less than)     1 year      
1.85% Notes Due 2020            
Derivative [Line Items]            
Face amount of debt           $ 1,250,000,000
Stated interest rate (as percent)           1.85%
Interest rate swap contracts            
Derivative [Line Items]            
Number of interest rate swaps held (in interest rate swaps) | interest_rate_swap 14   14     5
Total swap notional amount           $ 250,000,000
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Effect of Net Investment Hedges (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Foreign exchange contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income $ 10 $ 1 $ 15 $ 8
Foreign exchange contracts | Other (income) expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing (4) (8) (15) (23)
Euro-denominated notes        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income 162 (150) 182 (152)
Euro-denominated notes | Other (income) expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing $ 0 $ 0 $ 0 $ 0
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Summary of Interest Rate Swaps Held (Details)
Sep. 30, 2020
USD ($)
interest_rate_swap
Jun. 30, 2020
USD ($)
Feb. 29, 2020
USD ($)
interest_rate_swap
Dec. 31, 2019
USD ($)
Derivative [Line Items]        
Par Value of Debt   $ 4,500,000,000    
Total swap notional amount $ 27,151,000,000     $ 30,666,000,000
Interest rate swap contracts        
Derivative [Line Items]        
Number of Interest Rate Swaps Held (in interest rate swaps) | interest_rate_swap 14   5  
Total swap notional amount     $ 250,000,000  
3.875% notes due 2021 | Interest rate swap contracts        
Derivative [Line Items]        
Stated interest rate (as percent) 3.875%      
Par Value of Debt $ 1,150,000,000      
Number of Interest Rate Swaps Held (in interest rate swaps) | interest_rate_swap 5      
Total swap notional amount $ 1,150,000,000      
2.40% notes due 2022 | Interest rate swap contracts        
Derivative [Line Items]        
Stated interest rate (as percent) 2.40%      
Par Value of Debt $ 1,000,000,000      
Number of Interest Rate Swaps Held (in interest rate swaps) | interest_rate_swap 4      
Total swap notional amount $ 1,000,000,000      
2.35% notes due 2022 | Interest rate swap contracts        
Derivative [Line Items]        
Stated interest rate (as percent) 2.35%      
Par Value of Debt $ 1,250,000,000      
Number of Interest Rate Swaps Held (in interest rate swaps) | interest_rate_swap 5      
Total swap notional amount $ 1,250,000,000      
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Fair Value Hedges (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Loans payable and current portion of long-term debt    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Carrying Amount of Hedged Liabilities $ 1,155 $ 1,249
Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount 5 (1)
Long-Term Debt    
Derivative Instruments and Hedging Activities Disclosures [Line Items]    
Carrying Amount of Hedged Liabilities 2,309 3,409
Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount $ 62 $ 14
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset $ 239 $ 288
Fair Value of Derivative, Liability 298 97
U.S Dollar Notional Amount 27,151 30,666
Derivatives Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 158 222
Fair Value of Derivative, Liability 105 24
U.S Dollar Notional Amount 12,654 14,728
Derivatives Not Designated as Hedging Instruments    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 81 66
Fair Value of Derivative, Liability 193 73
U.S Dollar Notional Amount 14,497 15,938
Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 6 0
U.S Dollar Notional Amount 1,150 0
Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Other Assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 63 15
U.S Dollar Notional Amount 2,250 3,400
Interest rate swap contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability 0 1
U.S Dollar Notional Amount 0 1,250
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 30 152
U.S Dollar Notional Amount 4,120 6,117
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 59 55
U.S Dollar Notional Amount 1,881 2,160
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability 104 22
U.S Dollar Notional Amount 3,096 1,748
Foreign exchange contracts | Derivatives Designated as Hedging Instruments | Other Noncurrent Liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability 1 1
U.S Dollar Notional Amount 157 53
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Other current assets    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Asset 81 66
U.S Dollar Notional Amount 5,455 7,245
Foreign exchange contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability 171 73
U.S Dollar Notional Amount 8,042 8,693
Forward Contracts | Derivatives Not Designated as Hedging Instruments | Accrued and other current liabilities    
Derivatives, Fair Value [Line Items]    
Fair Value of Derivative, Liability 22 0
U.S Dollar Notional Amount $ 1,000 $ 0
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]    
Gross amounts recognized in the consolidated balance sheet, asset $ 239,000,000 $ 288,000,000
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset (140,000,000) (84,000,000)
Cash collateral received, asset 0 (34,000,000)
Net amounts, asset 99,000,000 170,000,000
Gross amounts recognized in the consolidated balance sheet, liability 298,000,000 97,000,000
Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability (140,000,000) (84,000,000)
Cash collateral received, liability 0 0
Net amounts, liability $ 158,000,000 $ 13,000,000
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Derivative Instruments, Gain (Loss) [Line Items]        
Sales $ 12,551 $ 12,397 $ 35,479 $ 34,972
Other (income) expense, net (312) 35 (630) 362
Other comprehensive income (loss) 10 (28) (190) 155
Interest rate swap contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of (loss) gain recognized in OCI on derivatives (1) (1) (3) (6)
Interest rate swap contracts | Other (income) expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Hedged items (14) 13 54 101
Derivatives designated as hedging instruments 0 (6) (76) (74)
Amount of gain recognized in Other (income) expense, net on derivatives (1) (1) (3) (3)
Foreign exchange contracts        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of (loss) gain recognized in OCI on derivatives (195) 186 (126) 183
Increase (decrease) in Sales as a result of AOCI reclassifications 23 (70) (65) (189)
Foreign exchange contracts | Reclassification out of Accumulated Other Comprehensive Income | Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest        
Derivative Instruments, Gain (Loss) [Line Items]        
Sales $ (23) $ 70 $ 65 $ 189
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Foreign currency | Other (income) expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Derivative Pretax (Gain) Loss Recognized in Income $ (7) $ (8) $ (138) $ 112
Forecasted transactions | Sales        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Derivative Pretax (Gain) Loss Recognized in Income 7 (11) 4 (7)
Treasury lock | Other (income) expense, net        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Derivative Pretax (Gain) Loss Recognized in Income 0 0 9 0
Forward Contracts | Research and development        
Derivative Instruments, Gain (Loss) [Line Items]        
Amount of Derivative Pretax (Gain) Loss Recognized in Income $ 22 $ 0 $ 22 $ 0
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Information on Available-for-sale Investments (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Debt Securities, Available-for-sale [Line Items]          
Debt securities, amortized cost $ 76   $ 76   $ 1,768
Debt securities, unrealized gains 0   0   17
Debt securities, unrealized losses 0   0   0
Debt securities, fair value 76   76   1,785
Publicly traded equity securities, fair value 1,477   1,477   838
Total debt and publicly traded equity securities, fair value 1,553   1,553   2,623
Unrealized net losses (gains) (43) $ 25 (512) $ (41)  
U.S. government and agency securities          
Debt Securities, Available-for-sale [Line Items]          
Debt securities, amortized cost 74   74   266
Debt securities, unrealized gains 0   0   3
Debt securities, unrealized losses 0   0   0
Debt securities, fair value 74   74   269
Foreign government bonds          
Debt Securities, Available-for-sale [Line Items]          
Debt securities, amortized cost 2   2   0
Debt securities, unrealized gains 0   0   0
Debt securities, unrealized losses 0   0   0
Debt securities, fair value 2   2   0
Commercial paper          
Debt Securities, Available-for-sale [Line Items]          
Debt securities, amortized cost 0   0   668
Debt securities, unrealized gains 0   0   0
Debt securities, unrealized losses 0   0   0
Debt securities, fair value 0   0   668
Corporate notes and bonds          
Debt Securities, Available-for-sale [Line Items]          
Debt securities, amortized cost 0   0   608
Debt securities, unrealized gains 0   0   13
Debt securities, unrealized losses 0   0   0
Debt securities, fair value 0   0   621
Asset-backed securities          
Debt Securities, Available-for-sale [Line Items]          
Debt securities, amortized cost 0   0   226
Debt securities, unrealized gains 0   0   1
Debt securities, unrealized losses 0   0   0
Debt securities, fair value $ 0   $ 0   $ 227
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2020
Dec. 31, 2019
Sep. 30, 2019
Dec. 31, 2018
Assets        
Investments $ 76 $ 1,785    
Publicly traded equity securities 1,477 838    
Derivative assets 239 288    
Liabilities        
Contingent consideration 829 767 $ 755 $ 788
Derivative liabilities 298 97    
Foreign government bonds        
Assets        
Investments 2 0    
Corporate notes and bonds        
Assets        
Investments 0 621    
Commercial paper        
Assets        
Investments 0 668    
Asset-backed securities        
Assets        
Investments $ 0 227    
Liabilities        
Primary weighted average life of collateral 5 years      
U.S. government and agency securities        
Assets        
Investments $ 74 269    
Fair Value, Measurements, Recurring        
Assets        
Investments 1,372 2,243    
Other assets 181 380    
Derivative assets 239 288    
Total assets 1,792 2,911    
Liabilities        
Contingent consideration 829 767    
Derivative liabilities 298 97    
Total liabilities 1,127 864    
Fair Value, Measurements, Recurring | Foreign exchange contracts        
Assets        
Derivative assets 116 169    
Liabilities        
Derivative liabilities 275 95    
Fair Value, Measurements, Recurring | Interest rate swap contracts        
Assets        
Derivative assets 69 15    
Fair Value, Measurements, Recurring | Currency options        
Assets        
Derivative assets 54 104    
Liabilities        
Derivative liabilities 1 1    
Fair Value, Measurements, Recurring | Interest rate swap contracts        
Liabilities        
Derivative liabilities 0 1    
Fair Value, Measurements, Recurring | Forward Contracts        
Liabilities        
Derivative liabilities 22 0    
Fair Value, Measurements, Recurring | Level 1        
Assets        
Investments 1,370 518    
Other assets 181 380    
Derivative assets 0 0    
Total assets 1,551 898    
Liabilities        
Contingent consideration 0 0    
Derivative liabilities 0 0    
Total liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Foreign exchange contracts        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts        
Assets        
Derivative assets 0 0    
Fair Value, Measurements, Recurring | Level 1 | Currency options        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Interest rate swap contracts        
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 1 | Forward Contracts        
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 2        
Assets        
Investments 2 1,725    
Other assets 0 0    
Derivative assets 239 288    
Total assets 241 2,013    
Liabilities        
Contingent consideration 0 0    
Derivative liabilities 298 97    
Total liabilities 298 97    
Fair Value, Measurements, Recurring | Level 2 | Foreign exchange contracts        
Assets        
Derivative assets 116 169    
Liabilities        
Derivative liabilities 275 95    
Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts        
Assets        
Derivative assets 69 15    
Fair Value, Measurements, Recurring | Level 2 | Currency options        
Assets        
Derivative assets 54 104    
Liabilities        
Derivative liabilities 1 1    
Fair Value, Measurements, Recurring | Level 2 | Interest rate swap contracts        
Liabilities        
Derivative liabilities 0 1    
Fair Value, Measurements, Recurring | Level 2 | Forward Contracts        
Liabilities        
Derivative liabilities 22 0    
Fair Value, Measurements, Recurring | Level 3        
Assets        
Investments 0 0    
Other assets 0 0    
Derivative assets 0 0    
Total assets 0 0    
Liabilities        
Contingent consideration 829 767    
Derivative liabilities 0 0    
Total liabilities 829 767    
Fair Value, Measurements, Recurring | Level 3 | Foreign exchange contracts        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts        
Assets        
Derivative assets 0 0    
Fair Value, Measurements, Recurring | Level 3 | Currency options        
Assets        
Derivative assets 0 0    
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 3 | Interest rate swap contracts        
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Level 3 | Forward Contracts        
Liabilities        
Derivative liabilities 0 0    
Fair Value, Measurements, Recurring | Foreign government bonds        
Assets        
Investments 2 0    
Fair Value, Measurements, Recurring | Foreign government bonds | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Foreign government bonds | Level 2        
Assets        
Investments 2 0    
Fair Value, Measurements, Recurring | Foreign government bonds | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Corporate notes and bonds        
Assets        
Investments 0 621    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 2        
Assets        
Investments 0 621    
Fair Value, Measurements, Recurring | Corporate notes and bonds | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Commercial paper        
Assets        
Investments 0 668    
Fair Value, Measurements, Recurring | Commercial paper | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Commercial paper | Level 2        
Assets        
Investments 0 668    
Fair Value, Measurements, Recurring | Commercial paper | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Asset-backed securities        
Assets        
Investments 0 227    
Fair Value, Measurements, Recurring | Asset-backed securities | Level 1        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | Asset-backed securities | Level 2        
Assets        
Investments 0 227    
Fair Value, Measurements, Recurring | Asset-backed securities | Level 3        
Assets        
Investments 0 0    
Fair Value, Measurements, Recurring | U.S. government and agency securities        
Assets        
Investments 0 209    
Other assets 74 60    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 1        
Assets        
Investments 0 0    
Other assets 74 60    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 2        
Assets        
Investments 0 209    
Other assets 0 0    
Fair Value, Measurements, Recurring | U.S. government and agency securities | Level 3        
Assets        
Investments 0 0    
Other assets 0 0    
Fair Value, Measurements, Recurring | Publicly traded equity securities        
Assets        
Publicly traded equity securities 1,370 518    
Other assets 107 320    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 1        
Assets        
Publicly traded equity securities 1,370 518    
Other assets 107 320    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 2        
Assets        
Publicly traded equity securities 0 0    
Other assets 0 0    
Fair Value, Measurements, Recurring | Publicly traded equity securities | Level 3        
Assets        
Publicly traded equity securities 0 0    
Other assets $ 0 $ 0    
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.20.2
Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Fair value, beginning balance $ 767 $ 788  
Additions 97 0  
Changes in estimated fair value 71 52  
Payments (106) (85)  
Fair value, ending balance 829 755  
Current liability     $ 140
Contingent consideration 829 $ 755 829
Sanofi Pasteur      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Fair value, beginning balance 625    
Fair value, ending balance 637    
Contingent consideration $ 625   $ 637
Contingent consideration, measurement input, discount rate (as percent)     0.115
Measurement Input, Discount Rate | Sanofi Pasteur      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Contingent consideration, measurement input, discount rate (as percent)     0.08
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories - Inventories (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Inventory Disclosure [Abstract]    
Finished goods $ 2,038 $ 1,772
Raw materials and work in process 6,073 5,650
Supplies 197 207
Total (approximates current cost) 8,308 7,629
Decrease to LIFO cost (99) (171)
Total current and noncurrent inventories 8,209 7,458
Recognized as:    
Inventories 6,128 5,978
Other assets $ 2,081 $ 1,480
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.20.2
Inventories - Narrative (Details) - USD ($)
$ in Millions
Sep. 30, 2020
Dec. 31, 2019
Inventory [Line Items]    
Inventories classified in Other assets $ 2,081 $ 1,480
Inventories Not Expected to be Sold Within One Year    
Inventory [Line Items]    
Inventories classified in Other assets 1,800 1,300
Inventories Produced in Preparation for Product Launches    
Inventory [Line Items]    
Inventories classified in Other assets $ 288 $ 168
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.20.2
Other Intangibles (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2019
Finite-Lived Intangible Assets [Line Items]    
Intangible asset impairment charges $ 612 $ 693
Sivextro [Member]    
Finite-Lived Intangible Assets [Line Items]    
Intangible asset impairment charges $ 612  
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.20.2
Long-Term Debt - Narrative (Details)
Jun. 30, 2020
USD ($)
Debt Instrument [Line Items]  
Face amount of debt $ 4,500,000,000
0.75% notes due 2026  
Debt Instrument [Line Items]  
Face amount of debt $ 1,000,000,000.0
Stated interest rate (as percent) 0.75%
1.45% notes due 2030  
Debt Instrument [Line Items]  
Face amount of debt $ 1,250,000,000
Stated interest rate (as percent) 1.45%
2.35% notes due 2040  
Debt Instrument [Line Items]  
Face amount of debt $ 1,000,000,000.0
Stated interest rate (as percent) 2.35%
2.45% notes due 2050  
Debt Instrument [Line Items]  
Face amount of debt $ 1,250,000,000
Stated interest rate (as percent) 2.45%
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.20.2
Contingencies - Narrative (Details)
$ in Millions
 1 Months Ended 9 Months Ended
Mar. 31, 2014
Case
Sep. 30, 2020
USD ($)
Case
Claim
Dec. 31, 2019
USD ($)
Legal Defense Costs      
Loss Contingencies [Line Items]      
Legal defense costs reserve | $   $ 255 $ 240
Zetia antitrust litigation [Member]      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters) | Claim   35  
Patents [Member]      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters)   3  
Loss Contingency, Claims Settled, Number   5  
Fosamax      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters)   3,590  
Fosamax | Femur Fracture Litigation | Federal      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters)   970  
Loss contingency, claims dismissed, number (in legal matters) 650    
Loss contingency, claims on appeal, number (in legal matters) 515    
Fosamax | Femur Fracture Litigation | New Jersey state court      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters)   2,340  
Fosamax | Femur Fracture Litigation | California state court      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters)   275  
Fosamax | Femur Fracture Litigation | Other state courts      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters)   4  
Januvia      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters) | Claim   1,465  
Januvia | Other state courts      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters) | Claim   6  
Januvia | Cases Company Agreed To Toll Statute Of Limitations      
Loss Contingencies [Line Items]      
Loss contingency, pending claims, number (in legal matters) | Claim   50  
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.20.2
Equity - Rollforward Reconciliations (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Shares, beginning balance (in shares)     3,577,103,522  
Equity, beginning balance $ 27,744 $ 27,737 $ 26,001 $ 26,882
Net income attributable to Merck & Co., Inc. 2,941 1,901 9,161 7,487
Other comprehensive income (loss), net of taxes 10 (28) (190) 155
Cash dividends declared on common stock (1,558) (1,392) (4,656) (4,262)
Treasury stock shares purchased   (1,405) (1,281) (3,730)
Share-based compensation plans and other 151 127 245 487
Net income (loss) attributable to noncontrolling interests 4 6 12 (73)
Distributions attributable to noncontrolling interests $ (22) (21) $ (22) (21)
Shares, ending balance (in shares) 3,577,103,522   3,577,103,522  
Equity, ending balance $ 29,270 $ 26,925 $ 29,270 $ 26,925
Cash dividends declared on common stock (in dollars per share) $ 0.61 $ 0.55 $ 1.83 $ 1.65
   Common Stock        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Shares, beginning balance (in shares) 3,577,000,000 3,577,000,000 3,577,000,000 3,577,000,000
Equity, beginning balance $ 1,788 $ 1,788 $ 1,788 $ 1,788
Shares, ending balance (in shares) 3,577,000,000 3,577,000,000 3,577,000,000 3,577,000,000
Equity, ending balance $ 1,788 $ 1,788 $ 1,788 $ 1,788
Other Paid-In Capital        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance 39,373 39,484 39,660 38,808
Treasury stock shares purchased       1,000
Share-based compensation plans and other 116 77 (171) (247)
Equity, ending balance 39,489 39,561 39,489 39,561
Retained Earnings        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance 49,724 45,295 46,602 42,579
Net income attributable to Merck & Co., Inc. 2,941 1,901 9,161 7,487
Cash dividends declared on common stock (1,558) (1,392) (4,656) (4,262)
Equity, ending balance 51,107 45,804 51,107 45,804
Accumulated Other Comprehensive Loss        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance (6,393) (5,362) (6,193) (5,545)
Other comprehensive income (loss), net of taxes 10 (28) (190) 155
Equity, ending balance $ (6,383) $ (5,390) $ (6,383) $ (5,390)
  Treasury Stock        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Shares, beginning balance (in shares) 1,048,000,000 1,010,000,000 1,038,000,000 985,000,000
Equity, beginning balance $ (56,850) $ (53,570) $ (55,950) $ (50,929)
Treasury stock shares purchased (in shares)   17,000,000 16,000,000 54,000,000
Treasury stock shares purchased   $ (1,405) $ (1,281) $ (4,730)
Share-based compensation plans and other (in shares) (1,000,000) (1,000,000) (7,000,000) (13,000,000)
Share-based compensation plans and other $ 35 $ 50 $ 416 $ 734
Shares, ending balance (in shares) 1,047,000,000 1,026,000,000 1,047,000,000 1,026,000,000
Equity, ending balance $ (56,815) $ (54,925) $ (56,815) $ (54,925)
Non- controlling Interests        
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Equity, beginning balance 102 102 94 181
Net income (loss) attributable to noncontrolling interests 4 6 12 (73)
Distributions attributable to noncontrolling interests (22) (21) (22) (21)
Equity, ending balance $ 84 $ 87 $ 84 $ 87
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation Plans - Expense Allocations (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]        
Pretax share-based compensation expense $ 126 $ 101 $ 354 $ 306
Income tax benefit (17) (14) (48) (42)
Total share-based compensation expense, net of taxes $ 109 $ 87 $ 306 $ 264
XML 74 R63.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation Plans - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 4,000,000 3,000,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 77.67 $ 80.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value $ 9.93 $ 10.63
Total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards $ 800  
Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards 2 years 1 month 6 days  
Restricted Stock Units (RSUs)    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares granted (in shares) 7,000,000 5,000,000
Weighted-average fair value per share granted (in dollars per share) $ 77.83 $ 80.03
Performance Share Units (PSUs)    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Shares granted (in shares) 773,000 609,000
Weighted-average fair value per share granted (in dollars per share) $ 75.22 $ 90.50
XML 75 R64.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation Plans - Assumptions Used for Options Granted (Details)
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Share-based Payment Arrangement [Abstract]    
Expected dividend yield 3.10% 3.20%
Risk-free interest rate 0.40% 2.40%
Expected volatility 22.10% 18.70%
Expected life (years) 5 years 9 months 18 days 5 years 10 months 24 days
XML 76 R65.htm IDEA: XBRL DOCUMENT v3.20.2
Pension and Other Postretirement Benefit Plans (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Other Postretirement Benefit Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost $ 13 $ 12 $ 39 $ 36
Interest cost 14 17 43 52
Expected return on plan assets (19) (18) (56) (54)
Amortization of unrecognized prior service credit (18) (20) (54) (59)
Net loss amortization (5) (3) (13) (7)
Termination benefits 0 1 0 1
Curtailments 0 (3) (1) (4)
Net periodic benefit cost (15) (14) (42) (35)
U.S. | Pension Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost 96 76 270 221
Interest cost 107 115 323 343
Expected return on plan assets (193) (202) (581) (613)
Amortization of unrecognized prior service credit (12) (12) (37) (37)
Net loss amortization 75 43 228 113
Termination benefits 1 3 5 7
Curtailments 1 5 4 6
Settlements 2 0 11 0
Net periodic benefit cost 77 28 223 40
International | Pension Plans        
Defined Benefit Plan Disclosure [Line Items]        
Service cost 77 58 225 178
Interest cost 35 44 103 133
Expected return on plan assets (104) (106) (310) (320)
Amortization of unrecognized prior service credit (3) (3) (9) (9)
Net loss amortization 32 16 94 47
Termination benefits 1 0 2 1
Curtailments 0 0 (1) 0
Settlements 0 0 2 0
Net periodic benefit cost $ 38 $ 9 $ 106 $ 30
XML 77 R66.htm IDEA: XBRL DOCUMENT v3.20.2
Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans (Narrative) (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2020
USD ($)
International  
Defined Benefit Plan Disclosure [Line Items]  
Expected future employer contributions, current fiscal year $ 375
Contributions by employer 123
U.S.  
Defined Benefit Plan Disclosure [Line Items]  
Expected future employer contributions, current fiscal year 200
Contributions by employer $ 184
XML 78 R67.htm IDEA: XBRL DOCUMENT v3.20.2
Other (Income) Expense, Net (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Component of Other Income / Expense of Nonoperating [Line Items]        
Interest income $ (9) $ (61) $ (48) $ (225)
Interest expense 203 231 624 674
Exchange losses 10 38 89 166
Income from investments in equity securities, net (1) (360) (16) (964) (50)
Net periodic defined benefit plan (credit) cost other than service cost (88) (128) (259) (409)
Other, net (68) (29) (72) 206
Other (income) expense, net $ (312) $ 35 $ (630) $ 362
XML 79 R68.htm IDEA: XBRL DOCUMENT v3.20.2
Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Component of Other Income / Expense of Nonoperating [Line Items]    
Interest paid $ 605 $ 629
Healthcare Services Segment    
Component of Other Income / Expense of Nonoperating [Line Items]    
Goodwill, Impairment Loss   $ 162
XML 80 R69.htm IDEA: XBRL DOCUMENT v3.20.2
Taxes on Income (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Tax Examination [Line Items]        
Effective income tax rate (as percent) 14.10% 18.70% 14.90% 14.50%
Internal Revenue Service (IRS) | Domestic Tax Authority        
Income Tax Examination [Line Items]        
Tax benefit recognized related to settlement       $ 360
Income taxes paid       $ 107
XML 81 R70.htm IDEA: XBRL DOCUMENT v3.20.2
Earnings Per Share (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Earnings Per Share [Abstract]        
Net income attributable to Merck & Co., Inc. $ 2,941 $ 1,901 $ 9,161 $ 7,487
Average common shares outstanding 2,529 2,558 2,530 2,572
Common shares issuable (1) 9 14 11 15
Average common shares outstanding assuming dilution 2,538 2,572 2,541 2,587
Basic earnings per common share attributable to Merck & Co., Inc. common shareholders $ 1.16 $ 0.74 $ 3.62 $ 2.91
Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders $ 1.16 $ 0.74 $ 3.61 $ 2.89
Common shares issuable under share-based compensation plans excluded from diluted earnings per common share because the effect would have been antidilutive (in shares) 5 3 5 2
XML 82 R71.htm IDEA: XBRL DOCUMENT v3.20.2
Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance $ 27,744 $ 27,737 $ 26,001 $ 26,882
Other comprehensive income (loss) before reclassification adjustments, pretax (143) 106 (362) 364
Tax 77 (72) 79 (65)
Other comprehensive income (loss) before reclassification adjustments, net of taxes (66) 34 (283) 299
Reclassification adjustments, pretax 94 (75) 121 (176)
Tax (18) 13 (28) 32
Reclassification adjustments, net of taxes 76 (62) 93 (144)
Other comprehensive income (loss), net of taxes 10 (28) (190) 155
Equity, ending balance 29,270 26,925 29,270 26,925
Derivatives        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance 15 66 31 166
Other comprehensive income (loss) before reclassification adjustments, pretax (195) 186 (126) 183
Tax 41 (39) 27 (38)
Other comprehensive income (loss) before reclassification adjustments, net of taxes (154) 147 (99) 145
Reclassification adjustments, pretax 22 (71) (68) (195)
Tax (5) 15 14 41
Reclassification adjustments, net of taxes 17 (56) (54) (154)
Other comprehensive income (loss), net of taxes (137) 91 (153) (9)
Equity, ending balance (122) 157 (122) 157
Investments        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance 0 48 18 (78)
Other comprehensive income (loss) before reclassification adjustments, pretax 0 8 3 139
Tax 0 0 0 0
Other comprehensive income (loss) before reclassification adjustments, net of taxes 0 8 3 139
Reclassification adjustments, pretax 0 (25) (21) (30)
Tax 0 0 0 0
Reclassification adjustments, net of taxes 0 (25) (21) (30)
Other comprehensive income (loss), net of taxes 0 (17) (18) 109
Equity, ending balance 0 31 0 31
Employee Benefit Plans        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance (4,162) (3,530) (4,261) (3,556)
Other comprehensive income (loss) before reclassification adjustments, pretax 2 (4) (19) (5)
Tax 1 0 12 6
Other comprehensive income (loss) before reclassification adjustments, net of taxes 3 (4) (7) 1
Reclassification adjustments, pretax 72 21 210 49
Tax (13) (2) (42) (9)
Reclassification adjustments, net of taxes 59 19 168 40
Other comprehensive income (loss), net of taxes 62 15 161 41
Equity, ending balance (4,100) (3,515) (4,100) (3,515)
Cumulative Translation Adjustment        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance (2,246) (1,946) (1,981) (2,077)
Other comprehensive income (loss) before reclassification adjustments, pretax 50 (84) (220) 47
Tax 35 (33) 40 (33)
Other comprehensive income (loss) before reclassification adjustments, net of taxes 85 (117) (180) 14
Reclassification adjustments, pretax 0 0 0 0
Tax 0 0 0 0
Reclassification adjustments, net of taxes 0 0 0 0
Other comprehensive income (loss), net of taxes 85 (117) (180) 14
Equity, ending balance (2,161) (2,063) (2,161) (2,063)
Accumulated Other Comprehensive Income (Loss)        
Accumulated Other Comprehensive Income (Loss) [Roll Forward]        
Equity, beginning balance (6,393) (5,362) (6,193) (5,545)
Equity, ending balance $ (6,383) $ (5,390) $ (6,383) $ (5,390)
XML 83 R72.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Reporting - Narrative (Details)
$ in Billions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2020
USD ($)
segment
Sep. 30, 2019
USD ($)
Segment Reporting [Abstract]        
Number of operating segments | segment     3  
Sales discounts | $ $ 3.4 $ 3.0 $ 9.6 $ 8.6
XML 84 R73.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Reporting - Sales of Company's Products (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Segment Reporting Information [Line Items]        
Sales $ 12,551 $ 12,397 $ 35,479 $ 34,972
Operating Segments        
Segment Reporting Information [Line Items]        
Sales 12,540 12,263 35,212 34,622
Other        
Segment Reporting Information [Line Items]        
Sales 11 134 267 350
United States        
Segment Reporting Information [Line Items]        
Sales 5,625 5,573 15,396 15,320
United States | Operating Segments        
Segment Reporting Information [Line Items]        
Sales 5,616 5,563 15,349 15,301
United States | Other        
Segment Reporting Information [Line Items]        
Sales 9 10 47 19
International        
Segment Reporting Information [Line Items]        
Sales 6,926 6,824 20,084 19,652
International | Operating Segments        
Segment Reporting Information [Line Items]        
Sales 6,924 6,699 19,863 19,322
International | Other        
Segment Reporting Information [Line Items]        
Sales 2 125 221 330
Total Pharmaceutical segment sales | Operating Segments        
Segment Reporting Information [Line Items]        
Sales 11,320 11,095 31,654 31,218
Total Pharmaceutical segment sales | Operating Segments | Keytruda        
Segment Reporting Information [Line Items]        
Sales 3,715 3,070 10,387 7,973
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lynparza (1)        
Segment Reporting Information [Line Items]        
Sales 196 123 519 313
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Lenvima (1)        
Segment Reporting Information [Line Items]        
Sales 142 109 421 280
Total Pharmaceutical segment sales | Operating Segments | Emend        
Segment Reporting Information [Line Items]        
Sales 39 98 115 336
Total Pharmaceutical segment sales | Operating Segments | Gardasil/Gardasil 9        
Segment Reporting Information [Line Items]        
Sales 1,187 1,320 2,941 3,044
Total Pharmaceutical segment sales | Operating Segments | ProQuad/M-M-R II/Varivax        
Segment Reporting Information [Line Items]        
Sales 576 623 1,390 1,794
Total Pharmaceutical segment sales | Operating Segments | Pneumovax 23        
Segment Reporting Information [Line Items]        
Sales 375 237 748 592
Total Pharmaceutical segment sales | Operating Segments | RotaTeq        
Segment Reporting Information [Line Items]        
Sales 210 180 601 564
Total Pharmaceutical segment sales | Operating Segments | Vaqta        
Segment Reporting Information [Line Items]        
Sales 51 62 139 167
Total Pharmaceutical segment sales | Operating Segments | Bridion        
Segment Reporting Information [Line Items]        
Sales 320 284 843 817
Total Pharmaceutical segment sales | Operating Segments | Noxafil        
Segment Reporting Information [Line Items]        
Sales 79 177 247 560
Total Pharmaceutical segment sales | Operating Segments | Prevymis        
Segment Reporting Information [Line Items]        
Sales 77 45 200 115
Total Pharmaceutical segment sales | Operating Segments | Primaxin        
Segment Reporting Information [Line Items]        
Sales 74 77 189 207
Total Pharmaceutical segment sales | Operating Segments | Invanz        
Segment Reporting Information [Line Items]        
Sales 51 57 159 206
Total Pharmaceutical segment sales | Operating Segments | Cancidas        
Segment Reporting Information [Line Items]        
Sales 50 62 148 191
Total Pharmaceutical segment sales | Operating Segments | Cubicin        
Segment Reporting Information [Line Items]        
Sales 39 52 116 207
Total Pharmaceutical segment sales | Operating Segments | Zerbaxa        
Segment Reporting Information [Line Items]        
Sales 43 35 112 88
Total Pharmaceutical segment sales | Operating Segments | Simponi        
Segment Reporting Information [Line Items]        
Sales 209 203 615 625
Total Pharmaceutical segment sales | Operating Segments | Remicade        
Segment Reporting Information [Line Items]        
Sales 82 101 242 322
Total Pharmaceutical segment sales | Operating Segments | Belsomra        
Segment Reporting Information [Line Items]        
Sales 81 80 244 223
Total Pharmaceutical segment sales | Operating Segments | Isentress/Isentress HD        
Segment Reporting Information [Line Items]        
Sales 205 250 646 752
Total Pharmaceutical segment sales | Operating Segments | Zepatier        
Segment Reporting Information [Line Items]        
Sales 28 83 122 304
Total Pharmaceutical segment sales | Operating Segments | Zetia        
Segment Reporting Information [Line Items]        
Sales 103 147 384 443
Total Pharmaceutical segment sales | Operating Segments | Vytorin        
Segment Reporting Information [Line Items]        
Sales 47 57 139 231
Total Pharmaceutical segment sales | Operating Segments | Atozet        
Segment Reporting Information [Line Items]        
Sales 111 97 348 283
Total Pharmaceutical segment sales | Operating Segments | Alliance revenue - Adempas (2)        
Segment Reporting Information [Line Items]        
Sales 83 50 216 144
Total Pharmaceutical segment sales | Operating Segments | Adempas        
Segment Reporting Information [Line Items]        
Sales 55 57 167 158
Total Pharmaceutical segment sales | Operating Segments | Januvia        
Segment Reporting Information [Line Items]        
Sales 821 807 2,449 2,539
Total Pharmaceutical segment sales | Operating Segments | Janumet        
Segment Reporting Information [Line Items]        
Sales 506 503 1,499 1,567
Total Pharmaceutical segment sales | Operating Segments | Implanon/Nexplanon        
Segment Reporting Information [Line Items]        
Sales 189 199 515 581
Total Pharmaceutical segment sales | Operating Segments | NuvaRing        
Segment Reporting Information [Line Items]        
Sales 58 241 184 700
Total Pharmaceutical segment sales | Operating Segments | Singulair        
Segment Reporting Information [Line Items]        
Sales 82 152 338 503
Total Pharmaceutical segment sales | Operating Segments | Cozaar/Hyzaar        
Segment Reporting Information [Line Items]        
Sales 91 116 292 329
Total Pharmaceutical segment sales | Operating Segments | Arcoxia        
Segment Reporting Information [Line Items]        
Sales 68 72 204 221
Total Pharmaceutical segment sales | Operating Segments | Nasonex        
Segment Reporting Information [Line Items]        
Sales 41 58 161 226
Total Pharmaceutical segment sales | Operating Segments | Follistim AQ        
Segment Reporting Information [Line Items]        
Sales 50 62 136 182
Total Pharmaceutical segment sales | Operating Segments | Other pharmaceutical (3)        
Segment Reporting Information [Line Items]        
Sales 1,186 1,149 3,478 3,431
Total Pharmaceutical segment sales | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Sales 5,218 5,180 14,202 14,202
Total Pharmaceutical segment sales | United States | Operating Segments | Keytruda        
Segment Reporting Information [Line Items]        
Sales 2,157 1,743 6,106 4,525
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lynparza (1)        
Segment Reporting Information [Line Items]        
Sales 107 71 297 186
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Lenvima (1)        
Segment Reporting Information [Line Items]        
Sales 82 65 270 169
Total Pharmaceutical segment sales | United States | Operating Segments | Emend        
Segment Reporting Information [Line Items]        
Sales 8 42 18 173
Total Pharmaceutical segment sales | United States | Operating Segments | Gardasil/Gardasil 9        
Segment Reporting Information [Line Items]        
Sales 579 761 1,209 1,579
Total Pharmaceutical segment sales | United States | Operating Segments | ProQuad/M-M-R II/Varivax        
Segment Reporting Information [Line Items]        
Sales 437 482 1,033 1,325
Total Pharmaceutical segment sales | United States | Operating Segments | Pneumovax 23        
Segment Reporting Information [Line Items]        
Sales 276 179 478 428
Total Pharmaceutical segment sales | United States | Operating Segments | RotaTeq        
Segment Reporting Information [Line Items]        
Sales 114 102 355 360
Total Pharmaceutical segment sales | United States | Operating Segments | Vaqta        
Segment Reporting Information [Line Items]        
Sales 32 36 79 103
Total Pharmaceutical segment sales | United States | Operating Segments | Bridion        
Segment Reporting Information [Line Items]        
Sales 162 133 412 381
Total Pharmaceutical segment sales | United States | Operating Segments | Noxafil        
Segment Reporting Information [Line Items]        
Sales 13 77 27 268
Total Pharmaceutical segment sales | United States | Operating Segments | Prevymis        
Segment Reporting Information [Line Items]        
Sales 32 22 87 60
Total Pharmaceutical segment sales | United States | Operating Segments | Primaxin        
Segment Reporting Information [Line Items]        
Sales 1 2 2 2
Total Pharmaceutical segment sales | United States | Operating Segments | Invanz        
Segment Reporting Information [Line Items]        
Sales 1 (1) 7 30
Total Pharmaceutical segment sales | United States | Operating Segments | Cancidas        
Segment Reporting Information [Line Items]        
Sales 1 0 2 5
Total Pharmaceutical segment sales | United States | Operating Segments | Cubicin        
Segment Reporting Information [Line Items]        
Sales 11 14 36 78
Total Pharmaceutical segment sales | United States | Operating Segments | Zerbaxa        
Segment Reporting Information [Line Items]        
Sales 20 20 57 45
Total Pharmaceutical segment sales | United States | Operating Segments | Simponi        
Segment Reporting Information [Line Items]        
Sales 0 0 0 0
Total Pharmaceutical segment sales | United States | Operating Segments | Remicade        
Segment Reporting Information [Line Items]        
Sales 0 0 0 0
Total Pharmaceutical segment sales | United States | Operating Segments | Belsomra        
Segment Reporting Information [Line Items]        
Sales 18 23 67 68
Total Pharmaceutical segment sales | United States | Operating Segments | Isentress/Isentress HD        
Segment Reporting Information [Line Items]        
Sales 92 102 243 304
Total Pharmaceutical segment sales | United States | Operating Segments | Zepatier        
Segment Reporting Information [Line Items]        
Sales 6 24 38 96
Total Pharmaceutical segment sales | United States | Operating Segments | Zetia        
Segment Reporting Information [Line Items]        
Sales (1) 5 (4) 11
Total Pharmaceutical segment sales | United States | Operating Segments | Vytorin        
Segment Reporting Information [Line Items]        
Sales 3 5 9 11
Total Pharmaceutical segment sales | United States | Operating Segments | Atozet        
Segment Reporting Information [Line Items]        
Sales 0 0 0 0
Total Pharmaceutical segment sales | United States | Operating Segments | Alliance revenue - Adempas (2)        
Segment Reporting Information [Line Items]        
Sales 78 48 200 137
Total Pharmaceutical segment sales | United States | Operating Segments | Adempas        
Segment Reporting Information [Line Items]        
Sales 0 0 0 0
Total Pharmaceutical segment sales | United States | Operating Segments | Januvia        
Segment Reporting Information [Line Items]        
Sales 342 367 1,110 1,223
Total Pharmaceutical segment sales | United States | Operating Segments | Janumet        
Segment Reporting Information [Line Items]        
Sales 105 129 361 462
Total Pharmaceutical segment sales | United States | Operating Segments | Implanon/Nexplanon        
Segment Reporting Information [Line Items]        
Sales 137 136 374 421
Total Pharmaceutical segment sales | United States | Operating Segments | NuvaRing        
Segment Reporting Information [Line Items]        
Sales 24 202 85 593
Total Pharmaceutical segment sales | United States | Operating Segments | Singulair        
Segment Reporting Information [Line Items]        
Sales 4 11 14 24
Total Pharmaceutical segment sales | United States | Operating Segments | Cozaar/Hyzaar        
Segment Reporting Information [Line Items]        
Sales 5 6 17 16
Total Pharmaceutical segment sales | United States | Operating Segments | Arcoxia        
Segment Reporting Information [Line Items]        
Sales 0 0 0 0
Total Pharmaceutical segment sales | United States | Operating Segments | Nasonex        
Segment Reporting Information [Line Items]        
Sales 0 4 9 2
Total Pharmaceutical segment sales | United States | Operating Segments | Follistim AQ        
Segment Reporting Information [Line Items]        
Sales 20 27 60 80
Total Pharmaceutical segment sales | United States | Operating Segments | Other pharmaceutical (3)        
Segment Reporting Information [Line Items]        
Sales 352 343 1,144 1,037
Total Pharmaceutical segment sales | International | Operating Segments        
Segment Reporting Information [Line Items]        
Sales 6,102 5,914 17,452 17,016
Total Pharmaceutical segment sales | International | Operating Segments | Keytruda        
Segment Reporting Information [Line Items]        
Sales 1,559 1,327 4,281 3,448
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lynparza (1)        
Segment Reporting Information [Line Items]        
Sales 89 53 223 126
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Lenvima (1)        
Segment Reporting Information [Line Items]        
Sales 60 44 152 112
Total Pharmaceutical segment sales | International | Operating Segments | Emend        
Segment Reporting Information [Line Items]        
Sales 31 56 96 163
Total Pharmaceutical segment sales | International | Operating Segments | Gardasil/Gardasil 9        
Segment Reporting Information [Line Items]        
Sales 608 558 1,732 1,464
Total Pharmaceutical segment sales | International | Operating Segments | ProQuad/M-M-R II/Varivax        
Segment Reporting Information [Line Items]        
Sales 139 141 356 469
Total Pharmaceutical segment sales | International | Operating Segments | Pneumovax 23        
Segment Reporting Information [Line Items]        
Sales 99 58 270 164
Total Pharmaceutical segment sales | International | Operating Segments | RotaTeq        
Segment Reporting Information [Line Items]        
Sales 96 78 246 203
Total Pharmaceutical segment sales | International | Operating Segments | Vaqta        
Segment Reporting Information [Line Items]        
Sales 19 26 60 65
Total Pharmaceutical segment sales | International | Operating Segments | Bridion        
Segment Reporting Information [Line Items]        
Sales 157 151 431 437
Total Pharmaceutical segment sales | International | Operating Segments | Noxafil        
Segment Reporting Information [Line Items]        
Sales 66 100 220 291
Total Pharmaceutical segment sales | International | Operating Segments | Prevymis        
Segment Reporting Information [Line Items]        
Sales 46 23 113 55
Total Pharmaceutical segment sales | International | Operating Segments | Primaxin        
Segment Reporting Information [Line Items]        
Sales 73 75 187 204
Total Pharmaceutical segment sales | International | Operating Segments | Invanz        
Segment Reporting Information [Line Items]        
Sales 50 58 152 176
Total Pharmaceutical segment sales | International | Operating Segments | Cancidas        
Segment Reporting Information [Line Items]        
Sales 49 62 147 187
Total Pharmaceutical segment sales | International | Operating Segments | Cubicin        
Segment Reporting Information [Line Items]        
Sales 28 38 80 129
Total Pharmaceutical segment sales | International | Operating Segments | Zerbaxa        
Segment Reporting Information [Line Items]        
Sales 23 15 54 43
Total Pharmaceutical segment sales | International | Operating Segments | Simponi        
Segment Reporting Information [Line Items]        
Sales 209 203 615 625
Total Pharmaceutical segment sales | International | Operating Segments | Remicade        
Segment Reporting Information [Line Items]        
Sales 82 101 242 322
Total Pharmaceutical segment sales | International | Operating Segments | Belsomra        
Segment Reporting Information [Line Items]        
Sales 63 57 177 155
Total Pharmaceutical segment sales | International | Operating Segments | Isentress/Isentress HD        
Segment Reporting Information [Line Items]        
Sales 113 149 403 449
Total Pharmaceutical segment sales | International | Operating Segments | Zepatier        
Segment Reporting Information [Line Items]        
Sales 22 59 83 208
Total Pharmaceutical segment sales | International | Operating Segments | Zetia        
Segment Reporting Information [Line Items]        
Sales 103 142 389 432
Total Pharmaceutical segment sales | International | Operating Segments | Vytorin        
Segment Reporting Information [Line Items]        
Sales 44 52 130 219
Total Pharmaceutical segment sales | International | Operating Segments | Atozet        
Segment Reporting Information [Line Items]        
Sales 111 97 348 283
Total Pharmaceutical segment sales | International | Operating Segments | Alliance revenue - Adempas (2)        
Segment Reporting Information [Line Items]        
Sales 5 2 16 7
Total Pharmaceutical segment sales | International | Operating Segments | Adempas        
Segment Reporting Information [Line Items]        
Sales 55 57 167 158
Total Pharmaceutical segment sales | International | Operating Segments | Januvia        
Segment Reporting Information [Line Items]        
Sales 479 440 1,339 1,317
Total Pharmaceutical segment sales | International | Operating Segments | Janumet        
Segment Reporting Information [Line Items]        
Sales 400 375 1,138 1,105
Total Pharmaceutical segment sales | International | Operating Segments | Implanon/Nexplanon        
Segment Reporting Information [Line Items]        
Sales 52 62 142 160
Total Pharmaceutical segment sales | International | Operating Segments | NuvaRing        
Segment Reporting Information [Line Items]        
Sales 34 39 98 107
Total Pharmaceutical segment sales | International | Operating Segments | Singulair        
Segment Reporting Information [Line Items]        
Sales 78 140 324 479
Total Pharmaceutical segment sales | International | Operating Segments | Cozaar/Hyzaar        
Segment Reporting Information [Line Items]        
Sales 86 110 275 313
Total Pharmaceutical segment sales | International | Operating Segments | Arcoxia        
Segment Reporting Information [Line Items]        
Sales 68 72 204 221
Total Pharmaceutical segment sales | International | Operating Segments | Nasonex        
Segment Reporting Information [Line Items]        
Sales 41 55 152 224
Total Pharmaceutical segment sales | International | Operating Segments | Follistim AQ        
Segment Reporting Information [Line Items]        
Sales 31 35 76 102
Total Pharmaceutical segment sales | International | Operating Segments | Other pharmaceutical (3)        
Segment Reporting Information [Line Items]        
Sales 834 804 2,334 2,394
Total Animal Health segment sales | Operating Segments        
Segment Reporting Information [Line Items]        
Sales 1,220 1,122 3,535 3,271
Total Animal Health segment sales | Operating Segments | Livestock        
Segment Reporting Information [Line Items]        
Sales 758 726 2,145 2,007
Total Animal Health segment sales | Operating Segments | Companion Animals        
Segment Reporting Information [Line Items]        
Sales 462 396 1,390 1,264
Total Animal Health segment sales | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Sales 398 337 1,124 966
Total Animal Health segment sales | United States | Operating Segments | Livestock        
Segment Reporting Information [Line Items]        
Sales 164 144 448 406
Total Animal Health segment sales | United States | Operating Segments | Companion Animals        
Segment Reporting Information [Line Items]        
Sales 234 193 676 560
Total Animal Health segment sales | International | Operating Segments        
Segment Reporting Information [Line Items]        
Sales 822 785 2,411 2,305
Total Animal Health segment sales | International | Operating Segments | Livestock        
Segment Reporting Information [Line Items]        
Sales 594 582 1,697 1,601
Total Animal Health segment sales | International | Operating Segments | Companion Animals        
Segment Reporting Information [Line Items]        
Sales 228 203 714 704
Other segment sales (4) | Operating Segments        
Segment Reporting Information [Line Items]        
Sales 0 46 23 133
Other segment sales (4) | United States | Operating Segments        
Segment Reporting Information [Line Items]        
Sales 0 46 23 133
Other segment sales (4) | International | Operating Segments        
Segment Reporting Information [Line Items]        
Sales $ 0 $ 0 $ 0 $ 1
XML 85 R74.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Reporting - Revenues by Geographic Area (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Revenue from External Customer [Line Items]        
Sales $ 12,551 $ 12,397 $ 35,479 $ 34,972
United States        
Revenue from External Customer [Line Items]        
Sales 5,625 5,573 15,396 15,320
Europe, Middle East and Africa        
Revenue from External Customer [Line Items]        
Sales 3,454 3,189 10,059 9,452
China        
Revenue from External Customer [Line Items]        
Sales 1,016 914 2,715 2,423
Japan        
Revenue from External Customer [Line Items]        
Sales 828 919 2,506 2,639
Asia Pacific (other than China and Japan)        
Revenue from External Customer [Line Items]        
Sales 735 756 2,129 2,217
Latin America        
Revenue from External Customer [Line Items]        
Sales 604 671 1,670 1,889
Other        
Revenue from External Customer [Line Items]        
Sales $ 289 $ 375 $ 1,004 $ 1,032
XML 86 R75.htm IDEA: XBRL DOCUMENT v3.20.2
Segment Reporting - Profits to Income Before Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Segment Reporting Information [Line Items]        
Profits $ 3,428 $ 2,347 $ 10,784 $ 8,673
Interest income 9 61 48 225
Interest expense (203) (231) (624) (674)
Depreciation and amortization     (2,721) (2,716)
Research and development (3,390) (3,204) (7,721) (7,324)
Restructuring costs (114) (232) (269) (444)
Total segment profits        
Segment Reporting Information [Line Items]        
Profits 8,424 8,168 23,347 22,678
Total segment profits | Pharmaceutical segment        
Segment Reporting Information [Line Items]        
Profits 7,974 7,747 22,010 21,437
Total segment profits | Animal Health segment        
Segment Reporting Information [Line Items]        
Profits 451 423 1,336 1,243
Total segment profits | Other segment        
Segment Reporting Information [Line Items]        
Profits (1) (2) 1 (2)
Other profits        
Segment Reporting Information [Line Items]        
Profits (12) 101 188 226
Unallocated        
Segment Reporting Information [Line Items]        
Interest income 9 61 48 225
Interest expense (203) (231) (624) (674)
Depreciation and amortization (395) (382) (1,173) (1,169)
Research and development (3,272) (3,110) (7,364) (7,045)
Amortization of purchase accounting adjustments (285) (329) (879) (1,105)
Restructuring costs (114) (232) (269) (444)
Other unallocated, net $ (724) $ (1,699) $ (2,490) $ (4,019)
EXCEL 87 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( /J&95$'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #ZAF516*9!TN\ K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9?B>R$Y)82;U96.G%@8K;.QF;+4UBQ-C:R1]^R5>FS*V!]C1TN]/ MGT"-"=+T$9]C'S"2PW0W^K9+TH0-.Q$%"9#,";U.Y93HIN:ACU[3](Q'"-I\ MZ"-"Q?D:/)*VFC3,P"(L1*8::Z2)J*F/%[PU"SY\QC;#K %LT6-'"40I@*EY M8CB/;0,WP PCC#Y]%] NQ%S]$YL[P"[),;DE-0Q#.:QR;MI!P-MN^Y+7+5R7 M2'<&IU_)23H'W+#KY-?5P^/^B:F*5[P0HN#U7JQE7%W$_:]=0?W MCXVO@JJ!7W>AO@!02P,$% @ ^H9E49E&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" #ZAF51%FM+>90& #1(@ & 'AL+W=OLV!4YS^"7J9 I4W H;WI%+CF+JD9ITJ..T^^E+,XZPX/JW%@.#T2IDCCC M8TF*,DV9?#SFB;@_[+B=Q8G+^&:F](G>\"!G-WS"U>_Y6,)1;ZD2Q2G/BEAD M1/+I8>?(?3<*]G6#ZHH_8GY?K'PG^E:NA;C5!V?18J&J]\7ZJ?5SP*MNM'96W=8'IMCP0(I[(O75H*:_5+&I6L/=Q)D>QHF2\&L,[=1P).ZX M)&,8,=(EQ8Q)7AST% CKGWOA7.2X%J%K1/;)N(Y.X0ZU&GP,\*;?PT5-'>;FC^QXRV#Y%5ZWAJ]DTS%ZI&<9?6T MT>GW]Q>XAIPIGA;_(#WXRQ[\J@=_30\?1%C"Y%#DZC'G30. -W>=[C?$1;!T M$;1S\:UD4G&9/))+G@NIFASA4DJ6'''47SKJMW,TYC(6D4XP GG>&")<:9%2 M/[UZ9>TM/>ZC./%-/XX23BS*]YK+) M"Z[A=OO!P$7,["_-[+ZS M1J^XW&>>Q0DL6=0,?KYPBNZ P ";_:=O;>8%5,=7!SI7T0( M41G/1(:AV"(R\)VN#[, ]L-=5GBVL-CK#%7%GU!0'VJHXZ((*I0#FX(V0CTU^+#I? MF(0E]E$8P@8&2@R/:DG,HZD-M%5MF*1 2G)<%O!ST3B:%AW;(H2:6D!;U8*3 ME,L;G6 ?04'-8$ZF.(&L)EK(8,Z6DKTH.5%*KY M1(GP%G!?[<3(UU(!6[,(8MBX"ZJ5@TI9;]COAC3P',?S?6]PT+MK\F4P3W$H M'\':-JK6MZ<):^K^V")@#9&A.FVY"SB-"PW5[YQ)<@HGF[,<%[.L_JD!/&VY M_I^[FF]1UOO"Y;YA%9 :R--VD =C$DR=P8[\@7SFS3F.2T'=<3S7<8,]S)F! M/,61O*@[JX.([>MG;U#.4]E,[Z6=F[(F%GBEX!L,>3LVK6,$^4$R)2]]=""8Q6VTE&U(GE,KT72:!07.+_\C!DQ5/9P M*B]B14X>PAG+H':OV[M:A"Z^3TXP1X;''HY3=]>EP:_D0B@H#%')]<,M-/L- M7KW^2Z6B@:6'TVV35,25-HZ#0:>'\ZY%\N$"D'P]W(N!I8?3;8/\PX4L^><; M1OKX"E;/>>=9W'U,V:#0?RD4^@:%_M90:%':. X&?OZ/PL\B /E'<"\KSZ.W MQ3^+D"W_#/]\&__V!L_G?1]3-OSS7XI_ON&?OS7^690VCH/AG_^C_+,(5/Q# MO1C^^=OBGT7(DG^!X5^ \X_^?]Y[V%P+#/^"E^)?8/@7;(U_%J6-XV#X%_PH M_RP".O]P+X9_P;;X9Q&RY=_*_^9L_/.>SWL/FVN!X5_P4OP+#/^"K?'/HK1Q M' S_@A_EGT5 UU^O?X29,0 ,M@5 B]"Z!.RMO#2@G]-5[U(4)-3_[JK?'UB> M7;ZO<52]I= SE]YPS_9BO( F?0E-G=P"9+.OW)^H#)?+J%81KH91(JZ\S MSB(N]07P^U3 :,X/= ?+MUB&_P%02P,$% @ ^H9E4?!KYG@W!0 )A0 M !@ !X;"]W;W)K^%K0@1X+XN*GX_60FS.'(CZ:1^=\^F$[H515Z1>P;XMBPQ^_.2%/3M? 1''R\>\M5:J!?. M=++!*S(GXL?FGLDGI_.RS$M2\9Q6@)'G\]$%/,M@K QJQ"\Y>>-[]T!1>:+T M13U<+<]'KIH1*9+S^*-U.NK&5(;[]Q_>O]?D)9DGS$E* MBU_SI5B?C^(16))GO"W$ WW[F;2$ N5O00M>_X*W%NN.P&++!2U;8SF#,J^: M*WYOA=@SD'[L!J@U0+J!WV/@M0;>9T?P6P/_LR,$K4%-W6FXU\+-L,#3":-O M@"FT]*9N:O5K:ZE77JE$F0LFO^;23DS3N]M9=CO/9D#>S>^NKV87C_)A_B@O M-]GM([C[#JYNT[N;#)R"'_,9./IR#+Z O (W>5'(4/.)(^0\E#=GT8YYV8R) M>L;TP VMQ)J#K%J2I<5^-FR?#-@[DG\G OH0X1(-.IR3S1AX[@E +G(M\TD_ M;0X3&YW_-GKVKT<_$,/K,L*K_7D]_JZJ!2T)F LLB*P( OQV\<0%DROZ]P'O M?N?=K[W[?;/%!;&F3&,6UF:JNKU.(0H".'%>]P-A0WE)=(B:F2@O\*/D$)59 M4'X2H0YUP"_H^ 6#ZJ64"WX"LG=9R3GA %=+<"?6A UH%W:^PT'ME&] GP'O MT[ Q#PX8Q;J$%E"2N)J")BA) J0):(*@Z_N>7<"H(QD-)XC<,_)J=0)6I"(, M%[6">"E+7ZZR4&TK-NJ1,1?D!QJKU (*8BTM9B8H\F)/HVX!12BT,X\[YO$@ M\P?""6:+=MUZ.2S8*-8IFRCD^?J>9T%!-XI]G;$)B\.HIV;# M7<\ O>%X*XI -OX-EU-;2#?"*X)@B'4:Y8-A8*^T.[Z%SC4MT,>!%=7QH2$NBPF1"^/ MF05SVIODN_8+#O=?>VKH,MP0MGCY^A,,W6]?<;GY)DO?^$2!QU8A0J/UE%FB M-VH6E,P2J,MAHA*Y&G1!3%3DQU&/(KM>#0XW:Y>8YPN085;)X'.PD1M=2LM2 MUH'Y&K-_(M.!W9H62\*XVC3!4F869HUOKCX>6Q5MYAGM:S6&H:ZHB7+'D=X1 M65#>.#12S$2A<0)[%-WU@'"X"1S0DO-MJ=;8+"^V]2'+_Z=N_"EU391-71,E MU37RU42A<:P7;V?OW*,D;%4?.''92VXKT?SA[=YVAUH7]5&.]OX2GJ70\GZF M#L'J)=1N\8! G T !@ !X M;"]W;W)K3S@1\ 0-.@1D" M[I290C(A;1]V]D'8 K2Q)2H)R/;7KR0[+LB"9C .^UNX1@LDOF[O MF9RYE984YXAP3 E@:#5P1OY-[&L!C?B&T8$?C8$*94GIDYI,TX'C*8]0AA*A M5$#YMT=CE&5*D_3C1ZG4J6PJP>/QB_9/.G@9S!)R-*;9=YR*S<#I.2!%*[C+ MQ ,]?$9E0*'2E]",ZU]P*+&> Y(=%S0OA:4'.2;%/WPNB3@2D'KL D$I$)@" M[3,"K5*@]5H+[5*@_5H+82F@0W>+V#5Q$RC@L,_H 3"%EMK40+.OI25?F*B- MLA!,?L523@S'=_-)/%_$$R!'B[LOT\GH44X6C_)O%L\?P=TG^65V_Q!_EK#I MMQA,YW(>@P;XNIB JW- ",TK$ MAH.8I"BUR$\NRT<7Y%W)1D5)\$+);7!1X0)MFZ#E78/ "SR+/^-7B_N1+9RW M68__M_43,EK5_FAI?:US^@042!8& >@*C&DNJ]%&E8D] E.2T!R!/T=++I@\ M\']=,->NS+6UN?89 M-*\5N&G;(H;W4-5U?@U(89JA)(.A6['2?0,KF$@^A#HA_Y&5;LU1SZ"DCFCX!FT3&Z9G4%+' M^-X93GH5)[V+G-PB@E98@&T&B8Y:TP%)"K8,4]F((+;'"0()0RD6%3$PITS@ MGYH4&R>]FJ>=P""E#O%#@Q,+I'9@ZYBCZG!"2511$EVD9+S+=YD^'D"60\(S M6'1"Z=^[8G_8 HYJ;O2,:,9U2,.O;0,;J&?LI[@.\MOVF'WO5_O@78RZ*%+) M29'"99'2!Z7*O5!5RMH>>);]:9!@P30"8Y]/;"!9T T6;.;"\ P/1VV4?SG[ MMC+]MBNLM'AZAX7F'69!^;UNRZ2FCNI%7?-06%#=3CLPN'&/NLT$B/=0!OKM_[-V+>L3]330W>WO]07[Y899&M,.,C02IKRFEV9 M158\!8J)H%O=ZRZID)VS'F[D\PDQ!9#?5Y2*EXDR4#W(AO\"4$L#!!0 ( M /J&95%4:<@K]P8 )@: 8 >&PO=V]R:W-H965T&UL MC5EK3]PX%/TKUA1U6RDPL?-N 8DR[!:)4M2ANY]-XF$BDG@V=GCLK]_K)$QF M8L=0B4X>Q_:YU[[W7#O'3[Q^$&O&)'HNBTJ:-+/**W=1(-&5)ZY=O MK.!/)S,\>WWP*[]?2_5@?GJ\H?=LR>3OS4T-=_-M+UE>LDKDO$(U6YW,SO"7 MO7WO_LS4>C+FC@IWSXI\\D^N363Q#&5O1II"_^--WUAO4$DQY(=K_ MT5./=6QMX?0.O-;1CUIJUH)*> M'M?\"=4*#;VIB]8W;6NP)J_4-"YE#6]S:"=/SW]>+RZNEQ<+!%?+GU>7B[-; MN/EV=G5V?7Z!EM\O+F[1(?J]7*!/!Y_1 E;62[7O):'DM4ES.8C$[*-\;Y!V/%C]]4FE!94B'R5LTP]^BG7K$:T M7= 0MX(Q=,TE^_@!A^[7T.B 4+<-DWCD !T4)%,.B+8.B*P.Z+BF?1!20Q!V M!"-M;#^,\(B@ 42BR$PPWA*,K01ON:3%.PC&VM@D#'8&[Q@:4)$?>V:*R99B M\N8BL@1PHHV)O6B\N T@/TS,O+ ["(MK97930ZU1RQ<'W114N0^6[@5DQ(TB MZR J4LX8U"2I#EMA5X% 8Z=("*C*(B<< AMHQ:YNF%A M@I.1^298X 83$X-WE!5;'? 7Y]D32*61&M87@TO\<=098#CQ23!!;= ]3-X1 M>9>5I-5]#OE5..B:22-18O!AJ*UM$\S'R810X4%/L5U0.Z(F?>[I>7KV=EV- MG8X"$_ $N4%&L5U'N_1@(:>+8YP O3$[ \SWDHGB-T)WPS*@^W2H& M$J)R,M]3RV)J4GO6NMA@R'V:=PTP$OA3N7\0)?R6*J6\9$C29V9WKBX]2:SY M5@=%WD1F(8,\$;L\+?+'/&-59N5'3-(0CM.+$15/Q"\9](/8]6._^GACPHE) M4'PW&%,UP.#?1#R1G8V475"N5+C?JG!?3(0[T16"A!X9EW$F&)F>[D%(B%U( M%FS%P)$9ZI?FK5J:1IZZ5N!(TSL3RH^FW#@H"K$K2B=WU[Q*W\K=/5E=.C#4 M$1I; PPGDW0'A2%VA?G!ZO2AVUI\I.7F*SKG1X[R\!%:2IX^K'F1L5I\_! 3 M''UMJS_Y8MNW#QI$[!ITSLL2A$:H41QTX!X%+L1QC6"[W3!TUDC8XN;_P70? MHM )7-=QNS\DUK2&G'0I1-.^]:"PC!SLPB\AKV]WZ\RIXI+HPH2C>%S O87: M-W^0+_*>G=.&YMDA<$WI)H=4861IT*7$C\O7TQ2>)0A M1NLJK^[-BU@7H0!CK8@SP'R@2"8X#EI%[%IUMK/QZ#66E[#_6*NSRD<&E8PP MT]9EZ3#T=O9S/6T3#"<3NPMOT"_/KE^[ ?9'>]0D7] =6_&:0+[G>(EKBE >+'CQI'C)^$>P!RYGJZ!01CCL52:8$$23,2$-TBE9Y?*3M8M MJ5,84B&H-@)CC6SA$-L"!QI^9NY\#3KJM*JW@E:U[ FWNUI63@_HD# M3\-F;5SL&3#)Q'FB-\BJ]YZ-FL6'NCZ2A$3C:MD$VPN3?7J#C'KV \\=D=^> MDDP0#;3C8-..T@0S["CG.Y\-U#>;'[2^SV%K5[ 5M'./(NBF[CZ#=#>2;]HO M"7=<2EZVEVL&&ZE: >#]BG/Y>J,^3FP_1IW^#U!+ P04 " #ZAF512H.E M0C<# #1" & 'AL+W=OMM-<\$1)6@$2!U5;:;=&F>_?B="],8AJK3IRS'=B]3W]CAT8\!-3E M!=C._&=^,Q[CC'="OJJ"4@T_2UZIB5-H77]R7945M"3J3M2TPB<;(4NB<2I? M7%5+2G(K*KD;>-[0+0FKG.G8KJWD="P:S5E%5Q)44Y9$_KJG7.PFCN^\+7QG M+X4V"^YT7),7FE+]HUY)G+F=EYR5M%),5"#I9N+,_$_SD;&W!G\RNE,'8S"9 MK(5X-9.'?.)X!HARFFGC@>#/ELXIY\818OR[]^ET(8WPSI\>%\O'=+D '*5/7Q\6LV>N3SZ_(%S5#N&[D_.I:[6(>N&$%7C,#Z"R_A:*(IMJ@&L8'/K")5Q@B'E5#, M]MS?L[72$COOGRO!PBY8:(,-+@2;<3Q!&($"GD7(1;/6FX9C7V>BJ71O,5N' M0^O0',_M-,&TMX<%ZS$9=B9'G(..J0H^NES;*F;#AN9HY'&O_=ZSBX:7*#CO,X57,N2A+["H\X]GK1ZB)A"WA#84;K&TN."=2 M08T55@4>O]L^^-9_?(#EW44GZ-=MCL#C#CS^#7"+IX TNL N^0]K?M,N]2+' M9_L]C+S]YX3\7:9'"21= LGO)\"4:@P\5O\*?W(&%49Q['MA%)PVS;M,C_A' M'?_H*O\S7MBJD;\@;3-(+6\?[NC\>'F#.!R$X>BTW'VF8>(E\6!TVNCNP85C M+OMO1+ZP2@&G&Q1[=S%ZD>T%VDZTJ.T=M!8:;S0[+/"=@TIC@,\W0NBWB;G6 MNK>8Z?]02P,$% @ ^H9E41% %(O:!@ K1L !@ !X;"]W;W)K9YJ9M1*I[^5(." P,[U)0&\DOZ[6NU/@N-'(7^H-6,:/>59H4Y& M:ZTW'\=CE:Q93M4'L6$%_+(2,J<:;N7]6&TDHZEME&=C['GA.*>\&)T>VVID-/,_SDEH&EB+OSA[5#O7R+BR%.*'N;E*3T:>4<0REFC3 M!85_#VS.LLST!#I^5IV.ZC%-P]WKY]XOK?/@S)(J-A?9=Y[J]@V MT[?B\1.K')J8_A*1*?L7/5:VW@@E6Z5%7C4&!3DORO_TJ0K$3@/HQ]T 5PUP MNT'0TX!4#8AUM%1FW3JGFIX>2_&(I+&&WLR%C8UM#=[PPDSC0DOXE4,[?3J_ M_GI^\75Q<8[@:G']^>I\=@(3NOQ\_7V!CM"WQ3EZ M^^8=>H-X@;[P+(/)4,=C#5I,C^.D&O>L'!?WC!NC+Z+0:X4NBI2E+]N/P8?: M$?SLR!D>['#!-A\0\=XC[&'/H6=^<',_'I!#ZK@2VQ_IBRM5:W0)BT2AE10Y MNMXP234O[M',)"[7G*F!88)ZF, .$_0,\Q46.B\2D3/7%)1M0]O6K.>'T]B? MDN/QPVYR)K6LR:#WL_0?2%U8[5HA+6"Y)Z)(>,904>LUS\U= M8@*UD>*!0QZ@Y2\DZDC1.E(?!T(5UIK"P5"=,ZAS":=E]2A21',A-?_7/G!% MK^QNLA,8/,5^*WHN(S]T1V]:*YT.*KTJ-"WN^1+B194R$$].K)B4D'?/.4F?W+&-.V,' MTY:\KLD1B7HRP?>:\NP-*EQ >-F1 56*0"+06_4F;-75RPP(6C)=1EZ?S!V* M^(,RKS5,LE.3WPU+$+3STF&%31EVBL*-*+RW.,)Z*6"]&%C9M:3LTL\X7?+, M480KT;@K>A*2J*W:84:"L$]W@PZ?[-5M^7&S4Q;W Z323CJB0MQ)5H<55(*^ M-&AHY >OHMY5\<#4X=3S&[[XD^&J0S=2?VXR5)'IO]R#PT&Y#+,!D>SM:>=#%SQ&>="O9$,=>ZF\@Y0]3JJV_T'#J MX3_17,B-D!8'K_"CRZG.:G"A+,0]?N"&97B89;-#]P>'>X.[-&M[XS Y\KV@ MSYL&>?@ Y.WN>=0K9#NH&'OM(NVRPGUXP0T6\3 6>UF-NSSS@_:&UV%$>E.C M01X^$'G?E-V-'4".2G,79$=!&+:7I H\;X.'7 >^2%Q1..H<"#S? MP\/ :_8R)CIJ#4>7(\UDCI9"0F M1#UR&XSA88R]V$QHR:C:RE](:9'\<&IU ,O'46?N'69D2OJ"VT +[SE:<;-U M+2"Z<'9-S6G?*EV++&72G:L.[ 1AYWV%TPS'/8))0R7V<">F$RXLME@ MA2.QT7VOND@7,6%[D^:P(4'/V9LT$"+_\]Q%7.>N*6Z+-$%6"O70Q<9F$TZ=.]\\YNF$(7JQ5++,$OGJIB>TLU0_/J$ EE MS+CUOG3N OC^ )OBHCI4W@*P)$\TN&Q^=_KG.':UJX?#!JC?XUH#*K+_1>$Y M2TS5L 3Y33\"UV:8M)>JRRSN\ M2+)M"O,I&W.[90.+-W@2F69_T&)+H;SZY0ME5+6QV5SN_&;V=<([9WBZ/(UC MTLGBKM4T#J<]X6F@2X:A^[KP7)@3G-F+2R[2/:$))J;%@FTTRY<0@>>W[:\, M3NAXX>RUL>2RBJ9^*SCCG0\?.9/W]GN00HG8%KK\=% _K;\YS>R7EM;S,__C MO/QRU'13?LCZ0B4DD$(96T&7WH5I=!:Y/9RS2A SAC M[RLA]/.-&:#^0G?Z'U!+ P04 " #ZAF51B:W8(2D" "!! & 'AL M+W=O(!Y VG*:4,91&*BD5 M2$"KIHR':0]N>FTLG#BS70K_?FG7.[&@:A$X02<^L8."TOF**4CHAD M_&XY@RZE ^[;[^P37SO5LN0&4R6?Q,H6P^ B@!6N^5;:N=K=8%O/P/'E2AK_ MA5T;&P:0;XU590LF!:6HFI6_MGW8 _3.#@"B%A#]+Z#? GSG6*/,ES7FEB>Q M5CO0+IK8G.%[X]%4C:C<7\RLIE-!.)NDTX?Q]4-V/0:RLNG=[7BT("=;T')_ M_;" Z032478#D[OI4P;',ZZQL@5:D7-Y E_A,1O#\=$)'(&HX%Y(23_'Q,R2 M-I>!Y:V.JT9'=$!'AO4I],,O$(51^ $\_1P^QIS@/0?O??\;SJ@C75NBKBV1 MY^L?DF.Y11I6"VH-*3<%3&C>#?P<+8W5-'N_/DG2[Y+T?9*S TGF2%PBM[B" MG%)\U+2&X-P3N OYDIP-8O:RWYA_0Z+!11?3"&-[ ^(NYSW7&U$9D+@F5'CZ M;1" ;@:^<:RJ_;&GI$E6<'W;OSEA>NBT5;=>!&Z MII'^_EH9MWTV.9_T-][HU3K2C?GE12M7ZE;%M^V-Q]5\D%+I1MF@G15>U<\F M5^=/KA_2>E[PJU;;,/I?D">%<^_IXF7U;+(@@Y11920)$C\;]5P90X)@QH.)J%0M.Q/?N.U/*OOS+ZDB*W\049Y>>'=5GA:#6GT M#[O*NV&V4M7^_CE,&NQ:]G9=+[\H\%:U,_%@,17+Q7+Q!7D/!C\?L+P' MGY'WBU])JS^R>U/QW-G@C*YD0H:M]MRG2VG0^=M%%$QVM]9U3@D'NUZ@R;&P38!=>M\Y&,A0-4OTJ$T+G0( @1]Z#3I+NXY")UEJ:W7<+ E]2ME ME9?&\'/5DO^02>:]M1PD3GH0)W^^NKHY9>LHED9%]151@]_"N@B1I>E0#F*M MO-)V1ED)"K>C\KH9[PAKUQG8B_" 6,D6:'G7V<1<6QW7;%R?PN-:$05HA=61 M]"'<@W[(XWQ]\Z?'R_/OGH8ANG^!*(,%%'!5^ ZT+):/4M&QN; G@-\8"6@$ M/J<+5\CWX D>:%<-?EM5JA"DUX:65+J4Q+RT*7Y68IVA5'?&B'LE_0Q &X-K ML-VUVG(1(W]"5N_ D2D O=I[%B9%+;7?!2BK/Q[_'6Z'F%$XR2%R%5X!:R:C MMNR\)SQ9&0&WF;@QTEK"# P[^Z6N:1L<(;!@>R!#' QI MO:NZ$H]K[QI>M]VS:YWM*@[L4B.[BF17T0403P@JFXB8J.V4TJLP'X!0XA2E MCDTED@Z.K)A?D@M6-KAB!H:! Y6(DWSK%(GQKENM(15U'+TNNIZ'\Y+!Y$,= M:) (!@SJXQ76R-K:F4KYD""\)Q)Y:C 38BUT?.FET#1I UHJ!C=S])U0UD48.QIU.*V%91 M!8:^JN/0+H9L5:A['W2M=\[7^"G7.J!P]M>J._A-1E$?D[Y43L,8HDET:_4&6*PVM](VH$C=5;>ET:-DI/0,\*<0T $@LK6 M9Q$[CP\,R(DDJ(+29:N X9)8269P#95^ .M"#?UJ0%E0U/D)\1[\1[D"G9Q/ M,8X7[P@MV(:Q_+U*-O=]UI%FGADT$_5,W'9%0(-5NY;>6S'E*^26X%.B*$94 M3T_^'^3#B>,^6>?0R,#-/X.B&C<5?;R#_,<./A-OT$ML1.ZO*L?CP=5NCL!L M8"N45B!N_KD#/I>+\T?)^=W8>'3#M<././GQZO;Z%#D+9"]X5*PZ6 ,R)XC% M/+KES3Q[8)C146"^H1!@STJC2)"(_K:NTHP31W4.-W6]8% *(?8SKL?:"NLQ>L$V:N M'61I.4H0\D^3[0/-YT3'0W]472L^.HJ?I>4V?#X:D# A;(% Z]C-,AYTCZ_' MG.A:&F7)"F"7IY_7L+0I4'[ U^.,+R#G*'#2B&H04N?3N"6]IQPDX3P?5(D< M$!\@HN?F2#,:&);Z#^YB9"Y1BNB)%/?M6J7ZSVPPZE2H2A6W-#)]5BTZ%>9Y MC-QR?\;-Z*9 P.H.=M'POU'$Z92?E66NV3EW3<24 MN!&':HI=#]B4OO;@.#@^;GAE9.;9XYG^7!9&M/(RI? H2;S&"/UWT'!//4#" M#]C7(^'[3Y& ^8J3^P4:2:/K<,"J1P-+/ZGL6&,?+V#GEH>D(\PTE@+L/(&. MQFWHJ;JC@Q4#912PW?$M4C_C8P/-3%3296;MU,IKQ51##XT>FN+3,3H'@W&R M:])Q8Z1*;:3I$JMQDXJJ/>M:%ECPF9GL7SE7<4N!37+H,]0\"]0HV?,TAX[; M#3MF)9-HCQ@J"S)2;@.=AST?''/GP=2! 7.$1UI)*U+$/\D;M?%A;8IO.JOP M:20)2U%C%=3 9^*%].9^8 Z2@26-CI$&GD%-SP.?5@N=UQ$,$!8C![&,160Y?NQ-( MQ_UTNLCO!.+8EWTJ@&+N35Q05_Z0.T?E% 8"&(,8'1 ,/>Z*^58#9G9$8!O5'X#'SMP&$*A\/3<[LH;ZK8T M"='41C%AWI4EO[89NW1LI/GO2Z0?PO=!OH>TKZBB/P)JK_@480BPWNJ+9M#>29LU*#[ <=0.>_I #IG!ZO\;%T@-ABG-!M4K'P/QR M<*W;D,ZUZ3"R-X1(=B"]ZSOJ0++TT^#MX8AG+XISJA"J(\R9AXS8?D)V,O)[ M,#[/]25],'(,A#CT\ ?IR?*/@=6Q-]7ST?>"1OD5?Q4A84!+^G0PW!T^O%RE M[PV[Y>FK#1"+; 5A5(VMB]EWWTZ$3U]"TD5T+7]]*%R,KN%_KRWU!+ P04 " #ZAF51=N<,Z(L6 !E0P & 'AL+W=O M'9;14J2R')E<9/IF;(I457A:+PS(OE(SYH30Y MG(Q&IX>IU-G>FU?\WG7QYI6IJT1GZKH099VFLEA?JL0\O-X;[_DW;O1B6=$; MAV]>Y7*A;E7U:WY=X-5ALTNL4Y65VF2B4//7>]/Q]Y?'M)X7W&GU4 9_"[K) MS)A[>G$5O]X;$4$J45%%.TC\LU)O59+01B#C=[?G7G,D/1C^[7?_D>^.N\QD MJ=Z:Y+]U7"U?[YWOB5C-99U4-^;A@W+W.:'](I.4_/_BP:X]Q8E1758F=0_C M=:HS^Z_\XO@0/' ^>N2!B7M@PG3;@YC*=[*2;UX5YD$4M!J[T1]\57X:Q.F, MA');%?A4X[GJS33ZO=:E)@Z5?7&C2B6+:"EPR43.3"'Y R&S6'S4$62AQ'11 M* 6Q5.6KPPH4T#Z'D3OMTIXV>>2T"_')9-6R%.^S6,7=YP]!>4/^Q)-_.7ER MPUN5#\71J"\FH\GHB?V.&G8<\7Y'C^QW69=XIRS!@'2F,W?]_YW.RJJ OW? M$T<<-T<<\Q''?Q/'GSR-;/K[,I>1>KT'HRU5L5)[_Q$)XO-2$7=RF:U%!&GJ MK%:EJ(S(ZZ*L%>RLW9SWJ/" *BLY2W2YI#V$F0OUI5)%)A,ADT3++,(690T: M9"D*3T^T34_"].AL(61+$)L ?X#OI7?9_E0G8(7)5%\49BV3:LV/%6:N*U$N9=&EJN\XO*"+U3F\ M&.UJHJ@N"@6F$25S4>5RLF 'IPKV)/!U@;D59C.;V490EWCV=B MK$Y,3F<-.X*526EPOQ4Y0>8H//:]JK C:(WKJ++BR'6N2./H'/5%IO1GA ]T M+"M(]&&IP?I4KNFIE09?4P,25S*IB3>%J1=+@4@Q",2:Q7LF-X9[+ZN&'WQ)R/JZ,(*#EYC#H+-(0RUT9L,9Q07\ M976VP.UFSOY!O"Y%9N@6>4L- 18ZPC;MAEB$,- RV.^')S5D3'*E MS4J]R/009WFI31^KHJ'H^=<'^#0S-72&#%)6?!:?GL$BQ%(RK8I( M@?& TQ3:=*8I9K:V9FVG0C8*@2>]6F[WQ#!VG<(QUQ;*,&I>6IKJJK.TX^R!J MY[HHJX'.!E$"S2(M!SG$Q4+FQ,%*%@M%I@HY12J'BHAJ71A2)W$/&98*6GX/ MBRUP<-8N&HO>S2\WXX.6_D;T"4 6I$%:K1>LK$2G-R^ZYMW'V\%X-";?@O]5 M>F;B]2 NZ@7YC=_J!2UK":-SK/#QJ'4A%?@S4_2A(JN4K.?82UPO03&((YWR MKR8-%T55D$:2N-C- 0Y6WK/GH)1=$*LT8 (4,9=?EHTFG0 9'I/Y0CI-4R&6L\7_]1IW(F M5BHV4!;1^_3SX/3X>'3 NK6IA,_KVL>KN\$XD%*K;MA\MSJ5K$\SZ!)Y<6M? MK41"77':T;D[NQH/0;"+@>W\9N#+PB!'46-1R-1K.U&Z^_Z01&HR8^U[S71H M=M<>%5KU_EFMH4NQ%+T<4B] (V]S0(MQ*6"20::(;?"BG9OUQ1*B!Q!H/,$@ M-Z7>7ABP@'DZ@ ;"4M@N=O'$>W3FA_J]9F6PR,+"C)+RI"1&FJ&&XM?&4.#[ MTS9^>8?O%3B5"-Y0A U<1.OW3T*D M>:*- LY 2%GI_60%Q0Z<$B6IG&U"-+3M M)K,"" D>!;02N!I49F!!EH#7PWF6-&ATQ-9BXQ+OTX.=/,@B9G!(:>EO6#JNR]?P25<9[ M1N:R133V0WJ<)+G(V-O2CF#2:<,C[%%'WLL]+]G.-9^[7L@*"JU#OY"0!$%+ M@-R%GB6,<\E>R4H=W@X >@/NVSP 9]8Y/054<]J"&IMFT''[YR>C4&?#RS3[ MV6@)JVJ!$:TM)3X/5@T!'C/G:%M "1>YVHB=[G;PA QL?8P"]T!629=+7-YG M4ZL@>'RN[]D8!0I0I@;O40/MKXE(7^(#6I9YI^+C^;LCPX?W- MI'5_UN]1N,W$M-2RSP]\TG&,K=^39^3,E(X74Y"&"!(XR4(M.%LDI$D9A]/, M7Z%6N.IM18E)7[R5F8SM8^_KPN2-,V&W.5,,1K -"YUHMJ;)&4J>@SLN)RV5 MNG=O6N0!FLC%PH\4=&%-AY5U3BE,"QJ:J_JT 7XBM7 %G'C[\>K3Y49L[)#' M*AF9P;QF;TM[.XNA+9R$+!#H!K]$-L )V2.%"LYT2JPIL-9D"^-R,%Z;D9NS MD5E&!3FE1P7EU=F&+DI;$V1Z4263OEC@'0@I1%?V04%9*)@+167,Z4AV&>86 MZ1T>(/01MK902B : MY_D2X@"?Y70>MV=^-]BV(ZQI;($\(R+]*%3WJ;ND))$3%ZI^9/4CT M^(?)21OR>OM'HP8DN( ;PHT' A(1:[S;A-[(P@H3\HB,]:[Y(3%QUA1>-C_P:)I%+6%3NV*$UK>J7I4%(J<+*1T V MIU+_JB&GG:)AASZ\'8J":NY<;;NE2DNF$O%C(E?@Q&:9- [-6F M+CM>AU/F5H1[BXJ:+!(T+AEYDO/K ;Z]LUY#&[ M*7E;-FQ+:002LSI'QKT"7ZC*<'Q\/ME5"'E_]>[=8'(^&ML2!#8EORU74B>L M412SL4>G)-:I,C21/XR4+RA9O?WE[NK=8'SA+8XLFTJY#3AN\N? _SQ>;NE< MV&8]5J$\7'X1CN@(Q@?0>%=*SBDX!7*J5KTHEC>J%2O B+C3:X!E:65K9&&S M(6 IEX,V8=,F(.AWDU];CW"WI'#B2Q-XZWE^]:D4;P\AL]VEV[)0W4HNX!'= MFJN?%'IA\$!\!%7<59P/OIW>W [>FKO!!#D.I86R+J4K@CL>>/TX:&V>NRO6 M:1#WY]@I9B7UY3@7T("^=@:TC6(U7$$*Z4'29:2YS_-3.OL@>O9]:Y8.0LQ- M5#MLM (9VB>+.DUQVB"%=TI<<; I5=,]=3;GR%6# 1JHLG3/N:(31\&CT],V M"GH@2[[O'O=LP-1.36KQW]EQ@&O;1,%]>MXFOW3D[NRWW^30I]WES^H<+N0> M/1YU'VUMM)- .\XO64MM$;'I<>%.CL5ACVN;V41.R^Q6O6SDLNW)#+2R5J5@ M/6%9*#M$L8),J!^(7<@A!KC7?P0L"X0<5GAM6LF*4NF2 H2-V%> ([JJ*W&- M_$O51= _#;V9C8WNWL09.S$AK&O5N*=+@&Q\#'' K-9)7%I?P45IFSYV@\!, M50]*N;3DP005RL!K[N"KY18]]32+F/]!79[: ##'!/RG@O12=93*N1QOPML' MB][=R06%G*7/0[RF[=AMP@:HAXAN(9:_1F!Y$14K8N6+X3AG_^+L M.1 G$/@1HQA0D0N>V1;Y>O# PRRD)@UP:6"5*"EVIBT08].#!Z,-X4OXNH*Y MW\83%TTRR;&'IP*0^[2%PZW2V8O@KG5D ]<*;IO]F^EQ[^KZYI\RS7]X=^ R MEM/6)_'%Z-V3B_;-6 $G33I)$=E;T(#O2HM5 MQIWG0>.&M(.4JPD:G*!-6J3^P+,3;;5@84S,$8J#'NMBXC-65R;>R$M+M6@@ MA&M_Q[;LZLM@Q(Z\1K94.F_YGP'_1BY_)\R_H@)PEKG$K<'0G0JI53X* QM= M\50!WX,_R",IQA%N:QK:S&?7 RAMH4\6I!&N'A'4\-G[(892)Z?KD6#Y,7QQ M1$Z];3_W-TH0K.&:ZFJSNNDW>&=F@F(:(H@N7>4%%Z5*>$,J!?*R\^0,"AU" M[,+4;H"',:]%-RW882TBWCXL#524N%0Q?S_)[<3#QB2>RW' 87KU[E;&3'Q8(V^?A,W:7M^,0679>J:9AP1Q*J#C(T-7D*P:UKQ'[M M8V:ON+N].Q!!ZN:G &@3JR)$3K=XYA&V>#\SB13_(VF(PP5A2U9?O"]6:F9$ M+UQRYS_\"&$VD93\#_LU+D0202VK_$%$0\W] K&LH?!?6V%]K$$Y[-8@OQ[$ MCC?0(]3<%S/S[%XV+SN6M_T:LI#((\%C13186JJ!).5[HN M%$\B\?0C)U.V Z*8*)U90I&,K'>V5$ 0G=ET=*QIT3X?2)(XK%B!"O"()@5= M_8SGBVB.I'830:X<;TV#4!UE4E6H!8'@R3_P"4%;@$: <<)"<6!F'\#W=_@Z;!E" M@MQG#N"1+S?ZBQ9^ 4.LM#/B"PL_6P(7/ MC"%!4UDG$<"V7&H'PH9G05N6!TBI6WMTWO@,K.*2AW,9=!.D87Z;=F84^(AF M?UP;75*3G_(Y&^:E"[EYX_7Y^=):ELO> 8J8+KYND(I$AE)#SL<0[N9$D65^ M-^70F6O7[U^NCTYM_BY(A24YYOS*#F29_+HN*RJ!& VJ[7 M1ON]=_GYYX/ 2!X?_=MI))>#B&):.+WW>/6?/>=&HF(+#VU^Y)"X;<%8!O&= M"(0DA.B_%[U]XJU3P/*@\2GC4SM^(MZ2ICOAOTI^[_./UY\G%V5G'/6YY6O:6 >V!4X2[(G5=L*W2^'][:4V4 6U;TID?!3;&)$*BN?CX:@=/*-PO3/]^?8#"DUI M;GQR]DAM;K/N=GK<+GRZ0G?Z;'7494'/C-QPN_R\,WCZ52,XXXM-"!6P<"A^ MR<0T+W0BQOW='F4*YN+DWSM3##W_+CL3LB+%*AY#GVS'#O&A#4"VQ-^GDR/E MBL V#S 9S\_88>.Z;03 JS9O4-,J%RL*$ 0(,Z:K-<60EZ=[:SN)3F4LN7(*W;)-(RJH'%JV :=P]M_/!=O^P)*PT/^5D).\H72=S:A]'C=+&P<5*QFWZ[P_VT E;_+,Y"JHU5/ MXJFC,2(O7Z9T7HBQP]D1XI8=&B$B+H[HJU9/#!2=CL35TY7A7F.2 T#9Y.RD"\K&_:.STR=AV5'_]&3\)"QC M_7M1Q9R*MRG,RV(=3I-%)E/7@WQY ?TO VGCOPBDA3T@^KX*8 I-@FRD>^$, M9[F&LUF0 G3Z@H6F<^:5KR4%UL@LW 4&I]93NH*6PX+#+H$O[95L?K>O&?]U M .KQ".&_ESKGGG'S&7^GG7PU9RK.\!_+Z(_/ODU&[X[IY/1>*$13O-(EEZ44 M69>M_DJ>9.7.R#=/LZE8/N6!%Q\J=\;)*V[2PV-0W8ZC8@OWN('??-G'0VN5 MYHE9T_4R]:4:6$HK%^-7>F4:H[+=;&#$F877@KX)*R^<&AR?[&J)GA\]TNX,YPW_ID[G2.SZ\OUA\-,' MP!L+_H&'THZ!VU]!:-YM?D-B:G\ZH5UN?X#B$W189Y1SS/'H:'AVLF<'O/R+ MRN3\0PHS4U4FY3^7C*QH 3Z?&U/Y%W1 \\L:;_X?4$L#!!0 ( /J&95'# M6R&PO=V]R:W-H965T#Q//]HD@..TW31):\1-%]C%?N!(G!DVDJA2DB>37[_G7E(2 M-0_;"5Q@N_T01Z,A+^^]//=Q*,VSE;$?BZ52I?B4)EGQ_&!9EODWIZ=%M%2I M+/HF5QF^F1N;RA(?[>*TR*V2,4]*D]/18'!VFDJ=';QXQO=N[(MGIBH3G:D; M*XHJ3:5=OU2)63T_&![4-][KQ;*D&Z M*#\&$B\&>"2,_8<1ZNX58RU>R ME"^>6;,2ED9#&EVPJ3P;RNF,-N6VM/A68U[Y M8D(*VMEME!P>ED\ M.RTAGT:=1E[62R=KM$?6I7AGLG)9B.^R6,7=^:?0JU%N5"OWK7RA+OE(T^ MBJ4L!#XJJV*AL]*(J#-#AC/*I2Q%;LV=CA4^*'%MTEQF:X"N7(H[1*7.%L(2 MDC'8 -YW"-N\1W/B*H*T+ ;Z[$=5^EL\;J$@RSHA&G>Z&N32EIFR15^\-!A M'[4JH"MI4&QH**WRD>H&1AKZT7TLK#[EIH"54*S0BTS/=83OH&[QT0VP:B5M M7$!MY*P8\H3A1:!0FL)96B;(/E&DBD*8.7_#:VE6R-\)E#=9WSGY[W^[& W/ MORU$:J!?N/@]SB938ET@B$GI&>6_OK@BE/U+92J2XG4F?JR2-= ]/._YW20S MPC$W;Z_%47#CN+O74BP2,R.S,*)4"QW!9.AD%NNN(8*!<>(WE)?!Q]8O^K,* MUVT,?KO.L ^?I3@RB<25GAT+E *1(NOI/(&[9!9A[\MUKK##S7!-.R*P>")R M QN/KE[=G& V-O"8[V!=)%-Q='/U_N88QBSU3)<0'%76PD1,D3DA%9;2>EBC ME 096H>V2L9WM'(L#&"K9=83,Q2EH@16<1^7P Z;"2%%"=]X3:'D+PX1&$?; M3MOTF]&\I'NE=;A[4(R9+PD!G"OLS7/ ,:8M),9][IT"PI7&#P M.)A>PCH"8JIBH#LCK[W.&L0FZWU(6.DD$=W]"S>O]7Q'!;\XUM86\5'DR@77 MS:N3(4O!Q=MAJTQ/O%'KTE:QY&]?IW.=?=:;/F-=8)G9]-P.Q7:AZ@U@D%0+ M(X[H_U25.@.P>C5D>L*7;2C:(@.;_NZ[-SW."W6PIIJR3W;"88Q-YNTN%7SP M$0X@?+V[NGD#Q,ERN9+P;0NOF:(M]7I[E#6HUAG\X1Q(VR.NV-B]L0K6RW$58RZK3E "1-'W[^ZQ5T:LE;0.\PN7@4T2U^DV4Y4U9<9E5DJ([3UCE 0:U';%\/4.9 (EOH?[?$ M/?;V*(G#/YIJ ]:]4UGE8JRS=N@]YR=9% ;2""EU@MTHN!!<9ZKW:'.DC98L M.)2%C@;\AI#Z7NET5MG"]P[P@-)<^PBYH7\I7.Q#\AB.Y$4T*I\A19)$\A-7 M!+0">S5BZVA'.VDVB'VW0ZF,R4VBRJ$@IN5RS=,A.E06TP^'_3,Q Q;))X 4 M-3N^C8Q5/8]Q=W@^'2"ANY'(J1;=#2?D$TJ 2(Y6FVXSD.B(S$74MYE:QK&F M3[VNXG77Z_)-/0CPC* ^"H%JC?#IPAFZ89!5BH1I&2PT_UJF< MD7="?#'VK>FBPE1CUV2B J_SE=_)P59A$!*'1AHCKK1']904@K$R5Q-2++!80?C@9!&[N:MJH]@A? "01A2F< MUS8M+G+)YNXZ"#!@0) MVTC)75,1-1U?R2BR%48^8)5< !@+23M/"!TT"-VQ4H^\M%IJ1,OA*+")+#D< M!9CEG9$ZW@2-0_TE3\#%12]HQ,AU^P75^Z@M\ED&!% Y(H;M$0(G-/VDW^P' M#*-!R8E\S:F$!L042$V?4Q-'F#I3+1Z!QG)) M)4"GZD%T-W!MLET0):ZQHN[9 Y>V*D*Q+;FMW&O<<#QM_'@/=E]O[@01RXT$,-)1?DU],ICLF"CYC'C'HJ.&T4!IUN5ERJ=0='Z(,B5YZ)>D:/D M9R97KQN]4=A_4@W]OT9Q,(F.6?>7WI9;.C-S]LK45$C;D.E( 3[;D@W@,D2M M '35*<^O"D7Y/M%SU32)4.N" J:HN/]T80+$_(;MI2+N-BF2Q5+,$[."=D4U MHR_)DQJ1I*TKG[1,MNB+6SXC9170C$%?VFN=N4/8C3S% =?M/8A]4Z5+:+%O M8".VMW,X)WZB9-*YGM'?T1A_IQA] M*,;#\:XY3?[)R/QEZWXTD?#8S$9"NS&:##% MV 'P TG9HN=;^\05H("2(?\A*,=G8C@<"5BPMS6"L,E$7(XA=K3EK1TP?84\ MXNX,>\Y][SFS4*(LMAN[;3A[KNIBL& /G+,'+L2-7#LQ6Z6F%7)5)W)BC!V! M=34FXG(T.H;*EV)Z?OXHJ4ZUGTQ6"WN[(8S*?KV7M!WO54[]*E==%U<.H]2F MWYM ^RSN=9U7ZKJT:^!WNI":DCRY"*?)W'YAM'2YLG:"52ZR))L.=B_7$ M4N5(S1'B!3D:8($K=692V=O)!.$!BYR:5D6G)6\.+G@0%*,6&R)#<3L.RGAT M0WCOU;^[@LIBDRH^9VN7",\PMJA+"XB'3M2\C_T1UZ,/_;JVU."L.6TM=>/< M@4]QZ9S4C=[)HOW,;=Y\W N.85K[''W-_1G(QK'$;HZ]2[DG8M5P1,U.M4L> M2*^5:Z0Z$=7S^8:^(204):XQ2Z'_JES+7NO9W8S>CE.8NE^E<[3@S)=[D7GB MRC/V[Q$,_1Y(W<.&W4YLLENN022%"W@J/W:;M2JGVX=GP8PPQAS=;1[3M#W( M4!RU5&4\FNXD%$V*O.QU^Q]+_ M- NO<_,])/Q+Z.GX?+"'T?AB\ /#^<_(0]W5CXA#;]LX=X7/\_KIX/("5>@1^#1\->/J3\-&ZU7IR M.CK\,]+1L[\J'?4P $V:$$4<#H@T3E :#\$*![OHXID I1P-IP+LZC%L<0AR M.123"S&]W-\WX.OQN1B>74"/LR=BBW6F>Y@G(N/C+\(X9'3;T[^ (:+^GP\> MDG<_-QP?@V0.0-VG?S O)',\QGVK%$P=/Y)2OI1KV'+U@T^UDUXG.6^\A!&0 M0\!'1S+9>*@21@/S@T;\$5\=NSZ07ZP)H"20)RI*>XL*JR;\%L,Z2OC!=O'# M]3&*5NPR6!$TS2RQ>=9^%2OH#/^C3D<:@DK0!9\D@^?7%+E$MT1>)2B%DNH' MM4$4Z4M01ER[-_&X[T>B@9F<<-*9 7"1SZ)@:CC#);5N \[%$9DFX2S/?0K3 MK$<\I_1$?5V_D]!YYD:O)+2I?]=> %Y=_R"E:N>7P"T E%SAQ>A=0T,O\I52LK*@KT R+D:OV^^GX0( M;AX2?C* [,:++ZQ=C< =FKQ>/[V,&ES MF_Y5I"UD:?<2C[OMB M?-$>FOQYNN_SOVCW7>>80W'!3VFH#1T-^:G09,*;L)4*FY,*.,F%]'2*/A&M M,_Y-+_SC(#<-8H ':NKI.] MOZ3!SMZ;N@GEYW^>]_D>Y[-C,^G_(]\&\P"*0(,_=#A>9N\S./*_?KAG:X^XW(.VD7 M.BM09.>8.NB?3P]" S1< !D !X;"]W;W)K&ULO5A;<]NX%?XK&-7MV#.R)9&2;&=MSSCI[G0[D\LDV?:A MTP>(!$4T%,$ H!7EU^]W#DB*5.3+[D-?)!($#KYS_X";K;%?7*Z4%]\V1>EN M1[GWU:O)Q"6YVDAW82I5XDMF[$9ZO-KUQ%56R907;8I)-)TN)QNIR]'=#8]] ML'ZT*L[T=S4;MP$>]SCT-3.YN*KE6GY3_K?I@\3;I MI*1ZHTJG32FLRFY'][-7K^J.*@@0!QM=&YJC;DA;VGUOIO[#NT&4EG7ICBG_KU.>WHZN12%4FZ\)_ M--M_J$:?!)KJ\OUS<1# M)'V8),WRUV%Y],CR:_'6E#YWXNEP_010.CQ1B^=U]*3 3ZJZ$/%T+*)I M-'U"7MSI%[.\^"7Z"5FFXJ,JI%>IN*=XT%XK)_YSO\(L!,A_G]AQWNTXYQWG M?]:B3RZG)'SE*IFHVQ&RS"G[H$8'6OQ:"B5ML8.-9M=C\5;9Y(N0567- _22 MHD0NK NSD@72IK\0,]96;L3I4-Z','PFI!.5M%Z8#%*0346*8%1"ES"3I.P1 MF4%,8A/D4U9;GRLK3.7U1G\G07@7;\RFDN7N;W^YBF:7/SG$:EEGLN\ 5U<5 MP)?*4\*.:=1LAPK'T%2%++VP/$<6^CL_C,6JUD7J2"M(-_:XV1RC3PT"IC0>5DF*&M:! M>*XMIL0$YTRB.;RVVN<,@;8L,> J79Z;+"-H[^U:EJ:\$/>N#[-5 3MX(]2# M+&K2NF>,S@",!?ZV$I9#B2:5 '5C4E6,L0)67CGUM5:EAZWA10C.-(5'FNJ@ M?8>Z1NY:QG$T+L:\5V+J(FT%[3KOMS((BD @*/*,ZH:3VMH @513FRKDWC,[ M"FF54-\J5&Y,ABE6BO7Q<)Z&PB0-HA1]7>U8CB)S9%0UXO'>]DF]J8L0N4@F M+[]AH?.N$0D/$KQ.1NL%?-4D'KW'!Q$^?<-QX"II/H8B%6NB@T M>?9S3V"[CIPM_<&RY?2O;;0^!G<+H123Z#0 +1+IP2-"/+:-,%<10LC3IVD#2JG5/4A@N-5:DV-1AS8%5.4!X M-@09BQC-I5UC/=6OH6NNIE-T3W8-69":2]])?9( \H,VM7NROCJ1 M2UAII53Y6-@.-0GP&8J'T(%YH"&"5 M[BU[$"6SB_D^@4'ZD#UK+@)65<922(\/5&HCC@I6C9I:F(1W:'+-!3]G!A^V MW"'EJL#T0('U=Q4RJQ'R!PS')6M7*5*"M'F%?2S2O<_&CIA)O",_/C?I](2" MJ@D$=T93VAIRWTO@]]P /K.17S#E#6 27"?) B>">W+T$Y[B&#\+>K@:C%]= MXP2)F\0Q; ]Y8*U*:GL.]I&@IHB5I@WDG M) CZTBLE]@E/Q>\U:\K3*#-?X%" >]ZAF/3_=NBQ,1 -!L9@?=6Q8-FU#-."2,1)1AAQS':Q NKCQ@Q-R!!D39Y^B- M1Z>);:YA@ZVRS%M65'!Z! Y]%83:@?^MBCTQ22\&7AZTY@#VD&50D1I0>ZZ, M>_L?>+'7W.DKB*D.OFG(G2FXT3/&ZD-!V#]:H1? MRI070L802F[(:E]SHX1V'+?4BXG,9FB/(2%HYDO\"J[BEU+1NDYDS\,=!MSF.H$M,(.^??PU,NL(.3PGAF2 M<3=R-[ MG2G2_]6N8P$9W5X102@#0: C $G,K-G@=4V$QM@=Q8_ATDR;&@OD M[[OCV0/Q_);TMJ2M/;ZZH*J0*WPQ)<7>^-CI@(^;+++5DE-N4)0:IK66N@QI M#ENY'V&SD;EG#%D_K6B%=_;O3JO$+,VA3HT*B;(>FW:GGO,!QA^*;-7<*>YU M0JIY@-@GW:ZEYGY2K1\CE.)TMXK/'4!\CN" ":-L'='-.NLPOK\2Q M2\!)[XIUH^! NDAV@JM8N&WM1KN[ZOMP1;N?'BZZW\+_E"&%RK!T>G&Y& D; M+H_#BS<57]BNC/=FPX_4Z96E"?A.ET#M"VW0W>#?_0Y02P,$% @ ^H9E M40:-CKA 'P I&X !D !X;"]W;W)K&ULQ3W9 M= M 'C([HE]D 2"0%965MZ95?KQ099?JJT0=?!UEQ?53\^V=;U_^>)%E6S%+JZ& M5:( M#V50-;M=7#Z^$KE\^.E9^$S?^)AMMC7>>/'SC_MX(^Y$_?O^0PF?7A@H:;83 M197)(BC%^J=GU^'+5Q-\GA[X5R8>*NOO3L\6S(!7KN,GK MC_+A5Z'F,T5XB#AIJEKNU,N P2XK^&_\5='!>6$Q.O!"I%Z( M"&\>B+!\'=?QSS^6\B$H\6F AAOJQQR:+>5L$O12I2__T7@)+!*])X MO8J. KP3^V$P'@V":!2-CL ;FWF."=[X +S7HLSN8^0 =Z)!7*3!KR+=9,4F MN$8&R>I,5,'KK$IR636E"/[G>@6/ _/\[Q$L)@:+"6$Q^5YJ?P.8X&E3_+05 MP8W<[>/B$?BI &L@AKN97 KJ0.Y#D#B@:>+0'Q-MG&Q$4$9UR+8R7MA 6=% M+4I1U>WO0-XR^"/BLH!QJT&0Q-4V6(,*X/?6<58&]W'>P*@P5%Q50D',LWB5 MY8QCO2UEL]D&H(( /@@QS'@GXH*?U-\BUDTE$,Y]7&:RJ8*U(5!F*3& #TG> MI$B(U-+*>6(87 <53#E;9TEEJ0Z ')MR?7W_UI$X?R'"G32O2AP!HB- MGBK ,Y2+UVN8"E &[@(QONYE)0!O&3!!O6<]*@,FN#YR]5F0UN(AXB2135$C M_J7(X3&"U8>9!IHT92F*Y#$HL^J+6F:<:; OY::,=P.@?/ *A'_XH+YZ]E^ M*[;L$X-HI" E38536J%R'P9OU+ W>MB/"."=!> RW1:&A)'B59Z!^DHU-8,M M\^H E&T.BR@"-DX=7( @!=S/"B!/3;?4FWIR%5('KFN@81!O8ESHX%X"X9"_ M'HG%FQIEO$.N%K>ZRV48%QYJ:.Z/3UY.S5"M*6O$D5D ]5*D#4P?'T2^9K%X M?,JP\&Y<@UEL\A1Y$>F T'X?W@V#5.9YK*=B2>',G&0$1EJ7 J^O,B"-!,;: M9D +> ^F;L@T<'D;["*P*5)*!+$KFZS%9-+2"8LR $(-R+(DR@0 'EH34'M@754*0 M/"8Y3N9Q#VHE!_(4$E1EB=.-BZ!^D$" MJP8GB70;.&45CH<@' *UL>>74Q;Y8(.*%XT=0N+AS9Q25 **5]M0&+LSAH$5 M1;KZJE(E8!XFLZJN5*,0Z(Y4$VE(S;2+![P,.#&#AFA(4N5ROP4:0 M\B-%"@0"EM,21!K8LU-&T#.E/1-9DM8$=.%%-B""4$!4M AZUJ#/1F9DI^HL MR?;,4B78HYA=3(T82D*!#^!B/V3U-M@W)2"'5,@E\(#ESGT#P^\54D#"A[A$ M5 MR.1AQ^V[",JN>9_Q:EA3F!,+EF#<'5HE2!V1(>?$%( 8$5K;W A4DK&>5 M$?#+ *3 M<47P"*5^ST\S>()'E^!V,%5)?,L);*\4LK[#I7W$*3>J*K:0QIQ M/HVM 41@!.02919C3D3L;:F%U!^S]_ HI5BB[$#67CX+(*+X/W-;7 Y@/$@ MI"$W -;L82OH%43+]0I0_Z$O0+,!:J'2(%=%Z2!WW6&50 #7025998&D"\U4 MWI-D(IUA*JM(_-&,&E:2SG"; D0\S_Z$9\BT: M]AOD,3)=$YV(]^#]'!@$'"*" 0KBCF0;J,8KJ76)(Q%:)K.*A@=W"A#FF==; MZ7$G LI@:1'50M8GB0#*.0!%!<@B_\)40;,G1AEV==#@&,G:].&9.:S& N98 M1+*$*Z"=AR@Z(K*X;+ >HXO=5R2[FKX0_X-3/ &D7F#R/C: M*94 !RDHT*+Q2KED7B/QRYB9'F)R4/#(";CLH%[0+SV@[GH1UKX7J0ZK$X*X M9O*QCJN:%:CP#$)]G"&2F2S,#A[>H(8F4T->":V=4=_ RCL)X/'%_L# 1S7. M*XD! #QVPF?4_E4'"ZVW 0V<5WMX1TBM+P%SBJT>ETJ)Q'C7SMQZY$V1J C& MO$/LU**"XY_VN'5#B.R4G*.APJD"C[\#'^:+9W,:!/$GKSM9%$-NG=<>$]3XC8#>[* M#%G@#>BMPM4O/)T=^+] S13U4+67M0J"T&'@X(>-9$M)D)-+3EJ+/9SPRH%F MJ :WV=FX8,-Y27XST&E .D1Y9UV/KM?4*1-&47Z)G%)^X9B"KFJ3ZS@^(EAX M4+.PBOGCP(M46]Y7!ZFMR/>^2FR]8GPU#ELMI?N7.*XYDH+@7AS(=Y@5]4/6 M 7X6^]K&(K5B,?R$ZW"ET4\S6"N$H0P">A;VEB&TF]!)&Z$!5UM8QBM0(#L. M,+CI/8J]#(? C*F9C$ 4*[@Y9K./Z M^4"TVTI[.$0UB;+*)#QL3B[KSTKTLV@O>RH*=<>/NQ@P\._S6#N\0JXTQW!! MG'YN% 8HO2B.X+:RTXK5"')Y\1:FS'(=,]#2@Z.'B*#[FXN:KE&9U.C%TD*; M;_+LCP;UG9,%M&K'7U2@;0ZZ'=Q64=8<2Y6\%)JQF/1^$DDM:7\^TGH(-G"V M<06K*E2%R&X7:OR4D >^@_EC ML'"8=STY#IE.S*QCV>0*,]QH4S.=T]@B[=<&0B]]!LC&QF(T)O>!.O.JEE=* M=\9[\/O +?TVR\B,_M=8QC>=+!TZJ#!G4@CLJ/;FM7N26JO:6Q/C:%:BR("? M&T K(16-WM>5:W-!*6)V!G792HC"%_6!L4&&O>AN3[#U!%7@&Z9>J5:A=%M+ M*(UM## L79/4C5)RRJ!WIHCD\00))\39_V_6+$QNQS_H2[SW9*19U6G=I-CF M +/<<@B.V()]>B@XL?XRN-ZA/XQ/?"C!M_H:7/P#Z'09O,6?O&TTBC3"X WLI=BL8 LM\ MOZ$"./+]=P.X>(YSVD';08I%]I !*)7]:=26VE&LOI,485!6)/J) 'JOQ M[.)'4F%^6:EZB/<.A4 ZM,ETE"W(RDJ6I7P@K6XU1,5>,0YGG"$3O]-$W*&T MXTFB9THJ^!Z:&;#U)IHR@QU(K. T#Y06,#L &]BG]9,!PE V MWM$+CBEQ2C28"S91/!BJ?5;#WYCS&!3ZOQ&KLL& !_D3-"G;PS9M*PYG \. MGC03 ![/H^E("P'G:LB-%:GVH/E]H_O)%P*\2ZZ>=!7>\W 838,50QP$X7 Q M_1O@]56D5X0/4JJ&5#=EVWI)7GYT7\,>9WN'0#4,()7#]> M@2&GL!4K 8D A*]H[.,,Y_NVCEOD)!+;,\@*'0UL19>R0$3U56STJY,=[4"+ M$0G@^)PU+>6,B2:JD-HE1D=_?8C+X%_:R7J-]NZWAMX@,^(*Z!TMZ:\"..R3 M1(["&Z CUF,1?#4:C8*)^AL-QVU( M^$A$=0@@HT&0JG$'88$Y^: M__\YH4\^AX.:@[&+FF,&3!?K"$M+E*&(++H^DU=<DNW\)95;&K2?+.RF+Z5V' #RI:6 MCRJIJN[FI"6013F90JXW*PM6&M%D"7^GY.J@GPD/?L('26=%@_%H&8P'$_@- M7@YH]0_,&;V*D1HCCI0/552Y*=&990:HQ*84&^*/E:@?!)6MVD6H T6XGIJP M\N$1@'FI/YO7>O'E>:ODZ]FJQ*'SX,9_&BG5=L8]T[WZHQ1KAGZ;&Q> MBLCL@ >N;R#/C8[#@JBU;%2%3WK8N[G.4YYXJ$S>D1BAES3CD0$Q&801(A^9 M.[-!&,Y/@U1TF"XM-H/%(@RF4XPHUO MLM"@W_:!!@K,G4_3,<54"PJQ2-=$@]ET A<1C F_\3*<#.;1PN-C\'S.X.6G M+A=$=J''KM/!A#3@S.?P.2C$Z5]([WD8+ :CB66-^1ANS)9C',-+[+J&\DY M<%)@/FX'6J"J9?+EB0,;K^\0WRN"A,LQ+\-D.=?4F//*#99C7+QHC 8B6M+U M'!0 OA8M\".] NIR!J]=4V2%^*UDNS>,O86JE4KM,0=/:EIQXT#L5MQA9T&) M$2=[16!95&J=G+.*8K[<]*1Y/:A9W9#"I<*F**DTB5TUE2!L$H%K9-+%-^"# M9C6'UF3Y+G6N/L]51$Q6<5_*^RPEMXS[\\D<%[V1FI-"M15[".L_4UN@5.Y@ M>XYEB>RI;%^%32[PW"/G$_;&5!.=,1(G*@_ 955H4M\!EHPPRXLS4Y58[%ZT ME.!F//)/J<6I)CIJV4BQ'4,E=@DYA_"<[F>V3IAH5;-'QP2^*L17<:[A;9O+ M4X;Q'\14KK=J$V>JBJ0X+'$YS"\]MGA?L[P/VUDB13Q$],@RH3]BGSP;F8MP M,KK4OQ<3]>NFM2@JS$Z[":?QQ&:E,&FF\8YJG=Q[J1J#CJ5#T;,]UGF& M2%W^97!.YD*__X%3V=3O_?Y;L[%]5W8WA T_37SC9&Y^L:E[UX,N;:#*,1!' MPA]U $I^Q92,$ER,R21=C,,(L[;CJ<[O7D0+OC&8S)'=QY/!R,5L/*)O M9O0I7-(G#(Y4YIWZ*F71#DT[?'C<5U716T93[B:#03;#\4E7%9RGA IU0E+W>2$+&7I;?(^47X"E0SF70I[JUD]N'Q*HSAG'#.E8I/A[<1 MF#:Q0RUB3GO8T6$I=$=-A\_17]!E.^OS(K\X'5:VLE]7KI!!YLL8Y!CM2V#.G)7!XO,9N< :T#EOH.!HQGFC_Y[YFDL M('-3'Y7J^G>YZ=[HCWZK&?&3;?5WQDH%IJI!;=$VNAC[2?(V4)B>ZO"CBKH:P?_R1X/!X!VVVC#3WOJ!>.:_F.H7!;]8V1>SBF>(D?.Y02MH\K*F M&7/(^+OE!?)P3WW?ULS_(+J]99IY'RBSO,&5+\SN2]0XB3>'Y\%\U]$LZ71KLX *PA904%UG9N3QAJD9R=*B@?V,68.3KTPFRUZ[]W(($^WH=DIT"%46S('0^S54-ESC))_WL$.EG ME%B?SS@ ;^7;YXMI\*%9Y5F24Q<4;;?J<"?:A!!"FWFP&"]<%'B#VJG7<: I MY6NCP0S]4P#G,".%OG[\_B2?LSL@:$[:+9I3,WB/,%$"Z_G%!'2ZUJLXE><7 M4XSL]"U=@L)MH\$?35Q2^@GWKVJZ#!J:89HTJ\8AFY6[QU'("HBM)DUVM2U)L\OKOP]5BP&3CL>.[.< M[<:YQX7:\ C7^SCC%4+A)>_4A"Z/P46,+BIM:0>09J>T;>T# #ML.XS3^[BH MP8_",TM4M[JNF)BA+%SLKE8;*7._:UJW-B@85%W"H52C/=5.+$5HRY.O[=3V M23<'F8D2H\='E3W=Q5]!(_TI*KX^VA3=AVFK'2/FMS,1 M\59 M%:J%(#/160ER1QXC NS5C6IB]<:H[#12 AM@[H&(F;-UYH-]*#W'?CPD(>1L)$A;_[F0* M;#>@HVZH7IDZ^>>= '"IS.5&DU@O0BV2;9']@>"Y-.SL0>L1!.\8GG[DD=2V M =4H57/XAN7^$I4R;F1U!_WECTNQ MDW>UG-1SLUMC;:GHVD[&[35YYVPA=8M$6-_^B(XW*:I7U$OPYA1EW/VH;LFQ MH.R^!J8:%8G3\6 \LLIJW\GQ;[7JT)I&"P<';\>__:8V1$52-U=R M,+#W,@!'/AV[>G*@WQ?P?U^@[T;XYT3[YQ0;W%C?O3XO!7,V]-'2NSZ= @@' MXYYB$]^=AMT4"M[C;R/OZ4A],X_<)K1H,E9>L3Z/!L+P\Z8\GW3&AENS+JYP MZXQICN;=2<*]<=0%B/?"1;=@BO?&BY[G%R.WYJ)G.KXTN?V>^H(!&L[ZKV=+ M[[I;)K8PG$?=MZ;NY0=[W)#9=,\'#MFEG?1=8NM?WS7VN/1>+Q;>-:L>TTX7 MJJ)[- G;*:LE*HD%-\T,1F$KH3A8AJ&GU)FO7,U\(^D8/>0I?40#&Z)^C;.( MEN9W?X9MKGX[J^L=GG3>$D?S:>_UTKM\:AVHI\03G4ZC_AODH1;%828(3UP= MX\-3?_L@8I-4W_5R[EXR$[FT]WB#>(87,AR$D9\,7<[-6BYF$U+6'\Q!)NCE MN/YLCW:G@!6#C)RK/&EP<0>N<8J+]?=XM_\A^"!E2>/1\9&\N0(+_-?7I-O> M29G:ACTVI+*L8%7+>PQ.G3?B^'(0Z"V^]K@5+&YC"$\5AUQ"2* \"L\ M? 3[.>%;%=NB%XHG':"7^D!'V(KT2A]QD',3Y=H98*K.JD/W5%2JTN:71VQZ M3;H*G;>7X!%[B:K>UG0(@GLLIPY^]_&C=N'4P2J8V,(#A,1NG\M'(0)S;%P> M.\4YU\_J.,EN54RAV3[SE'Q3IAKMS:9#ZKR.3>5SNK#LOEZ_XQ(W\#K !NT# M1MB?)ZYI'50QQ&Y7>.) 7K7C>PVXA\ET4:)9 R+X"_)\-ISIG7J<2ED,E^:& M[JQQ7O7S*\&%PE/G[G5,N5D&OOWU2N]H?NM^_-_1D2? MAQ.[:=4]P3#N=*@_NHL+N!Y]E!O.]ATDW=*8!HC(C M?:%/*&S!TN>#6<*UJ.5(D#H$MI2/<0[?[C7/ =0P'$[_AK$KKK5J!%B35=3' MC\FT273B1O>'W^-QS* [*IE3_@9Q\V>@3[MHD3>:=#9;TM1 7IV$:.5E;NC0 M,YW$L^*D>@U(2V<[94 !W<_,&\ZV2,[]Q*2MKW2*S^1^V)&!=Q=_XY.%J?M= M(5=[&RQ5DX.1>.Q>.:2G,M7XY#.#HZ1P2 "WR]1V@=\@2 TBM2/ 7:)C0]"I MA=RJX?*=SXU6/<#[A3HWWVP\_2[^9,UQ*&-QAPUA!X[4.'"6M\Z$)H<,W\#U M<+A.S7L849>1+[+.F0.ROF/!8O*;>',F+;$^#HJ.D_FJ&G-<=\.<+06W.J=+ MJ=-#^G0\M3.V]UBV-E1>6!^IM?ORLE][#FC#_/-QY-A\.NBXU/8P;LV/2W6+ MX=SS$>*Z3_$1;'AV\238L^%8/S]T;=<#GP2N*,-"B&N'#F G\:Q2WHC;-WHB MPQ,;;MYSF:782).>\^N!8"\R\LN3#AS7=VP[((E),R'R3EHCJZH&SPA$SPU$)_*FH18:JX M%IBF)@P#*@ :/(;6Z70+@#@(..6)4+O9;667/E*E36/P."R_4-G=@"CRO92_,L>:Q.3O)QDNH%0A>6C8;+#P -(!8ZJU+ M= A$";"VLJ+S/N#2S7AM].F7^G2HK0#3O$7Y,MN_%+#]-@;/&2BA0R-^I6R? M[*JYU\_N@VT@SYO\L4+OIGH );-EMUEM:^/_28)C5E(EY6LJ&^V1%EB8Y+/* MU/RJO2S:__* 5:1:?G7L=\\!>6S.&HZY%-;!)I' MYQVBI7.8IXH*3AQY<<9!%[=V@,F^U00G3W2D*+SYS MLG6"B +\'>2D556AJB4C^WX]+/I !^NH!@3LZ'+RL;U^I/H?#F!UR?4@MKSU MM,.=/NG)VXIPK50#BDMG5ZJV/^W-JNU=PJ>]W0.[ADD]JO#XP+97?9Z3^DC* ME ZE1)-1<5""REM5B]TMGAPLV]VWWG'Y7J>_GP@[4 8=],Y3.TKJ]"9SMK%[ MVY[(:G<*#P_O2%7AI5%V*/[Z'P*U",B^L=.WU>/EZO_9DN-N!WR(S@\#7[Y@ M_G-0R/S@Z;R-]$,\GZV]YYE.N<*NH*0[(0HB?3XXE"0$Q=*=3]__KWKA_.

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end XML 88 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 89 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 90 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1137 391 1 false 172 0 false 9 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.merck.com/role/CoverPage Cover Page Cover 1 false false R2.htm 1001002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME CONDENSED CONSOLIDATED STATEMENT OF INCOME Statements 2 false false R3.htm 1002003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME Statements 3 false false R4.htm 1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET CONDENSED CONSOLIDATED BALANCE SHEET Statements 4 false false R5.htm 1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 5 false false R6.htm 1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS Statements 6 false false R7.htm 1006007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) Sheet http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical) Statements 7 false false R8.htm 2101101 - Disclosure - Basis of Presentation Sheet http://www.merck.com/role/BasisofPresentation Basis of Presentation Notes 8 false false R9.htm 2103102 - Disclosure - Acquisitions, Research Collaborations and License Agreements Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements Acquisitions, Research Collaborations and License Agreements Notes 9 false false R10.htm 2107103 - Disclosure - Collaborative Arrangements Sheet http://www.merck.com/role/CollaborativeArrangements Collaborative Arrangements Notes 10 false false R11.htm 2111104 - Disclosure - Restructuring Sheet http://www.merck.com/role/Restructuring Restructuring Notes 11 false false R12.htm 2116105 - Disclosure - Financial Instruments Sheet http://www.merck.com/role/FinancialInstruments Financial Instruments Notes 12 false false R13.htm 2129106 - Disclosure - Inventories Sheet http://www.merck.com/role/Inventories Inventories Notes 13 false false R14.htm 2133107 - Disclosure - Other Intangibles Sheet http://www.merck.com/role/OtherIntangibles Other Intangibles Notes 14 false false R15.htm 2135108 - Disclosure - Long-Term Debt Sheet http://www.merck.com/role/LongTermDebt Long-Term Debt Notes 15 false false R16.htm 2137109 - Disclosure - Contingencies Sheet http://www.merck.com/role/Contingencies Contingencies Notes 16 false false R17.htm 2139110 - Disclosure - Equity Sheet http://www.merck.com/role/Equity Equity Notes 17 false false R18.htm 2142111 - Disclosure - Share-Based Compensation Plans Sheet http://www.merck.com/role/ShareBasedCompensationPlans Share-Based Compensation Plans Notes 18 false false R19.htm 2147112 - Disclosure - Pension and Other Postretirement Benefit Plans Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans Pension and Other Postretirement Benefit Plans Notes 19 false false R20.htm 2151113 - Disclosure - Other (Income) Expense, Net Sheet http://www.merck.com/role/OtherIncomeExpenseNet Other (Income) Expense, Net Notes 20 false false R21.htm 2155114 - Disclosure - Taxes on Income Sheet http://www.merck.com/role/TaxesonIncome Taxes on Income Notes 21 false false R22.htm 2157115 - Disclosure - Earnings Per Share Sheet http://www.merck.com/role/EarningsPerShare Earnings Per Share Notes 22 false false R23.htm 2160116 - Disclosure - Other Comprehensive Income (Loss) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLoss Other Comprehensive Income (Loss) Notes 23 false false R24.htm 2163117 - Disclosure - Segment Reporting Sheet http://www.merck.com/role/SegmentReporting Segment Reporting Notes 24 false false R25.htm 2202201 - Disclosure - Basis of Presentation (Policies) Sheet http://www.merck.com/role/BasisofPresentationPolicies Basis of Presentation (Policies) Policies 25 false false R26.htm 2304301 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Tables) Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables Acquisitions, Research Collaborations and License Agreements (Tables) Tables http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements 26 false false R27.htm 2308302 - Disclosure - Collaborative Arrangements (Tables) Sheet http://www.merck.com/role/CollaborativeArrangementsTables Collaborative Arrangements (Tables) Tables http://www.merck.com/role/CollaborativeArrangements 27 false false R28.htm 2312303 - Disclosure - Restructuring (Tables) Sheet http://www.merck.com/role/RestructuringTables Restructuring (Tables) Tables http://www.merck.com/role/Restructuring 28 false false R29.htm 2317304 - Disclosure - Financial Instruments (Tables) Sheet http://www.merck.com/role/FinancialInstrumentsTables Financial Instruments (Tables) Tables http://www.merck.com/role/FinancialInstruments 29 false false R30.htm 2330305 - Disclosure - Inventories (Tables) Sheet http://www.merck.com/role/InventoriesTables Inventories (Tables) Tables http://www.merck.com/role/Inventories 30 false false R31.htm 2340306 - Disclosure - Equity (Tables) Sheet http://www.merck.com/role/EquityTables Equity (Tables) Tables http://www.merck.com/role/Equity 31 false false R32.htm 2343307 - Disclosure - Share-Based Compensation Plans (Tables) Sheet http://www.merck.com/role/ShareBasedCompensationPlansTables Share-Based Compensation Plans (Tables) Tables http://www.merck.com/role/ShareBasedCompensationPlans 32 false false R33.htm 2348308 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables Pension and Other Postretirement Benefit Plans (Tables) Tables http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans 33 false false R34.htm 2352309 - Disclosure - Other (Income) Expense, Net (Tables) Sheet http://www.merck.com/role/OtherIncomeExpenseNetTables Other (Income) Expense, Net (Tables) Tables http://www.merck.com/role/OtherIntangibles 34 false false R35.htm 2358310 - Disclosure - Earnings Per Share (Tables) Sheet http://www.merck.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.merck.com/role/EarningsPerShare 35 false false R36.htm 2361311 - Disclosure - Other Comprehensive Income (Loss) (Tables) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossTables Other Comprehensive Income (Loss) (Tables) Tables http://www.merck.com/role/OtherComprehensiveIncomeLoss 36 false false R37.htm 2364312 - Disclosure - Segment Reporting (Tables) Sheet http://www.merck.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://www.merck.com/role/SegmentReporting 37 false false R38.htm 2405401 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details) Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details) Details http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables 38 false false R39.htm 2406402 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details) Sheet http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details) Details 39 false false R40.htm 2409403 - Disclosure - Collaborative Arrangements - Narrative (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails Collaborative Arrangements - Narrative (Details) Details 40 false false R41.htm 2410404 - Disclosure - Collaborative Arrangements - Schedule of Transactions (Details) Sheet http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails Collaborative Arrangements - Schedule of Transactions (Details) Details 41 false false R42.htm 2413405 - Disclosure - Restructuring - Narrative (Details) Sheet http://www.merck.com/role/RestructuringNarrativeDetails Restructuring - Narrative (Details) Details 42 false false R43.htm 2414406 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details) Sheet http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails Restructuring - Charges Activities by Type of Cost (Details) Details 43 false false R44.htm 2415407 - Disclosure - Restructuring - Activities by Program (Details) Sheet http://www.merck.com/role/RestructuringActivitiesbyProgramDetails Restructuring - Activities by Program (Details) Details 44 false false R45.htm 2418408 - Disclosure - Financial Instruments - Narrative (Details) Sheet http://www.merck.com/role/FinancialInstrumentsNarrativeDetails Financial Instruments - Narrative (Details) Details 45 false false R46.htm 2419409 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails Financial Instruments - Effect of Net Investment Hedges (Details) Details 46 false false R47.htm 2420410 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details) Sheet http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails Financial Instruments - Summary of Interest Rate Swaps Held (Details) Details 47 false false R48.htm 2421411 - Disclosure - Financial Instruments - Fair Value Hedges (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails Financial Instruments - Fair Value Hedges (Details) Details 48 false false R49.htm 2422412 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details) Details 49 false false R50.htm 2423413 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details) Details 50 false false R51.htm 2424414 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) Sheet http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details) Details 51 false false R52.htm 2425415 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details) Details 52 false false R53.htm 2426416 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails Financial Instruments - Information on Available-for-sale Investments (Details) Details 53 false false R54.htm 2427417 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Sheet http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) Details 54 false false R55.htm 2428418 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Sheet http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details) Details 55 false false R56.htm 2431419 - Disclosure - Inventories - Inventories (Details) Sheet http://www.merck.com/role/InventoriesInventoriesDetails Inventories - Inventories (Details) Details 56 false false R57.htm 2432420 - Disclosure - Inventories - Narrative (Details) Sheet http://www.merck.com/role/InventoriesNarrativeDetails Inventories - Narrative (Details) Details 57 false false R58.htm 2434421 - Disclosure - Other Intangibles (Details) Sheet http://www.merck.com/role/OtherIntangiblesDetails Other Intangibles (Details) Details http://www.merck.com/role/OtherIntangibles 58 false false R59.htm 2436422 - Disclosure - Long-Term Debt - Narrative (Details) Sheet http://www.merck.com/role/LongTermDebtNarrativeDetails Long-Term Debt - Narrative (Details) Details 59 false false R60.htm 2438423 - Disclosure - Contingencies - Narrative (Details) Sheet http://www.merck.com/role/ContingenciesNarrativeDetails Contingencies - Narrative (Details) Details 60 false false R61.htm 2441424 - Disclosure - Equity - Rollforward Reconciliations (Details) Sheet http://www.merck.com/role/EquityRollforwardReconciliationsDetails Equity - Rollforward Reconciliations (Details) Details 61 false false R62.htm 2444425 - Disclosure - Share-Based Compensation Plans - Expense Allocations (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails Share-Based Compensation Plans - Expense Allocations (Details) Details 62 false false R63.htm 2445426 - Disclosure - Share-Based Compensation Plans - Narrative (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails Share-Based Compensation Plans - Narrative (Details) Details 63 false false R64.htm 2446427 - Disclosure - Share-Based Compensation Plans - Assumptions Used for Options Granted (Details) Sheet http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails Share-Based Compensation Plans - Assumptions Used for Options Granted (Details) Details 64 false false R65.htm 2449428 - Disclosure - Pension and Other Postretirement Benefit Plans (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails Pension and Other Postretirement Benefit Plans (Details) Details http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables 65 false false R66.htm 2450429 - Disclosure - Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans (Narrative) (Details) Sheet http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans (Narrative) (Details) Details 66 false false R67.htm 2453430 - Disclosure - Other (Income) Expense, Net (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetDetails Other (Income) Expense, Net (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 67 false false R68.htm 2454431 - Disclosure - Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details) Sheet http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details) Details http://www.merck.com/role/OtherIncomeExpenseNetTables 68 false false R69.htm 2456432 - Disclosure - Taxes on Income (Details) Sheet http://www.merck.com/role/TaxesonIncomeDetails Taxes on Income (Details) Details http://www.merck.com/role/TaxesonIncome 69 false false R70.htm 2459433 - Disclosure - Earnings Per Share (Details) Sheet http://www.merck.com/role/EarningsPerShareDetails Earnings Per Share (Details) Details http://www.merck.com/role/EarningsPerShareTables 70 false false R71.htm 2462434 - Disclosure - Other Comprehensive Income (Loss) (Details) Sheet http://www.merck.com/role/OtherComprehensiveIncomeLossDetails Other Comprehensive Income (Loss) (Details) Details http://www.merck.com/role/OtherComprehensiveIncomeLossTables 71 false false R72.htm 2465435 - Disclosure - Segment Reporting - Narrative (Details) Sheet http://www.merck.com/role/SegmentReportingNarrativeDetails Segment Reporting - Narrative (Details) Details 72 false false R73.htm 2466436 - Disclosure - Segment Reporting - Sales of Company's Products (Details) Sheet http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails Segment Reporting - Sales of Company's Products (Details) Details 73 false false R74.htm 2467437 - Disclosure - Segment Reporting - Revenues by Geographic Area (Details) Sheet http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails Segment Reporting - Revenues by Geographic Area (Details) Details 74 false false R75.htm 2468438 - Disclosure - Segment Reporting - Profits to Income Before Taxes (Details) Sheet http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails Segment Reporting - Profits to Income Before Taxes (Details) Details 75 false false All Reports Book All Reports mrk-20200930.htm exhibit311-rule13ax14a.htm exhibit312-rule13ax14a.htm exhibit321-section1350.htm exhibit322-section1350.htm mrk-20200930.xsd mrk-20200930_cal.xml mrk-20200930_def.xml mrk-20200930_lab.xml mrk-20200930_pre.xml http://xbrl.sec.gov/country/2020-01-31 http://fasb.org/us-gaap/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/srt/2020-01-31 true true JSON 92 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mrk-20200930.htm": { "axisCustom": 0, "axisStandard": 36, "contextCount": 1137, "dts": { "calculationLink": { "local": [ "mrk-20200930_cal.xml" ] }, "definitionLink": { "local": [ "mrk-20200930_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "mrk-20200930.htm" ] }, "labelLink": { "local": [ "mrk-20200930_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml" ] }, "presentationLink": { "local": [ "mrk-20200930_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml" ] }, "schema": { "local": [ "mrk-20200930.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd" ] } }, "elementCount": 650, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 5, "total": 5 }, "keyCustom": 25, "keyStandard": 366, "memberCustom": 94, "memberStandard": 72, "nsprefix": "mrk", "nsuri": "http://www.merck.com/20200930", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.merck.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2107103 - Disclosure - Collaborative Arrangements", "role": "http://www.merck.com/role/CollaborativeArrangements", "shortName": "Collaborative Arrangements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2111104 - Disclosure - Restructuring", "role": "http://www.merck.com/role/Restructuring", "shortName": "Restructuring", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2116105 - Disclosure - Financial Instruments", "role": "http://www.merck.com/role/FinancialInstruments", "shortName": "Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2129106 - Disclosure - Inventories", "role": "http://www.merck.com/role/Inventories", "shortName": "Inventories", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InventoryDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2133107 - Disclosure - Other Intangibles", "role": "http://www.merck.com/role/OtherIntangibles", "shortName": "Other Intangibles", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2135108 - Disclosure - Long-Term Debt", "role": "http://www.merck.com/role/LongTermDebt", "shortName": "Long-Term Debt", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2137109 - Disclosure - Contingencies", "role": "http://www.merck.com/role/Contingencies", "shortName": "Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2139110 - Disclosure - Equity", "role": "http://www.merck.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2142111 - Disclosure - Share-Based Compensation Plans", "role": "http://www.merck.com/role/ShareBasedCompensationPlans", "shortName": "Share-Based Compensation Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2147112 - Disclosure - Pension and Other Postretirement Benefit Plans", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans", "shortName": "Pension and Other Postretirement Benefit Plans", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1001002 - Statement - CONDENSED CONSOLIDATED STATEMENT OF INCOME", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "mrk:CostsExpensesAndOther", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2151113 - Disclosure - Other (Income) Expense, Net", "role": "http://www.merck.com/role/OtherIncomeExpenseNet", "shortName": "Other (Income) Expense, Net", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2155114 - Disclosure - Taxes on Income", "role": "http://www.merck.com/role/TaxesonIncome", "shortName": "Taxes on Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2157115 - Disclosure - Earnings Per Share", "role": "http://www.merck.com/role/EarningsPerShare", "shortName": "Earnings Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2160116 - Disclosure - Other Comprehensive Income (Loss)", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLoss", "shortName": "Other Comprehensive Income (Loss)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2163117 - Disclosure - Segment Reporting", "role": "http://www.merck.com/role/SegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2202201 - Disclosure - Basis of Presentation (Policies)", "role": "http://www.merck.com/role/BasisofPresentationPolicies", "shortName": "Basis of Presentation (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2304301 - Disclosure - Acquisitions, Research Collaborations and License Agreements (Tables)", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables", "shortName": "Acquisitions, Research Collaborations and License Agreements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2308302 - Disclosure - Collaborative Arrangements (Tables)", "role": "http://www.merck.com/role/CollaborativeArrangementsTables", "shortName": "Collaborative Arrangements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2312303 - Disclosure - Restructuring (Tables)", "role": "http://www.merck.com/role/RestructuringTables", "shortName": "Restructuring (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2317304 - Disclosure - Financial Instruments (Tables)", "role": "http://www.merck.com/role/FinancialInstrumentsTables", "shortName": "Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1002003 - Statement - CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2330305 - Disclosure - Inventories (Tables)", "role": "http://www.merck.com/role/InventoriesTables", "shortName": "Inventories (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2340306 - Disclosure - Equity (Tables)", "role": "http://www.merck.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2343307 - Disclosure - Share-Based Compensation Plans (Tables)", "role": "http://www.merck.com/role/ShareBasedCompensationPlansTables", "shortName": "Share-Based Compensation Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i4e806f577f1d4161a6ec76c5fe843849_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2348308 - Disclosure - Pension and Other Postretirement Benefit Plans (Tables)", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables", "shortName": "Pension and Other Postretirement Benefit Plans (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i4e806f577f1d4161a6ec76c5fe843849_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2352309 - Disclosure - Other (Income) Expense, Net (Tables)", "role": "http://www.merck.com/role/OtherIncomeExpenseNetTables", "shortName": "Other (Income) Expense, Net (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2358310 - Disclosure - Earnings Per Share (Tables)", "role": "http://www.merck.com/role/EarningsPerShareTables", "shortName": "Earnings Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2361311 - Disclosure - Other Comprehensive Income (Loss) (Tables)", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossTables", "shortName": "Other Comprehensive Income (Loss) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2364312 - Disclosure - Segment Reporting (Tables)", "role": "http://www.merck.com/role/SegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2405401 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details)", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "shortName": "Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i320a221119db4c07bc18a27ee248eb45_D20201001-20201031", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2406402 - Disclosure - Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details)", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "shortName": "Acquisitions, Research Collaborations and License Agreements - Fair Value of Assets Acquired and Liabilities Assumed (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i4a9981d1599f4c9fb7d007f0ce761c8e_D20200701-20200731", "decimals": null, "lang": "en-US", "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1003004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2409403 - Disclosure - Collaborative Arrangements - Narrative (Details)", "role": "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "shortName": "Collaborative Arrangements - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i06643769b6074ed7af3fc99bd07dea13_D20170701-20170731", "decimals": "-8", "lang": "en-US", "name": "mrk:UpfrontAndMilestonePaymentsMadeToCollaborativePartner", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2410404 - Disclosure - Collaborative Arrangements - Schedule of Transactions (Details)", "role": "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "shortName": "Collaborative Arrangements - Schedule of Transactions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "if30c830280f947a689d5b271c94dc69a_I20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ReceivablesNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-8", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2413405 - Disclosure - Restructuring - Narrative (Details)", "role": "http://www.merck.com/role/RestructuringNarrativeDetails", "shortName": "Restructuring - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "2", "lang": "en-US", "name": "mrk:EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2414406 - Disclosure - Restructuring - Charges Activities by Type of Cost (Details)", "role": "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "shortName": "Restructuring - Charges Activities by Type of Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i86bc194130fc4723a34b349df3e25fc6_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:RestructuringAndRelatedCostIncurredCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i953cc45283754d089c0fca74403dda73_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2415407 - Disclosure - Restructuring - Activities by Program (Details)", "role": "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "shortName": "Restructuring - Activities by Program (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i953cc45283754d089c0fca74403dda73_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestructuringReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2418408 - Disclosure - Financial Instruments - Narrative (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "shortName": "Financial Instruments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i4a02f583d3964919b4c27e3a5357ca81_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2419409 - Disclosure - Financial Instruments - Effect of Net Investment Hedges (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "shortName": "Financial Instruments - Effect of Net Investment Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i4a02f583d3964919b4c27e3a5357ca81_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i41f558a03fc74d9786822fef7d1da9ac_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2420410 - Disclosure - Financial Instruments - Summary of Interest Rate Swaps Held (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "shortName": "Financial Instruments - Summary of Interest Rate Swaps Held (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i8b88f2c1e0ae4b73ae87608bb4344f2d_I20200930", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i2dbc854f67d845b19f16eeb52ee6dd09_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:HedgedLiabilityFairValueHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2421411 - Disclosure - Financial Instruments - Fair Value Hedges (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails", "shortName": "Financial Instruments - Fair Value Hedges (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i2dbc854f67d845b19f16eeb52ee6dd09_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:HedgedLiabilityFairValueHedge", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2422412 - Disclosure - Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "shortName": "Financial Instruments - Fair Value of Derivatives Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "ib4207f99483f4b8f940795c3f462096f_I20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1004005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEET (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeAssets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2423413 - Disclosure - Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "shortName": "Financial Instruments - Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:DerivativeAssetNotOffsetPolicyElectionDeduction", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2424414 - Disclosure - Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "shortName": "Financial Instruments - Location and Amount of Pretax (Gains) Losses of Derivatives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i56d164fbd15a4cc49a0af40f291a943f_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i72e5d87e256e412ea33e143ad6b5753a_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2425415 - Disclosure - Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "shortName": "Financial Instruments - Income Statement Effects on Derivatives Not Designated as Hedging Instruments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i72e5d87e256e412ea33e143ad6b5753a_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2426416 - Disclosure - Financial Instruments - Information on Available-for-sale Investments (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails", "shortName": "Financial Instruments - Information on Available-for-sale Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i953cc45283754d089c0fca74403dda73_I20191231", "decimals": "-6", "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2427417 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "ibe06cede262f48698bafa7ad43037553_D20200101-20200930", "decimals": null, "lang": "en-US", "name": "mrk:InvestmentsPrimaryWeightedAverageLifeofCollateral", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i953cc45283754d089c0fca74403dda73_I20191231", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2428418 - Disclosure - Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "role": "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "shortName": "Financial Instruments - Information About Changes in Liabilities for Contingent Consideration (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2431419 - Disclosure - Inventories - Inventories (Details)", "role": "http://www.merck.com/role/InventoriesInventoriesDetails", "shortName": "Inventories - Inventories (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryFinishedGoods", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InventoryNoncurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2432420 - Disclosure - Inventories - Narrative (Details)", "role": "http://www.merck.com/role/InventoriesNarrativeDetails", "shortName": "Inventories - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "ica983717d6fb4ff095964b0c590cae02_I20200930", "decimals": "-8", "lang": "en-US", "name": "us-gaap:InventoryNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2434421 - Disclosure - Other Intangibles (Details)", "role": "http://www.merck.com/role/OtherIntangiblesDetails", "shortName": "Other Intangibles (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "us-gaap:IntangibleAssetsDisclosureTextBlock", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i6e8d271d2ed8412a9c691bc954924f4b_D20190701-20190930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ImpairmentOfIntangibleAssetsFinitelived", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i41f558a03fc74d9786822fef7d1da9ac_I20200630", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2436422 - Disclosure - Long-Term Debt - Narrative (Details)", "role": "http://www.merck.com/role/LongTermDebtNarrativeDetails", "shortName": "Long-Term Debt - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "ia564edcd14034ec790ba4a71ee6a8622_I20200630", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetImpairment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "ie3bda94820614e02831a1a380b925d56_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LitigationReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2438423 - Disclosure - Contingencies - Narrative (Details)", "role": "http://www.merck.com/role/ContingenciesNarrativeDetails", "shortName": "Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "ie3bda94820614e02831a1a380b925d56_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:LitigationReserve", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesIssued", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i953cc45283754d089c0fca74403dda73_I20191231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2441424 - Disclosure - Equity - Rollforward Reconciliations (Details)", "role": "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "shortName": "Equity - Rollforward Reconciliations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2444425 - Disclosure - Share-Based Compensation Plans - Expense Allocations (Details)", "role": "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails", "shortName": "Share-Based Compensation Plans - Expense Allocations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2445426 - Disclosure - Share-Based Compensation Plans - Narrative (Details)", "role": "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails", "shortName": "Share-Based Compensation Plans - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2446427 - Disclosure - Share-Based Compensation Plans - Assumptions Used for Options Granted (Details)", "role": "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails", "shortName": "Share-Based Compensation Plans - Assumptions Used for Options Granted (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2449428 - Disclosure - Pension and Other Postretirement Benefit Plans (Details)", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails", "shortName": "Pension and Other Postretirement Benefit Plans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i98260ed9d3df462fb119a0a027f31ba2_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanServiceCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "if9ad3599c3a84146ad4a9b8040fa9260_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2450429 - Disclosure - Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans (Narrative) (Details)", "role": "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails", "shortName": "Pension and Other Postretirement Benefit Plans Pension and Other Postretirement Benefit Plans (Narrative) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "if9ad3599c3a84146ad4a9b8040fa9260_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InvestmentIncomeInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2453430 - Disclosure - Other (Income) Expense, Net (Details)", "role": "http://www.merck.com/role/OtherIncomeExpenseNetDetails", "shortName": "Other (Income) Expense, Net (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2454431 - Disclosure - Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details)", "role": "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails", "shortName": "Other (Income) Expense, Net Other (Income) Expense, Net - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2456432 - Disclosure - Taxes on Income (Details)", "role": "http://www.merck.com/role/TaxesonIncomeDetails", "shortName": "Taxes on Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)", "role": "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical", "shortName": "CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i1cde861334fc459fa80a684680fc7c3f_I20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:RestrictedCashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2459433 - Disclosure - Earnings Per Share (Details)", "role": "http://www.merck.com/role/EarningsPerShareDetails", "shortName": "Earnings Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i41f558a03fc74d9786822fef7d1da9ac_I20200630", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2462434 - Disclosure - Other Comprehensive Income (Loss) (Details)", "role": "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails", "shortName": "Other Comprehensive Income (Loss) (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:OciBeforeReclassificationsBeforeTaxAttributableToParent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2465435 - Disclosure - Segment Reporting - Narrative (Details)", "role": "http://www.merck.com/role/SegmentReportingNarrativeDetails", "shortName": "Segment Reporting - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfOperatingSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2466436 - Disclosure - Segment Reporting - Sales of Company's Products (Details)", "role": "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails", "shortName": "Segment Reporting - Sales of Company's Products (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i93e5ad4e49ee427b88261bddb79599d5_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2467437 - Disclosure - Segment Reporting - Revenues by Geographic Area (Details)", "role": "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails", "shortName": "Segment Reporting - Revenues by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "iad5224a3d0f2449a99a2d218b2fc048d_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i486b34b93c1f43e096e999364d31b9be_D20200701-20200930", "decimals": "-6", "first": true, "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2468438 - Disclosure - Segment Reporting - Profits to Income Before Taxes (Details)", "role": "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails", "shortName": "Segment Reporting - Profits to Income Before Taxes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i93e5ad4e49ee427b88261bddb79599d5_D20200701-20200930", "decimals": "-6", "lang": "en-US", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2101101 - Disclosure - Basis of Presentation", "role": "http://www.merck.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "2103102 - Disclosure - Acquisitions, Research Collaborations and License Agreements", "role": "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements", "shortName": "Acquisitions, Research Collaborations and License Agreements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "mrk-20200930.htm", "contextRef": "i35ef2a299cbb49f39a986d8f721813eb_D20200101-20200930", "decimals": null, "first": true, "lang": "en-US", "name": "mrk:AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 172, "tag": { "country_CN": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "CHINA", "terseLabel": "China" } } }, "localname": "CN", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_JP": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "UNITED STATES", "terseLabel": "U.S.", "verboseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r669" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r670" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntitiesTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Container to assemble all relevant information about each entity associated with the document instance", "label": "Entities [Table]", "terseLabel": "Entities [Table]" } } }, "localname": "EntitiesTable", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r671" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r671" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r671" ], "lang": { "en-US": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Information [Line Items]", "terseLabel": "Entity Information [Line Items]" } } }, "localname": "EntityInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r672" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r671" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r671" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r671" ], "lang": { "en-US": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r671" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r667" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r668" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "mrk_A0.500Notesdue2024Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "0.500% Notes due 2024 [Member]", "label": "0.500% Notes due 2024 [Member]", "terseLabel": "0.500% Notes due 2024" } } }, "localname": "A0.500Notesdue2024Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A0.75notesdue2026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "0.75% notes due 2026", "label": "0.75% notes due 2026 [Member]", "terseLabel": "0.75% notes due 2026" } } }, "localname": "A0.75notesdue2026Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A1.125Notesdue2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.125% Notes due 2021 [Member]", "label": "1.125% Notes due 2021 [Member]", "terseLabel": "1.125% Notes due 2021" } } }, "localname": "A1.125Notesdue2021Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A1.375Notesdue2036Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.375% Notes due 2036 [Member]", "label": "1.375% Notes due 2036 [Member]", "terseLabel": "1.375% Notes due 2036" } } }, "localname": "A1.375Notesdue2036Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A1.45notesdue2030Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.45% notes due 2030 [Member]", "label": "1.45% notes due 2030 [Member]", "terseLabel": "1.45% notes due 2030" } } }, "localname": "A1.45notesdue2030Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A1.85NotesDue2020Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.85% Notes Due 2020 [Member]", "label": "1.85% Notes Due 2020 [Member]", "terseLabel": "1.85% Notes Due 2020" } } }, "localname": "A1.85NotesDue2020Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A1.875Notesdue2026Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "1.875% Notes due 2026 [Member]", "label": "1.875% Notes due 2026 [Member]", "terseLabel": "1.875% Notes due 2026" } } }, "localname": "A1.875Notesdue2026Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A2.35NotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.35% Notes Due 2022 [Member]", "label": "2.35% Notes Due 2022 [Member]", "terseLabel": "2.35% notes due 2022" } } }, "localname": "A2.35NotesDue2022Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.35notesdue2040Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.35% notes due 2040 [Member]", "label": "2.35% notes due 2040 [Member]", "terseLabel": "2.35% notes due 2040" } } }, "localname": "A2.35notesdue2040Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.40NotesDue2022Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.40% Notes Due 2022 [Member]", "label": "2.40% Notes Due 2022 [Member]", "terseLabel": "2.40% notes due 2022" } } }, "localname": "A2.40NotesDue2022Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.45notesdue2050Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.45% notes due 2050 [Member]", "label": "2.45% notes due 2050 [Member]", "terseLabel": "2.45% notes due 2050" } } }, "localname": "A2.45notesdue2050Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_A2.500Notesdue2034Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "2.500% Notes due 2034 [Member]", "label": "2.500% Notes due 2034 [Member]", "terseLabel": "2.500% Notes due 2034" } } }, "localname": "A2.500Notesdue2034Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "mrk_A3.875NotesDue2021Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "3.875% Notes Due 2021", "label": "3.875% Notes Due 2021 [Member]", "terseLabel": "3.875% notes due 2021" } } }, "localname": "A3.875NotesDue2021Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "xbrltype": "domainItemType" }, "mrk_AcceleratedDepreciationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Accelerated Depreciation [Member]", "label": "Accelerated Depreciation [Member]", "terseLabel": "Accelerated Depreciation" } } }, "localname": "AcceleratedDepreciationMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "mrk_AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information related to acquisitions, divestitures, research collaborations and license agreements.", "label": "Acquisitions Research Collaborations And License Agreements [Text Block]", "terseLabel": "Acquisitions, Research Collaborations and License Agreements" } } }, "localname": "AcquisitionsResearchCollaborationsAndLicenseAgreementsTextBlock", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreements" ], "xbrltype": "textBlockItemType" }, "mrk_AdempasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Adempas", "label": "Adempas [Member]", "terseLabel": "Adempas" } } }, "localname": "AdempasMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AllianceRevenueAdempasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alliance Revenue - Adempas [Member]", "label": "Alliance Revenue - Adempas [Member]", "terseLabel": "Alliance revenue - Adempas (2)" } } }, "localname": "AllianceRevenueAdempasMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AllianceRevenueKoselugoMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alliance revenue - Koselugo", "label": "Alliance revenue - Koselugo [Member]", "terseLabel": "Alliance revenue - Koselugo" } } }, "localname": "AllianceRevenueKoselugoMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "domainItemType" }, "mrk_AlliancerevenueLynparzaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Alliance revenue - Lynparza [Member]", "label": "Alliance revenue - Lynparza [Member]", "terseLabel": "Alliance revenue - Lynparza (1)" } } }, "localname": "AlliancerevenueLynparzaMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AmortizationOfPurchaseAccountingAdjustments": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortization of purchase accounting adjustments.", "label": "Amortization Of Purchase Accounting Adjustments", "negatedLabel": "Amortization of purchase accounting adjustments" } } }, "localname": "AmortizationOfPurchaseAccountingAdjustments", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_AnimalHealthsegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Animal Health segment [Member]", "label": "Animal Health segment [Member]", "terseLabel": "Total Animal Health segment sales", "verboseLabel": "Animal Health segment" } } }, "localname": "AnimalHealthsegmentMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AntelliqMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Antelliq [Member]", "label": "Antelliq [Member]", "terseLabel": "Antelliq" } } }, "localname": "AntelliqMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "mrk_ArQuleMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ArQule [Member]", "label": "ArQule [Member]", "terseLabel": "ArQule" } } }, "localname": "ArQuleMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "mrk_ArcoxiaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Arcoxia [Member].", "label": "Arcoxia [Member]", "terseLabel": "Arcoxia" } } }, "localname": "ArcoxiaMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_AstraZenecaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "AstraZeneca [Member]", "label": "AstraZeneca [Member]", "terseLabel": "AstraZeneca" } } }, "localname": "AstraZenecaMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "domainItemType" }, "mrk_AtozetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Atozet [Member]", "label": "Atozet [Member]", "terseLabel": "Atozet" } } }, "localname": "AtozetMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_BayerAGMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bayer AG [Member]", "label": "Bayer AG [Member]", "terseLabel": "Bayer AG" } } }, "localname": "BayerAGMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "domainItemType" }, "mrk_BelsomraMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Belsomra [Member]", "label": "Belsomra [Member]", "terseLabel": "Belsomra" } } }, "localname": "BelsomraMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_BridionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Bridion [Member].", "label": "Bridion [Member]", "terseLabel": "Bridion" } } }, "localname": "BridionMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet": { "auth_ref": [], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net", "label": "Business Combination, Recognized Identifiable Assets Acquired (Liabilities) Assumed, Other Assets And Liabilities, Net", "terseLabel": "Other assets and liabilities, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredLiabilitiesAssumedOtherAssetsAndLiabilitiesNet", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CaliforniaStateCourtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "California state court.", "label": "California State Court [Member]", "terseLabel": "California state court" } } }, "localname": "CaliforniaStateCourtMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_CancidasMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cancidas [Member].", "label": "Cancidas [Member]", "terseLabel": "Cancidas" } } }, "localname": "CancidasMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_CasesCompanyAgreedToTollStatuteOfLimitationsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cases Company Agreed To Toll Statute Of Limitations[Member]", "label": "Cases Company Agreed ToToll Statute Of Limitations [Member]", "terseLabel": "Cases Company Agreed To Toll Statute Of Limitations" } } }, "localname": "CasesCompanyAgreedToTollStatuteOfLimitationsMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_CollaborativeArrangementProfitSharing": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Profit Sharing", "label": "Collaborative Arrangement, Profit Sharing", "terseLabel": "Alliance revenue - profit sharing" } } }, "localname": "CollaborativeArrangementProfitSharing", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementSalesNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangement, Sales, Net", "label": "Collaborative Arrangement, Sales, Net", "terseLabel": "Collaborative Arrangement, Sales, Net" } } }, "localname": "CollaborativeArrangementSalesNet", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CollaborativeArrangementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative Arrangements [Abstract]", "label": "Collaborative Arrangements [Abstract]", "terseLabel": "Collaborative Arrangements [Abstract]" } } }, "localname": "CollaborativeArrangementsAbstract", "nsuri": "http://www.merck.com/20200930", "xbrltype": "stringItemType" }, "mrk_CommercialMilestoneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commercial Milestone", "label": "Commercial Milestone [Member]", "terseLabel": "Commercial Milestone" } } }, "localname": "CommercialMilestoneMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "mrk_CompanionAnimalsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Companion Animals [Member]", "label": "Companion Animals [Member]", "terseLabel": "Companion Animals" } } }, "localname": "CompanionAnimalsMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ComponentofOtherIncomeExpenseofNonoperatingLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Component of Other Income / Expense of Nonoperating [Table]", "label": "Component of Other Income / Expense of Nonoperating [Line Items]", "terseLabel": "Component of Other Income / Expense of Nonoperating [Line Items]" } } }, "localname": "ComponentofOtherIncomeExpenseofNonoperatingLineItems", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails", "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "mrk_ComponentofOtherIncomeExpenseofNonoperatingTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Component of Other Income / Expense of Nonoperating [Table]", "label": "Component of Other Income / Expense of Nonoperating [Table]", "terseLabel": "Component of Other Income / Expense of Nonoperating [Table]" } } }, "localname": "ComponentofOtherIncomeExpenseofNonoperatingTable", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails", "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "stringItemType" }, "mrk_ContingentPaymentsCollaborativeArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents payments that may be made in the future contingent upon the achievement of regulatory and/or sales milestones as part of a collaborative arrangement.", "label": "Contingent Payments Collaborative Arrangement", "terseLabel": "Contingent milestone payments collaborative arrangement" } } }, "localname": "ContingentPaymentsCollaborativeArrangement", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_CostsExpensesAndOther": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total of cost of sales, operating expenses and nonoperating income or expense.", "label": "Costs Expenses And Other", "totalLabel": "Total Costs, Expenses and Other" } } }, "localname": "CostsExpensesAndOther", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "monetaryItemType" }, "mrk_CozaarHyzaarMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cozaar/Hyzaar [Member].", "label": "Cozaar Hyzaar [Member]", "terseLabel": "Nasonex" } } }, "localname": "CozaarHyzaarMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_CubicinMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cubicin [Member]", "label": "Cubicin [Member]", "terseLabel": "Cubicin" } } }, "localname": "CubicinMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_DebtSecuritiesandEquitySecuritiesFVNI": { "auth_ref": [], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Debt Securities and Equity Securities, FV-NI", "label": "Debt Securities and Equity Securities, FV-NI", "totalLabel": "Total debt and publicly traded equity securities, fair value" } } }, "localname": "DebtSecuritiesandEquitySecuritiesFVNI", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "mrk_DevelopmentMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Development Milestones [Member]", "label": "Development Milestones [Member]", "terseLabel": "Development Milestones" } } }, "localname": "DevelopmentMilestonesMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "mrk_DunboyneMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Dunboyne", "label": "Dunboyne [Member]", "terseLabel": "Dunboyne" } } }, "localname": "DunboyneMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "mrk_EisaiMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Eisai [Member]", "label": "Eisai [Member]", "terseLabel": "Eisai" } } }, "localname": "EisaiMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "domainItemType" }, "mrk_EmendMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Emend [Member].", "label": "Emend [Member]", "terseLabel": "Emend" } } }, "localname": "EmendMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_EstimateOfCumulativePreTaxCostsThatWillBeNoncash": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Estimate of cumulative pre tax costs that will be noncash.", "label": "Estimate Of Cumulative Pre Tax Costs That Will Be Noncash", "terseLabel": "Estimate of cumulative pre tax costs that will be noncash" } } }, "localname": "EstimateOfCumulativePreTaxCostsThatWillBeNoncash", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Estimate of cumulative pre tax costs that will result in cash outlays (primarily from employee separation expense).", "label": "Estimate Of Cumulative Pre Tax Costs That Will Result In Cash Outlays", "terseLabel": "Estimate of cumulative pre tax costs that will result in cash outlays" } } }, "localname": "EstimateOfCumulativePreTaxCostsThatWillResultInCashOutlays", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "percentItemType" }, "mrk_EurodominatedNotesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Euro-dominated Notes [Member]", "label": "Euro-dominated Notes [Member]", "terseLabel": "Euro-denominated notes" } } }, "localname": "EurodominatedNotesMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "domainItemType" }, "mrk_FederalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Federal.", "label": "Federal [Member]", "terseLabel": "Federal" } } }, "localname": "FederalMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_FemurFractureLitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Femur Fracture litigation.", "label": "Femur Fracture Litigation [Member]", "terseLabel": "Femur Fracture Litigation" } } }, "localname": "FemurFractureLitigationMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_FollistimAqMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Follistim AQ [Member].", "label": "Follistim Aq [Member]", "terseLabel": "Follistim AQ" } } }, "localname": "FollistimAqMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_FosamaxMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Fosamax [Member].", "label": "Fosamax [Member]", "terseLabel": "Fosamax" } } }, "localname": "FosamaxMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_GardasilGardasil9Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gardasil/Gardasil 9 [Member].", "label": "Gardasil/Gardasil 9 [Member]", "terseLabel": "Gardasil/Gardasil 9" } } }, "localname": "GardasilGardasil9Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_HealthcareServicesSegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Healthcare Services segment [Member]", "label": "Healthcare Services Segment [Member]", "terseLabel": "Healthcare Services Segment" } } }, "localname": "HealthcareServicesSegmentMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_IAVIMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "IAVI [Member]", "label": "IAVI [Member]", "terseLabel": "IAVI" } } }, "localname": "IAVIMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "mrk_ImmuneDesignMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Immune Design [Member]", "label": "Immune Design [Member]", "terseLabel": "Immune Design" } } }, "localname": "ImmuneDesignMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "mrk_ImplanonNexplanonMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Implanon/Nexplanon [Member].", "label": "Implanon/Nexplanon [Member]", "terseLabel": "Implanon/Nexplanon" } } }, "localname": "ImplanonNexplanonMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_IntangibleAssetMeasurementInput": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible Asset, Measurement Input", "label": "Intangible Asset, Measurement Input", "terseLabel": "Present value discount rate" } } }, "localname": "IntangibleAssetMeasurementInput", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "decimalItemType" }, "mrk_InternationalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "International [Member]", "label": "International [Member]", "terseLabel": "International" } } }, "localname": "InternationalMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_InvanzMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Invanz [Member].", "label": "Invanz [Member]", "terseLabel": "Invanz" } } }, "localname": "InvanzMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoriesProducedinPreparationforProductLaunchesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inventories Produced in Preparation for Product Launches [Member]", "label": "Inventories Produced in Preparation for Product Launches [Member]", "terseLabel": "Inventories Produced in Preparation for Product Launches" } } }, "localname": "InventoriesProducedinPreparationforProductLaunchesMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoryNetAndInventoryNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.merck.com/role/InventoriesInventoriesDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total of current and noncurrent inventories.", "label": "Inventory Net And Inventory Noncurrent", "totalLabel": "Total current and noncurrent inventories" } } }, "localname": "InventoryNetAndInventoryNoncurrent", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_InventoryNotExpectedtobeSoldWithinOneYearMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inventory Not Expected to be Sold Within One Year [Member]", "label": "Inventory Not Expected to be Sold Within One Year [Member]", "terseLabel": "Inventories Not Expected to be Sold Within One Year" } } }, "localname": "InventoryNotExpectedtobeSoldWithinOneYearMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_InventoryTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Inventory [Table]", "label": "Inventory [Table]", "terseLabel": "Inventory [Table]" } } }, "localname": "InventoryTable", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "mrk_InvestmentsPrimaryWeightedAverageLifeofCollateral": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Investments, Primary Weighted Average Life of Collateral", "label": "Investments, Primary Weighted Average Life of Collateral", "terseLabel": "Primary weighted average life of collateral" } } }, "localname": "InvestmentsPrimaryWeightedAverageLifeofCollateral", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "durationItemType" }, "mrk_IsentressIsentressHDMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Isentress/Isentress HD [Member].", "label": "Isentress/Isentress HD [Member]", "terseLabel": "Isentress/Isentress HD" } } }, "localname": "IsentressIsentressHDMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_JanumetMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Janumet [Member].", "label": "Janumet [Member]", "terseLabel": "Janumet" } } }, "localname": "JanumetMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_JanuviaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Januvia [Member] .", "label": "Januvia [Member]", "terseLabel": "Januvia" } } }, "localname": "JanuviaMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_KeytrudaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Keytruda [Member]", "label": "Keytruda [Member]", "terseLabel": "Keytruda" } } }, "localname": "KeytrudaMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LegalDefenseCostsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Legal Defense Costs [Member]", "label": "Legal Defense Costs [Member]", "terseLabel": "Legal Defense Costs" } } }, "localname": "LegalDefenseCostsMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_LenvimaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lenvima [Member]", "label": "Lenvima [Member]", "terseLabel": "Alliance revenue - Lenvima (1)", "verboseLabel": "Lenvima" } } }, "localname": "LenvimaMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_Licenseoptionpaymentrelatedtocollaborativearrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "License option payment related to collaborative arrangement", "label": "License option payment related to collaborative arrangement", "terseLabel": "License option payment related to collaborative arrangement" } } }, "localname": "Licenseoptionpaymentrelatedtocollaborativearrangement", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_LivestockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Livestock [Member]", "label": "Livestock [Member]", "terseLabel": "Livestock" } } }, "localname": "LivestockMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_LongTermDebtCurrentMaturitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long Term Debt, Current Maturities [Member]", "label": "Long Term Debt, Current Maturities [Member]", "terseLabel": "Loans payable and current portion of long-term debt" } } }, "localname": "LongTermDebtCurrentMaturitiesMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "domainItemType" }, "mrk_LongTermDebtExcludingCurrentMaturitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Long Term Debt Excluding Current Maturities [Member]", "label": "Long Term Debt Excluding Current Maturities [Member]", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtExcludingCurrentMaturitiesMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "domainItemType" }, "mrk_LossContingencyClaimsonAppealNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Loss Contingency, Claims on Appeal, Number", "label": "Loss Contingency, Claims on Appeal, Number", "terseLabel": "Loss contingency, claims on appeal, number (in legal matters)" } } }, "localname": "LossContingencyClaimsonAppealNumber", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "mrk_LynparzaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Lynparza [Member]", "label": "Lynparza [Member]", "terseLabel": "Lynparza" } } }, "localname": "LynparzaMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_MilestonePaymentsMadetoCollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Milestone Payments Made to Collaborative Partner", "label": "Milestone Payments Made to Collaborative Partner", "terseLabel": "Milestone payments made to collaborative partner" } } }, "localname": "MilestonePaymentsMadetoCollaborativePartner", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_NasonexMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nasonex [Member].", "label": "Nasonex [Member]", "terseLabel": "Cozaar/Hyzaar" } } }, "localname": "NasonexMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_NewJerseyStateCourtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "New Jersey state court member.", "label": "New Jersey State Court [Member]", "terseLabel": "New Jersey state court" } } }, "localname": "NewJerseyStateCourtMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_NoxafilMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Noxafil [Member].", "label": "Noxafil [Member]", "terseLabel": "Noxafil" } } }, "localname": "NoxafilMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_NuvaringMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "NuvaRing [Member].", "label": "Nuvaring [Member]", "terseLabel": "NuvaRing" } } }, "localname": "NuvaringMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_OffsettingAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative positions subject to master netting arrangements as if they were presented on a net basis.", "label": "Offsetting Assets And Liabilities [Table Text Block]", "terseLabel": "Information on Derivative Positions Subject to Master Netting Arrangements as if they were Presented on a Net Basis" } } }, "localname": "OffsettingAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "mrk_OtherCountriesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other Countries [Member]", "label": "Other Countries [Member]", "terseLabel": "Other" } } }, "localname": "OtherCountriesMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherNonoperatingIncomeExpenseOther": { "auth_ref": [], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": 6.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Other nonoperating income and expense items not separately disclosed.", "label": "Other Nonoperating Income Expense, Other", "negatedLabel": "Other, net" } } }, "localname": "OtherNonoperatingIncomeExpenseOther", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "mrk_OtherPharmaceuticalMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other pharmaceutical.", "label": "Other Pharmaceutical [Member]", "terseLabel": "Other pharmaceutical (3)" } } }, "localname": "OtherPharmaceuticalMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_OtherStateCourtMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Other state court.", "label": "Other State Court [Member]", "terseLabel": "Other state courts" } } }, "localname": "OtherStateCourtMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_PaymentsToAcquireBusinessFourNetOfCashAcquired": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Payments to Acquire Business Four, Net of Cash Acquired", "label": "Payments to Acquire Business Four, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of Peloton Therapeutics, Inc., net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessFourNetOfCashAcquired", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "mrk_PelotonMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Peloton", "label": "Peloton [Member]", "terseLabel": "Peloton" } } }, "localname": "PelotonMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "mrk_PensionandOtherPostretirementBenefitPlansNarrativeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pension and Other Postretirement Benefit Plans (Narrative) [Abstract]", "label": "Pension and Other Postretirement Benefit Plans (Narrative) [Abstract]", "terseLabel": "Pension and Other Postretirement Benefit Plans (Narrative) [Abstract]" } } }, "localname": "PensionandOtherPostretirementBenefitPlansNarrativeAbstract", "nsuri": "http://www.merck.com/20200930", "xbrltype": "stringItemType" }, "mrk_PharmaceuticalsegmentMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pharmaceutical segment.", "label": "Pharmaceutical segment [Member]", "terseLabel": "Total Pharmaceutical segment sales", "verboseLabel": "Pharmaceutical segment" } } }, "localname": "PharmaceuticalsegmentMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_Pneumovax23Member": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Pneumovax 23[Member].", "label": "Pneumovax 23 [Member]", "terseLabel": "Pneumovax 23" } } }, "localname": "Pneumovax23Member", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_PrevymisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Prevymis [Member]", "label": "Prevymis [Member]", "terseLabel": "Prevymis" } } }, "localname": "PrevymisMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_PrimaxinMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primaxin [Member].", "label": "Primaxin [Member]", "terseLabel": "Primaxin" } } }, "localname": "PrimaxinMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ProQuadMMRIIVarivaxMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ProQuad/M-M-R II/Varivax [Member].", "label": "ProQuad MMR II Varivax [Member]", "terseLabel": "ProQuad/M-M-R II/Varivax" } } }, "localname": "ProQuadMMRIIVarivaxMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ProbableContingentPaymentsCollaborativeArrangement": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Probable Contingent Payments Collaborative Arrangement", "label": "Probable Contingent Payments Collaborative Arrangement", "terseLabel": "Probable contingent payments collaborative arrangement" } } }, "localname": "ProbableContingentPaymentsCollaborativeArrangement", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_RecognizedAsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Recognized as.", "label": "Recognized As [Abstract]", "terseLabel": "Recognized as:" } } }, "localname": "RecognizedAsAbstract", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "stringItemType" }, "mrk_RegulatoryMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regulatory Milestones [Member]", "label": "Regulatory Milestones [Member]", "terseLabel": "Regulatory Milestones" } } }, "localname": "RegulatoryMilestonesMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_RemicadeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Remicade [Member].", "label": "Remicade [Member]", "terseLabel": "Remicade" } } }, "localname": "RemicadeMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_RestructuringReserveNoncashActivity": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Noncash activity affecting the restructuring reserve, including accelerated depreciation.", "label": "Restructuring Reserve Noncash Activity", "negatedTerseLabel": "Non-cash activity" } } }, "localname": "RestructuringReserveNoncashActivity", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "monetaryItemType" }, "mrk_RotateqMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "RotaTeq [Member]", "label": "Rotateq [Member]", "terseLabel": "RotaTeq" } } }, "localname": "RotateqMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_RoyaltyRatePercentage": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Royalty Rate, Percentage", "label": "Royalty Rate, Percentage", "terseLabel": "Royalty Rate, Percentage" } } }, "localname": "RoyaltyRatePercentage", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "percentItemType" }, "mrk_SalesBasedMilestonesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sales-Based Milestones [Member]", "label": "Sales-Based Milestones [Member]", "terseLabel": "Sales-Based Milestones" } } }, "localname": "SalesBasedMilestonesMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "mrk_SalesDiscounts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sales Discounts", "label": "Sales Discounts", "terseLabel": "Sales discounts" } } }, "localname": "SalesDiscounts", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_SanofiPasteurMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sanofi Pasteur [Member]", "label": "Sanofi Pasteur [Member]", "terseLabel": "Sanofi Pasteur" } } }, "localname": "SanofiPasteurMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "mrk_SeagenMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Seagen", "label": "Seagen [Member]", "terseLabel": "Seagen" } } }, "localname": "SeagenMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "mrk_SegmentReportingUnallocatedOtherExpensesNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Other net expenses not allocated to segments.", "label": "Segment Reporting Unallocated Other Expenses Net", "negatedLabel": "Other unallocated, net" } } }, "localname": "SegmentReportingUnallocatedOtherExpensesNet", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "mrk_SentinelMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sentinel [Member]", "label": "Sentinel [Member]", "terseLabel": "Sentinel" } } }, "localname": "SentinelMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "mrk_SimponiMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Simponi [Member].", "label": "Simponi [Member]", "terseLabel": "Simponi" } } }, "localname": "SimponiMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_SingulairMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Singulair [Member].", "label": "Singulair [Member]", "terseLabel": "Singulair" } } }, "localname": "SingulairMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_SivextroMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Sivextro", "label": "Sivextro [Member]", "terseLabel": "Sivextro [Member]" } } }, "localname": "SivextroMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/OtherIntangiblesDetails" ], "xbrltype": "domainItemType" }, "mrk_StockholdersEquityLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "[Line Items] for Stockholders Equity [Table]", "label": "Stockholders Equity [Line Items]", "terseLabel": "Stockholders Equity [Line Items]" } } }, "localname": "StockholdersEquityLineItems", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "stringItemType" }, "mrk_StockholdersEquityTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Stockholders Equity [Table]", "label": "Stockholders Equity [Table]", "terseLabel": "Stockholders Equity [Table]" } } }, "localname": "StockholdersEquityTable", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "stringItemType" }, "mrk_ThemisMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Themis [Member]", "label": "Themis [Member]", "terseLabel": "Themis" } } }, "localname": "ThemisMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "mrk_TukysaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tukysa", "label": "Tukysa [Member]", "terseLabel": "Tukysa" } } }, "localname": "TukysaMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "mrk_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Upfront and milestone payments made to partner as part of collaborative arrangement.", "label": "Upfront And Milestone Payments Made To Collaborative Partner", "terseLabel": "Upfront and milestone payments" } } }, "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "mrk_VaqtaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vaqta [Member]", "label": "Vaqta [Member]", "terseLabel": "Vaqta" } } }, "localname": "VaqtaMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_VelosBioMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "VelosBio", "label": "VelosBio [Member]", "terseLabel": "VelosBio [Member]" } } }, "localname": "VelosBioMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "mrk_VytorinMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Vytorin [Member] .", "label": "Vytorin [Member]", "terseLabel": "Vytorin" } } }, "localname": "VytorinMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ZepatierMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zepatier [Member]", "label": "Zepatier [Member]", "terseLabel": "Zepatier" } } }, "localname": "ZepatierMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ZerbaxaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zerbaxa [Member]", "label": "Zerbaxa [Member]", "terseLabel": "Zerbaxa" } } }, "localname": "ZerbaxaMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ZetiaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zetia [Member] .", "label": "Zetia [Member]", "terseLabel": "Zetia" } } }, "localname": "ZetiaMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "mrk_ZetiaantitrustlitigationMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Zetia antitrust litigation [Member]", "label": "Zetia antitrust litigation [Member]", "terseLabel": "Zetia antitrust litigation [Member]" } } }, "localname": "ZetiaantitrustlitigationMember", "nsuri": "http://www.merck.com/20200930", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_AsiaPacificMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Asia Pacific [Member]", "terseLabel": "Asia Pacific (other than China and Japan)" } } }, "localname": "AsiaPacificMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r181", "r194", "r195", "r196", "r197", "r199", "r201", "r205" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items [Axis]" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r181", "r194", "r195", "r196", "r197", "r199", "r201", "r205" ], "lang": { "en-US": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items [Domain]" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r70", "r133" ], "lang": { "en-US": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "stringItemType" }, "srt_LatinAmericaMember": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Latin America [Member]", "terseLabel": "Latin America" } } }, "localname": "LatinAmericaMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r400", "r406", "r574", "r575", "r576", "r577", "r578", "r579", "r598", "r641", "r644" ], "lang": { "en-US": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r400", "r406", "r574", "r575", "r576", "r577", "r578", "r579", "r598", "r641", "r644" ], "lang": { "en-US": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r208", "r311", "r312", "r599", "r640", "r642" ], "lang": { "en-US": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/ContingenciesNarrativeDetails", "http://www.merck.com/role/OtherIntangiblesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r208", "r311", "r312", "r599", "r640", "r642" ], "lang": { "en-US": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/ContingenciesNarrativeDetails", "http://www.merck.com/role/OtherIntangiblesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r341", "r400", "r406", "r574", "r575", "r576", "r577", "r578", "r579", "r598", "r641", "r644" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r341", "r400", "r406", "r574", "r575", "r576", "r577", "r578", "r579", "r598", "r641", "r644" ], "lang": { "en-US": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/OtherIncomeExpenseNetDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r401" ], "lang": { "en-US": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/OtherIncomeExpenseNetDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r209", "r210", "r311", "r313", "r643", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664" ], "lang": { "en-US": { "role": { "label": "Geographical [Domain]", "terseLabel": "Geographical [Domain]" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r209", "r210", "r311", "r313", "r643", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665" ], "lang": { "en-US": { "role": { "label": "Geographical [Axis]", "terseLabel": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r288", "r401", "r567" ], "lang": { "en-US": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/OtherIncomeExpenseNetDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]" } } }, "localname": "AOCIAttributableToParentNetOfTaxRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis": { "auth_ref": [ "r55" ], "lang": { "en-US": { "role": { "documentation": "Information by legal entity of counterparty. A counterparty is the other party that participates in a financial transaction.", "label": "Legal Entity of Counterparty, Type [Axis]", "terseLabel": "Legal Entity of Counterparty, Type [Axis]" } } }, "localname": "AccountsNotesLoansAndFinancingReceivablesByLegalEntityOfCounterpartyTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities.", "label": "Accounts Payable and Accrued Liabilities [Member]", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r43" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Trade accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r4", "r27", "r214", "r215" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable (net of allowance for doubtful accounts of $89 in 2020 and $86 in 2019)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableSale": { "auth_ref": [ "r234" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease from sale of accounts receivable.", "label": "Accounts Receivable, Sale", "terseLabel": "Accounts Receivable, Sale" } } }, "localname": "AccountsReceivableSale", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r21", "r607", "r625" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesMember": { "auth_ref": [ "r47" ], "lang": { "en-US": { "role": { "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.", "label": "Accrued Liabilities [Member]", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "AccruedLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": { "auth_ref": [ "r76", "r82", "r85", "r489" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.", "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]", "terseLabel": "Employee Benefit Plans" } } }, "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r41", "r263" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "terseLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "auth_ref": [ "r82", "r488" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]", "terseLabel": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest" } } }, "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "auth_ref": [ "r82", "r92", "r488" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "terseLabel": "Derivatives" } } }, "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "auth_ref": [ "r73", "r74", "r75", "r82", "r85" ], "lang": { "en-US": { "role": { "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]", "terseLabel": "Investments" } } }, "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r30", "r79", "r81", "r82", "r627", "r649", "r650" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "auth_ref": [ "r553", "r554", "r555", "r556", "r557", "r559" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r78", "r82", "r85", "r142", "r143", "r144", "r489", "r645", "r646" ], "lang": { "en-US": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Loss", "verboseLabel": "Accumulated Other Comprehensive Income (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "auth_ref": [ "r71", "r82", "r85", "r489", "r554", "r555", "r556", "r557", "r559" ], "lang": { "en-US": { "role": { "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "terseLabel": "Cumulative Translation Adjustment" } } }, "localname": "AccumulatedTranslationAdjustmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r255" ], "lang": { "en-US": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Weighted average useful life of acquired finite-lived intangible assets" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r28" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Other paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r142", "r143", "r144", "r424", "r425", "r426" ], "lang": { "en-US": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Other Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllOtherSegmentsMember": { "auth_ref": [ "r176", "r194", "r195", "r196", "r197", "r199" ], "lang": { "en-US": { "role": { "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items.", "label": "Other Segments [Member]", "terseLabel": "Other segment sales (4)", "verboseLabel": "Other segment" } } }, "localname": "AllOtherSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "auth_ref": [], "calculation": { "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, after Tax", "totalLabel": "Total share-based compensation expense, net of taxes" } } }, "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r34", "r216", "r233" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r165" ], "lang": { "en-US": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Common shares issuable under share-based compensation plans excluded from diluted earnings per common share because the effect would have been antidilutive (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetBackedSecuritiesMember": { "auth_ref": [ "r224", "r342" ], "lang": { "en-US": { "role": { "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.", "label": "Asset-backed Securities [Member]", "terseLabel": "Asset-backed securities" } } }, "localname": "AssetBackedSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r131", "r189", "r196", "r203", "r231", "r483", "r490", "r547", "r605", "r624" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r6", "r7", "r63", "r131", "r231", "r483", "r490", "r547" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r534" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "auth_ref": [ "r222" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Debt securities, unrealized gains" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "auth_ref": [ "r223" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedTerseLabel": "Debt securities, unrealized losses" } } }, "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r220", "r240" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Debt securities, amortized cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r218", "r221", "r240", "r611" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_TradingSecurities", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": 3.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale", "terseLabel": "Debt securities, fair value", "verboseLabel": "Investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r410", "r422" ], "lang": { "en-US": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by location on balance sheet (statement of financial position).", "label": "Balance Sheet Location [Axis]", "terseLabel": "Balance Sheet Location [Axis]" } } }, "localname": "BalanceSheetLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BalanceSheetLocationDomain": { "auth_ref": [ "r502", "r507" ], "lang": { "en-US": { "role": { "documentation": "Location in the balance sheet (statement of financial position).", "label": "Balance Sheet Location [Domain]", "terseLabel": "Balance Sheet Location [Domain]" } } }, "localname": "BalanceSheetLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r396", "r402" ], "lang": { "en-US": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r396", "r402", "r457", "r458" ], "lang": { "en-US": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition, Contingent Consideration [Line Items]", "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]" } } }, "localname": "BusinessAcquisitionContingentConsiderationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionCostOfAcquiredEntityTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of direct costs of the business combination including legal, accounting, and other costs incurred to consummate the business acquisition.", "label": "Business Acquisition, Transaction Costs", "terseLabel": "Transaction costs" } } }, "localname": "BusinessAcquisitionCostOfAcquiredEntityTransactionCosts", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Acquisitions Research Collaborations And License Agreements Transactions [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": { "auth_ref": [ "r463", "r465", "r466", "r470" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.", "label": "Business Combination, Consideration Transferred, Liabilities Incurred", "terseLabel": "Additions" } } }, "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "auth_ref": [ "r121", "r474" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Changes in estimated fair value" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": { "auth_ref": [ "r472" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.", "label": "Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High", "terseLabel": "Contingent consideration, maximum" } } }, "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "auth_ref": [ "r464", "r467", "r471" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.", "label": "Business Combination, Contingent Consideration, Liability", "periodEndLabel": "Fair value, ending balance", "periodStartLabel": "Fair value, beginning balance", "terseLabel": "Contingent consideration" } } }, "localname": "BusinessCombinationContingentConsiderationLiability", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "auth_ref": [ "r464", "r468" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.", "label": "Business Combination, Contingent Consideration, Liability, Current", "terseLabel": "Current liability" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "auth_ref": [ "r539" ], "lang": { "en-US": { "role": { "documentation": "Value of input used to measure contingent consideration liability from business combination.", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "terseLabel": "Contingent consideration, measurement input, discount rate (as percent)" } } }, "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r460" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "terseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": { "auth_ref": [ "r460" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other", "terseLabel": "Other net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": { "auth_ref": [ "r460" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables", "terseLabel": "Accounts receivable" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "auth_ref": [ "r460" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-term Debt", "terseLabel": "Debt assumed and paid" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets": { "auth_ref": [ "r460" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax asset attributable to deductible temporary differences and carryforwards acquired at the acquisition date.", "label": "Business Combination Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Assets", "terseLabel": "Deferred tax assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r460" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred income tax liabilities", "terseLabel": "Deferred income tax liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets": { "auth_ref": [ "r460" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 8.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Indefinite-Lived Intangible Assets", "terseLabel": "IPR&D" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIndefiniteLivedIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r460" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangible assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": { "auth_ref": [ "r459", "r460" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles", "terseLabel": "IPR&D" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": { "auth_ref": [ "r459", "r460" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of inventory recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory", "terseLabel": "Inventories" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r459", "r460" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "totalLabel": "Total identifiable net assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r459", "r460" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment", "terseLabel": "Property, plant and equipment" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r460" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Consideration transferred" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed": { "auth_ref": [ "r456" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of any issuance related costs which have not been expensed.", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Issuance Costs Not Expensed", "terseLabel": "Share-based compensation payments attributable to precombination service" } } }, "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresIssuanceCostsNotExpensed", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Business Combinations [Abstract]", "terseLabel": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r39", "r124" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r118", "r124", "r126" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $45 at September 30, 2020 included in Other Assets)", "periodStartLabel": "Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $258 at January 1, 2020 included in Other Assets)" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r118", "r552" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net Decrease in Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r39" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents, at Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": { "auth_ref": [ "r530" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments", "negatedTerseLabel": "Derivatives designated as hedging instruments" } } }, "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": { "auth_ref": [ "r530" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.", "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge", "negatedTerseLabel": "Hedged items" } } }, "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r129", "r131", "r158", "r159", "r160", "r162", "r164", "r172", "r173", "r174", "r231", "r547" ], "lang": { "en-US": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "auth_ref": [ "r475", "r476", "r478" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.", "label": "Collaborative Arrangement Disclosure [Text Block]", "terseLabel": "Collaborative Arrangements" } } }, "localname": "CollaborativeArrangementDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangements" ], "xbrltype": "textBlockItemType" }, "us-gaap_CollaborativeArrangementMember": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.", "label": "Collaborative Arrangement [Member]", "terseLabel": "Collaborative Arrangement" } } }, "localname": "CollaborativeArrangementMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommercialPaperMember": { "auth_ref": [ "r299" ], "lang": { "en-US": { "role": { "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.", "label": "Commercial Paper [Member]", "terseLabel": "Commercial paper" } } }, "localname": "CommercialPaperMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]", "terseLabel": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r284", "r285", "r286", "r296" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/Contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockDividendsPerShareDeclared": { "auth_ref": [ "r307" ], "lang": { "en-US": { "role": { "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.", "label": "Common Stock, Dividends, Per Share, Declared", "terseLabel": "Cash dividends declared on common stock (in dollars per share)" } } }, "localname": "CommonStockDividendsPerShareDeclared", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r142", "r143" ], "lang": { "en-US": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CoverPage", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r26" ], "lang": { "en-US": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "periodEndLabel": "Shares, ending balance (in shares)", "periodStartLabel": "Shares, beginning balance (in shares)", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r26" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2020 and 2019" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Retirement Benefits [Abstract]", "terseLabel": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r88", "r90", "r91", "r98", "r616", "r635" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive Income Attributable to Merck\u00a0& Co., Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "auth_ref": [ "r97", "r105", "r615", "r634" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.", "label": "Comprehensive Income (Loss) Note [Text Block]", "terseLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomeNoteTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLoss" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContingentConsiderationByTypeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of contingent consideration.", "label": "Contingent Consideration by Type [Axis]", "terseLabel": "Contingent Consideration by Type [Axis]" } } }, "localname": "ContingentConsiderationByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContingentConsiderationTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Description of contingent payment arrangement.", "label": "Contingent Consideration Type [Domain]", "terseLabel": "Contingent Consideration Type [Domain]" } } }, "localname": "ContingentConsiderationTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateDebtSecuritiesMember": { "auth_ref": [ "r342", "r390", "r651" ], "lang": { "en-US": { "role": { "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "label": "Corporate Debt Securities [Member]", "terseLabel": "Corporate notes and bonds" } } }, "localname": "CorporateDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CorporateNonSegmentMember": { "auth_ref": [ "r194", "r195", "r196", "r197", "r199", "r205", "r207" ], "lang": { "en-US": { "role": { "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.", "label": "Corporate, Non-Segment [Member]", "terseLabel": "Other", "verboseLabel": "Other profits" } } }, "localname": "CorporateNonSegmentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r101", "r599" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Cost of Goods and Services Sold", "terseLabel": "Cost of sales" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost of Sales [Member]", "terseLabel": "Cost of sales", "verboseLabel": "Cost of sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs, Expenses and Other" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_CurrencySwapMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.", "label": "Currency Swap [Member]", "terseLabel": "Foreign currency" } } }, "localname": "CurrencySwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtCurrent": { "auth_ref": [ "r44" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.", "label": "Debt, Current", "terseLabel": "Loans payable and current portion of long-term debt" } } }, "localname": "DebtCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Debt Disclosure [Abstract]", "terseLabel": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r301" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "Debt Disclosure [Text Block]", "terseLabel": "Long-Term Debt" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/LongTermDebt" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r19", "r21", "r22", "r606", "r608", "r622" ], "lang": { "en-US": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r563", "r565" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount of debt", "verboseLabel": "Par Value of Debt" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFairValue": { "auth_ref": [ "r546" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.", "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of loans payable and long-term debt, including current portion" } } }, "localname": "DebtInstrumentFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r49" ], "lang": { "en-US": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "verboseLabel": "Stated interest rate (as percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails", "http://www.merck.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r50" ], "lang": { "en-US": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r50", "r134", "r303", "r304", "r305", "r306", "r562", "r563", "r565", "r621" ], "lang": { "en-US": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/LongTermDebtNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtLongtermAndShorttermCombinedAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Represents the aggregate of total long-term debt, including current maturities and short-term debt.", "label": "Debt, Long-term and Short-term, Combined Amount", "terseLabel": "Debt, carrying amount" } } }, "localname": "DebtLongtermAndShorttermCombinedAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r226" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r122", "r132", "r443", "r448", "r449", "r450" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r433", "r434" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred Income Taxes" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsCurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed within one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Current", "terseLabel": "Other current assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxesAndOtherAssetsNoncurrent": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other assets expected to be realized or consumed after one year or normal operating cycle, if longer.", "label": "Deferred Income Taxes and Other Assets, Noncurrent", "terseLabel": "Other Assets" } } }, "localname": "DeferredIncomeTaxesAndOtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": { "auth_ref": [ "r318", "r357", "r384", "r390", "r391" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": { "order": 5.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Gain (Loss)", "negatedLabel": "Net loss amortization" } } }, "localname": "DefinedBenefitPlanAmortizationOfGainsLosses", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": { "auth_ref": [ "r318", "r358", "r385", "r390", "r391" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": { "order": 4.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.", "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)", "terseLabel": "Amortization of unrecognized prior service credit" } } }, "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanContributionsByEmployer": { "auth_ref": [ "r334", "r342", "r344", "r388", "r390", "r391" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.", "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer", "terseLabel": "Contributions by employer" } } }, "localname": "DefinedBenefitPlanContributionsByEmployer", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": { "auth_ref": [ "r371" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": { "order": 6.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.", "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits", "terseLabel": "Termination benefits" } } }, "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]", "terseLabel": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear": { "auth_ref": [ "r388", "r391" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of contributions received and expected to be received by defined benefit plan from employer in current fiscal year.", "label": "Defined Benefit Plan, Expected Future Employer Contributions, Current Fiscal Year", "terseLabel": "Expected future employer contributions, current fiscal year" } } }, "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsCurrentFiscalYear", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": { "auth_ref": [ "r318", "r356", "r383", "r390", "r391" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": { "order": 3.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.", "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets", "negatedLabel": "Expected return on plan assets" } } }, "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanInterestCost": { "auth_ref": [ "r318", "r323", "r355", "r382", "r390", "r391" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": { "order": 2.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.", "label": "Defined Benefit Plan, Interest Cost", "terseLabel": "Interest cost" } } }, "localname": "DefinedBenefitPlanInterestCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": { "auth_ref": [ "r353", "r380", "r390", "r391" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)", "totalLabel": "Net periodic benefit cost" } } }, "localname": "DefinedBenefitPlanNetPeriodicBenefitCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": { "auth_ref": [ "r319", "r360", "r387" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": { "order": 7.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment", "negatedLabel": "Curtailments" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": { "auth_ref": [ "r319", "r360", "r387" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": { "order": 8.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.", "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement", "negatedTerseLabel": "Settlements" } } }, "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanServiceCost": { "auth_ref": [ "r321", "r354", "r381", "r390", "r391" ], "calculation": { "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails": { "order": 1.0, "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.", "label": "Defined Benefit Plan, Service Cost", "terseLabel": "Service cost" } } }, "localname": "DefinedBenefitPlanServiceCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r122", "r184" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "negatedLabel": "Depreciation and amortization", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r67", "r69" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral.", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Net amounts, asset" } } }, "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r65", "r69" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative assets.", "label": "Derivative Asset, Not Offset, Policy Election Deduction", "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, asset" } } }, "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r64", "r68", "r546" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "netLabel": "Gross amounts recognized in the consolidated balance sheet, asset", "terseLabel": "Derivative assets", "verboseLabel": "Fair Value of Derivative, Asset" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAverageRemainingMaturity1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Average remaining period until maturity of the derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Derivative, Average Remaining Maturity", "terseLabel": "Maximum average period of maturities of contracts in years (less than)" } } }, "localname": "DerivativeAverageRemainingMaturity1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DerivativeCollateralObligationToReturnCash": { "auth_ref": [ "r66", "r69", "r526" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation to return cash collateral under master netting arrangements that have not been offset against derivative assets.", "label": "Derivative, Collateral, Obligation to Return Cash", "negatedLabel": "Cash collateral received, asset", "terseLabel": "Cash collateral received from counterparties" } } }, "localname": "DerivativeCollateralObligationToReturnCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeCollateralRightToReclaimCash": { "auth_ref": [ "r66", "r69", "r526" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 3.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of right to receive cash collateral under master netting arrangements that have not been offset against derivative liabilities.", "label": "Derivative, Collateral, Right to Reclaim Cash", "negatedLabel": "Cash collateral received, liability", "terseLabel": "Cash collateral advanced to counterparties" } } }, "localname": "DerivativeCollateralRightToReclaimCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeContractTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.", "label": "Derivative Contract [Domain]", "terseLabel": "Derivative Contract [Domain]" } } }, "localname": "DerivativeContractTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DerivativeGainLossOnDerivativeNet": { "auth_ref": [ "r504" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.", "label": "Derivative, Gain (Loss) on Derivative, Net", "terseLabel": "Amount of gain recognized in Other (income) expense, net on derivatives" } } }, "localname": "DerivativeGainLossOnDerivativeNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentRiskAxis": { "auth_ref": [ "r503", "r506", "r512", "r521" ], "lang": { "en-US": { "role": { "documentation": "Information by type of derivative contract.", "label": "Derivative Instrument [Axis]", "terseLabel": "Derivative Instrument [Axis]" } } }, "localname": "DerivativeInstrumentRiskAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about derivatives and hedging activities.", "label": "Derivative Instruments and Hedging Activities Disclosures [Table]", "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]" } } }, "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "auth_ref": [ "r500", "r503", "r512", "r521", "r522", "r528", "r531" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table]", "terseLabel": "Derivative Instruments, Gain (Loss) [Table]" } } }, "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]" } } }, "localname": "DerivativeInstrumentsGainLossLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": { "auth_ref": [ "r532" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.", "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred", "negatedTerseLabel": "Pretax net unrealized losses on derivatives maturing within next 12 months estimated to be reclassified from AOCI to sales" } } }, "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": { "auth_ref": [ "r511", "r513" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.", "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net", "negatedTerseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income", "terseLabel": "Amount of Derivative Pretax (Gain) Loss Recognized in Income" } } }, "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilities": { "auth_ref": [ "r64", "r68", "r546" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 1.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Liability", "netLabel": "Gross amounts recognized in the consolidated balance sheet, liability", "terseLabel": "Derivative liabilities", "verboseLabel": "Fair Value of Derivative, Liability" } } }, "localname": "DerivativeLiabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "auth_ref": [ "r67", "r69" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral.", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "totalLabel": "Net amounts, liability" } } }, "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "auth_ref": [ "r65", "r69" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails": { "order": 2.0, "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, elected not to be offset, deducted from derivative liabilities.", "label": "Derivative Liability, Not Offset, Policy Election Deduction", "negatedTerseLabel": "Gross amount subject to offset in master netting arrangements not offset in the condensed balance sheet, liability" } } }, "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonDerivativePositionsSubjecttoMasterNettingArrangementsasiftheywerePresentedonaNetBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivative [Line Items]", "terseLabel": "Derivative [Line Items]" } } }, "localname": "DerivativeLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativeNotionalAmount": { "auth_ref": [ "r497", "r499" ], "lang": { "en-US": { "role": { "documentation": "Nominal or face amount used to calculate payment on derivative.", "label": "Derivative, Notional Amount", "terseLabel": "Total swap notional amount", "verboseLabel": "U.S Dollar Notional Amount" } } }, "localname": "DerivativeNotionalAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeTable": { "auth_ref": [ "r496", "r498", "r499", "r500", "r501", "r508", "r512", "r525", "r527", "r531" ], "lang": { "en-US": { "role": { "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.", "label": "Derivative [Table]", "terseLabel": "Derivative [Table]" } } }, "localname": "DerivativeTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DerivativesFairValueLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Derivatives, Fair Value [Line Items]", "terseLabel": "Derivatives, Fair Value [Line Items]" } } }, "localname": "DerivativesFairValueLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "auth_ref": [ "r500" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Designated as Hedging Instrument [Member]", "terseLabel": "Derivatives Designated as Hedging Instruments" } } }, "localname": "DesignatedAsHedgingInstrumentMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DevelopedTechnologyRightsMember": { "auth_ref": [ "r462" ], "lang": { "en-US": { "role": { "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.", "label": "Developed Technology Rights [Member]", "terseLabel": "Technology Rights" } } }, "localname": "DevelopedTechnologyRightsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r430" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Share-Based Compensation Plans" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Share-based Payment Arrangement [Abstract]", "terseLabel": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_DividendsCommonStockCash": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.", "label": "Dividends, Common Stock, Cash", "negatedLabel": "Cash dividends declared on common stock" } } }, "localname": "DividendsCommonStockCash", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DividendsPayableCurrent": { "auth_ref": [ "r10", "r47" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Dividends Payable, Current", "terseLabel": "Dividends payable" } } }, "localname": "DividendsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Tax Authority [Member]", "terseLabel": "Domestic Tax Authority" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EMEAMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Regions of Europe, Middle East and Africa.", "label": "EMEA [Member]", "terseLabel": "Europe, Middle East and Africa" } } }, "localname": "EMEAMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r99", "r147", "r148", "r149", "r150", "r151", "r156", "r158", "r162", "r163", "r164", "r168", "r169", "r617", "r636" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic earnings per common share attributable to Merck & Co., Inc. common shareholders", "verboseLabel": "Basic Earnings per Common Share Attributable to Merck\u00a0& Co., Inc. Common Shareholders (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r99", "r147", "r148", "r149", "r150", "r151", "r158", "r162", "r163", "r164", "r168", "r169", "r617", "r636" ], "lang": { "en-US": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Earnings per common share assuming dilution attributable to Merck & Co., Inc. common shareholders", "verboseLabel": "Earnings per Common Share Assuming Dilution Attributable to Merck\u00a0& Co., Inc. Common Shareholders (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r165", "r166", "r167", "r170" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings Per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EarningsPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r552" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "terseLabel": "Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r436" ], "lang": { "en-US": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective income tax rate (as percent)" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "auth_ref": [ "r421" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Total pretax unrecognized compensation expense related to nonvested stock options, RSU and PSU awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r421" ], "lang": { "en-US": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average period in years of recognition for nonvested stock options, RSU and PSU awards" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "auth_ref": [ "r420" ], "calculation": { "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails": { "order": 2.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.", "label": "Share-based Payment Arrangement, Expense, Tax Benefit", "negatedLabel": "Income tax benefit" } } }, "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue from External Customer [Line Items]", "terseLabel": "Revenue from External Customer [Line Items]" } } }, "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r142", "r143", "r144", "r146", "r152", "r154", "r171", "r232", "r302", "r307", "r424", "r425", "r426", "r444", "r445", "r553", "r554", "r555", "r556", "r557", "r559", "r645", "r646", "r647" ], "lang": { "en-US": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesFvNi": { "auth_ref": [ "r545" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_TradingSecurities", "weight": 1.0 }, "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails": { "order": 2.0, "parentTag": "mrk_DebtSecuritiesandEquitySecuritiesFVNI", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI", "terseLabel": "Publicly traded equity securities, fair value", "verboseLabel": "Publicly traded equity securities" } } }, "localname": "EquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "auth_ref": [ "r230" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": 4.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Gain (Loss)", "negatedLabel": "Income from investments in equity securities, net (1)" } } }, "localname": "EquitySecuritiesFvNiGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "auth_ref": [ "r230", "r637" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedTerseLabel": "Unrealized net losses (gains)" } } }, "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesMember": { "auth_ref": [ "r16", "r20", "r226", "r623", "r653", "r654", "r655" ], "lang": { "en-US": { "role": { "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.", "label": "Equity Securities [Member]", "terseLabel": "Publicly traded equity securities" } } }, "localname": "EquitySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r227" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity investments without readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount": { "auth_ref": [ "r228" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from downward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount", "terseLabel": "Unrealized losses recognized on investments in equity securities without readily determinable fair values" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r228" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount", "terseLabel": "Cumulative unrealized losses on investments" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of gain from upward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount", "terseLabel": "Unrealized gains recognized on investments in equity securities without readily determinable fair value" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount": { "auth_ref": [ "r229" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative gain from upward price adjustment on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount", "terseLabel": "Cumulative unrealized gains on investments" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on Recurring Basis [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "auth_ref": [ "r534", "r535", "r536", "r543" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.", "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r390", "r535", "r571", "r572", "r573" ], "lang": { "en-US": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r534", "r535", "r538", "r539", "r544" ], "lang": { "en-US": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r342", "r344", "r349", "r390", "r535", "r571" ], "lang": { "en-US": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r342", "r344", "r349", "r390", "r535", "r572" ], "lang": { "en-US": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r390", "r535", "r573" ], "lang": { "en-US": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r540", "r543" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Information About the Changes in Liabilities for Contingent Consideration" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "auth_ref": [ "r541" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedTerseLabel": "Payments", "terseLabel": "Payments of contingent consideration" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r390", "r571", "r572", "r573" ], "lang": { "en-US": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r542", "r544" ], "lang": { "en-US": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Measurements, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "auth_ref": [ "r502", "r508", "r528" ], "lang": { "en-US": { "role": { "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]" } } }, "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r224", "r225", "r235", "r236", "r237", "r238", "r239", "r241", "r242", "r243", "r244", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597" ], "lang": { "en-US": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FinancialInstrumentsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.", "label": "Financial Instruments Disclosure [Text Block]", "terseLabel": "Financial Instruments" } } }, "localname": "FinancialInstrumentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstruments" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r253", "r256", "r259", "r260", "r600", "r601" ], "lang": { "en-US": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r253", "r258" ], "lang": { "en-US": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "auth_ref": [ "r259", "r600" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Finite-Lived Intangible Assets, Net", "terseLabel": "Finite-lived intangible assets" } } }, "localname": "FiniteLivedIntangibleAssetsNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinitelivedIntangibleAssetsAcquired1": { "auth_ref": [ "r254" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.", "label": "Finite-lived Intangible Assets Acquired", "terseLabel": "Acquired rights" } } }, "localname": "FinitelivedIntangibleAssetsAcquired1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "auth_ref": [ "r548", "r549", "r550", "r551" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.", "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Exchange losses" } } }, "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ForeignExchangeContractMember": { "auth_ref": [ "r342", "r519" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.", "label": "Foreign Exchange Contract [Member]", "terseLabel": "Foreign exchange contracts" } } }, "localname": "ForeignExchangeContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeFutureMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A standardized contract, traded on a futures exchange, to buy or sell a certain currency, at a specified future date, at a fixed exercise rate (expressed as an exchange).", "label": "Foreign Exchange Future [Member]", "terseLabel": "Forecasted transactions" } } }, "localname": "ForeignExchangeFutureMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignExchangeOptionMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "An option that allows the holder to buy (if call) or sell (if put) an underlying currency at a fixed exercise rate, expressed as an exchange, during a specified period (an American option) or at a specified date (a European option).", "label": "Foreign Exchange Option [Member]", "terseLabel": "Currency options" } } }, "localname": "ForeignExchangeOptionMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignGovernmentDebtSecuritiesMember": { "auth_ref": [ "r342", "r651" ], "lang": { "en-US": { "role": { "documentation": "Debt security issued by government not domiciled in United States of America (US).", "label": "Debt Security, Government, Non-US [Member]", "terseLabel": "Foreign government bonds" } } }, "localname": "ForeignGovernmentDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignPlanMember": { "auth_ref": [ "r395", "r399", "r405" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Foreign Plan [Member]", "terseLabel": "International" } } }, "localname": "ForeignPlanMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ForwardContractIndexedToIssuersEquityIndexedShares": { "auth_ref": [ "r533" ], "lang": { "en-US": { "role": { "documentation": "The number of issuer's shares to which the forward contract is indexed.", "label": "Forward Contract Indexed to Issuer's Equity, Indexed Shares", "terseLabel": "Forward contract, shares" } } }, "localname": "ForwardContractIndexedToIssuersEquityIndexedShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ForwardContractsMember": { "auth_ref": [ "r517" ], "lang": { "en-US": { "role": { "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date.", "label": "Forward Contracts [Member]", "terseLabel": "Forward Contracts" } } }, "localname": "ForwardContractsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r246", "r248", "r604" ], "calculation": { "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.", "label": "Goodwill and Intangible Asset Impairment", "terseLabel": "Intangible asset impairment charges" } } }, "localname": "GoodwillAndIntangibleAssetImpairment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r122", "r247", "r249", "r251" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill, Impairment Loss", "terseLabel": "Goodwill, Impairment Loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgedLiabilityFairValueHedge": { "auth_ref": [ "r523" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liability hedged in fair value hedging relationship.", "label": "Hedged Liability, Fair Value Hedge", "terseLabel": "Carrying Amount of Hedged Liabilities" } } }, "localname": "HedgedLiabilityFairValueHedge", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": { "auth_ref": [ "r524" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.", "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)", "verboseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase (Decrease) Included in the Carrying Amount" } } }, "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_HedgingDesignationAxis": { "auth_ref": [ "r500", "r522" ], "lang": { "en-US": { "role": { "documentation": "Information by designation of purpose of derivative instrument.", "label": "Hedging Designation [Axis]", "terseLabel": "Hedging Designation [Axis]" } } }, "localname": "HedgingDesignationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_HedgingDesignationDomain": { "auth_ref": [ "r500" ], "lang": { "en-US": { "role": { "documentation": "Designation of purpose of derivative instrument.", "label": "Hedging Designation [Domain]", "terseLabel": "Hedging Designation [Domain]" } } }, "localname": "HedgingDesignationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": { "auth_ref": [ "r122", "r261" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.", "label": "Impairment of Intangible Assets, Finite-lived", "terseLabel": "Intangible asset impairment charges" } } }, "localname": "ImpairmentOfIntangibleAssetsFinitelived", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIntangiblesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r95", "r189", "r195", "r199", "r202", "r205", "r602", "r613", "r619", "r638" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Profits", "totalLabel": "Income Before Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Statement [Abstract]", "terseLabel": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r265" ], "lang": { "en-US": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r438" ], "lang": { "en-US": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityNameAxis": { "auth_ref": [ "r438" ], "lang": { "en-US": { "role": { "documentation": "Information by name of taxing authority.", "label": "Income Tax Authority, Name [Axis]", "terseLabel": "Income Tax Authority, Name [Axis]" } } }, "localname": "IncomeTaxAuthorityNameAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityNameDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority, Name [Domain]", "terseLabel": "Income Tax Authority, Name [Domain]" } } }, "localname": "IncomeTaxAuthorityNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Income Tax Disclosure [Abstract]", "terseLabel": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r437", "r441", "r442", "r446", "r451", "r453", "r454", "r455" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Taxes on Income" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/TaxesonIncome" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]", "terseLabel": "Income Tax Examination [Line Items]" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r439" ], "lang": { "en-US": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]", "terseLabel": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r132", "r153", "r154", "r187", "r435", "r447", "r452", "r639" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "terseLabel": "Taxes on Income" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r119", "r125" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Income Taxes Paid", "terseLabel": "Income taxes paid" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapital": { "auth_ref": [ "r121" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.", "label": "Increase (Decrease) in Operating Capital", "negatedLabel": "Net changes in assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapital", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r262" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for all or part of the information related to intangible assets.", "label": "Intangible Assets Disclosure [Text Block]", "terseLabel": "Other Intangibles" } } }, "localname": "IntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIntangibles" ], "xbrltype": "textBlockItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r252", "r257" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Other Intangibles, Net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r93", "r183", "r561", "r564", "r618" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r125" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "terseLabel": "Interest paid" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRateContractMember": { "auth_ref": [ "r342", "r518" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.", "label": "Interest Rate Contract [Member]", "terseLabel": "Interest rate swap contracts" } } }, "localname": "InterestRateContractMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InterestRateSwapMember": { "auth_ref": [ "r518" ], "lang": { "en-US": { "role": { "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.", "label": "Interest Rate Swap [Member]", "terseLabel": "Interest rate swap contracts", "verboseLabel": "Interest rate swap contracts" } } }, "localname": "InterestRateSwapMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "Internal Revenue Service (IRS) [Member]", "terseLabel": "Internal Revenue Service (IRS)" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InventoryDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Inventory Disclosure [Abstract]", "terseLabel": "Inventory Disclosure [Abstract]" } } }, "localname": "InventoryDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_InventoryDisclosureTextBlock": { "auth_ref": [ "r245" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.", "label": "Inventory Disclosure [Text Block]", "terseLabel": "Inventories" } } }, "localname": "InventoryDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/Inventories" ], "xbrltype": "textBlockItemType" }, "us-gaap_InventoryFinishedGoods": { "auth_ref": [ "r57" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 1.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.", "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods" } } }, "localname": "InventoryFinishedGoods", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryGross": { "auth_ref": [ "r60" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.merck.com/role/InventoriesInventoriesDetails_1": { "order": 1.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Inventory, Gross", "totalLabel": "Total (approximates current cost)" } } }, "localname": "InventoryGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLIFOReserve": { "auth_ref": [ "r61" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails_1": { "order": 2.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount by which inventory stated at last-in first-out (LIFO) is less than (in excess of) inventory stated at other inventory cost methods.", "label": "Inventory, LIFO Reserve", "negatedLabel": "Decrease to LIFO cost" } } }, "localname": "InventoryLIFOReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Inventory [Line Items]", "terseLabel": "Inventory [Line Items]" } } }, "localname": "InventoryLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_InventoryNet": { "auth_ref": [ "r3", "r60" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 1.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.", "label": "Inventory, Net", "terseLabel": "Inventories", "verboseLabel": "Inventories (excludes inventories of $2,081 in 2020 and $1,480 in 2019 classified in Other assets - see Note\u00a06)" } } }, "localname": "InventoryNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryNoncurrent": { "auth_ref": [ "r62" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 2.0, "parentTag": "mrk_InventoryNetAndInventoryNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.", "label": "Inventory, Noncurrent", "terseLabel": "Inventories classified in Other assets", "verboseLabel": "Other assets" } } }, "localname": "InventoryNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical", "http://www.merck.com/role/InventoriesInventoriesDetails", "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InventoryWorkInProcessAndRawMaterials": { "auth_ref": [ "r58" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 2.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate carrying amount as of the balance sheet date of items held by the entity which are partially completed at the time of measurement and unprocessed items that will go through the production process and become part of the final product. Includes supplies used directly or indirectly in the manufacturing or production process. This element may be used when the reporting entity combines work in process and raw materials into an aggregate amount.", "label": "Inventory, Work in Process and Raw Materials", "terseLabel": "Raw materials and work in process" } } }, "localname": "InventoryWorkInProcessAndRawMaterials", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r103", "r182" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "negatedLabel": "Interest income", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails", "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LegalCostsPolicyTextBlock": { "auth_ref": [ "r127", "r128", "r295" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.", "label": "Legal Costs, Policy [Policy Text Block]", "terseLabel": "Legal Costs, Policy" } } }, "localname": "LegalCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalEntityTypeOfCounterpartyDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Nature of the other party participating in a financial transaction.", "label": "Legal Entity Type of Counterparty [Domain]", "terseLabel": "Legal Entity Type of Counterparty [Domain]" } } }, "localname": "LegalEntityTypeOfCounterpartyDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r45", "r131", "r197", "r231", "r484", "r490", "r491", "r547" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r33", "r131", "r231", "r547", "r610", "r630" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r48", "r131", "r231", "r484", "r490", "r491", "r547" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "verboseLabel": "Payables, current" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r534" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r12", "r13", "r14", "r22", "r23", "r131", "r231", "r484", "r490", "r491", "r547" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "terseLabel": "Payables, Noncurrent" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationReserve": { "auth_ref": [ "r52", "r287" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.", "label": "Estimated Litigation Liability", "terseLabel": "Legal defense costs reserve" } } }, "localname": "LitigationReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtNoncurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.", "label": "Long-term Debt, Excluding Current Maturities", "terseLabel": "Long-Term Debt" } } }, "localname": "LongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r50" ], "lang": { "en-US": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]", "terseLabel": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r50", "r300" ], "lang": { "en-US": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]", "terseLabel": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "auth_ref": [ "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r297", "r298" ], "lang": { "en-US": { "role": { "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.", "label": "Loss Contingency Nature [Axis]", "terseLabel": "Loss Contingency Nature [Axis]" } } }, "localname": "LossContingenciesByNatureOfContingencyAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Loss Contingencies [Line Items]", "terseLabel": "Loss Contingencies [Line Items]" } } }, "localname": "LossContingenciesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingenciesTable": { "auth_ref": [ "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r297", "r298" ], "lang": { "en-US": { "role": { "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.", "label": "Loss Contingencies [Table]", "terseLabel": "Loss Contingencies [Table]" } } }, "localname": "LossContingenciesTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LossContingencyClaimsDismissedNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of claims dismissed.", "label": "Loss Contingency, Claims Dismissed, Number", "terseLabel": "Loss contingency, claims dismissed, number (in legal matters)" } } }, "localname": "LossContingencyClaimsDismissedNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyClaimsSettledNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of claims settled.", "label": "Loss Contingency, Claims Settled, Number", "terseLabel": "Loss Contingency, Claims Settled, Number" } } }, "localname": "LossContingencyClaimsSettledNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LossContingencyNatureDomain": { "auth_ref": [ "r287", "r288", "r289", "r291", "r292", "r293", "r294", "r297", "r298" ], "lang": { "en-US": { "role": { "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.", "label": "Loss Contingency, Nature [Domain]", "terseLabel": "Loss Contingency, Nature [Domain]" } } }, "localname": "LossContingencyNatureDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LossContingencyPendingClaimsNumber": { "auth_ref": [ "r290" ], "lang": { "en-US": { "role": { "documentation": "Number of pending claims pertaining to a loss contingency.", "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Loss contingency, pending claims, number (in legal matters)" } } }, "localname": "LossContingencyPendingClaimsNumber", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r5", "r46" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities, Current", "terseLabel": "Short-term investments" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesNoncurrent": { "auth_ref": [ "r40" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in marketable security, classified as noncurrent.", "label": "Marketable Securities, Noncurrent", "terseLabel": "Investments" } } }, "localname": "MarketableSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_MaterialReconcilingItemsMember": { "auth_ref": [ "r199" ], "lang": { "en-US": { "role": { "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.", "label": "Segment Reconciling Items [Member]", "terseLabel": "Unallocated" } } }, "localname": "MaterialReconcilingItemsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r537" ], "lang": { "en-US": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Measurement Input, Discount Rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r537" ], "lang": { "en-US": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails", "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r56", "r131", "r231", "r547", "r609", "r629" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling Interests" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "auth_ref": [ "r307" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "negatedTerseLabel": "Distributions attributable to noncontrolling interests" } } }, "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r118" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Used in Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r118" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used in Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r118", "r120", "r123" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash Provided by Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r86", "r89", "r96", "r123", "r131", "r145", "r147", "r148", "r149", "r150", "r153", "r154", "r161", "r189", "r195", "r199", "r202", "r205", "r231", "r547", "r614", "r633" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net Income Attributable to Merck\u00a0& Co., Inc.", "totalLabel": "Net Income Attributable to Merck\u00a0& Co., Inc.", "verboseLabel": "Net income attributable to Merck\u00a0& Co., Inc." } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EarningsPerShareDetails", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r86", "r89", "r153", "r154", "r486", "r493" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: Net Income (Loss) Attributable to Noncontrolling Interests", "verboseLabel": "Net income (loss) attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": { "auth_ref": [ "r318" ], "calculation": { "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": 5.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.", "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component", "terseLabel": "Net periodic defined benefit plan (credit) cost other than service cost" } } }, "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted and Issued Accounting Standards" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/BasisofPresentationPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r142", "r143", "r144", "r307", "r479" ], "lang": { "en-US": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non- controlling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NondesignatedMember": { "auth_ref": [ "r500" ], "lang": { "en-US": { "role": { "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).", "label": "Not Designated as Hedging Instrument [Member]", "verboseLabel": "Derivatives Not Designated as Hedging Instruments" } } }, "localname": "NondesignatedMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfInterestRateDerivativesHeld": { "auth_ref": [ "r497", "r499" ], "lang": { "en-US": { "role": { "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.", "label": "Number of Interest Rate Derivatives Held", "terseLabel": "Number of Interest Rate Swaps Held (in interest rate swaps)", "verboseLabel": "Number of interest rate swaps held (in interest rate swaps)" } } }, "localname": "NumberOfInterestRateDerivativesHeld", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsNarrativeDetails", "http://www.merck.com/role/FinancialInstrumentsSummaryofInterestRateSwapsHeldDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r177" ], "lang": { "en-US": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OciBeforeReclassificationsBeforeTaxAttributableToParent": { "auth_ref": [ "r82" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount before tax and reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "OCI, before Reclassifications, before Tax, Attributable to Parent", "terseLabel": "Other comprehensive income (loss) before reclassification adjustments, pretax" } } }, "localname": "OciBeforeReclassificationsBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "auth_ref": [ "r82", "r92" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "totalLabel": "Other comprehensive income (loss) before reclassification adjustments, net of taxes" } } }, "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OneTimeTerminationBenefitsMember": { "auth_ref": [ "r267" ], "lang": { "en-US": { "role": { "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities.", "label": "One-time Termination Benefits [Member]", "terseLabel": "Separation Costs" } } }, "localname": "OneTimeTerminationBenefitsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r194", "r195", "r196", "r197", "r199", "r205" ], "lang": { "en-US": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments", "verboseLabel": "Total segment profits" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r141", "r155", "r175", "r495" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsMember": { "auth_ref": [ "r502", "r528" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other assets.", "label": "Other Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r42" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r481", "r482", "r488" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "verboseLabel": "Net unrealized (loss) gain on investments, net of reclassifications" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r77", "r79", "r481", "r488" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan, attributable to parent.", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent", "negatedLabel": "Benefit plan net gain and prior service credit, net of amortization" } } }, "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r481", "r482", "r488" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 4.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Cumulative translation adjustment" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "auth_ref": [ "r80" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "negatedTerseLabel": "Tax" } } }, "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "auth_ref": [ "r79" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "verboseLabel": "Net unrealized (loss) gain on derivatives, net of reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r72", "r79", "r505", "r510", "r529" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "terseLabel": "Amount of (loss) gain recognized in OCI on derivatives" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": { "auth_ref": [ "r79", "r83" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax", "terseLabel": "Increase (decrease) in Sales as a result of AOCI reclassifications" } } }, "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": { "auth_ref": [ "r514" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax", "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other Comprehensive Income" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "auth_ref": [ "r515" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "negatedLabel": "Amount of Pretax (Gain) Loss Recognized in Other (income) expense, net for Amounts Excluded from Effectiveness Testing" } } }, "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r87", "r90", "r92", "r97", "r302", "r553", "r558", "r559", "r615", "r634" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other Comprehensive Income (Loss) Net of Taxes:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r87", "r90", "r481", "r482", "r488" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Other comprehensive income (loss)", "totalLabel": "Other comprehensive income (loss), net of taxes" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCOMPREHENSIVEINCOME", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCurrentAssetsMember": { "auth_ref": [ "r502", "r528" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other current assets.", "label": "Other Current Assets [Member]", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Income and Expenses [Abstract]", "terseLabel": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r314", "r431" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "Other Income and Other Expense Disclosure [Text Block]", "terseLabel": "Other (Income) Expense, Net" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNet" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherIntangibleAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Intangible assets classified as other.", "label": "Other Intangible Assets [Member]", "terseLabel": "Other intangible assets" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherInventorySupplies": { "auth_ref": [ "r59" ], "calculation": { "http://www.merck.com/role/InventoriesInventoriesDetails": { "order": 3.0, "parentTag": "us-gaap_InventoryGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before valuation and LIFO reserves of other supplies used within the manufacturing or production process expected to be consumed within one year or operating cycle, if longer.", "label": "Other Inventory, Supplies, Gross", "terseLabel": "Supplies" } } }, "localname": "OtherInventorySupplies", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/InventoriesInventoriesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r8", "r9", "r47" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Accrued and other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r51" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Other Noncurrent Liabilities", "verboseLabel": "Other liabilities, noncurrent" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncashIncomeExpense": { "auth_ref": [ "r123" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.", "label": "Other Noncash Income (Expense)", "negatedLabel": "Other" } } }, "localname": "OtherNoncashIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNoncurrentAssetsMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent assets.", "label": "Other Noncurrent Assets [Member]", "terseLabel": "Other Assets" } } }, "localname": "OtherNoncurrentAssetsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.", "label": "Other Noncurrent Liabilities [Member]", "terseLabel": "Other Noncurrent Liabilities" } } }, "localname": "OtherNoncurrentLiabilitiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsFairValueofDerivativesSegregatedbetweenthoseDerivativesthatareDesignatedasHedgingInstrumentsandthosethatareNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r104" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 5.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": -1.0 }, "http://www.merck.com/role/OtherIncomeExpenseNetDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "negatedLabel": "Other (income) expense, net", "negatedTotalLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherIncomeExpenseNetDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other Nonoperating Income (Expense) [Abstract]" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).", "label": "Other Nonoperating Income (Expense) [Member]", "terseLabel": "Other (income) expense, net" } } }, "localname": "OtherNonoperatingIncomeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsEffectofNetInvestmentHedgesDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": { "auth_ref": [ "r316", "r317", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r365", "r366", "r368", "r371", "r375", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r398", "r399" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.", "label": "Other Postretirement Benefits Plan [Member]", "terseLabel": "Other Postretirement Benefit Plans" } } }, "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_OtherRestructuringMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Restructuring and related activities classified as other.", "label": "Other Restructuring [Member]", "terseLabel": "Other" } } }, "localname": "OtherRestructuringMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PatentsMember": { "auth_ref": [ "r462" ], "lang": { "en-US": { "role": { "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.", "label": "Patents [Member]", "terseLabel": "Patents [Member]" } } }, "localname": "PatentsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "auth_ref": [ "r106", "r109", "r135" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.", "label": "Payments for (Proceeds from) Other Investing Activities", "negatedLabel": "Other" } } }, "localname": "PaymentsForProceedsFromOtherInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "auth_ref": [ "r113" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow to reacquire common stock during the period.", "label": "Payments for Repurchase of Common Stock", "negatedLabel": "Purchases of treasury stock" } } }, "localname": "PaymentsForRepurchaseOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRestructuring": { "auth_ref": [ "r116", "r270" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.", "label": "Payments for Restructuring", "negatedLabel": "(Payments) receipts, net" } } }, "localname": "PaymentsForRestructuring", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDividendsCommonStock": { "auth_ref": [ "r113" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.", "label": "Payments of Ordinary Dividends, Common Stock", "negatedLabel": "Dividends paid to stockholders" } } }, "localname": "PaymentsOfDividendsCommonStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessThreeNetOfCashAcquired": { "auth_ref": [ "r109" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with a third acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Business Three, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of Antelliq Corporation, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessThreeNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessTwoNetOfCashAcquired": { "auth_ref": [ "r109" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with a second acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Business Two, Net of Cash Acquired", "negatedTerseLabel": "Acquisition of ArQule, Inc., net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessTwoNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r107", "r469" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Payments to Acquire Businesses, Gross", "terseLabel": "Payment to acquire business" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r107" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "negatedTerseLabel": "Other acquisitions, net of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireInvestments": { "auth_ref": [ "r109" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.", "label": "Payments to Acquire Investments", "terseLabel": "Payments to Acquire Investments" } } }, "localname": "PaymentsToAcquireInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r219" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of securities and other investments" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r108" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedLabel": "Capital expenditures", "terseLabel": "Payments to Acquire Productive Assets" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r341", "r343", "r349", "r367", "r369", "r370", "r371", "r372", "r373", "r390", "r392", "r393", "r394", "r407" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "Pension and Other Postretirement Benefit Plans" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlans" ], "xbrltype": "textBlockItemType" }, "us-gaap_PensionPlansDefinedBenefitMember": { "auth_ref": [ "r315", "r317", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r365", "r366", "r368", "r371", "r375", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r395", "r402", "r403", "r404", "r405" ], "lang": { "en-US": { "role": { "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.", "label": "Pension Plan [Member]", "terseLabel": "Pension Plans" } } }, "localname": "PensionPlansDefinedBenefitMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_PerformanceSharesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share-based payment arrangement awarded for meeting performance target.", "label": "Performance Shares [Member]", "terseLabel": "Performance Share Units (PSUs)" } } }, "localname": "PerformanceSharesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "auth_ref": [ "r111" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.", "label": "Proceeds from Issuance of Long-term Debt", "terseLabel": "Proceeds from issuance of debt" } } }, "localname": "ProceedsFromIssuanceOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "auth_ref": [ "r112", "r115", "r135" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.", "label": "Proceeds from (Payments for) Other Financing Activities", "terseLabel": "Other" } } }, "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRepaymentsOfShortTermDebt": { "auth_ref": [ "r135" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The net cash inflow or outflow for borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Proceeds from (Repayments of) Short-term Debt", "terseLabel": "Net change in short-term borrowings" } } }, "localname": "ProceedsFromRepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "auth_ref": [ "r106" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.", "label": "Proceeds from Sale, Maturity and Collection of Investments", "terseLabel": "Proceeds from sales of securities and other investments" } } }, "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r110", "r423" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r1", "r86", "r89", "r117", "r131", "r145", "r153", "r154", "r189", "r195", "r199", "r202", "r205", "r231", "r481", "r485", "r487", "r493", "r494", "r547", "r619" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net income", "totalLabel": "Net Income" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r17", "r18", "r264", "r632" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property, Plant and Equipment, at cost, net of accumulated depreciation of $18,572 in 2020 and $17,686 in 2019" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_PublicUtilitiesInventoryAxis": { "auth_ref": [ "r36" ], "lang": { "en-US": { "role": { "documentation": "Information by type of inventory held.", "label": "Inventory [Axis]", "terseLabel": "Inventory [Axis]" } } }, "localname": "PublicUtilitiesInventoryAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PublicUtilitiesInventoryTypeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tangible personal property that is held for sale in the ordinary course of business, in process of production for such sale or is to be currently consumed in the production of goods or services to be available for sale.", "label": "Inventory [Domain]", "terseLabel": "Inventory [Domain]" } } }, "localname": "PublicUtilitiesInventoryTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/InventoriesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r27", "r35", "r631", "r652" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "verboseLabel": "Receivables" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": { "auth_ref": [ "r82" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 1.0, "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent", "negatedLabel": "Reclassification adjustments, pretax" } } }, "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "auth_ref": [ "r82", "r92" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "negatedTotalLabel": "Reclassification adjustments, net of taxes" } } }, "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationFromAociCurrentPeriodTax": { "auth_ref": [ "r80", "r84" ], "calculation": { "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails": { "order": 2.0, "parentTag": "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).", "label": "Reclassification from AOCI, Current Period, Tax", "terseLabel": "Tax" } } }, "localname": "ReclassificationFromAociCurrentPeriodTax", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income" } } }, "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r195", "r199" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.", "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]", "terseLabel": "Reconciliation of segment profits to income before taxes" } } }, "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RepaymentsOfLongTermDebt": { "auth_ref": [ "r114" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.", "label": "Repayments of Long-term Debt", "negatedLabel": "Payments on debt" } } }, "localname": "RepaymentsOfLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r432", "r666" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 3.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "negatedLabel": "Research and development", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "verboseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentInProcess": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.", "label": "Research and Development in Process", "terseLabel": "Charge for acquisition of Peloton Therapeutics, Inc." } } }, "localname": "ResearchAndDevelopmentInProcess", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedCashAndCashEquivalents": { "auth_ref": [ "r15", "r124", "r126", "r603", "r626" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Restricted Cash and Cash Equivalents", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWSParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Restructuring and Related Activities [Abstract]", "terseLabel": "Restructuring and Related Activities [Abstract]" } } }, "localname": "RestructuringAndRelatedActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "auth_ref": [ "r283" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.", "label": "Restructuring and Related Activities Disclosure [Text Block]", "terseLabel": "Restructuring" } } }, "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/Restructuring" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": { "auth_ref": [ "r269", "r272", "r278", "r282" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of costs incurred to date for the specified restructuring cost.", "label": "Restructuring and Related Cost, Cost Incurred to Date", "terseLabel": "Cumulative costs since program inception" } } }, "localname": "RestructuringAndRelatedCostCostIncurredToDate1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "auth_ref": [ "r269", "r272", "r278", "r282" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.", "label": "Restructuring and Related Cost, Expected Cost", "terseLabel": "Expected restructuring and related cost" } } }, "localname": "RestructuringAndRelatedCostExpectedCost1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringAndRelatedCostIncurredCost": { "auth_ref": [ "r269", "r272", "r278", "r282" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.", "label": "Restructuring and Related Cost, Incurred Cost", "terseLabel": "Total pretax restructuring costs", "verboseLabel": "Expense" } } }, "localname": "RestructuringAndRelatedCostIncurredCost", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringCharges": { "auth_ref": [ "r122", "r268", "r275", "r280" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 4.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.", "label": "Restructuring Charges", "negatedLabel": "Restructuring costs", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringCharges", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringChargesMember": { "auth_ref": [ "r271", "r275", "r281" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.", "label": "Restructuring Charges [Member]", "terseLabel": "Restructuring costs" } } }, "localname": "RestructuringChargesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestructuringCostAndReserveAxis": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Information by type of restructuring cost.", "label": "Restructuring Type [Axis]", "terseLabel": "Restructuring Type [Axis]" } } }, "localname": "RestructuringCostAndReserveAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]", "terseLabel": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RestructuringReserve": { "auth_ref": [ "r270", "r276" ], "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.", "label": "Restructuring Reserve", "periodEndLabel": "Restructuring reserve, ending balance", "periodStartLabel": "Restructuring reserve, beginning balance" } } }, "localname": "RestructuringReserve", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestructuringReserveRollForward": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Restructuring Reserve [Roll Forward]", "terseLabel": "Restructuring Reserve [Roll Forward]" } } }, "localname": "RestructuringReserveRollForward", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r29", "r307", "r427", "r628", "r648", "r650" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r142", "r143", "r144", "r146", "r152", "r154", "r232", "r424", "r425", "r426", "r444", "r445", "r645", "r647" ], "lang": { "en-US": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanSponsorLocationAxis": { "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r368", "r371", "r376", "r377", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r395", "r399", "r405" ], "lang": { "en-US": { "role": { "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Axis]", "terseLabel": "Retirement Plan Sponsor Location [Axis]" } } }, "localname": "RetirementPlanSponsorLocationAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanSponsorLocationDomain": { "auth_ref": [ "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r368", "r371", "r376", "r377", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r395", "r399", "r405" ], "lang": { "en-US": { "role": { "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.", "label": "Retirement Plan Sponsor Location [Domain]", "terseLabel": "Retirement Plan Sponsor Location [Domain]" } } }, "localname": "RetirementPlanSponsorLocationDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetirementPlanTypeAxis": { "auth_ref": [ "r315", "r316", "r317", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r365", "r366", "r368", "r371", "r375", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r398", "r399", "r402", "r403", "r404", "r405" ], "lang": { "en-US": { "role": { "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Axis]", "terseLabel": "Retirement Plan Type [Axis]" } } }, "localname": "RetirementPlanTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_RetirementPlanTypeDomain": { "auth_ref": [ "r315", "r316", "r317", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r365", "r366", "r368", "r371", "r375", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r395", "r396", "r397", "r398", "r399", "r402", "r403", "r404", "r405" ], "lang": { "en-US": { "role": { "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.", "label": "Retirement Plan Type [Domain]", "terseLabel": "Retirement Plan Type [Domain]" } } }, "localname": "RetirementPlanTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r94", "r131", "r180", "r181", "r194", "r200", "r201", "r208", "r209", "r212", "r231", "r547", "r619" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Sales" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesMember": { "auth_ref": [ "r520" ], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.", "label": "Sales [Member]", "terseLabel": "Sales", "verboseLabel": "Revenue" } } }, "localname": "SalesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r82", "r558", "r559" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Changes in AOCI by Component" } } }, "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherComprehensiveIncomeLossTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.", "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Information on Investments in Debt and Equity Securities" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": { "auth_ref": [ "r473" ], "lang": { "en-US": { "role": { "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]", "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsInformationAboutChangesinLiabilitiesforContingentConsiderationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r457", "r458" ], "lang": { "en-US": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails", "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsFairValueofAssetsAcquiredandLiabilitiesAssumedDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]", "terseLabel": "Collaboration Arrangements" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r374", "r375", "r378", "r379", "r390" ], "lang": { "en-US": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]", "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansPensionandOtherPostretirementBenefitPlansNarrativeDetails", "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "auth_ref": [ "r503", "r512", "r522" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "terseLabel": "Location and Amount of Pretax (Gains) Losses of Derivatives" } } }, "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "auth_ref": [ "r508" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "terseLabel": "Fair Value of Derivatives on a Gross Basis Segregated between those Derivatives that are Designated as Hedging Instruments and those that are Not Designated as Hedging Instruments" } } }, "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r164" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Calculations of Earnings Per Share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EarningsPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r409", "r419", "r429" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Amounts of Share-Based Compensation Cost Recorded in Consolidated Statement of Income" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": { "auth_ref": [ "r208" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.", "label": "Revenue from External Customers by Products and Services [Table Text Block]", "terseLabel": "Sales of Company's products" } } }, "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r534", "r535" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r509" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.", "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]", "terseLabel": "Amounts Recorded on Balance Sheet Related to Fair Value Hedges" } } }, "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r253", "r258", "r600" ], "lang": { "en-US": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIntangiblesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfInterestRateDerivativesTableTextBlock": { "auth_ref": [ "r512" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of interest rate derivatives, including, but not limited to, the fair value of the derivatives, statement of financial position location, and statement of financial performance location of these instruments.", "label": "Schedule of Interest Rate Derivatives [Table Text Block]", "terseLabel": "Summary of Interest Rate Swaps Held" } } }, "localname": "ScheduleOfInterestRateDerivativesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "auth_ref": [ "r11", "r36", "r37", "r38" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.", "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventories" } } }, "localname": "ScheduleOfInventoryCurrentTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/InventoriesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": { "auth_ref": [ "r353" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.", "label": "Schedule of Net Benefit Costs [Table Text Block]", "terseLabel": "Components of net cost of defined benefit plans" } } }, "localname": "ScheduleOfNetBenefitCostsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/PensionandOtherPostretirementBenefitPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "auth_ref": [ "r516" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Effect of Net Investment Hedges on OCI and the Consolidated Statement of Income" } } }, "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": { "auth_ref": [ "r511", "r513" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.", "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]", "terseLabel": "Income Statement Effects of Derivatives Not Designated as Hedging Instruments" } } }, "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.", "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]", "terseLabel": "Other (Income) Expense, Net" } } }, "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r461" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Fair Value of Assets Acquired and Liabilities Assumed" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r273", "r274", "r277" ], "lang": { "en-US": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]", "terseLabel": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails", "http://www.merck.com/role/RestructuringNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "auth_ref": [ "r273", "r274", "r277" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.", "label": "Restructuring and Related Costs [Table Text Block]", "terseLabel": "Charges Related to Restructuring Program Activities by Type of Cost" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "auth_ref": [ "r270", "r279" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "terseLabel": "Charges and Spending Relating to Restructuring Activities by Program" } } }, "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "auth_ref": [ "r100", "r209" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Consolidated revenues by geographic area" } } }, "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r94", "r211" ], "lang": { "en-US": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]", "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingRevenuesbyGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r189", "r192", "r198", "r250" ], "lang": { "en-US": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r410", "r422" ], "lang": { "en-US": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r414" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Assumptions Used to Determine Weighted-Average Fair Value of Options Granted" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityTableTextBlock": { "auth_ref": [ "r302" ], "lang": { "en-US": { "role": { "documentation": "Tabular disclosure of changes in the separate accounts comprising stockholders' equity (in addition to retained earnings) and of the changes in the number of shares of equity securities during at least the most recent annual fiscal period and any subsequent interim period presented is required to make the financial statements sufficiently informative if both financial position and results of operations are presented.", "label": "Schedule of Stockholders Equity [Table Text Block]", "terseLabel": "Equity" } } }, "localname": "ScheduleOfStockholdersEquityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r176", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r194", "r195", "r196", "r197", "r199", "r200", "r201", "r202", "r203", "r205", "r212", "r640" ], "lang": { "en-US": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails", "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Segment Reporting [Abstract]", "terseLabel": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r176", "r178", "r179", "r189", "r193", "r199", "r203", "r204", "r205", "r206", "r208", "r211", "r212", "r213" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r102" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME": { "order": 2.0, "parentTag": "mrk_CostsExpensesAndOther", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFINCOME", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.", "label": "Selling, General and Administrative Expenses [Member]", "terseLabel": "Selling, general and administrative", "verboseLabel": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpensesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r121" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS_1": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails": { "order": 1.0, "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Pretax share-based compensation expense", "verboseLabel": "Share-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDSTATEMENTOFCASHFLOWS", "http://www.merck.com/role/ShareBasedCompensationPlansExpenseAllocationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r412" ], "lang": { "en-US": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Shares granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r412" ], "lang": { "en-US": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted-average fair value per share granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r417" ], "lang": { "en-US": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r416" ], "lang": { "en-US": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r418" ], "lang": { "en-US": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r413" ], "lang": { "en-US": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r408", "r411" ], "lang": { "en-US": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share Price", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r415", "r428" ], "lang": { "en-US": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected life (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ShareBasedCompensationPlansAssumptionsUsedforOptionsGrantedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r0", "r176", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r191", "r194", "r195", "r196", "r197", "r199", "r200", "r201", "r202", "r203", "r205", "r212", "r250", "r266", "r272", "r282", "r640" ], "lang": { "en-US": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/OtherIncomeExpenseNetOtherIncomeExpenseNetNarrativeDetails", "http://www.merck.com/role/SegmentReportingProfitstoIncomeBeforeTaxesDetails", "http://www.merck.com/role/SegmentReportingSalesofCompanysProductsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r24", "r25", "r26", "r129", "r131", "r158", "r159", "r160", "r162", "r164", "r172", "r173", "r174", "r231", "r302", "r547" ], "lang": { "en-US": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r54", "r142", "r143", "r144", "r146", "r152", "r154", "r171", "r232", "r302", "r307", "r424", "r425", "r426", "r444", "r445", "r553", "r554", "r555", "r556", "r557", "r559", "r645", "r646", "r647" ], "lang": { "en-US": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/FinancialInstrumentsLocationandAmountofPretaxGainsLossesofDerivativesDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Cash Flows [Abstract]", "terseLabel": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Financial Position [Abstract]", "terseLabel": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Statement of Comprehensive Income [Abstract]", "terseLabel": "Statement of Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r26", "r31", "r32", "r131", "r217", "r231", "r547" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Total Merck\u00a0& Co., Inc. stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Merck\u00a0& Co., Inc. Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityBeforeTreasuryStock": { "auth_ref": [], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.", "label": "Stockholders' Equity before Treasury Stock", "totalLabel": "Stockholders' equity before deduction for treasury stock" } } }, "localname": "StockholdersEquityBeforeTreasuryStock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r131", "r142", "r143", "r144", "r146", "r152", "r231", "r232", "r307", "r424", "r425", "r426", "r444", "r445", "r479", "r480", "r492", "r547", "r553", "r554", "r559", "r646", "r647" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-US": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Equity, ending balance", "periodStartLabel": "Equity, beginning balance", "totalLabel": "Total equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET", "http://www.merck.com/role/EquityRollforwardReconciliationsDetails", "http://www.merck.com/role/OtherComprehensiveIncomeLossDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r130", "r307", "r310" ], "lang": { "en-US": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StockholdersEquityOther": { "auth_ref": [], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.", "label": "Stockholders' Equity, Other", "negatedTerseLabel": "Share-based compensation plans and other" } } }, "localname": "StockholdersEquityOther", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityOtherShares": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Number of increase (decrease) in shares of stock classified as other.", "label": "Stockholders' Equity, Other Shares", "negatedLabel": "Share-based compensation plans and other (in shares)" } } }, "localname": "StockholdersEquityOtherShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r560", "r566" ], "lang": { "en-US": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r560", "r566" ], "lang": { "en-US": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r560", "r566" ], "lang": { "en-US": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/AcquisitionsResearchCollaborationsandLicenseAgreementsAcquisitionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradingSecurities": { "auth_ref": [ "r612" ], "calculation": { "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in net income (trading) and investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Debt Securities, Trading, and Equity Securities, FV-NI", "totalLabel": "Investments" } } }, "localname": "TradingSecurities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r224", "r225", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597" ], "lang": { "en-US": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryLockMember": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Customized agreement that fixes the yield or price on a specified treasury security for a specific period.", "label": "Treasury Lock [Member]", "terseLabel": "Treasury lock" } } }, "localname": "TreasuryLockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsIncomeStatementEffectsonDerivativesNotDesignatedasHedgingInstrumentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockMember": { "auth_ref": [ "r53", "r308" ], "lang": { "en-US": { "role": { "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Treasury Stock [Member]", "terseLabel": "Treasury Stock" } } }, "localname": "TreasuryStockMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TreasuryStockShares": { "auth_ref": [ "r53", "r308" ], "lang": { "en-US": { "role": { "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.", "label": "Treasury Stock, Shares", "terseLabel": "Treasury Stock, Shares" } } }, "localname": "TreasuryStockShares", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockSharesAcquired": { "auth_ref": [ "r26", "r302", "r307" ], "lang": { "en-US": { "role": { "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.", "label": "Treasury Stock, Shares, Acquired", "terseLabel": "Treasury stock shares purchased (in shares)" } } }, "localname": "TreasuryStockSharesAcquired", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_TreasuryStockValue": { "auth_ref": [ "r53", "r308", "r309" ], "calculation": { "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.", "label": "Treasury Stock, Value", "terseLabel": "Less treasury stock, at cost: 1,047,343,390 shares in 2020 and 1,038,087,496 shares in 2019" } } }, "localname": "TreasuryStockValue", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CONDENSEDCONSOLIDATEDBALANCESHEET" ], "xbrltype": "monetaryItemType" }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "auth_ref": [ "r302", "r307", "r308" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.", "label": "Treasury Stock, Value, Acquired, Cost Method", "negatedLabel": "Treasury stock shares purchased" } } }, "localname": "TreasuryStockValueAcquiredCostMethod", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EquityRollforwardReconciliationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r477" ], "lang": { "en-US": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/CollaborativeArrangementsNarrativeDetails", "http://www.merck.com/role/CollaborativeArrangementsScheduleofTransactionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfRestructuringDomain": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Identification of the types of restructuring costs.", "label": "Type of Restructuring [Domain]", "terseLabel": "Type of Restructuring [Domain]" } } }, "localname": "TypeOfRestructuringDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/RestructuringActivitiesbyProgramDetails", "http://www.merck.com/role/RestructuringChargesActivitiesbyTypeofCostDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "auth_ref": [ "r342", "r620" ], "lang": { "en-US": { "role": { "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).", "label": "US Government Agencies Debt Securities [Member]", "terseLabel": "U.S. government and agency securities" } } }, "localname": "USGovernmentAgenciesDebtSecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/FinancialInstrumentsFinancialAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.merck.com/role/FinancialInstrumentsInformationonAvailableforsaleInvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": { "auth_ref": [ "r440" ], "crdr": "debit", "lang": { "en-US": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.", "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities", "terseLabel": "Tax benefit recognized related to settlement" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/TaxesonIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ValuationAllowancesAndReservesDomain": { "auth_ref": [ "r136", "r137", "r138", "r139", "r140" ], "lang": { "en-US": { "role": { "documentation": "Valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]" } } }, "localname": "ValuationAllowancesAndReservesDomain", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "auth_ref": [ "r136", "r137", "r138", "r139", "r140" ], "lang": { "en-US": { "role": { "documentation": "Information by valuation and qualifying accounts and reserves.", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]" } } }, "localname": "ValuationAllowancesAndReservesTypeAxis", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/ContingenciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "auth_ref": [ "r164" ], "calculation": { "http://www.merck.com/role/EarningsPerShareDetails": { "order": 2.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.", "label": "Weighted Average Number Diluted Shares Outstanding Adjustment", "terseLabel": "Common shares issuable (1)" } } }, "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r157", "r164" ], "calculation": { "http://www.merck.com/role/EarningsPerShareDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-US": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "totalLabel": "Average common shares outstanding assuming dilution" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r156", "r164" ], "calculation": { "http://www.merck.com/role/EarningsPerShareDetails": { "order": 1.0, "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0 } }, "lang": { "en-US": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Average common shares outstanding" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2020-01-31", "presentation": [ "http://www.merck.com/role/EarningsPerShareDetails" ], "xbrltype": "sharesItemType" } }, "unitCount": 9 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "220", "URI": "http://asc.fasb.org/topic&trid=2134417" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18726-107790" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08.(e),(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column B))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(1)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column C(2)))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column D))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-09(Column E))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690" }, "r141": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "http://asc.fasb.org/topic&trid=2122394" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r175": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8475-108599" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599" }, "r213": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563" }, "r226": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117539-209714" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=120269885&loc=SL75117546-209714" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456" }, "r245": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "330", "URI": "http://asc.fasb.org/topic&trid=2126998" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "http://asc.fasb.org/topic&trid=2144416" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.3)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 5.P.4)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(c))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r283": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "420", "URI": "http://asc.fasb.org/topic&trid=2175745" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308" }, "r286": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14394-108349" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14453-108349" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14472-108349" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751" }, "r296": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12053-110248" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601" }, "r301": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "http://asc.fasb.org/topic&trid=2208564" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046" }, "r314": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "http://asc.fasb.org/topic&trid=49130413" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "712", "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(10)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(9)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(8)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(j)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(k)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(6)(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(4)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(5)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(6)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(7)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2919-114920" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4587-114921" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(b)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r407": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r431": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "http://asc.fasb.org/topic&trid=2122503" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r455": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "38", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5504-128473" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "25", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "30", "Subparagraph": "b", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "c", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e7008-128479" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r478": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "808", "URI": "http://asc.fasb.org/topic&trid=5833765" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r495": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579240-113959" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5579245-113959" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5580258-113959" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41620-113959" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41638-113959" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "4C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624171-113959" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "4CC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998890-113959" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4CCC", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109998896-113959" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "4D", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "4E", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624181-113959" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "4EE", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL109999712-113959" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41641-113959" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=d3e41678-113959" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "182", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29,30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "25", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=120519210&loc=d3e90205-114008" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13433-108611" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "35", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=121605123&loc=d3e30226-110892" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3,4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30690-110894" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(3),(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(1)(a))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(c))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.4)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.6(d))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(1)(b))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(d))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(1)(i)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column B))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column C))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-15(Column D))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r667": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r668": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r669": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-13" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312" }, "r670": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1-" }, "r671": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r672": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226016-175313" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a),(b),(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i),(j),(k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(i-k)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6904-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "17A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "17B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=121640130&loc=d3e1436-108581" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227" } }, "version": "2.1" } ZIP 93 0000310158-20-000030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000310158-20-000030-xbrl.zip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

K>0%B=S?8+"_1X4N](24^&WI_ M^(L[MV-<)U[\*;?[..!&R8]&Y9W+5G?G74()*]Y>X]#U!XW>,-MP^1XVS2.= M1;J=O;+1B24ZG!K^%)\JA?>-HW(XZ>-^&@;<2U+6Y;;_\\9/[.>15MIW?9R5 M0YP#=WAX_O!]_/Z_DW8/_SCH-GPZ?P->>3L-0_:CCS)1 OJC=#FT%K_Q$UX/5ZK1 M/PG[C?Y^MZ0A7"20#?;=X*O':'QT7PZUC'/TX?,'^?G9>UJ>$BW/B M#_!9RH>&[\_#0@P7%ROYI_WA2(8C+6)A:2.ZT_YYPM>$TKY>G/1Z.)11 BR. MKX0G3OI/3[O+ORUS8'3T)%.>2>G=26S)"*,R20FT]*++2RN[J7^][?7E8<*Q MYE/?SC+_?!9H K[!]\Y37OW:ZL[2Y,"MSGKJ+S71P4E_T,ZG-A+JTM/&L/^N"T,O>\T-W"C+](+@1LLT(N3+"QV? M]/HGY?KXPM8)OAVH+'2+[NO)X6BW<)OL-'XJG]:_6FTB\E)98"TQK MQK@J)_4KD2XZD:JY)5*D+8>F>@]-RU)N\Q"!78BPT$JOF'O7_K6!DDRN>:%_ MA/R+]^A=F%A(/D=O,;+MYQ\P OWED,W/,WWS#8BW>V.R,5P;@G M_,)DOVJG+S=^>C&<_VXG_?Q\YDX,WC\ HI<-@_%'*O2R$N,_B61P7XAM@M%/:NVSN];G^Y6'*]%^=OF$N[X[S: M\[ MV#M:%ZV=U4^MH]>?6J]:A\VC]4]E//C]8_/5&XKW.6T>?;U)UQ5[1ZVCW9W MFFOK? _OML:=[A[S(RI\>HTU-&\;Y]=C=O7;-5RX-8-?K]L_'F?FYE3>NCB* MHW6=O;B0@MA8+/;8OLE@7JS%FUZ!AI%!,YSFWT[Z.+#^?$:D)VK0G/ZQT_QL MT CJG&0LH"UC\(L1FABP0+00W/GL!.7VQ[49GJ#>>)R13*]XQ>T8;?UZK[[R MV3CY[&*27PWG^,5HBBNO_8C7Z%5>8UHKJJ4CD@5&P$$FIF0"6TH3$YPQ#OD. MO':/(L/3#6/F[P0,2Z[@M5'.=KYNIVBX/X1F9Z<[W-DYZ8^"C?BDHU)RUQ18 MZ?:&]SH\+3?_V,9;XVT;'7RT;K&&/K3[0S.VXSJAE+)$X[8<92YO[@]<)[I> M[#=*BGP[?K6M=+[IWV#B)_?S]6'#QATBSS.U9'>///?WT^'AQ:HV?L*U&D: M1^43OA]>_7+3:S?U)[AA [O8_9KVOI?Z(?OQA"+DM] MNQH@=]H54,OZEMF6=QHM+ M[NQV7^^^S\*.';8GN]8;L'3;%[UMK'SWS:6WLO-E^U#O#>^[MO=\_V=EX>;;[Z MYB@ACA.=Y9V_<'SQH,GQ7CMXKYT N[R)S_ER?^\ '>FWNS *ZEWN4LJ +JYD MB@C)T92SF1/K%26)0O2!L6"*\UM*2):4O$$7?8V?_DF7)1TI@V/7:WQPAR?I MF]-#! SFMCCGI$7X\C1WCBPESC@!ZA1ZTU(1 MRZ@ET92&DYXZZ?.H_L!NM_?^G(0OYON1JL/,EWS'1 U.693:44 I+HU8L_"Y MU#D3(=%J0HQ9?K\H;V0-.*\5FA BYA(-LL13ZHAW5N*2&%P4M[3"EAF7_Z?1 MZ@Y0).))*OTIOE]UK@IM-1K&*;&71@,%'VC4AGC%AQ+KB D1B#&91C2'%5=V M:#3\4D7TSB):[89'E>)+NP&)!9.*TU]8FEC.X:C=\3[ZY M,D'G@&@'"91GZZ420BC!D X4JW;#N.7WBWIR2"QV6(M$<2D(6$^)L]$1EJ76 MF4H6)%M:*;$&^I7= $^9E!\HM-5NN*O$7@DV"!62#YZDD"T!%RBQ4-H')]"& M>A><<$.[H5%%],XB6NV&1Y7B2[N!Y>!U$HQ8EC3:#<*CW8#RK#U7SCEN]$6] MPVHWW)1C,CR-'!4W#&@&ZP# ANR"4DX:5^V&,@% A"K4(6%J") M"]R4NEDI1I=88E#B#49_'6]03YF4'RBTU6ZXJ\1>J3 ;&+4$7TKB):[89'E>)+NR$Z&_*MC:=,ALQUC*"L5XDN[@7HI +0FY7 28$,:J0KX\! M30>7>&E%5NV&F^6[G$,#:Z2A+B+FHU-16A\\&L=99Y:JW3!F^157[0;J!'*) M!B)HV:>@E!-CT )FPEDA#+IO495X@_@ZWB">M#/W0*&M=L-=)?;2;L@YY P\ M$9^4))"3)\X%38)0V67/A"D[:V6?0JC5*J-WE-%J.#RJ&%\Q'$+P(C%#7,Z4 M@.9 D'$=T9!LEE%8'M@##(=['-2>9FN7G?V+!B[E+$E_W_72L'1C&.7F]X=/ MWST9#(]%#WN[]"].:87#;G]X L6?5SXIAT\VPZ"+%QOE\0OVK 3(Z?.+7BPO MAW5G\6TGG?8(+*,[+GT)H,R]I,XI;= ;4=;[E*!4-[, C+/D_MXH5T57A2TU M8@KM(W?8_W]+&ZV77\#H.3Y7[ [.WW!-0?'A(P[7=WLXBLW+QT120I[!M].Y M1-=#3N*^@[^5Y2DZM$V0W@T!J3."9;@7DB0W@8*C:6F%/Y."/L,5>@9"7P#C M8H57QG+^]'%[B)AE)OA]CI_B)RV]^>5K#G1^591&?*7%#F1EXZ'Q*4E3CNCNHH/.^E4B_[0SJ?JG.==^53Y\.C MEQ]Q'H=R,OCV(R->6_FW[_WRE51<_5JN/42:*OGIB=OHA0+!D0-H NXL)$"M MJMS?>NGB,_N]2]OA'=HEO>3>HZ2BR#QWAQ_=:7_IER]%#Z7LXG'YLBY/?/O! MWN))[L[V-]QH6CJ#\5L=,=\9HA&9_T5A[LY=W-Z!_R\;? 7N1"O[!%H%L^+F W;!7^]'( M%*]DN"#+^P,R'"/S/6#]SR]!RON?,_.]EH]U_>^P_JK41\$/=DJE2OQI&.<9 M5E__C/7B@6]T0OW WTI$MI+^_BVTAVQ4L""B4"E@*>[ M_IS?2 &_N4-7.G-O[ZGN_[FEAK?]?<;+P^['ZM_OS@++V<9 M^'65Q[#*0I?F:25W=]!MW(#S&L1;Z.57=4?C$9I%W64[@]?MC-F'2CGDVW0= M]VY(@*5)-]._]AMK[7XXZ?=+RFAI[;W:<8>G_?8P!?62-PNQCMK_E/=LI?[) MX6#XELWC-!K2HQ+J2+PKFTY"1$3=()Z!#6*HC#K[<&%<#WW+00_79LB,?_:Z M(<637JKVY0(ML60+3(DUN#7/XBDH,I [*1=PO=/&2Q<&W5Z_L;/O!HVF.VVL MYIS"H/'R9("D=&&X56Y:G,5?:&Z:+7/M>\G--;MY#K*;A5A:V=SYS_K6U=3F M1F7#!6%#4=EP-IS7FMT\%WA12RM_I'?N<.2UIK(:U31 M &.75K;:_?<7+G0EPL59UTD2X:R_=='HM6X]SP4*2Y[&F\YEQ^S&MCLW#:N-+,OFRDO!G5/3JW3"L;+Y(<2%[I>%'I6%4ZG@,8 E]:6?^TW_;M MNAFT2&LJ%SEWYV%E?RJQ3$0(Y=+*-DZM&]P[!V9BA: J84U?5N1W3V9]4U#Q M5A7]OBH_.!<%%TMAGMFMN#AQ>Y)_7][_=+U!8Z-!KB0H;W1&96GQG=\*QBW7 M0"Q=(TU7BBG*[V4M36DJBM$]J@3,EF\XYW+/V5 _F T[D6J9/TP.&%;+;*YO MO?CO:!K^Y8Z.?VV\V%Q^UMAHO5ANK+;6&MMO?MO>6-M8W=I8W[Z1-F;E65YL MMM;66]OK:_@0K>W-/S;65G?PE^T=_-9<;^TT-E^6)]MLKL_\H_STIN-.8GN0 MXK/&/QOM3@/O<5C."C32IY".!XWCU!L5Q&ZXH^X)2NO/-]#3V$9^NY+=(U&Z M7\G5$4L\2H%5NZRIOD^!50G+H,=?6]0N@]3WNNKW7Y-"U+'.T5CM.,O+3C74 M96X5Z?J*'NX5Z)ID&=K;/=4.FNZIT<3W[?<;ZVABQ*%-N(U$G8;="P1]=H<> M(P_+*Y^]Z6GA7^XR.T]&W+^IJ__]NOESL=BE^<6X'O@648I%FCAFQT$2BSDW M5:C&(U0_X%;OPOMW/70H(CD?80@IY7R[QAXS?^1^N'7^M2"-[=%I8QXV&__Y M>,]_];E[Y98S]> WMGDZZ<>O>CR!45Z MR*P#")1JY*U5BB(@GGK+YJDZ2^: MI%TV>R+J%KV>3OKDG7/'S[?2A]0Y*6VFSKLZJ2EW=6JU[5$X>MG9/&C2W;,W M'_?67G]JGKT_W3MXS5MGO[>;:QNP>[#?;NZ\/]M<>_E^[^CW]W^(K?W=HT^' MFT=O1&MM;W_W;/]@\^UKV5S;:N^M_;7?6FNU6P=-OG?P$L?WU_O-MWN?/X/W M.MGC;]3>3J"MHY<'FZ^:..V/B>8GK0>+[6?)7X*O%]17PJF<@UBQPQ!8P[&Y1E/E@)ED,&7XB/ MV7/BPQ\J\4V>^,X^$U]11UFP0')4AD!B0+P,F623<;F\X:DDC2'Q"?MM#[Q* M?)7X*O%=$)^0*7/'K0W>@\W".FM4-%ES9IA(_MJVN)7X)DI\[#/Q!::,35(2 M)K0C8$PF!C47D3**')1@0OFE%2&?@;:5^"KQ5>*[D?BXY8SSY&G(# S++BL0 MA@][@W.FX-SB8]7BFQ[QB4M75W)E3'3(="8@\25*C+(:?_*,BYB>%^.X_:"IN4T@O-Z@ MWN"NS;SOL;MP'8VH44;F+ *77P"W'+3K7[>G\/GA^=T>_EJ[:J[MBTF&TLN2 M;.97W6[LKW;B=NI]:(?4W^X>QFIQW,'B:+VX$ES7*.U"9TU,MHE H(HX:23Z M6X[9$'SDJ5@1A/,G <(7QN&!\)50,R4@J@&AO,@%G M&+%")N(]4%#4X=(.86PMK3!>7!A/,LQ983PN&+,K,+9.!Q.)5MX0D)H1YR 2 M!YY[-*F"H')IQ3ZSE1U=(!\*#0J.:X4\N MH8T=&35*^&@9BTLKC#X#$#.$X_M&ZN;,O1^E"J9#_..[9XUWJ9-Z[G 8F'/Q MJ-UI]P>]X7'8>SG]UTS)XO'3))W^\X5Z-5HFI*C5+Q;I/+!:N>HN7+5])0 @ MM(M>AD"B,)1 1IJR+B>2=:+&>L&R3TLK_!G(!WL.WZ&+QS(YOKKEO4R.)P'I M208 *J0? ]*7P8 *25I):%2!@(^1^*MBR0'S@2SFN,*%DA+\^#LB0KIV87T M)(,!%=*/ >G+P("U.3LD:*)RL@2X &*\C@2TE\:!3#J%I17]3)@'.Q05TK,+ MZ4D&!BJD'P/2ET$")GW0.60"^!,!ZQ6Q,1F"YI:UT5@!I0Z4?J:YFB%(/Y$4 M@"$PMU(_N5[8'\8&8OJ0#KO'I710S0:8A<# Q>H@,ZU=KDVEI7O0TM73=@Z8 MUB$6,@*DI[-&GBN2Q(9E=<14RS8)F8JRE M!" 'XI&;23+*1.I3M/;<5:A)>@N,Y,F>Y:E('AN2+YU^RT5$:YH27$!-P"7$ M-#@@*B:>372)CY L^"SIY*>4&(""/^B=A,%)#T>.3]L?W"_[_TG$(\?@[W]# M.Y>S_V+?]=[5XX1W8YO3*[Z\4M%'2PV)64L":/ 3K]"KU]0FGP2#Z,S2"F,/ MYIJZ9S"[&!V#)U\Q.FZ,7GKITKEH2YD#!4P0$-J@;1\Y84$[I2-$FM BX.+! M";\5H[.+T3'XZ!6CX\;HI?\M<_94:46$$Y: QY^\IAK7(@=C'&09-6)4U72: M!<;H&+SOBM%Q8_32LXZ*&;!.$B\Y)9 2)=Z+2+)4";P/0I83< "S9.L^II9\;:11)>M;HI*>VG_[3-!WLX3*TNIWN<2IY/)UW&\,%J8&] MN]//YM5S]"PX'9TON7DVQY/W,AM#0.N2?Y<,L3(S8M&N8]2F&),M109G* Y?43MN M_3IVQ[NB=9QHO73!.==:1 W$XU(1D-(0DZ,CV4CA7 C*1;JTHL2W26E5O\XL M4B?K?5?].@'$7CKD"JT@7*U$A!&E@F7VQ&?NB061+1>:GR:1^7[4>S\LU]&_J":ZVHE#]JHD=1>2NGKZ/0F>!;KF M:$?82" P47K+H%P[R%XPHX&Q4G"'\7&=JYN90N-C*3-:26':2?25%,9$"I>1 M 68EYXH% LQQ IYYXJ( (@-R/)/>(*\/R_?0L=7$J*SP=%AA$@GYE17&Q J7 M$0AJ0;D@'0GHO2 K6$UL=K&4]S)11"VL%F(< M15A6_XXR*@@201$T(\7M)0[=7Q)B]LE*E9$]A^T%N)F7?D:3:.16"69FXBN5 M8&:08$X_$XP'I:-VG"1!=4GE &)<2H0K%9T38(2AI=:A@-HBMQ+,+(9J*L', M'L&TKE@P3+MLHB#61(H.7BF%Y"4E+B<=HHDI"1@&@[49UY'MRC!/AV$F6=.A M,LP,,S?4B?E=B6@NQ'0^M4@C4)%@Y:M)8!> M-)HX/J"QXP*A.OJ4@^?"I:45J*6E%QFH8R\348$Z)J!>"78HJ[54F62A!8$L M2S259Z)!XLH$DYC-Y8QK[=2RP$"=?$RB8OBA&+X23Q#&Y4"E)NCPH;7/P1,? MO2,*"9@+7$%CQ-(*>Z;8@VLY5A3/+HHG[_=7%#\8Q9>:F"JIM!*>6!5UJ:U, MB8/ 263<^+)J5*>"8BYGJ2;,TT[L:*7!0]SU&JN<9#['G[TN4E2)55::NA-- M;5SU[).-U"272%1>$@ N".H:3X)*,5**[KTR97?4PKB.N=>]BZ?#!Y-,OZA\ M<'\^N#1;G*#:42<4-5ZRTIX"'EXROJ0AC N0?J=]_WK@, M;C1^*BCXN;$Z&/3:_F3@_&%J#+J-+Q-W&A>9.[6[Q>1R%W"1+G.PKJ[/3K>F M58V!RYI78Q_&*"E]"79 9@1T0BYSIASE9T"1Y<#)4A!XAL*S=9-E]@(4%< 3 M!O"E,9(913O1EK.T*A'(WA(?DR">!70HI9&ZI"7-4G/L"N#9BRA4 $\6P%>B M"]SS(+APA$J+ ;)B4O,$I<%Z! ]")&75JXIB5T1/-L(ODN%W<_-EYTEY^5-R\_6N#F6DZ[;L*F2FG_?+SGGVTNG]'\CR_(O1+W MG8C[]=4P".6*BQR ".E#.>%AB.,.4)BD,-*"UZ4Q24D!&5?O\(78XJGT5^EO MBNDNE?X>1']7[%;N(0F&UBICF8 #BC\)2RP$%UC,1FH^RGBI]%?IK]+?;&3W M5/I["/U=3?"Q+' K/$E"%?J+@3A4581*SY*G&IS1PP0?5>FOTE^EO]E(9JKT M]R#ZNW)@FG*K/9*>#!8(\(3.;PBL]"!BP"1PZM0PG\G,3;[S&%H4\8>&-C^/ M*+8_7-SX_!*DO/^YO;A&NQ-39_"%9R_OQ:+IC[N_/SSJS[^3+VAH(PW MALJ_5A47@GUQNZ&X?U89M*J,6ZB,-U?CI=*YR)4.1%E;"HH*0ZQ'V]E%"B"D M1H>G')%99N-*/+D+,4^XRQ-7QJN,]P08[X'!T M$R(JHTK-AU((AD=)G/.1R(3VN$A<22F65OBR'5?1N4=GO >F>(XN=LW8GFJ< M]#L1TG[_Y*@<&5UK'YX,&6&B,=-QK]NB:9^QS\_"::?'CKD.<9%BU4]WTD^[ M7Y0@SX'2Q 6)3CL"-$GB):Z'R$G8G*13)HXGZOH(:F"":0P/&^\]TQPJYU;. MG;6H;^7<>W+NE6)P1C)CC"-:(]V"!HX^@9-$6*1;;V3,7HPG[ELYMW)NY=RY MCSM7SKT?YUZ)/'M&@49(Q 3-"5C*B:'6H=F;G H\JF!'D>A%F'7\:**?LC2/$"J:]F\&(L(R%6.F5<%!N]0-1P;2A-@+XB)!!@ ME?N;V:6K'SH?^I'KO6MWAO-GOZ3:D$JICT=G#WWMHS;7MU[\]XLH^&:)@K=> M+#=66VN-[3>_;6^L;:QN;:QO?SL?YV.=E6=YL=E:6V]MKZ_A0[2V-__86%O= MP5^V=_!;<[VUT]A\B:\T_]Q:_P^^;>.O]?*XT\!Z'I?7MS]\,?:;P\J7HGU.+Q$M> 8,<&CVC79D+CAI1#0[^T!WWT_.+ M'WZ-[?[QH3M]WNX,QS#\T#453'[]V(Z#_>?6+ALIBH8\WW$[O_SH5;8\5)Y? MT>/H-:F70L M]&!N9:%>;Y!\?B9[FV<:\>\L/=7.?B^E1A/?M]]OK'=BBO_VO5]6MM/Q(!WY MU&L(^NS&9_YV'6^LQC:GT]/"O]QE=IZ,N%^))]RS<-?L+7:)S(WK@6\$PF). M'+/C((G%G)LJ5.,1JEI9L%86K,45:F7!<<=5-[?/XZI'ZWQS[1UKG:WS)E__ MM+GS&EJOUO&>?[7W#E;Y[L'K3\VU5=E\^]?195RUU6Z]VOBXMQ;;>VM[ATT< M2W.M";L[+_=W#]Y\:O)=N;A,ZNUA6LE64J^=6Z@@M"?F>?R2]QSU600!C-I:R63,0;SXCD-#IO MHH*+/IJ5_"KY5?*K507GGOS89_(3VEJFI"4I2$/ RD!,\)98SI-,RF3G6*TI M6,FODE^M*;@@Y"<^DY_V6N/:>!)5 *@!#')!8+6NM3@ BHO]_0J"LYQ2'-S ML#\Z\'K<2_NITV]_2%\U4BU!SVYN[+A/J?_\-E'T!TW8;<+K]0;U!G>XP7WW M+*XC%R:7M;P&SU^?8I\=@!?XGG1Z"<=QEF+CI\,AJ-^Y=J>!VAFGLOW!#1#U M_6>-S@CIO10.7;_?SCC^0MSW:Y%\S20N8'NW,43N;VCO-B3F+WCYTGYYX?K[ M+P^['_^3XKOT"I=RV (N#U)OZZNU6^U$).X_70\%LUH]=[!Z6B^N!/NY4UY3 M-'/ :D& 9DH\YT <*RX[M4F*%"4,!6DRC;39!1J]-D ^7W#CT\A.M'N?$C] MP1$.>]S1B?EM/C^]M,*SU.M&I++;4M_J!]<^+/FQ>)$^,MEV"B>]]J"=^JOQ MX&2TKKC^F[E07K;AZ(< M.,.]+^;.O_YA4"G^.J;"IU.HYOP@NV=^B> N=L\8 AAWM'LJ^*<"_LNPAM7, M9AL884)G A*_^.P-B3Q'IBT5 @SZ.@\)65;(SS#D)Q_1J)"?"N0OPQM9:>6C MCX1[P]'OT8*X)"EQ+N+_='%9-$+>5,C/#^0G&]RH0)]AH%\&.#Q 1LM>$NT8 M)4!](#[*1 2EDE$E(TL2@4X?7-%IC' ?4Q;&[3*I;FHX\$6 9/I-!WY+G93; M@\;Q(=Z[Q#>&@0_7B8WC7KO;:^!E/[1#:H1>BNW!YQ"(.RJ@.AN&/Z[O)K#@ M(=^93M!8PR7MI'B^MG_BTE9:?#Q:O'HFDQL F;@B/)?,?.8S<11='K1]'05E M?4QQ:>7A7:WJ%L_LXGWRD8Z*]\GB_3+$41B<>6H(Y\R6[5Q&7#F&&%)F-$N/ MZU_,(%GQOKAXGWR8H^)]LGB_C&\X=%X#5XYH2DM\PR#>D[/$ 9?9)15T"HCW ML9V[JX"?0CNI?= M'@ZQ\^*DA\053G?*:HV&5S+3+M>N\M^C\=_IE8"&"MPD+3Q)D T!!9+88!1^ M@:09VG%/-C!J;LZ,[R1._F(1F6!&6"!RS!'2,P!6"!.6'1[2N\.3U,@ M7FF6T(R#J*, M\S0[1@(N*X&<)7$L29)X",*J;%A@:%C8A\1!*E4L!E7,8GBE$L2C$,25A)& M-B#C4([#L+)5XM"4R.AY.%'*^PAO;"G4)\>5$CKKQ8EOTX-]%L,MMTTLN:YL M\2-T9AOWI"Y:"?NQS\_"J)9)=G:[1N%<*)NJ4>ZB4:[64'%!&ZMT)"Q")L"- M)][@%UU<"Z_ @!OU>9,/SD)\!.J>Q/;=6,9[ZVXAE8HK%<]^G[E*Q6.CXBM= MY[+6WGA=.BVY4J@W$9LX)\(Q+807D<6RK?#,Z&_K=U8JKE1\J M%8^-BJ\$8IUU*:5 %/."@"P-0%52) LE#=40;+1+*^:9U=4JKE1.0EYY'KOVIW1[?F7#!822GYOW*"T/\(D_S8W<,*L,!S!SGYJ MN("HPWN?XAHT.MT!7MWU\,^EUO8@O>NYP\:QZPVK3 WV4S\5LH@(V%2T7V>X ME&Z O^1VQW5"&]_>'^ ?AB6ZE[\\QGEE22Z-CH;]^ M;,?!_@5Y7?G@N8S1RX\XCX,X&=S\D4=?[EO.-FF(!OGJ8.N5KV7$0Z)3.F5( M"%,OD'FY-I0FX,Y" @%6N;\Y7[KXT'[O\KCO.S2Y>LF]1]SC0SYWAQ_=:7_I MER^A@#CX:NZ_GK;1Y*S\V_?PHU^OW\TO?K/$DY]V?>VT-]>W7OSWB]V>S;+; MTWJQW%AMK36VW_RVO;&VL;JUL;Y]H[C.RK.\V&RMK;>VU]?P(5K;FW]LK*WN MX"^_K?ZQVGJQWMC^S_KZSLP_Q$]O.NXDMI$TGC7^B2S3P'LG_(0D>H;0;]GV^0PZD2]DUJYIRA"K2N*!XY--M'6Y"?J6RH%7'PA^ZX MGYY?_/!K;/>/#]WI\W9G.(;AAZ[98CU'KK7+FNH"WO-=X?/+G^-Z>8CKKS3Y MZ#4-^$EUX\MTF=WXVOZZO=?D^)^5_W>6!E;1O_T5I?]P<;['3J9 M?F(2GHLT8)OMRBX^^B3L9:"N=SPTS><-)EH=9CJE7LK)P4'C >)QVU.AT[S&3!0S MGF)!']??'Y8I#N6']+^3]@=W6%S ZPOY/+A@V1Q''J][Q(4)'K(0DU%,",@! MI,W.4*<,*$-ST$'DOS<>OGV#$K;:B>7;^J6N%ZO!#'^"U:;_]J[^X$NHOOWSMH?FKMX/_YWL%E M]'#CX][1FX^[_+5LGOUVM+GS6C0/WL/>J^9IZV"U1 T_XC5/FVLOWW\3/3SX M[6AOY[>#O;7W9\U7N[*U%DXW=_;?[YYM\.9:B1K^]G[O8.-C\^U6;EZM,"2$ M8D%(0ZP1@0 +@?C$+9'!V_:%$>2;('^E3+>O&MJLPI-;!E+]WV8 M(:'N8:8!+4@:Z0L6*Q2JA5N+)/3KGT=D9E46BR0600'99HV@ELS("/<3QY=P M;W%IE7"IT90;*RQ9U(@)01!W*B MO41.>4T+(3SG>FU==X5<)5Q:B>*/=T<+ MWQR.QE,$1OR@V;FS+>YX&R3JHN:AT"73::18XB*X0 M!BN&&"P2XL%[I"152 HC2%H]F9+"V\::#UYWKTXT6BW]15JZX!!2@@!R;)%( M/7!Y 5JJL2A0@/62K+!*%RDS0CZ$\DG791#-2M%W1R VG,L1P-3D.P"G3N&S M)W73JWY_],4,74C;7L>/9G8:9_V+,:5/T8 MK^=/T>KR%709=+C69;A./_SK]O343\*?5MQ[SRPP'G^*W\(] M-_:MT-H'ZI#B8 ARIS"RN/!(8.PC6(,@$"X5]L#J[!'&V@SLW)Y%U8K<_18Y MOKNQ+T( =L@\4E@$Q)4#:XI&AV04QA$GN/& MU*YO)I->[ 6?1IV+X75,3@CLH,XDA,[.:!K*?53\UH8'5VB7"BU67!(K&LW: M+ E&>8YB@+V$:TEA:_$4%1ALPA ,5E$D4DG.J63ZA;?ZNME]75A M! *HBD(XAUS!+>* K=/7UC< '$"!<$2.P)!,5KZU( M1>MFOG,&L1EB@"7Q95&'/?,U3#:&/B]6>1*D=5E= :V:B=JXD )''Y"3J0YE M4:1V*M(@+YR-E'(2 UU;YUUQ_8H[KE!8+;B)^W0'!U(&BD4E,5? 2RPF1,R6!>(\.]0]%[(3 61(94 M!5]VN;KAVLLKU%KEGM;ON#B:?OJ 5MLU:L5HS'G'0MJP[M7@;"E_SV%&==1( MQ12(Q28B@Z-%GC!,*9;*VM17N\OD3>7OK0RM:=O)/01:TP+#30+#@N<8(8FR M4B&3@2%&CY001?;1P'H99S3+&1KB[-F0%06&U7';W'PAQY_4W9?CT3$,Z*3; M>=DWR7LS])U4M.$XT9]NQTQA8B;P2WW2S+G98-;/=6Y].!Z#"IJL\ZN77[BQ M&.IF8Z3P>S_D[I)#OS%(C2:_Y=?KB[3]OO7] =>,;=O6=PK^TO, ?LXV ;KIW*BG\@ M__VV]75W[].7[90QMO>6[NZY_6@MD<5@=Q&F(P9;2XGD&B:J M6YQ#37XN-XRPIW>7&K;"B9.M+CTH7=K:Q[0P!>8&L8(XQ(M40Z;P!2I4C*(@ MH;!4@B[)KOC.*;;KIR<^8B9\"SO@A6K8YD9=01-K(WECWWH=P$:VL/T(CCCA M&FF3:5+AU_3\Z9+B%_;Q%AIM$AI,Y,G#-&*.D0!@0 M''%,%%(A&*1\H"$P5Q!E4H_U+B[:6,"]B 7\-1KY+[U^OPT$K"K+J5>HQ:U+ MX=:+)J/AA21:"XJDLOG0OD;**8^(\DZ(*&G =&V=XB[E-W7J=V483>OU?PB, MID6!JZ+ @KT4A1!&28D8C@1QQ2C2AAM48%\8'$R4(H7^=)?3XKZ@P.JX^._N M2,C6<&J&!SW;#Y,N7'G:YF:N*I=9K%29G 6+]2)70YPFDO M#-AG2D2!.%4$6*1:^RYT:T29NMYV85>4Z+$+\"(18<2-@"3)[ M$6NKM]Z<&Z/ _V@Z59KOZWZ*=DVA>N* M\+;=)$"2$D*)CHCYU#LD8H*T8"*%KCCUE"HO-W*\)_6S_,0^$^+ M$[\0)Q8TB#HFE<$%(MH 3@CJD*'>(X,]U49&Z0TNJT#>U)'ZU6-!]\,3]'/M M>G\Q,WUH'> N_?P/!L)O[0!RB\Z70N=72RP.>V.\\8A9$\!(%0KIB!5BG!"P M7YG -K$XW57X;+7$%352;\.-U>)=BW=W=8,2915<8I.0URN)",_6Z'U+J_QR*M7_CV"+W>. MS4GN;)=6HALM_EP9?Q;V(F:F@/\"PJ8 >S'E>JD0*;(Z4"R<$![;M776%625\.>1 M][#:&QL?%CV+*R;8MD"Y#)C]2U&KBL$!"<)\RS2*R MAD?D5&$%YD%321(^P=ZR0NT5VG8H]X]0M+I[,[J[X!;*,"QB.OP?>>(6A" # M\(MPRAVW$0,*7=%-7(>5\/9 MV^+55?#J4Y-KX. $D3:F=HH&<47!%M)@"RE"C#9:>Q7CVCHA7:%7R1AJNZ/< M/[+1:N\-:>^";3BKL??8(E-0L!2B$.C%_-+LY8/(GJ-?+#6QBZ @P=+5<\8U@6/BK$9:K]6XA4 M%)Q&5-BHL;7284O7UK5JW14/6$.OSB!:#?U%&MHD"DY9$3!2BH"&RL(B54@@ M"K'P!@/A)X:MK4MV4X=66Z?$M55OL_>YY\/0WP1%>!0FS&TD@-1KTCI,KX%, M2[7%?&&EE,$@(:A$7!<4:VE;>1 M>5\PJZDC2&"7FIN15.HX.A1D42@3;<"IRR$HKUHEY7V@1SVOU([UO !'6]5G MQ6A'ZS2])F@M5?DB+'@6E$*V(, XA(I(4^I34_BHHO+.XI"KF7)\[3J&#^EX M9(L'J\)D6CRX/AXL2$SD7%!&'2H+>[FB0(J8 IB,X<+".A4: Q[0+KU^/OH] M.CYXCRG.W^DY(+UNWSKV@/66I M]H51\%-U?UJ#;L4.[;1&W17![>T2\>$,*R(MDJE!#7>1(RNT0H!MS@@3:,SG M=F@7T[94>^OH64'FT^+"S>%"(]$72\X*0I#"VB.N-4$V4H64![O(X$ +H?-Y M/GU]UM,Z>VY#:[?#V'TJ5^9_S.#XC\[ST=-N\OP\[;R9CMRGPU$?GG+R/_^/ MHD3^<9U2F3=B4=[/&]Q2KOE7O$RC-\'?\9FJFP;\S_5E8W+K:(G"[1?S$%N&FV\^K+>*Y MQA__>XC=X-W0O->SW<%;O'UT\.W#(,W+5K&[^0J>_]^'VX-WO=WWVW#=CXZ!R;<>=S6N;E@S,702]1=U=_9#8]'(WA"[Z#.A?JRB2)ZN3F0/>G MF7I#@[*Z3!;C;35G!31G=^_%/B-2&D(4*IA,E51U@2R+!0I<>*M ;Y0LOH/# MY\K6-2"XE:T')%L@0\*XPB'K' 6;DL5T1*N +=\&;SVS2HK4[:O N(O+_W\" MGDN16WELWII,9E? Y3O1G7*LK=[7Q>0[V>];N5HIN;**2LFD0#(&D*N@)++:>A2H(F!\L52Z*]48+*3L M$@S_4OK3>-SI#3L)F7(MO"1*[:GS.X^@-?0QFZVM?_RRBM@\_$55JFF'I 5" MPR7H#C!C@X2D6&IIM';YN+E4UZ[/V1XW7UVMO87X5JNUU]7:152K$+J((AA$ M9*ISAW% L-41^"T*[0HBE)&KI[6/O,Q=F:YS;'H> :EPYK@W-?VVSMV=TXD- MF+\T#--_"6NS-7Q>KDP#KUJHNA14+17OYTSC(EJ.#& 6XL0S,/JX09HI@857 MCIL Y%QWN;IV2<(L4)0\+X M@GA,I7>E(@MQ4_G#;=6\:VOHZS U\*+O!#,>PGC:LOUW3SCJ-7E1+I"%?KTKA_A*-5Y)M7Y 7A8!@;+&@.W <@'%(B51B,"F65Y\Z2(,C:.A== M@<_Z\ULOQ]WU#JIUH.X=-!H^MHAV&43[MM07(&A5I*(SR%%6(& F M&ND8*1+66,F==IR%E#C"%#L#:+^U7I"'H-E79R6M9J^<9B^X"C'#%?5]= \(56>C'H6X,MA;QS, M9#8^:;VDEP>"I?+]QFON"X^15)$CKBQ%BEJ#<"KJKPTK%&=KZTIT,6X+SK40 ML8).C18B?@E$G#0@@CALT^DPJC#\T!09%1DR$BOC"VTUX0 1I*N*>U.JX)$[ M/?X.DTEG6BE(?6;43&$J)M/?5SZE?_4R^9>PYDTUBC;;^A*(L_6=;.M7<+]7 M7[??IW^WV3;,Q_;>OWL[>UM?TCSL[OG!Q\&K+W!]=CK;>F?OT[[')$8C)>+& MP8] '=(L:& X@4K ?I3"+I8BZ[C+,N.Z=1\GG)U:N7]]]*X8I*X;>W^\82 M[*QB*$IF4ET/#/LGT&[L/!>2,B=]+G2(F>IB);MWN'8I7%OJQL)#4%@9BT10 M0-HM2P=U'466!XL#(H>]-YH76.KPP>W(ESO,6#R^+!@N=X9JV( MPB''M4.<>H(,=1Z9R((F0AJ=BO92X#DWEJJ[LI[PAT&"4M%:^-!XU(?W#H#W M3,,X3*9M,Y;;9CC+L+7=&X[& %;U>K2@=2G06FJQHIB(,07W2304<8<-LC8$ MI)1QL.](8XJPMJ[X?>FAT/9761EUOSJ!:=7]9M5]P5%TI (+*U",6B N"K!9 M*#?(D-1:@$F%*5M;U_=&W5LG3;_UNMP[K\O6T/5G:5)?CL9I@!O3Z;AG9U-C M^V%OM,PZ6]2[$NHMM5/1A12>,X^L4V1$HXB2ID.A!GX47IJZ/UIF]!Z M:E8&0^[$4]-BR&U@2*/?7!#44N!+T1-3ELE55"CD89T=5B+BX'+O[7N4"GU- M[TYY,1C!Z;&M.+M2/P4 UV*\UY^:ZJ2R:T MBOFT(N\R?V^LXYDS,PXX/>L+P]708P%Y)1>/LZ2;/C\C!T MC$NE5,SP)(56AZ,I7-V,X>5AIPI-9? WBLIQ>>4:H&P>E3637&+Q]W'HFVGO<_CC M2\]/#VO@:'RQ6F"\^(JQ,(;9].*OK,I\L$ M9U0"70F<<#9UP+LT_56OVEP_'BU-=!0'8+WUXLV%XKHJS_)\=V?SQVMS8@S_> M[,$_VR]V]CJ[?W:>;[SY5^?/OW??K_[C/'D[-#/? _3H=OZ1SLO /?J@TY/? M+A"\&QN@_BF-/;4570#J%20E76K ?)$Y7;QV_@IN?"] M[UV6D*>"Z"M=]OOO%;]HL/3G!O0#M]Q5N]*NC ]M_DSZ9YZIA(I5>JH=>*6S M#1\[G'1> "GQ>5]Z$XZ!?M@P[C#<77KD1[.>#5? %3W J[?8R?=V4P_\,UVO M']#$-0ZA/J9CV)NFJHDKXW;V^+[6^.[GQ[W=_=,Q M4MPZA(VPP1NG93KUH;M$GJV5>.]/I;668$,M&G4FS4(!6X090;'C4-Q#J^MBZ[ MG-Q4:O>]ZV9S)^7C_=%L,DTQB4EG.NJ, RB9Z_5#9S@G=NGU])=+]L'Q>/2Y MYX/OV)/.:&X@F+F!\/MU+(2;X.B_[!HK47*/D*>TN+/"=9OA& 2D9S(VIQIB M9I!2.[_E%]IR3JM#FYL+!;_W0\Z_'?J-QGJU6]DEMK*=-PU"#>ME=&IX;B./ MB#LB4K-%@B(E1GBI1)!V;9UV8657:"MKRSS=8P;:*O3-*_2"FRI+F;;.(V^P M1MQ[4&U!,9*>TI3U&KQR6:')MF- M$YWMN$,S/@AM_\5?3TN6H>JOTFD,AX MQ[C_F_7*_-F4UOLR]$=3^'7O,(S-<9C!>"=E=+87["28L3L$S-H,GV&=CA-*;0U?CDB(!8Y M&A@81$(B8!<:>QZE2C5=L;5=MO2VI+2"&T ME!Q%%2WBA@EDF'7(4A^-),2*B-?6M;IV^^;6BW&S8948QN/@Y_$V\[7U6]RZ MWZ)>A;)1ZY[Y^N+K<3K-]2P,0URASO+W!)D6+@MM!<;>>B1EI*DM1D *IRK4 M01B!'7&2I;[R-U5QMG59W):V7J8/\PT0B7E#YE9O;X%1?-EGQM@"8X>D,B&% M.3E2!:6("2JMXLH77*^MLW-*Q_]\A^75Z8A:\HCR(.D!FUJQEUP MB;P0S](Z/&\L0PM%EX"BW>?-C(L"-HNBH CSH@##)DBD&. 1EYS(*(LB) K! MBE5*'6Q]$:ONBVBU]":TM)'BRXFVA@-#,+1([24T,C(0Q+$)M/"62NE!2W&; M1+%2K&%W>AC&C]+=&T M,:P0*%*>F#RUR2/(4(#UD1Y>=$*NK=-T1']E_(*MCR$?^':'9GA0-O+.:9>3 M?!BDOR@<^"@=#K?,)GXZ=QSP*G4+#INA_'=K.*_L\-P<]Z;I&RV(_?RIQKV- M9G'=P+ QR4OJJ$CG&@N+="$UPJE;#>$X2 PP5G0%4]=@':U?8H65^38/@K3* M?//*O*C/ZK#F'H,>.X;!@)!>(25%0*9@4@J5^F>F[.HN%V=9R9TH\V.I6'0Q M%\E5BUXV3B5?JFQ1VS9F55@*K&5:RGHEGYV\G:28[GPU%XO9 MRE .[%4I\I MP[3UEB,%.Q$ G$V)G:Q S.N""RM884*:?*_*X M-?P<)C=1Y/$RLW2EVBRK>X,'7R2HLBP[(?F\?6\Z&U^/4M_#77!5G7LOS4DN MWK0WVDA'U\8!-D0_2ZI<'N!L=[_+[7[;3;8<9?0R>?1L]+#[!4^12\\1MQ(L'R)<\@% MKPS'BEA%4XT7QAYC/O-=J.'+V=@=F@E<(B( M GQ030*A7*VMRS9@^$ U]DY)1:O,-Z',"V)AC+;,8@-BY3SBD1;(%D LX"_M M/',JIL+&0"S4=8R$%8@9WA]BD6H)!%]YN"8@V+^.8MQ?*VA5'1K5XOT):_<& MEF[;3-.JG6P,_?-1OQ_R8">[<6NQ<"UZ70J]WB[U!G=<8D+2(0T9$%\BUN70JW/C29":"5"4(*)(AFB,.: M(<.\0]QY4X4U)*E4PH%A'WRB+-G4'*2>(5(T7 ^,;0J_65 MK+"Y<:?AFU;!;U;!%_1$!6&#H!&%HDCT)#*DM;8HNHB]T*%@.!_^$G1%LKT> MFX_DXFK\K<=DI=C)8/SI8N#ZQMD^]6^P-P*QAB2(L5R M8O1("Z-1,)1S&[ W!5U%TZKUF=Q'X:\/17S(#3WQDOQMIK[*S7WI%'_ M05..4V%>HF@*P02DG )%UMQ%$;R4*?.<7JN\3>OAN&KMW<=AS=PN0[B@H&<- M.'^.QLU\M+P>\S/Q;0V)Z_LG-O:)<2XR9\%VT8 Y5 JD@FJ(Z5ZO9>J]_((JUW=LO]BCFG7K7O5(MTUD>YHJ:IO MQ()$'GSJ?#CA;6SNP/JZ$&Z'UGH<%4/A3?1Y^_1\* %GRN!SU+Q76%3LK(P"%;- M(*ZE0L83AJ*0RDB-0V%PLJ;U.5V_V_/?*ZO"JW?^NU7>FU+>!7,(%A"7TM3- M4U#$<>&0X8HA&PN',2?*>+.*YQ$>O(MBN39>;S*9F:$+*6OYRG3B_EHX*\HF MFG;-5K5"+31= YJ6BN\2X _"$HPH*S3B)'GI"Q$1%056'JA%/N;)NWRE.@^W M+HO5)A>M0M^R0C>XAF%4*>X1:*] G%*3$I(LLBX0HB466HJDT+HX6U"[+7!W M.^7]IZE9[6Q\ H,8N4^MUV(U>,8B^B4$RKS#>G MS N.(0T5V"J*E$K%*%,XQ 9+TT&&((D35)*4^=P%XV$UE/G!.S(V>RF5;>@G MG6/3\YWIJ*06AZ.^#^,VS6*U&,9NG"]7"TA7!:2EZK@Q>"*C8\@[K!"W/!VJ M4A(IK)B4*@H=3$Y0EFPU0K.M ^,AL(M6D6]&D9O>"Q(% RK!"+.(%V A: ]+ M%GU!4ZS$*LZ3(E/=5IV[BQ!)^!K&KC?)(9+,,#JCXUSNY9$Y,>ZTKDNS8TA: M@]UR"5Y4:].6A+@< "W5M54&!Q8H1QX(!)@VH4 V.U*%B=8)YV YU];%M7VG MK:=B=37VYNNYM!I[TQI[THA@PF:>PAQ&.M!3HAPR"@ODM7&*V<)*D](R^;4[ M=K7^B-NHY/(XK)7;.=W1\(+F!9D?VVI/.%X1>98*OP5K"]@.++*% :[@'$&& M>X^P<)YAPKW2$HP5N2+IX*W/805]#JT6WXT6-_KP.!JCUL#S:>+Y(%W(2LX1 MZ#0WC/' #%E;I]ZZ(+=4 M=4X3Q8AF$C$M&.(\M>NA)B+/E:>^$)0*G?VJ^ :.CZQ,!9<;.?S?@L;JG75M M0>/7@<:"&0$#$ER%@!3'J;!U$9$U0(^DYL('HXL"N[5UT57%#:1YK%X%EP=5 M^NY%C,'E>OPOOE9%.5Z;:>@\S[_G$[1)H[HENWKQ?[/>9U";=+;6#'WG=9A, MQSTW!'D9 MO/RV5":/2LNHPA0L29O2XAS@I8Q@209&L H%9P9(EKJI@S0K0[/:0GGWBV:U M(+)R(-+(@*$1H,)&%%3JNQBP0.G4#A*2&2>8Q3$D=U1;,V_5&5=R56T&EX[Z MY )HOYA>M:;HW?BOK@64+V%21F"XEE)22PO\W9^EA6I"<@G3+;)>"EE?+-$S M%JUGV"+#.)BSBA&D+'7(%2*(@@B&"0-D[1;L.DG"K0_L\0'/KR-G+;JL-KHT MG&7$$!P\05&' O'H"J0D_%G@ FNJB67)PZZOP]L>GZ?,]S[7=ZV^C]*'?]?U M!7I##Y+^.](9M^X")WZ>UG7,M/,L'/2&PQ2N',7.AV#&G2>]K(\PH/'BXW.1 M@ FX>!:(6IUIR%T^X9G^<0G8U 5SCA=4,5EPCY5V.#HC.R/9_E9"2T(9 M^;X;[ PBMN;H=6!M:[K]O(*UYQI__.\A=H-W0_->SW:/_GT$USG;+*O/" C(!.QNM1=BP M=*3!=4F#=R*X69[M< MKRAR7-,[75X,1G!Z;*T5]$,KZ 6\#+9"Z9\XWP+*]L3],X,N:0$1YX,2A#$> M@7/I:!0V0G&A@'-)QV*"S)])!&@MH!N%ONWO6$!O3[;?OSO:/GK[;6>O?[2] MF<;TBN]\L&WZN@<6T-?=O4]?MH^V3W;VP%K:? L,+#@; M#$;6:X)XX8"!:>N02)$]CW6(IEA;YV?;Z"6U>1..IV%@P=!A^&HVT*UAV[GL MYCR$NU-R\X\KNMYN8'X>#.N[.H2UK&\UH6]A+Q:::&9H0%@9C[CT&!F!/2+$ M1L4]I9J0Q/HXOJENY3=)KFXQK':]\9ZV-UN4;E'ZAE$::Z&%X 9S(;F)V#+B MN+;!*Z C4=C2J]>B]/U!Z85M3C&GDBF/8)=-:?H\(LT*@.J@<:#!,6Q#0FDE M'PQ*9]O]GU-C^^$]87E[N@QN#H0MC&]?7VG2U[W#T#'.C09P[Y,4 M QR.IG!U,X:7A\#@I^%@;/J=8S/.B?K3P]XD:3'8M.FP(_R6)](D\SB6)UW@ MTY,IO)#.!S^]T%JN!L'I4UG 0(]'DUY:_-_'H6^FO<_ACR\]/SVL0:7QQ6J! M\>(KQL(89M.+O[(J=,H(:/].(,\X(&2(/5'O+!&=4*HP#IT;S (JD MA=EG?*W^TN%XX7\X",B.@_F$3(2'_-WTOYB3R=H_E^40A/#4W)^>MKN8G%(? M ,5'8Y,7%10\C-.GUM9WLD1.1YWG<[E[WI2[/^=R]Z:6NTGGR6QH9KX'[Y\V M.^NY+A]S_7_M&&;HC)C^Y$+(M1_H>A;N[WN&TBNWWT,Y2R29*^CMW_W4M."G M19Z&K__=__CWC;9IN^.=HXVV,>CUX./?_V[]_']N\.=P2ORX>APL+OW MH=A]OTU@[^Z'?[T^^?C>'UO*Q8?!N_[VM[??/K[?IMN;'N[]\=.'=+WW+^C' MS7>]W;\^%#M'GXH/W][%[ @ZV'>6.><*BV@1(^*8.Z1 \N$'ASG7%@PN4E*X MWG 6_$8B8$0QS@KBA9.:$Z6!K@5CI BRB-32N-8)0**.$PB/9^&7+^_N^, , M>]\RA"PP OZHUOWE.$Q Y\J79A.0R,ED$T8X[N7B5\ &3TE&+TP>L53PG5?[ M4A5<<4X1C85#W :,M ?+6T0G"\TH#TZ?EHJ@*9-*T4 9Y\0X$Y0UO/ 1!(GH MX$Y+15Z=['UOK$_-"RM963_[=Q.SX;UJ#/G+Y5+]X;#ST08#OYASN.%\3[T$ M!S-71/.T_R>YW1&+AE@-?SS7[K')K/H6-# M&':.QP'8)US\>#9.C7FFB0JDSXYG_5"&<\;A8-;/4S%)MB'\?3P:3W-&V[#S M)QB+'8+1JZ>=I-SCM.?T3[H=!V3>]!+'+B1(98$@]>,KC=/N#, Q D/OY_>0+SV[O-+RWPSQ3F9, '_EK8^/E;WET M:4+[81I^8NH2#0="OG"I'X9QZ V?=F!I\@D.X'F]0?,;D\/1K _CA>D))H\% M[G(T&Y;6^)?>]# /KE['\^\*LU": 5Z4U&&!9YF_6V*[3FLZV%HXL]I%LC7K%^JQ^@XC"OQA;] _NUR&(VLY& 8'.Y89PY/ 1SS8HLE6*@VSBZX8*]6*LWZ_CR7H21>Z8'2H\)3 M@>[U*RUVL_$XVZ!F"NIWCL1<''UMB,POC;3F*_[>FX(XNI\0D)=],QPF%("I M1;LQIH=^/X*IF4_ZOX+I3P^[G6<]L&=A3&9<*N"+27(E]":'\.UG8Y/:*,#T MCO)0JX6[>#965V.V%OB08:%;X@D\\A#0U26(F>8GA7$FA4I=(]+S0X.X:JPF4S'/3O+SP)K M7WUD/N33]RCK5V=;M[S9Y!!4I6J9D6%_^9) F\+7XY#3$^!;_S>#18^P%P%T MFZ\HCD.H=\OZ@FE">GFC6%PXJ_7;IV^>=F+P:3M+R@I3FRZ2MMWC$4Q4>?=S MYK*Y.:0[P:,,)Y7[-VUQ,-ZR>VG:94',#F#SA3E #>CGD_-088=D"MSD"&C MFV#LN ?H-1K#!]-P)Z&?ZD0X WOWZ+.9.-CLQPMIZ-6'1SJ_V)B]I.Y_#-.> MN1W[^OP!=)Z$;S"&0<^&W_)$KM;\O#N!)8:UO\LI6LQ0*6F] 0B$B_.,.>Y/P]-1GPU?0A22HRX=AS2J),T'8S. ._;@CC533\H+0QM]&5;[I@^?0Q\V=Y^I7,W&T@B/RYWF MZ1R8\H7R]EM]*>_58'89V^OG.D2@.?!O)J]QY&:3DKX!D0ZPE*".2U],=P=L M"^-0 *N5.\ 5<$VQ"P#67Z(&I &>. M_J>@SH8YD9XCSR0DNR2AX!B(2%HKV&)(MS.9V:.$(/ UX F?0CGFV@ 8Y1R5 M],WL3X;[OIG9"3#_L+ UZE%T\U^PMDET'0!E@W.E=VYB0\H+EPE\K*;&3+)5 M4IMO37;7.Y_*_="T>'K&?/Z%;AE0UH9?93PJM_H\CM;_ECTM=/M@/PH1"A4M M@I\2\5A8I%,FO&=6$BJ8Y-Z<\:==QFI:&5;\.J0X#,#.AA]EDWDA''GK8 MZ2?WD]S^>P9@3C$1)5(L8A/G/6+GV0C^Z3SY<^/-L]]RJW>8"R"BG8,9J&[N M^EZJ=\/WD#T(XP!8U>F/,E[ 9Q8:WAL".YR5*I[Q<^ERP'4S:\I^DP68+ M??^<>YK^9-1Q54FO_#6 MJMXX;QV+>YK/!O#1]@."O]#$]$-N=Y\@?3;.FT6W\L;4=Y^5'5_@.6 '&WW) M]P*T'J<8DJ^?(='VII MPU_Y^V#7?@&X'H[R8[KI*?K]\P#=F1TGAY0O>]E<'$B]-[X24(X=F.J<*YH. M750* J)_KN27GK(^R$0."<)TF_$X"5$Y.]E"]"45@ 4&D:Z9V#2Y1H!/)0L$ M7K4G'0<;+TQ$$IPOAZ'<[:N]OV&KP!X,_U8/:67&V5>J:5 MA%'GT"4,ZG-(#"X)V,$P,XO%PSW9>/.\(["XMLQUX8EZP*I*&E(RH4%OF.:N MUKA2_HX;GO6D-DVO9XZYEU-YOJA>M K7D,K5VXNV2B$\%Z=W1M/.!Z"-U7YU M/[>F37C26OOT6>T#QI85ZCM[3^FEF_O68\--4/L'%EO-LHX"_SW.KHESMK/F M54!??X=[#$:?T[OA:_*I9^5L".G"8#/A[#AI$]JXU;A<^F/RNWPFP&3,,QFAWG"]H=%V;LF[Y#FS]I=%\ MSD<:#C0W&\S*C"!4/E3#,5UB?Q(%N Q8EZF&09Z^X\4%4Z2G].E5X:!I\UF6 MX3>E-B5"D^'@U,I7NWDB'/4$V\& RQ]RF%@+O@VV]R06KEP:PG8_2KOT_!DO!^7 MYO8I,)I[,,LMN_0.I[-ALSK0<>K>2226(7(0S&26>6H]CKK;MZ];$^;/P>V^ M)/Z?S.TT)WFS-BZ'')N/=!Z1O[R.UWZ:92U=4I6?@(%65WY"5[:SI^M\32DG M!!YZOI9)P%,]ODS31CGP 6_;V=CGJ-EI 7V2 ]R95'ZK9[R4A>2%^BWM,F"% MI NG/2+]F4*T2T;B? \_I13'9>WRR6*0R43TO;E>-?;C;+2!$.5-- 6WL[;7 MDMSM' 9_4+HZJ\C\8>]X4OKS2X?;$O4V^0'*0/NY#U".].SD+2E"-IG2/)>^?>4X+S]F.;[^ MZ/-MQ/M_V;D)>^PZS#HCDX,USQ>6/[RZ,?1_]UP2B(V#<2C7?45<]GB[/B)S])9O?_MX^/'H M\-/.7Z^^;B>7_>!#\2$=C:'O>COO/\#WW;?MO_X\.NVRW]D[^+8S^'.P^]K4J>_&DS.:).BX)G">/$5TR_WTND9-*9S&#QS*01 M$#V[D/V\D-F.TPG![VQC[[1JN$#5@/F(K1,'0[X]&) MZ8.Q5%KEL3FT,0X?.Z%+Y,\HV5TN#2+RN22]#CS M('UBZE]!VN!7()8^[X>3R@,[,":[K8U7I MWHF21]AD1WG@DTGI<$X]%R;C)RSV9SN7R^9++#&=99BJAO;B_!=>( O MA]FA/BA3>.?YIZ=]S&?N\3 ,P4; HYGJYCOO0" GSWJC.@FZ_ONW1B+<]!#L MDC199>)9RIF@\QIW$DUWP-%DNITJ5XYEMW&XZU% /K^9Y) M25;9>5D['E+R)TAK=L1DCTS2U[SF]2"S,%VFI(QA6,5@*2D"YLP1XY2A0EO! MM9>!NI*:D)J:$'+JR*^\Q)'?NC/IWFBC?*!G_<@HR_;1BV)W M;^-D&_[>V?OP=>=@OU!@\=!4]I(50%^\C$@[IY",KK".!&M%JCX.9LL%AW1A MK^GGC.%&ADV-3 ZT$91H?-),)7ZZ$*)D=R>G^V< 43"3#T,?S'70HGS MLP_ MLKW1,4C?P+B<%F3Z\QQ,^+?T2C5RC+*#I#>>)-U'KF^2"S[MN>,JM2@IT!3 M(U0I6,F5D1Q^)R 6"=(_ 09- J#T)]AQQG#CX>)#I//D]>YK\MMB_'/HZI=Y M]@F5>P>F\D_,MX?TF._^?H- MKLY5@U0:4?^!/GQ[*#,S3]('UL,+-VGU/TE M-X(-.6Y0.A/*0)_IO$Q.Q7(I2O]>]5*'SJ>R,QTG6%VX-H.9UO3D&(:;]]&, MRX>ARL\$RV*0$35!D[_X+-$+UQH^D4O1X!](PZ&VE?&8/L=+8&Z>,5!=EPTX8? M:2%GBQ2N[E*VF"VC3J&L\%4=1G@ N\NB]M+I[>5- /495GM+^4VY2[D;-/<@D[Y3+2;O+1#6MX4%_9'/V8)WDESUN MH)DP#I Y>)AJ( M=,3YE]LZ^S0;&=CX'@'&0XR?;_T&"<_Q;MSQSOJQ*/]:8 MO[?>(=(0LX72P,7/UX?2?YF\-XE+E2BQ$*FFL%?BO?3L>;^L#0&XR@@0X&@$ M&_)2QF25TMET )[__"8ESPQ')4I5&=K#9OBPU,_5RM[]3S@!U?1WG.!\#/(_ MAM7*$_I;CDR.T\$L- P'9;["TAIW.X>@!&"8S)$=E6[-TQ]L"$.6+@1@DN)% MF1"=(QTU0-IY.\<\H'*#!9^N^5NMR@/C M MP/PWA5JJS<(1_;XL#'TEE;6Q E%#5(>NT1 M-[1 6LF 5*&"$CY@B^W:NL!G6YN6'&!0TK&*":R:B%S(T+<6HA6*>,<5@*-Q&KH0P1<&IQ3$*(_@%!?78):3BSS(8_KR*(&X!1'X-?F^4 MT[+&DQ?Y(:I7WU1C;)$CR^BR\LPSFMT(V)$3XM*OO3+-)"Y M".#'+0+PZKX'&8 UI\BHR!#GBJ?.V!(YY8)6G&*K "[H.9M'RO$HU[XZL%0E M40/_7]4]I Z# -?87%#N%Z7+N@4&^'O[:/L;4 I7%+&@P2 2F(5-Q &E*+!" M/*V#P(HZ#U(A*/T!-/SZC?,:V/?*N*Y!U88>8R&Y]09_^U<9W M<5HCUZ>XC#8QB@VEA!#M+7=86@>J164(E*M@>5&%.7 =YL#7Z#K2*M$-*5&Q M_6J?:2R]!ZY$) /JI H)U,F#!:X9 PKCA2 :-LD?Z% ^AE3[1MO-\N>T[ SD0>+",PBZ, LQBLY*@\ M4R%E[R87"GUZD6K/XYN+&B.7$0Z;REGSHE".%!Q6'ZQPKXR1E@:%.;9W*!R/ M%_6S<-"=@_V(G8ZP52.M6.H?%5/O;0(&LPO&TG+[7EM7Q8^\K86FX55802P:26(CIM66S!Y*[DA6\?[$O'&0Z:@A6=#.A4)-42 MYY'7SBN)B\(5-/EC?Y0MD:N>F%0\<"$J3W^JLMEJ1Z1!JJK(:Z/.H!U]/I4- M4&W7!_!:(MYUT#J=+>G/)FFW[E=YK&7&8R.:O#?[=#(QG2?363KF.>S9%#'N M3 8I96DP @MYEK;]Y7P.F.W#GNU-1^/N^4D0_WKQFBZB@&7X+R40##L;DYXI M#_!L][R'2[]( <*<:9MNW]G(2;6F$2LI<%9B,6G,I566$P?309;ZC.LDA$_5BV4N1:\\2#(- MXW%ZX'Q0;C([3IF%BS2(^:/6V7RYFEI.P("9>/[WUO:S4\'RI>&5Y1Q&*,YR MD"D?)"J-I72):H7*S(#E:'C?S%-!PC!'3',"X@0^DRJ.C88'H_H 757+J [5 M&Y<2MRY>J'IK+B.X*9L4!#XX(,?=SH')W1V:^2+E%SLI.10F%P0UI])40ZX2 M/\\,?6D.)B!KJ6A2GH)A60TU?2F?TQJ?H)0LPP M-=AZ+J1S;3#Y[K>K@Z_;&_N<<*\\QLC+*!$WG"(M'$;82AX]\!N:D_O(#^A- MK;-?4FF3>5S 3%H+]Y>Z@Z]HUB[C1[DK- CIE4Q<"?8M%2)*Q@3G"BAJP8)C M8.Y*3*C4K15S5VI^LK.Q+X3)UBS2W&+$/1B[5BB++* T!C.F$"3EC/PH])N$ M,>]MM6Q->SG+O#R_D5*;TNSG%-M$%RX4'UA=FW!X28( BJP1S#NPAKF#'<38 MZ)FD!1/$P ;R PFB32EY71XH>0W;Y4O8WE)-FX-%Q _11RL1.>2'=U_M%ZJ( M'*=*C05.(3^MD<82(\%A>^928T=)"@2?D8C_-SLN+[6R0BKL(K=.$\,CY0JL M54L%3<7V)=BO[U,H2T/5(B<,L,F1S+P:B.%(J",09,Y($%@JFU]89.V=E MYS[6JCA$:8#VTT:9MX6*N)^I[]YDG/??1-WP98)X3L_L79A!79]K,ND$0DZ( M3T?#AK,(TUD6]H#?TC&[DTZN.%3&CS9G0SLZ28?>ME(P+.WN"2KWS*?@G(9HM9*P^I)PR<&IIBDS /3\4A%RL 4PP5*+8F1$LH5/AJA MA ?/?5H2'Z&%_5SMZ);BB[>_K)/"]@Y MG90(.Z.3TQLC+;Q$8/N!V%IIHP'1!:CY"?NB]+\-4_GMO#HK)%^)?UY1MLX* M5FYZ7WUH2?#:M(NY;)&=+_L2!(GB2%$H0I(M0Y$M6$3*>DV$BJ$00&?)63J[ M)%IUV=WR]/DY/I&%RW,R&;E>IFN+ ,4"*!\ O\T%J/LGY[/9'(E(33YR,]M< MO>%-$NIAZ'?^[)O/L'GL&3NI#A!6;[Q)9RC'LT'G^6$JDI 9[;O>V!H'%'9\ M7)^(N^R)<*RTXDP'Q0O"&>;6XD"]"5$$C94]DW@HKY$J]=,GPA^=2NZ]2$5L MF#$NAA3X)DPB'K1 UFB+"$])A(Q;0-RU=7Z.H[@S5\&YO,P+9]2U,.#?:2CE MP1R85)Z\3NDY-F,#FE>Z1_WH8'*C]*:$[50E(?FMDN/T:IN.DUXJ[;4,@G/J M@:I9V&RD\@7'C&A\DY+Z9ZKD$/K H?W6?-S+NPUYO-*ZV$"*[8540"N>9%\,C@J,'*BL9&ZBEU0$XXOJC'^")S;U%;>'YV^/Q:,"FQ=)C] MZY>4H\+Q* V3'$?!K336^>@+R[G'A7,A5N3E.N)SD^1XJW[.5MZ2K_WHQ;?M M@WWE&*P784@*@P$IJ4'6NH!(D")ZSIF*<6W]AU1X>IIY5(F,57^MJF]!;K*7 MBPC-0[N]QAJ>@VP_*<8YDN=#"AKGRLFSJB1178<[!XZ,.TS],J>S7,QBS-4ZTS.9%.4:3?)XD@R53W3U<5;9$&:0<@R^S3L+ M >,9-^9I-@EQUN\DU,P3];T:>=QHK8@GA=:1.QVM]*!R$3M80.)4.!?,&_H' MO,S][F?CU$;QM/;5ZE2"^-_G@?C[S-5 XU+*PT%XFT?^=R^&QZM:"^4[Y@P#L_5-J.-EHN37I_/VR\V3IW9Q2MWRY2L:B'%6C#]A@U!_.4GN_SZ#$J?!'\HV>5YODQ=;F)J(*D[(JR*AL MLGNV FY;\7:IXJW\7L7;MGCMO2Y>>VZ]SA_6WSS=FYT6,D0/C)EKKHG3A<74 M*L; Q/$$7[8G^AT)^KQ=5,Z> RQ9JKFU5 !HGH/73.G[B7)8SW??;6TBHFNC M\J#J,S%/4YT7=&DX5"ZNA+0$?.71LY(%U8FK/Y71MP30=:Z&/Z]&3*X!DA*' M4B6LG\H=FN^1\QZXBV*<0 =[X?.\W?.BO\)\2N=-G+^7@-1=/JI:%LBIGC+Y MA>M:.?#2C^>KFVI5EC=)7/.\/)86KL7I972^%78*D]EXRF1F?- M)!MO-EZ_0<]'[Q#M/,DGCLQL4O4_.JCFH):/WQ9$-9LDOJCAXHP'I9YC' M7GU\HC<8P-W0 &R"?E5X;%[,K^Q[D8O_CV:Y16;JHS"I"_^G,DZ7]4MRP@/' MU@H)]IRCV#+.O,3,1R:EMW4^BZ@-!'&3(=36+UF;!]L%F 2"R&"(8(B0E.T2 MBP)IB0-R)@JAC54"\[5U)L[&T!=^R3H#.MF7GW+7EUY=H?$J3C+/B@ M=1$PYB$=_.-262*(-IS!@"O'SG4DY1S'SB)9,M&;GJ\:PC:2)">OTV^[<7\#9U_1K![!0%2AE(F'7<"MB=>% 9KZPV/ MUA@J+&\%:(4$Z.W7G8U]#L!2,! @R7P2(((1+)-"1F"F.74DQ'0,6?Q @G[( MK8'W7%Z:M$M^:\4=(9IC$A4VUH,EWDA:^E:85DB:Z_66?>VY)$7"5W+=LD;=QC.JYT\Q, M0BJVU"F]"F!QU:?PJD:8C;B-G?7ZOF[5/)R?85SV@]8=Q;)=_V74J!;;> MG^3E+B+%8$$2#MQN$(1B+0+RTOAKL+(JZ=V10F.#=1S%T! M;37AE0,D+'61KV.@G4GR&0X64=.\%1^/4TPIN2"RF)>="Q=^M,J+!NN=O$^Y M75!OT*A:=:8:S4]ELI3^#U3UB%ET 3IU!++S9.OEZ_\Q@^,_-G^[=/;+G6C$ M-;(6JG8HY\=?'[$F??BV<[#ON2@TYA(H*"6@3EXC[0N+%-7">\N84B$E7%[L M4>F6BO"PI>@Y/&*5#P[[S%)9ZDA\+ M;:-68FV].)OYLI";I6;L5TS%NU]BM%D]\9[YVL(/VWFUKU/$,8:(+#6I5J7Q MR%!-D!>1>.VM9)JMKKMP7((A!<"J8 MA6U-IP//E&*D@M!(*IS^4,0RV-;8V=-5G>81@MS<>M$]<-F2R.9,!6!U%MHI M2Z1QKF4>#UL]@/MK-/(I7OF(9>8@);TKP!JP)R32(75N):EI:Y%<1T.M7>V:3JI5)2=C8OPUV[3D:-^E%50_EAE5Z8JIG.AYI"D).E M;UK8S#J-7);Q:%:UDLW))64:P2*K($M1FMLOAR/ FS1+TX>14K!MSJ8JEBZ\ MW.*VBMEN;&V^Z;RKYFXKE6G.+L2ZB>;6QKNMG%0 ZEHWFRV=@JD6U]P\'HT/ M#.R_);#[D-U[E=NL%) Y_8WJV6A/AW32#TI>_Y-IC/?JQQG987YHL.(Y=BA5\T.R**@"(UYY0M;6Q=.SM:*6#+!?FDUS70%JBXW=H-2\ M2+X?J@4.+/6-L2*5D[(,&6<]4K8(/!6#L]ZNK9,?A1MSP2%4AO,N2 BM>\77 M$O2T00MS*FNROZ>4XY+;FR< O M$T_+NJTA#ZHW+ <:AN[DW$*P,*!TSWD=VI)=RO[FU:1_ :Y.4L$_%AOH"IC3F0TY"I/C#O/+!%!+ MX?SFKA?%(1L/F9LT-_(G8@^^<3!9).9VGB4JWJ2&DPNFIR9T31Y?PB) (E#. M'VO/67KY5^;IQS,+/"V9D6.3C.B+^WTW MTH-/EW4N@VZ?P_CD3.#K)[+\S[1[K;.(001'TW)G:_B!CDWOTEX=18(B,0I% MO>6*I^-L1:KNKBEATN&ZJCLA M6_+&UIZE?D%#^V>NX[1UOIQ+@JI!;:%LA% MYQ&7BB.3$D")+QR3)-4US@TAS@DF+ZJWI]3/2_;&\T1&+XD1FD5NC+6"B((; M$7$A3('KE+W32W_-T,6;M,'D?/R%TWEOX7:9+,KA;8(.]4?I;,0D-=Q,2O%\ M-,D=A:JF>O[Q\J"C+9R"IT%S%Z) DDF* D]TDYPQ @0).N8M2:FX*FZF OO/.^FD;&/0'\ 5DJ\7+M$_N:QBP!!1 MO^J Z0\L,GG; M02" ]'7S(?'.L_$,3,M% =M3[4">/-O[SV\-]KBP)TIO:V71-/RM2^SQ&7+) M6AUD(IY.$I^IB_O=0^E7YO3K_VO'_UR_T%9XG(?=57O8_7$==O_AX?53A]V] M4\+R0F(1%8\L]?L*P;!((B;6.;VV_KUJ,:P(D1JJM;.6Z\BTT4IX%24EL'.& MNGT;6:JG>ZI5N3L,'C!O-YY-^T@M.G^81+27MK(]&-*S_LA]>F3T97?OP]?= M5_NP@)PS31 IJ$2<<()L< 2E=O(%M9+[&$^OO$BM&(5V/&#*@R@,]CQ*C*-@ M8.E1N]8)P F/$YR-9^&210]6Q?%R4<&H[(L[E8I2GGU8)$Q5X?FRHF.Y,>>] M- 7V^BG,__N/'%/5UI& LC%CY6R4#&R^QXP!LE .C1Y/PN_U+W_XWN2X;TY^ M[PWSL^4O_?$YC+/OIYIRN&:%PUH_505+4#P=P_^^OGR%TD\S2O]SZL^^I_A3 M6J@+W\9/R87O?>^RA#TM./VIR_XS#WE\:KL6Y5PEPMM/<_W_K;&UQ:;EDX/W M=]PA^5/U+7[VH]4=+_I.M29IQ>!+G;QG=&J)K2](C[^F2S8UH!_B]/02E8)P MTSJ@+L^7\T;]Y!^)B5:&RV2QMUP\?U>=BY+]W/)L?/?9:S@H&JTSH40XQ^K+RH_ALL\.RFO>^$?"8OT[M,RN> MO_GC5EYW- M9X<[]!7>V7OQY>/[U_WMO7=PO32V\CMPK]E'^E;LT#^/MC?_?;2[YTYVZ+\' M.ZFZX%\OV,?-5V1[[UG_XU]OO^Z\!^8Y^#-N]_#7O_=>3+??X"_[/#7N!J," M 9VTB$L&]#(X#FS31^#_CK#4HH'PB_IH_3(52N]>4I6NAO8Q_W=E0+\+\S@K M\2*G]:R_J'83_1J7GGA:7(FCG..>27* 6+[>Z0DVDU!:^T_(:4/Y-*6AEUO> MG1XK2[7'%^X[F)PTTQR:80BN.-!$:@0 P9(PF*,;"2J&D*@0H%.W2 %BEVV=6>L!HK>:&]]CUP.V,;A7#=MXT,$P$9H6F&)'DZ^3:>&0-DA\YYUTH;'VJMSXHE4YH-?RJ5X*O^\O-GMQS_&J/Z58C55@!82%;N,F=_Z4#\HB[#];UGUPO\/%(LO!/76@N* MEP/%W><-4$QMZ*71' GN ^*4"V0CH\AHH8W&3%I!D_N,%#?E/EN]<,C5F-X< M%^]&GVNOR\.(=]#KQ#M:@GH)D[KUUET%,I>\=9HIIBE#(OW@A:-(10V_&:MX M:L^$N5I;+\YI*G!OB625_T?/X/7-$\W_G[TO?XKC:-+^5SK8_3:D"(JW[D/O M!A%8DKWR&B1;V [Y%Z).:#3,S,XAA/[Z+ZN[YP"&8] ^J-??%HCN[JJLPG MG\S*RGR4;*&K"H#=T;9]_W0]MVRBE<]/B^OW3K8GEJ(EW:O8L][?R=:CMB([ M!SX0H7-17NVX1UP" =>&882ECYXD+@+/->DVI5DQ[5X)DM_=!/VK2OR^O@(" MRZ>:+L08;LK,1[(ZQK-J=1=;]$Y'^:ZBP71+WY#V4R_NY;_WPO+OD'=]XV&$ M&ZL47E&DT YO5Z.P*HQ8-S3,X9ZY6H5UG<.F+'M]_7ZN!)?KGU6CFZ\!?[Y\ M^ZR7]&7(!FAUN:#4.=2VQ*I($\/) 6J[9%5(6DKCI=)!"+X8M=E\M/C"?OIN MM/E,?LZ1>-?MCV?HBNC3A->[GV3^]HZ___T@V,2CB1XQ32+BV!&D;0*P-(9+ MX2TC.K>)I@MJ6/V_%92RO$VMEA\8J>C30:IIL=9[J--Z^3SP7,/R*Z3F%D+R MV$T_JV[BQ%PJ[_,A=GHC ,?]N6[BDV(_S6=-*_&Z2!,LESV,MROVLZ![3776 MNQ@">':FO6"+N4[F\RUT1C#!L:HX<'36[WTM;9[+L:^7S>8V.HC^UW\8+OY= MO/B?=S]/_O'R3I6#%2 M@HC_W=\Y@3'SO MV^>ONX?@:%#IG, H:BX1%[D0?V &J6 X,8)3[#!8T:T%%=.;*DC_GBO^F N: MU;([A8*JF,=1KY.K-4_;(R_J0KV,- D;&;=&TYS9*W._3!D"B%B $2>??*97 MWRE$;:.Z^Q"YL]W3@Y08=<1R)*/0B"?%D'62(J*HTSXE*QS?V+YR/VE2AZ;J MM/;GUL>M1#&$H/+B9,D)H: E,ZBIKQ SA.+K"61.1U- MT"(;2WS5T4 W5_UM81'F& ]SY3PE0@7C(F"<"F;@+7YB(0G^:QT "XG=43!R22P$$1[ MJM;]>D?"WW>+G?Z@[!1D4 J;N_XK7O4%_T@?JQ>3= M*A">(\"Q"L^&\C##!4QHEO/I%FG=;WXS3YV/35/JNL= KYLCNU7CAURDLYQT MI1_&V1O%4>STBR]YWQ1,UJ"$I]TLDLT!NOH 4!],;N^TF_]Y:"LC[ =E'8(' MJ+1YXS!A6Y8P>JZZ7"JG?*')+N-6V[X.K3SAU5#>IE M8"1:)KVCX!E'SQD&YSY@*1US"HQ[9!,8X1,8@1=MK?S5[[7ZW'<]>L$D=APY MJ03B(H'/&R1'1EI $N^X,R[7RF=7U\K/W43JN:RE<(P47TP 65JJ]L?[HCUYQ=*+TS[;F*-O2Q-Q'S5&C MK_YI6W.TK3GZP#5'S]'AMN!H6W"T+3BZBB, =Z2U;<'1NZ3[_U&^_P6N_^83 MW?OEYY/=-W^4P$_YWLD>W/?G\I]?=BG\]_,_;SJ7T_U_><>KXP''G_ GN/;> M+[]V/AT?TD_TW;?=OW_]_.G;)_CO'Y_?_WVAX*CEUA&2' )>"-X5-@E9%AAR MS!J,E8_,D8UM1MIZH^NCOCNUFS!LTI>RUOQ@]9Z>.H#5SG?]S3^FB]C"V%(P M-E\_A9I$.)$"2&]RU M(MT/<7I^'1%JLG!G+20M 4E[\]5+G'/<,L]1%"D@[I1"Q@5 **.3,0)8EG8; MV^:[(6D-3N(_)4CZ,.CU83AGFT6_8YO#--DE/K?GW=*HIP!2DZ7\D!>R<0BK M96Q!:QG0FJ\?H@.WA "%DL9% *U@D?$\(!LQR=WJ@B(Y[^5'+E?^>!TFKCNY MG!LJ#F,:=^IM\"(G5^?]S6J7X[KN@M9;0D4T+!K-DW*&>&4%,UQ)0JQD"[>Z MY[8LX6G\JS >G$4[N*CL$^W]^>KF G]73P@*#M-M#^.?U3/\5J;8:N[-FEOB MTXGF7MSTW/W[Y\^[\/O=DU\_[QZ_97MO0@?&\GGWV^'I^_W?OW[Z]O9L]]M; MO)?K/\Q2=LC>/ES_]( Q@Z,T&!%0%O"GI$,&.X<"C0YD0%" _(UMHB\>*T77 MB1I)Q@OO"0=B!- B3)(I<.>M3DH[[UI1^^%$[?WO!TDIX9AF"$N!$? +!ZZ[ M),@[ ""# T[";VQ3?E'4BBP&P[:G3NLEWT! 'ZFGSH_1D>+!X&>N5G*BV F" MD=-527= #>T3 0FEVK.D(HNRJD^TH+Q[ZUNW32G6L2G%.KK7S_,$TL/BUOP> MA5+)F^@DPLPFQ+4SR-@HD9.".4XI]E1M;(NV*47;E.)Y0]80GA->M0?C[K8S1=N9 MHNU,L<:@W ;T[I*\=Z'D. ^8\Z!05$0C[KU%%E.!-":*,'HAO;9Q1=NXHFU<\<1AOVU@>#IM+'R02L2(<<2>IQ LTRP(&YRD"7.E%V-XV\;B-F4NWK]Y M1W8/#Y+D'CL6D>/"((ZU0#82BI3A(>8>(=+G\HRD;6/1MK&X71N+P90"Y8H: MG=SW (3!CD:#THWKRABY& ]@F2_[%= -S[H15AL&F&N^^095 ,6RI*1=,8A?^/+_&<9&+[D"F'Y"I.Z*O7L-_?* MOQQ7^2$/4%CI+EQ^9R9EKWO#T?LT8>UO8?U'9_NS?"O$=YN,3V3L\ M\%+CX(A"7%/X$W4 O@V&1&OG1- TJ"0VMOG5Q7VKGEQS-9!\GE4P&H B(X"- M"Q7\+E1"FHC89A:783FL^JM,$"?+8_A2#G-=_A3S9O[I49EK7(*%&L34J8&F M[*Y9+>L"\LL+++X[N1D#(_^)N:,AJJDXJS/39D_Z]4-@)7U0@S/ MAJ-XDK^8\C4FW8^JOC#+->50W"5C(H%1@?W!1F+G8W4 BE#B+A^*8?C^.P;] M<%9F?X?LGAY(6(G(54)!"0)."F%(&R,1BU7-;9VJEBT,7X[IS%>/S5[*2HKN MS5H<3'CN)6]\R9K%7BCNJ8Q8.LM=/GV%M0G!(T&-(5PY8EG.IUM07G1:7_Y7JI(^DK^("E.@"W,T]_=H6@&W#^XALO?.0.WQ5R_YJ#([ZH(Y8[_5&M9OVNI>]]]Q= M+">!Y$W/*H[S,UB ;M7:KNIC5WD]Q8MQUXY#[F[W\E$=S1>-,,^-8W[YEHE@ M/)( +JX 'KR6C@N%9=(\,6_ FXJ6I>S,.N_-QO:$4F1G:-JZ#5Y/8^:C(SNZ MCP;5]4;C^8W.?-5;;7968WCWX8__LB?]?[]98G?S>[>M+B/?@HVLNOBZBHE' M:H)CDC/@>QA'3JWAN=>GD?: LXWKY8L\1/A++90FMG7E[M,U)1Z8B(E:8+'> M.5[U?3%:!IW &=*$Q:K$ \685($3>&&R13]OJ%_G$NFN5T<[Y[I$OBF'OM/+ M&[C[<+N?0!(_/[8%/YM8\'>G8+D%6.G33_0=^[3_Q]'>FY_+?_8_G>W^_>OQ MIY-W NXC]O9_)Y>*)QSO@.7N@)7^Z?C3<3C:^^4MAM]T]H[???UTLE=^.OX, M8_A,]M[\!1;\D.W^#LX#=R$JC)3-S0FX4\A8PA!6R6C*HGL#\"%(M"B?C:G@W',R7MSBU#,]^J\U$C^YB8$ M-]_\_& #D2X('E/N5J",A^\0I:65(3+,.'^B30OJR-$1X&A%4^K04:_PYZ;: MSDUU#;RY PX@8H6,DXVTJO/[%SNH(LE5FE!E=YON79OY-P"[=;^J7=UN MLV+LBL">[8SSLG MS29C&>?G@LS]33?(T+GS2@_'-W_R:R;9-:LMXF ?M8")/OZ-1U".A]D[> M)OHG=J.W3W!?^EVW^'4,5AB?R'9^=%I:A4#S4J4Y?'[Z&9Y,&PY^\[%:G?SKH@Z=]L\:+7 ML?"J="\K9G,R[HS*/K 4D#.?_>2S?J8XTZ^756"YES?U^CUXQA<[;SX@^#6H MR,OJ';BO'<;:Q+[XL//'AY?P1$>ERYVV"E_'/CJ3+N--M!IN-+)9,_/-FDW/ M?/OLJUL-,PIOA-F2LWJ:JNJ2 -ASWRNJ6 MS1S5A"H4\W.4WYL\(MPK X;-:C?;^:JX8-[:G0: BA&,K#.L\:>.8?7!

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�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�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�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